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ABSTRACT 
Many small molecules and drugs bind strongly to the plasma proteins 
and in particular to human serum albumin •. or HSA. The degree of binding 
of a drug to HSA maY limit its availability to the receptor sites and 
excretory systems and so have profound effects on its biological activity 
and ha 1 f-l i fe. 
Various reports of harmful side-effects occurring in vivo and 
arising from competition between drugs for plasma binding sites have been 
published. In order to understand and possibly predict these sometimes 
lethal effects. it is important to develop rapid and reliable methods for 
studying drug-protein phenomena. 
Fluorescence spectroscopy is an extremely sensitive technique and 
fluorescence titrations may be performed quickly and simply. The binding 
of the fluorescent probes warfarin and 8-anilino-l-naphthalene sulphonic 
acid has been studied in solutions of HSA and in human sera. An accurate 
procedure has been developed for the determination of binding constants 
for such interactions. The method requires no prior separation of protein-
bound and unbound fractions. Computer programs have been written to process 
experimental data and generate binding curves and constants. 
Di splacement of the bound probes by competitors has yielded 
information on the number and nature of the binding sites of various drugs. 
Results from the spectroscopic method were compared with those obtained 
from equilibrium dialysis experiments. Specially designed dialysis cells 
were tested. and the binding curves produced using these were similar to those 
yielded by the fluorescence titrations. 
Flow-injection analysis has .been used to automate procedures. 
Once optimized. the system could handle large numbers of samples rapidly 
with minimum reagent consumption. The binding and displacement of probes 
in both albumin and serum samples investigated with the flow-injection 
apparatus have given results in excellent agreement with those obtained 
from theo'static' fluorescence titrations. 
The applicability of derivative and synchronous fluorescence 
spectroscopy to drug-protein binding work has been examined. 
The clinical implications of certain results have been considered. 
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CHAPTER 1 
Introducti on 
1.1 An Overview of Drug-Protein Binding 
The biological activity of a drug is profoundly influenced by its 
interaction with protein molecules. Almost every drug exerts its 
pharmacological effect by binding to some kind of protein in the body. As 
well as being necessary for drug-receptor interactions and metabolism to 
take place. protein binding also governs the absorption. distribution and 
excreti on characteri sti cs Qf drugs. Consequently a thorough unders tandi ng of 
the nature and number of binding sites for specific ligands would lead to a 
better understanding of the therapeutic and toxic effects of drug 
administration. 
Several comprehensive reviews of the literature on drug-protein 
binding have already been published. The first was Goldstein's classic 
report which surveyed and summarized the major contributions in the field 
up to 1949. Subsequently. Meyer and Guttman (1968) produced a review which 
contained comprehensive tabular data. similar in form to that employed by 
Goldstein (1949). but summarizing the findings of more recent studies. A 
sequel to this review has been compiled by Vallner (1977). An important 
series of papers from a conference covering all aspects of drug-protein 
binding was published in 1973 (Anton and Solomon. 1973); this has been 
extended by the general review of Bridges and Wilson (1976). Keen (1971) 
and Jusko and Gretch (1976) have compiled interesting works which focus 
mainly on the role of drug-protein binding in pharmacokinetics. The latest 
review (Wilkinson. 1983) covers some recent findings in the broad area of 
drug-protein binding but concentrates primarily on the effects of the 
phenomenon on pharmacokinetics in man. 
The aim of this, the first section of the introduction. is to 
examine the biological significance of drug-protein binding; the importance 
of the more specific areas covered in later sections may then be appreciated. 
1.1.1 The Effect of Protein Binding on Drug Distribution 
Most drugs are carried from their sites of absorption to their 
sites of action and elimination by the circulating blood. Drugs. other 
xenobiotics and endogenous compounds may be transported in the blood stream 
in simple solution. as a suspension or associated with blood constituents 
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such as albumin, globulins, 1ipoproteins and erythrocytes. The binding 
of drugs to plasma proteins is probably completely reversible but it is 
only unbound or free drug which diffuses through the capillary walls, reaches 
the site of action, and is subject to elimination from the body. The 
relationship of plasma protein binding to the processes that establish the 
concentration of drug at the receptor site are shown in Figure 1.1. 
Whatever the route of administration, almost all therapeutic agents 
reach their sites of action via the systemic circulation. The capillary 
wall, through which the blood is in contact with the tissue fluids, is the 
initial barrier to drug distribution. Indeed, the exchange of water and 
solutes between the blood and the tissue fluids takes place almost entirely 
through the walls of the capillaries. 
Blood capillaries are lined with endothelial cells. These cells 
are about 0.2 micron in diameter and contain most of the organelles present 
in other cell types, including pinocytotic vescicles that probably serve 
specific transport functions for macromolecules. The capillary endothelial 
cells are surrounded by a basement membrane of about 20 to 30nm thickness 
which resembles the ground substance. 
Most capillaries in muscle and skin are of the continuous type 
with no discontinuities between cells. The exchange of material across their 
walls is largely by the diffusion of very small molecules in accordance with 
concentration gradients. The bulk movement of water and permeable substances 
is therefore determined by osmotic and hydrostatic pressures. 
More permeable capillaries termed fenestrated capillaries have 
pores between the cells of the endothelial wall. Many vascular channels 
consist of fenestrated capillaries but they are particularly abundant in the 
renal glomeruli and the intestinal mucosa. Their pores allow low molecular 
weight compounds to pass directly from the circulation to the extravascular 
space while restricting the passage of plasma proteins and other high 
molecular weight constituents of the blood. As a result only that fraction 
of a drug which is not bound to serum proteins or red blood cells can cross 
these capillaries by passive diffusion. 
Even more permeable endothelial walls are present in the sinusoids 
of organs such as the liver, spleen and bone marrow. Sinusoids are capillar\y-
like structures with large diameters. They are termed discontinuous 
capillaries because there are large gaps in the abutments between the 
endothelial cells. There is no impairment to the passage of even the largest 
macromo1cules and blood cells can enter or leave the circulation through 
the gaps. 
DOSAGE FORM 
OF DRUG 
P1 asma 
Drug bound to 
protein 
II 
Free drug 
Organ of 
Elimination 
Exterior of 
body 
~ 
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Interstitial Fluid 
Drug bound to 
protei ns 
11 
I 
Free drug 
Target Cells 
Drug b oun d to 
inert sites 
1 l 
Free drug 
, 
J t 
Drug receptor 
complex 
INTENS ITV OF 
PHAR~'ACOLOGIC 
EFFECT 
Actual tissue 
sensitivity 
FIGURE 1.1 Representation of the diffusion equi1ibria that occur to 
relate the concentration of drug in plasma to the drug 
concentration at the receptor site and subsequent intensity 
of drug effect (From Reidenberg, 1981). 
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A number of body compartments, including the eye, mammary gland, 
the fcct~: and the greater part of the brain, are effectively separated from 
the circulation by membranes lacking the pores which render the capillary 
walls permeable to drugs. Free drug tends to come into equilibrium across 
these membranes but the rate of attainment of equilibrium is determined by 
the degree of ionization of the drug and its lipid solubility. Lien (1981) 
has examined tile relationship bet\~een the structural and physiochemica.1 
properties of drugs and their passage across various body membranes. 
Evidence that only the unbound fraction of a drug is available for 
transport to extravascular sites has been provided by studies of the 
antibacterial action of sulphonamide drugs. In 1943 Davis postulated that 
the bound fraction of a sulphonamide was probably devoid of bacteriostatic 
action. Anton (1960) was able to demonstrate experimentally that a1bumin-
bound sulphonamide is not available for antibacterial action and that the 
potency of these agents is due to the free drug. 
Providing they do not bind preferentially cr irreversibly to 
tissue sites, it is clear that highly protein-bound drugs are likely to be 
localized initially in the plasma compartment, particularly at doses \~here 
the high affinity sites are not saturated. Under these circumstances plasma 
protein-bound drugs can serve as a reservoir replenishing by dissociation 
some of the free drug that diffuses out of the bloodstream through the 
capillary membranes and is lost by metabolism and excretion. This 
equilibration process depends on the readily reversible binding of drugs 
to plasma proteins and tends to maintain the concentration of unbound drug 
at a therapeutically useful concentration oVer a cor.siderab1e range of total 
plasma concentrations. Thus plasma proteins have an important buffering 
role for many drugs enabling them to be given only a few times a day rather 
than by continuous infusion. Plasma protein binding could also reduce the 
free concentration of some drugs be1o\~ that required to elicit a toxic 
response, thus rendering the drug safe for therapeutic use. 
Once drug distribution is complete, the concentration of unbound 
drug in the tissues and the tissue compartments of the extracellular fluid 
can equal that in the plasma. This has been shown experimentally by Howe11 
et al (1972) who measured unbound levels of penicillin in synovial fluid 
and serum samples. As shown in Figure 1.1, it is not the total but rather 
the free drug concentration in the serum that correlates with the 
concentration at the sites of action. 
The rate of reaching an equilibrium distribution between the drug 
in the blood and in a tissue depends largely on the tissue's rate of 
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perfusion. Equilibrium between drug in plasma and tissue is rapidly 
achieved in the lung, brain, liver and kidney which are richly perfused. 
Muscle (at least, when in a resting state) is less rapidly perfused and 
equilibrium distributions are reached more slowly. Adipose tissue does not 
have an extensive blood supply and equilibration of drugs into it from the 
blood is even slower than with muscle. 
In the steady state, the concentration of bound drug in the plasma 
will depend on the quantities of binding material present in both plas~a and 
tissues, and on the affinity of the drug for the binding sites of these 
materials. For drugs which are highly bound in both plasma and tissues, the 
tissue binding will tend to draw free drug from the plasma leading to a 
lowered plasma drug concentration. With tricyclic antidepressants and 
phenothiazines, for example, almost all of the drug in the serum is bound to 
albumin, however, because of extensive tissue binding, the circulating drug 
in the plasma represents only a small fraction of the total drug in the body 
(Koch-Weser and Sellers, 1976). 
The extent to which a drug is distributed through the body is 
usually measured in terms of its 'apparent volume of distribution'. At 
distribution equilibrium the volume of distribution of total drug is: 
Vd - amount of drug in body 
- plasma concentration of drug 
It is the apparent volume of fluid a drug would occupy if the total amount 
administered were in solution at the same concentration as in plasma. 
Depending on its physical and chemical properties, a drug 
exhibits different apparent volumes of distribution. For some drugs Vd may 
.correspond to an anatomical or physical compartment such as plasma volume, 
extracellular fluid, or total body water. Thus a drug that is tightly bound 
to plasma proteins has a volume of distribution of about 31 which corresponds 
to the plasma volume. Warfarin is extensively bound tc plasma proteins and 
has a smqll apparent volume of distribution - indeed, its Vd is identical 
to that of injected albumin (Til1ement, 1978). 
• Drugs that pass through the capillary endothelium but not through 
cell membranes, and which are not protein-bound or lipid soluble, have a 
volume of distribution of about n equal to that of the extracellular fluid 
volume. If the drug passes through cell membranes but is not bound to any 
tissue constituents or selectively taken up into any particular cells, it 
will be evenly distributed through the body water when equilibrium is 
reached and will have a volume of distribution of about 421: such a drug is 
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ethanol. However. if a drug is selectively bound to constituents of tissues 
or i, I.a~,," Ufo' by tissue cells. the apparent volume of distribution is a 
purely mathematical concept: some drugs may have volumes of distribution 
several hundred times the body volume. The volumes of distribution of many 
of the most commonly administered drugs have been tabulated by Bowman and 
Rand (198:». 
The apparent volume of distribution is a function of the relative 
binding of a drug in blood and tissue. Clearly a decrease in blood binding 
will lead to an increase in the volume of distribution. whereas a decrease 
in tissue binding will lead to a decrease in the volume of distribution. 
A simple theoretical model to explain quantitatively the effects of plasma 
protein binding on the steady-state drug distribution in the body has been 
described by Martin (1965). Using this model it has been calculated that 
the binciiny of drugs to plasma proteins will have an effect on distribution 
only if associations constants are greater than 104 M-l • At low plasma 
levels a drug with a high association constant. say 105 M-l • will be almost 
completely bound to plasma proteins. When the concentration of the drug 
increases. however. available plasma protein binding sites become fewer as 
saturation approaches. more of the drug diffuses into the tissues and the 
fraction remaining ~lithin the vasculature is reduced. For such drugs there 
will be a concentration range over which small changes in the plasma level 
may exert a profound influence on the distribution of the drug within the 
body. The simple model suggests that the controllable therapeutic dose range 
may be narrow for highly bound drugs. Levy (1973) has demonstrated that the 
distribution and elimination of the highly bound drug dicoumarol is affected 
by its plasma protein binding but emphasized that such effects are likely to 
be less pronounced for drugs not so extensively bcund. 
The simplified model of Martin (1965) made early contributions to 
an understanding of the effects of drug-protein hinding and drug dosage on 
pharmacokinetics. However. the analysis assumed that drug binding to the 
plasma proteins was only important in the intravascular compartment. As 
outlined below. there is now evidence to suggest that plasma proteins are 
widely distributed throughout the extravascular fluids. 
D&spite its high molecular weight. albumin is not exclusively 
retained in the plasma. The extravascular space consists of many different 
anatomical compartments of varying pool size. each of which has its own 
characteristic exchange rate with the vascular compartment. Most plasma 
dis,(aJearance curves of albumin can be resolved into three components. The 
component with the longest half-life of about 17 to 18 days reflects the 
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catabolism of albumin. The other t~~ components with half-lives of 6 
hOl"~ ""U ""uut 28 hours indi cate that there are at least two di sti nct groups 
of extravascular compartments which contain albumin and are in equilibrium 
with the vascular compartment. The model most often used to depict albumin 
distribution is therefore a three-compartment model with an intravascular 
(plasma) compartment and two extravascular compartments. In those tissues 
with discontinuous capillaries such as the liver, spleen and intestine, and 
high plasma perfusion rates, distribution occurs rapidly as is represented 
by the extravascular compartment with the smaller volume of distribution. 
Those tissues with continuous capillaries, such as muscle and skin, and with 
smaller plasma perfusion rates are represented by the larger and more slowly 
exchanging extravascular compartment (Courtice, 1971). 
The total amount of extravascu 1 ar a 1 bumi n in the body has been 
computed by several kinetic methods: it appears that about 55 to 65% of the 
total exchangeable albumin is located outside the plasma (Jusko and Gretch, 
1976). Once it is realized that an appreciable quantity of albumin is 
distributed both extravascularly and intravascularly, it is logical to 
extend the analysis of Martin (1965) to account for the binding of drugs 
in an extravascular compartment, namely in the interstitial fluid. This 
yields a three-compartment model which illustrates some further theoretical 
and practical aspects of the effect of the drug-protein interaction on 
drug distribution. Nevertheless, this model is still a simplified 
representation of what actually occurs in the body under steady-dosing 
conditions. Other factors such as binding to tissue proteins and 
partitioning into fatty deposits could serve to further complicate drug 
distribution. More sophisticated models are required to describe adequately 
the distribution of most drugs. 
Physiological pharmacokinetic models have been used successfully 
to describe the distribution and elimination of certain drugs: this work 
has been reviewed by Jusko and Gretch (1976). All the parameters used in 
such models have a specific physio10gic or physiochemica1 basis. The major 
regions of the body known to be of importance in drug distribution are 
considered and each tissue region is separated into three compartments, 
the capillary plasma volume, the internal water and the extracellular water. 
The different tissue regions receive a designated plasma flow and realistic 
plasma and tissue albumin concentrations are employed. 
~ie and Tozer (1979) have produced equations which should be 
helpful in analysing and predicting alterations in the volume of distribution 
of any drug not only when there is a change in the unbound fraction in the 
plasma, but when there is a change in the unbound fraction in the 
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extracellular fluids outside the plasma, in the volumes of the extracellular 
fluids, or in the extravascular to intravascular plasma protein ratios as 
occurs in many diseases and other abnormal physiological states. Faed (1981) 
has also stressed the importance of considering drug binding in the 
interstitial fluid as well as in the plasma when examining the pharmacokinetics 
of drugs which are highly bound to plasma proteins and have a small 
apparent volume of distribution. 
1.1.2 The Effect of Protein Binding on Drug Metabolism 
The main organ concerned with drug metabolism is the liver, and 
many drugs are substrates for the microsomal enzyme systems of hepatocytes. 
Hepatocytes constitute about 60% of the mass of the liver: Bowman and 
Rand (1980) have discussed the structures and metabolic functions of these 
cells in some detail. 
Although hepatocytes are the major sites of drug metabolism, the 
kidney, lung, intestinal mucosa, plasma and nervous tissue also contain 
important drug-metabolizing enzymes. The reactions in tissues other than 
the liver may have important local consequences due to the formation of 
end-products with altered pharmacological activity or toxicity which exert 
their effects in the vicinity of the sites of production. While the same 
may be true of the liver, reactions taking place in this organ can have far-
reaching consequences ariSing from the inactivation of endogenous hormones, 
drugs and toxic substances - that is, detoxifications, and the formation of 
pharmacologically active metabolites from inert precursors or prodrugs. 
In general, the metabolism of a drug renders it more soluble •. 
A number of qualitative and semiquantitative observations have 
indicated that the binding of drugs to plasma proteins can influence their 
rates of metabolism. Newbould and Kilpatrick (1960) showed that the rate 
of acetylation of two long-acting sulphonamides in a perfused liver 
preparation decreased when plasma was added to the perfusion fluid and the 
rate of metabolism was dependent on the concentration of unbound drug. 
Anton and Boyle (1964) showed that albumin interfered with the acetylation 
of sulphamethoxypyridazine in an in vitro enzyme system. Wiseman and 
Nelson (1964) reported a rank-order correlation between the rates of in vivo 
metabolism of a number of sulphonamides and the degree of protein binding. 
These and other results suggest that only free sulphonamide is accesible to 
the drug-metabolizing enzymes. For most drugs, however, it is not knO\~n 
whether only free or total drug is available for metabolism in the liver 
(Jusko and Gretch, 1976). 
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Theoretical considerations of the effect of protein binding on 
drug-metabolism have been published by Gillette (1971). These suggest that 
if the activity of drug-metabolizing enzymes in the liver are so high that 
virtually all the drug is cleared from the blood as it passes through the 
liver, then an elevation in the binding of the drug to plasma proteins will 
accelerate its metabolism by increasing the rate at which it is carried to 
the liver. So for drugs with high extraction ratios, plasma protein binding 
may have a transport function, bringing the drugs to the metabolizing organ. 
Alternatively, if very little of a drug is metabolized as it passes through 
the liver, that is, if the drug has a low extraction ratio, an increase in 
plasma protein binding may either decrease its metabolism or have little 
effect; in these circumstances, protein binding may have a storage function. 
In considering the possible mechanisms that restrict the metabolism 
of highly bound drugs, one might conclude that the plasma could be 
completely cleared of unbound drug as it passes through the liver and that 
the rate of dissociation of the drug-protein complex limits the elimination 
of the bound form. For this mechanism to be limiting, however, the half 
time for dissociation of the complex would have to be about equal to or 
greater than the mean transfer time of the blood through the sinusoids of 
the liver. Gillette (1973) has provided evidence to suggest that the rate 
of dissociation of the drug-protein complex is seldom rate limiting in the 
metabolism of drugs. Lassman (1981), on the other hand, concludes that the 
dissociation of some albumin-bound drugs could be the rate limiting step in 
their clearance from the liver. 
In a recent development, Weisiger et al (1981) have considered 
the uptake of long-chained fatty acids in the liver. Although tightly bound 
to albumin, these compounds are effectively removed from the plasma during 
its passage through the liver. Uptake of fatty acids has been attributed 
to their spontaneous dissociation from albumin in the bulk aqueous phase 
and the subsequent diffusion of free ligand to the surface of the liver 
cells. Weisiger et al (1981) present evidence that the uptake of long-chain 
fatty acids takes place by a saturable binding of the fatty acid-albumin 
complex with a receptor for albumin on the liver cell surface: their data 
suggest that the concentrations of albumin and albumin-bound fatty acid are 
the print; pal determi nants of uptake. The exi stence of a hepatocyte 
receptor for albumin may also be supported on theoretical grounds. Under 
physiological conditions only about 0.1 % of long-chain fatty acids are not 
bound to albumin. If this small fraction alone were to account for uptake, 
its regeneration from the fatty acid-albumin complex would need to be 
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extremely rapid to account for the overall extraction observed during a 
singlp r~~5 through the liver. However, the half-life for the dissociation 
of long-chain fatty acids from high-affinity sites on albumin is significantly 
longer than the time required for blood to pass through the liver (Svenson 
et al, 1974). Thus the putative albumin receptor may provide a mechanism 
by which the probability of uptake of fatty acids can be increased. 
Participation of the hepatic albumin receptor in the uptake of other 
endogenous and exogenous ligands has yet to be demonstrated. 
According to Bridges and Wilson (1976), newly synthesized serum 
albumin may be involved in the removal of metabolites from the liver. Large 
quantities of serum albumin are synthesized on the hepatic endoplasmic 
recticulum and secreted out of the cell. It is possible that this newly 
synthesized albumin might bind drug metabolites which are being formed on 
the endoplasmic recticulum and facititate their clearance from liver cells. 
This mechanism would explain the lack of hepatic damage caused by some 
active metabolites formed in the liver cells. 
1.1.3 The Effect of Protein Binding on Drug Excretion 
Three processes contribute to renal excretion: glomerular 
filtration, tubular secretion and tubular reabsorption. The first two 
processes remove drugs and thei r metabo 1 i tes from the blood, whereas the 
latter diminishes renal clearance. The effect of plasma protein binding on 
the renal excretion of a drug depends on the relative importance of these 
processes. 
Glomerular filtration relies upon the passive diffusion of unbound 
ligand across the glomerular membrane. There is no apprecia&le movement of 
plasma proteins through the glomerular membrane but the free fraction of 
almost all drugs is readily filtered. Hence the concentration of drugs 
in the glomerular filtrate generally equals the free drug concentration in 
the serum. For this reason, Keen (1971) has described the glomerular 
filtrate as a true ultrafiltrate of plasma. Since only free drug is 
filtered by the glomeruli, plasma protein binding of a drug ~,;ll tend to have 
a retaining effect. The glomerular elimination of highly albumin-bound 
drugs can be extremely slow. Kakemi et al (1952) found an approximate. 
inverse relationship between the binding of a series of salicy1ates and 
their rates of excretion. However, such a correlation is likely to hold 
only when elimination is predominantly determined by the rate of glomerular 
fil trati on. 
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Tubular secretion is primarily an active process and has a 
certain selectivity towards acids, bases and various endogenous compounds. 
Consequently, it can be inhibited by compounds that compete for the same 
transport system. Unlike glomerular filtration, the tubular secretion of 
drugs is not generally 1 imi ted by protein binding. Only free drug can be 
secreted by the tubules, and in contrast to glomerular filtration, active 
tubular secretion decreases the concentration of free drug in the blood. 
However, the dissociation of the drug-protein complex is usually so rapid 
that any free drug withdrawn from the serum by active transport mechanisms 
can be replaced virtually instantaneously. Consequently, even drugs which 
are more than 90% bound to serum albumin at therapeutic concentrations, 
can be removed almost completely from the blood by tubular secretory 
mechanisms during a single pass through the kidney (Koch-Weser and Sellers, 
1976a). Nevertheless, it is probable that protein-binding accelerates the 
rate of elimination of a drug which is actively secreted by the tubules 
because it increases the plasma drug concentration and so delivers more 
drug. to the sites of secretion. 
As with hepatic clearance, it is possible to distinguish between 
drugs with high and low renal extraction ratios. As the rate of glomerular 
filtration is about 120ml/min, a drug which has a high renal clearance 
approaching renal blood flow (1500ml/min)must be predominantly secreted and 
not reabsorbed. Clearly, the eliminaticn of such a drug is affected by 
change in renal blood flow rather than by changes in protein binding or the 
capacity of active transport systems; for a lowly cleared drug the opposite 
is true. 
The importance of plasma protein binding in hepatic biotransforn~tion 
is generally analogous to that in the renal excretion of drugs. Thus drugs 
that enter the hepatocyte by simple diffusion are protected from 
biotransormation to the extent of their binding to plasma proteins, while 
on the other hand, the biotransformation of drugs that are concentrated in 
the hepatic cell by active transport mechanisms is unlikely to be limited 
by their·protein binding. 
Lipophilic nonionized drugs are passively reabsorbed from tubular 
urine across an intact tubule membrane. In general, ionized drugs are not 
reabsorbed but if the degree of ionization of a drug can be altered by 
changing urine pH, then its reabsorption and hence renal clearance will be 
affected. According to Koch-Weser and Sellers (1976a) binding to serum 
albumin can limit the rate of elimination of drugs that are lipid soluble 
at the pH of tubular fluid by increasing their back-diffusion from the 
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gloneru1ar filtrate into the blood. 
Drugs may be actively secreted into bile. Consequently protein 
binding is unlikely to limit biliary secretion. Indeed, it has been 
suggested that protein binding may assist biliary excretion. However, 
the effect of plasma protein binding on biliary excretion is still a matter 
of conjecture (Keen, 1971). 
Salivary excretion of drugs appears to involve a process of 
passive diffusion which excludes the protein bound fraction. Nevertheless, 
it should be noted that when the pH of the saliva differs from that in the 
plasma, free drug may be unequally distributed between the two fluids. 
1.1.4 The Effect of Protein Binding on the Pharmacological Activity of Drugs 
Since protein binding inhibits the activity of a number of drugs, 
it is generally considered that only free drug can reach the sites of action 
and exert a pharmacological effect (Anton, 1960; Keen, 1971; Kunin et a1, 
1973; Koch-Weser and Sellers, 1976a). The finding that the biological 
effect of drugs and endogenous 1igands increases when they are displaced from 
plasma protein binding sites (Agge1er et a1, 1967; Anton, 1973) also suggests 
that it is the unbound fraction which is active. 
Binding to serum albumin decreases the maximum intensity of action 
of a single dose of most drugs because it lowers the peak concentration of 
unbound drug at the receptor sites. The magnitude of this effect is 
directly proportional to the fraction of the administered dose which binds 
to serum albumin. 
Binding to plasma proteins slows the elimination of drugs that 
are removed from the serum by glomerular filtration or by passive diffusion 
to the sites of hepatic biotransformation. It therefore increases the 
duration of action of a single dose of such drugs. Indeed, the duration of 
action of many drugs correlates ~Iith the degree of their albumin binding. 
However, drugs that are highly bound to plasma proteins may have a high 
degree of binding at inactive tissue sites which would also lead to a long 
half-life and duration of action. On the other hand, by increasing the rate 
of delivery to the sites of elimination, binding to plasma proteins may 
shorten the duration of action of drugs that are actively transported into 
renal tubules or hepatic cells. Clearly, the effects of protein binding 
on the pharmacological activity of a drug are not simple but depend on the 
particular pharmacokinetic characteristics of the compound. 
The rate of intravenous injection of highly albumin-bound drugs 
can be important for the intensity of their pharmacological action. During 
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rapid intravenous injection of such drugs the binding capacity of the plasma 
proteins in the limited blood volume with which the drug mixes may be exceeded. 
If this occurs, the rapid introduction of strongly bound drugs into the 
circulation produces a much higher concentration of free drug than when 
administration is slO\~ enough to allow mixing with the entire blood volume 
during the injection. The increased level of free drug in the serum can be 
reflected in a higher drug concentration at the sites of action in rapidly 
perfused tissues. A more intense pharmacologic action after rapid rather 
than slow intravenous injection has been demonstrated for highly bound 
drugs that act on tissues with a high perfusion rate. 
It is apparent that it is usually only the free drug and drug 
metabolite concentration in the plasma which could be expected to correlate 
directly with the therapeutic and toxicological effects of the drug. Most 
often, however, it is the total drug blood level which is measured in 
clinical pharmacology studies (Greenblat et al, 1982; Marks, 1979a). 
Interpretation of data based on total blood levels rests on the assumption 
that there is a simple correlation between free drug levels and total drug 
blood levels. For moderately or poorly bound drugs this may be valid, but 
it is frequently not justified for highly bound drugs. When the protein 
binding sites of a highly bound drug are nearly saturated, small changes 
in the total blood level may mask very significant increases in free drug 
levels. It is hardly surprising that for many strongly bound drugs poor 
correlations have been reported between biological effects and total drug 
blood levels. The use of total drug measurements to guide therapy may 
sometimes lead to errors in dosing (Koch-Weser, 1972). This point is 
further emphasized in the book by Wartak (1983) which provides a general 
account of the application of pharmacokinetic principles to drug therapy. 
There is considerable interest in the possibility that saliva might prove 
more useful than blood as the fluid in which drug assays should be performed. 
One advantage is that for many drugs their concentration in saliva reflects, 
more or less accurately, the concentration of unbound drug in the plasma; 
unfortunately this is not true for all drugs (Marks, 1979b). 
It is by no means certain, however, that a protein-bound drug is 
invariably therapeutically and toxicologically inactive. The fact that 
drugs which are deliberately covalently bound to serum albumin often cause 
specific antibodies to be produced when the drug-protein complex is 
injected into experimental animals implies that drugs bound to proteins may 
still be able to interact with some receptor sites. It is possible that large 
polar drug molecules which are not normally able to pass across cell 
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membranes may be taken up into cells by pinocytosis when bound to protein. 
Fer ::~~: ~:":i'!e in protein uptake the possibility of drug absorption in 
the albumin-bound form should not be discounted (Weisiger et a1, 1981). 
The effect of tissue binding on the pharmacological activity of 
drugs is obviously very important. If an alteration of plasma protein 
binding is to be pharmaco10gica11y significant, it must be associated with 
a simultaneous and corresponding change in tissue binding (Kurz and Fickt1, 
1983). Should tissue binding remain constant or change in the opposite 
direction, the displacement of a drug from plasma binding sites is of little 
significance or has no pharmacological effect at all. The consequences of 
altered drug-protein binding in vivo are considered in the next section. 
1.2 Factors Which Alter Drug-Protein Binding in Vivo 
1.2.1 Drug Displacement Interactions 
The plasma proteins have only a limited capacity for binding drugs, 
and competition for binding sites bet\~een concomittantly administered drugs 
is a common cause of drugs interactions in man. However, while the problems 
associated with multiple-drug therapy are very widely appreciated (Figure 
1.2), it is important not to overestimate or overstate the importance of 
plasma protein binding displacement as a mechanism of drug interaction. 
There are a number of proteins in the blood which bind drugs, and 
each protein may have several binding sites. The sites that avidly bind 
one drug may be different from those that avidly bind another. For this 
reason not all highly bound drugs displace one another from plasma proteins. 
Nevertheless, when two or more drugs bind to the same sites on a 
macromolecule, there will be a simple competition between the drugs for 
these sites (Figure 1.3) the mutual displacement of the interacting drugs 
is a function of their concentrations and their relative affinities for 
the common binding sites. Compounds with a high affinity will tend to 
displace drugs with a lower affinity and so the mutual displacement of 
interacting drugs tends to take place to differing extents. When two drugs 
compete for binding sites, the displacement of only one drug is likely to 
be clinically important. The latter is referred to as the displaced drug 
(Koch-Weser and Sellers, 1976b), while the other component of the interaction 
is called the displacing agent. 
Drug displacement interactions can also occur between compounds 
which bind to different sites on a protein molecule. When a drug binds to 
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"You'll be glad to know that of the 17 drugs we gave you, and the 
43 side effects they caused, we found 6 of the drugs to be effective, 
and we've cleared up 28 of the side effects." 
FIGURE 1.2 The Problems of Multiple-Drug Administration (From 
Current Contents. Life Sciences 26 (23). June 7. 1982). 
Non-ComRetitive 
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FIGURE 1.3 Simultaneous Interactions Between Two Ligands and One 
Macromolecule. 
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a serum protein, it may induce structural changes in the tertiary 
conformation of the macromolecule which modify the shape of specific 
binding sites for other groups of drugs. This modification may lead to 
a non-competitive displacement interaction (Figure 1.3). 
A wide range of drugs are bound to plasma proteins and may thus 
enter into interactions involving binding displacement. Many potential 
drug-drug interactions have been identified, but the majority of drug 
displacement interactions are probably of insufficient magnitude to have 
a clinical effect or may be obscured by other factors in vivo. 
Sometimes the metabolite of a drug rather than the drug itself 
may be involved in a displacement interaction. For example, trichloroacetic 
acid, a metabolite of chloral hydrate displaces warfarin from its albumin 
binding sites (Sellers and Koch-Weser, 1970). Some drugs may be converted 
in the body to metabolites that compete with the parent compound for 
binding to serum and tissue proteins (Gillette, 1973). 
An unusual mechanism is responsible for a number of displacewent 
interactions involving aspirin. The acetyl group of aspirin can become 
covalently attached to lysine residues on albumin molecules. The albumin 
binding of flufenamic acid, phenylbutazone and possibly other anionic drugs 
is modified in the presence of aspirin (Pinkard et al, 1973). 
Rondanelli et al (1983) have considered some general aspects of 
the clinical pharmacology of drug interactions. The clinical 
significance of interactions which involve the displacement of drugs from 
plasma protein and tissue binding sites has been discussed by D'Arcy and 
McElnay (1982) and McElnay and D'Arcy (1983). The pharmacokinetics of 
drug displacement interactions and the factors which determine their 
severitJhave also been reviewed by McElnay and D'Arcy (1980). KQch-Weser 
and Sellers (1976b) have considered the clinical consequences of the 
competition between drugs for serum albumin binding sites, and 
pharmacokinetic models of drug-drug interactions have been reviewed by 
Aarons (1981). Some of the more important aspects of drug displacement 
interactions ~Iill be examined below. 
If a bolus injection of a displacing drug is given to a patient, 
displacement of the primary agent will be almost immediate while 
distribution and therefore re-equilibration will take a short time. This 
means that the free drug plasma concentration \~i 11 rise and total drug 
concentration will remain the same immediately after injection. During this 
initial period, the displacement of even a small amount of highly bound 
drug can cause a large increase in the free fraction of the drug in serum. 
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Thus displacement from albumin of 1% of a 99% bound drug will double the 
free fraction. It is important to stress that this does not mean that the 
free drug concentration in the plasma wtll be doubled: the displaced drug 
does not re~ain confined to the circulation but quickly distributes 
throughout the body and may localize in tissues. Hence displacement 
interactions are often of a transient nature. 
After redistribution, any remaining increases in the free drug 
concentration in the serum and extracellular fluid depend on the new volume 
of distribution of the drug. If this volume is large, changes in the 
plasma free drug pool caused by displacement from plasma proteins are too 
small to affect the total body free drug pool and therefore too small to 
have a significant effect on free drug concentration in the plasma or 
tissues after re-equilibration. Since the apparent volume of distribution 
of most drugs far exceeds the plasma volume (an exception is warfarin), 
D'Arcy and McElnay (1982) have suggested that the ultimate consequence of 
the majority of plasma protein binding displacement interactions is a 
decrease in the total drug concentration in the plasma while the free drug 
concentration remains essentially unchanged. Since pharmacological actions, 
including toxicities, correspond to free drug in the plasma, such drug 
displacement interactions would have no adverse side-effects. On the other 
hand, if much of the displaced drug is normally present in the circulation, 
that is, the apparent volume of distribution is small, the concentration 
of free drug in the serum and at its receptor site may rise suffi ciently 
after redistribution to increase the intensity of drug action in a 
clinically important fashion. Gillette (1973) has calculated that the 
displacement of drugs from plasma proteins will be important when more than 
90$ of the drug in the blood is bound; only then will the plasma bound 
fraction represent a significant proportion of the total drug in the body. 
The major consequence of a drug displacement interaction is an 
increase in the free drug concentration leading to an augmentation of the 
therapeutic response and a possible increase in toxic side-effects. 
Potentiation of a drug's pharmacologic action is not the only consequence of 
its partial displacement from plasma proteins; both drug elimination and 
metabolism may be affected by displacement interactions. 
After displaced drug has diffused out of the plasma into the 
tissue compartment and a new equilibrium distribution established, the total 
drug concentration in the plasma will be at a new, reduced level. Thus 
for drugs that are removed from the circulation by active transport 
mechanisms in the kidney or liver, displacement from plasma proteins 
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decreases the rate at which drug is delivered to the sites of elimination. 
This can temporarily increase the half-life of a drug. 
An elevated free drug level, if it occurs, will also tend to 
increase t~e free drug concentration at the sites of metabolism and 
elimination. For drugs which are removed primarily by glomerular filtration 
or passive diffusion into hepatic cells, this action results in a higher 
rate of elimination which is reflected in a shortened half-life. This 
compensatory mechanism will minimize the expected increase in the therapeutic 
effect of the displaced drug. 
The pharmacokinetic time course of the displacement interaction 
between two drugs is quite complex. It is determined by the rate and extent 
to which the interacting drugs accumulate in the body - which is a function 
of their half-life and dosing schedules - and by the sequence of their 
administration. If metabolites of one or both drugs also compete for 
plasma protein binding sites, the interaction becomes even more complicated. 
The clinical significance of a drug-drug interaction depends on 
t~e magnitude of the change in the concentration of the active species at 
their sites of pharmacological action and the degree of change that can be 
tolerated. The latter is determined by the therapeutic index of the drug. 
The smaller the difference between toxicity and efficacy, the greater the 
likelihood that a drug interaction will have serious therapeutic 
consequences. 
There are a nurrber of instances \~hen the di spl acement of one drug 
by another is likely to be dangerous. When the displacing agent is 
administered by rapid intravenous injection the concentration of unbound 
drug could be increased almost instantaneously and thus the richly perfused 
organs such as the endocrine glands, liver, heart and brain, could be 
exposed to very high and possibly toxic concentrations of unbound drug 
during the period of redistribution. Aarons and RO'.~land (1981) have 
discussed methods of moderating drug displacement by adjusting the rate and 
timing of administration of the displacing agent •. 
If a patient's plasma protein binding is decreased due to drug-
drug competition for binding sites, then the wonitored total drug level 
will be lowered. However the corresponding 'plasma free drug level, and 
hence the therapeutic effect, are virtually unaltered by the majority of 
drug displacement interactions. Nonetheless, because drug monitoring is 
usually concerned with total drug in the plasma, the patient's dosage may 
be increased in response to the lo\~ total concentration; the total body pool 
of drug \~il1 increase and with it both total and free concentrations in the 
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plasma. As most drugs being monitored in patients have a narrow therapeutic 
range (this is tie reason for monitoring), the increase in free 
concentration after dosage adjustment is likely to give rise to toxicity 
(D'Arcy and McElnay, 1982). 
Another important facet of drug di splacement interactions at plasma 
protein binding sites is the displacing agent may resemble the displaced 
drug so closely that it also blocks active transport systems in the kidney 
or drug-metabolizing enzymes in the liver and other organs. Thus, after 
repeated administration of the drug and the displacing agent, the steady-
state level of unbound drug could increase, not because of drug 
displacement. but because the compensatory elimination mechanism is 
inhibited (Gillette, 1973). 
From the foregoing discussions it is clearly possible to predict 
which drugs are likely to be involved in clinically important displacement 
interactions. Such drugs are highly bound to plasma proteins at normal 
doses, have a small apparent volume of distribution, and display a 
relatively narrow range of therapeutic concentrations at their sites of 
action. As few highly bound drugs satisfy the second and third criteria, 
the proportion which are subject to clinically significant displacement-
induced potentiation of their actions is very much smaller than suggested 
by the many albumin binding interactions that have been demonstrated in 
vitro. 
The coumarin anticoagulants are involved in the most hazardous 
interactions (Koch-Weser and Sellers, 1976b; Stratton et al, 1982). The 
most frequently cited cases involve the displacement of warfarin by highly 
acidic drugs such as phenylbutazone, indomethacin, mefenamic acid, 
oxyphenylbutazone, trichloroacetic acid and various sulphonamides, leading 
to an increased anticoagulant effect which may give rise to spontaneous 
haemorrhage. Further details concerning the pharmacology and pharmacokinetics 
of warfarin are included in the review by Sawyer (1983). The displacement 
of the oral hypoglycaemic drug tolbutamide by phenylbutazone and other 
drugs also has clinical significance since it can result in a sudden 
hypoglycaemic crisis (Christensen, 1963). Anton (1960) showed that 
phenylbutazone displaces certain long-acting'sulphonamides from serum 
albumin and thereby enhances their antibacterial action, but the clinical 
significance of these and other interactions remains in doubt (Koch-Weser 
and Sellers, 1976b). 
Some clinically important drug interactions that are usually 
attributed simply to changed albumin binding of one or both drugs actually 
involve other mechanisms as well. D'Arcy and McElnay (1982) suggest that 
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there are probably no major drug interactions in which plasma protein 
bindino disolacement alone is the evoking mechanism. Certainly, the 
interaction between warfarin and phenylbutazone in man is multifactorial 
(O'Rei11y, imaGoulart, 1981). 
Endogenous, as well as exogenous compounds, can compete with 
drugs for serum protein binding sites. The displacement of highly bound 
drugs by fatty acids and other naturally occurring substances may have 
important implications for the effectiveness or safety of drug therapy. 
Furthermore, when attention is focused on drugs as displacing agents, 
competition with endogenous compounds is known to have serious 
toxicological consequences. 
Despite reports in the literature, the involvement of endogenous 
material in the displacement of drugs from plasma proteins is sometimes 
ovprlnnkpn. Tsutsumi et al (1975) have shown that at therapeutic 
concentrations of diazepam, binding to HSA is inhibited by laurate. 
Wosilait and Ryan (1979) have demonstrated that the binding of warfarin to 
HSA is affected in a complex fashion depending on the concentration of 
free fatty acid. Spector et al (1973) also produced evidence to suggest 
that changes in free fatty acid concentration within the physiological 
range alter the binding of certain drugs to serum albumin. The presence 
of one or more lipid-soluble endogenous binding inhibitors in human plasma 
can alter the binding characteristics of salicylate (Cham et al 1982). 
An example of an extensively studied and important competitive 
binding effect is the displacement of bilirubin by a number of strongly 
bound drugs. At a time when premature babies \~ere routinely treated with 
sulphisoxazole to protect them against infection, it was noted that toxic 
jaundice and lethal kernicterus were significantly more frequent than in 
children receiving penicillin (Silverman et al, 1956). Sulphisoxazole can 
displace bilirubin from serum albumin (Odell, 1959) and following 
redistribution free bilirubin may enter the brain to give rise to the toxic 
sympto~s. Many studies have since been conducted to examine the effects 
of other drugs on the displacement of bilirubin from albumin and Lamola 
and co-workers (1979) have shown that albumin is the major binding protein 
for bilirubin in whole blood. Salicylate displaces bilirubin from human 
serum albumin (Brodersen, 1974) and so could also potentiate the risk of 
bilirubin encephalopathy in jaundiced human neonates. Ahlfors et al (1982) 
have recently studied this interaction in vivo and make a detailed 
assessment of its clinical significance. 
The hypothesis that free unconjugated bilirubin enters the central 
nervous system causing sUbsequent cellular damage has recently been 
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questioned (Ritter et al, 1982; Levine et al, 1982). Levine et al suppcrt 
t:;~ :: ~:;-;;:.t; ... c hypothesis that kernicterus results from the uptake of 
albumin bound bilirubin following breakdown of the blood brain barrier. 
However, this view has been seriously challenged by Wennberg and Ahlfons 
(1982) and by Odell (1982). 
There are other instances when the ability of drugs to displace 
endogenous ligands has important clinical consequences. It has been 
suggested that the activity of nonsteroidal anti-inflammatory agents such 
as phenylbutazone, salicylate and indomethacin may be related to their 
ability to displace corticosteroids from plasma proteins (Brodie, 1965). 
McArthur et al (1971) have proposed the vie\1 that the antirheumatic 
activity of certain drugs may be mediated through their ability to displace 
endogenous ly pl asma protei n-bound tryptophan and other small pepti des. 
So far only plasma protein binding displacement interactions have 
been discussed; for manY compounds, competition for tissue binding sites 
may be of greater signift.cance. Indeed the ratio of tissue mass to albumin 
mass is of the order of 100:1. It is also important to recall that 
displacement can occur from both intravascular and extravascular albumin. 
Since the apparent volume of distribution of most drugs far 
exceeds the plasma volume, the bulk of the total drug pool of the body is 
in the tissues. Tissue binding displacement will give rise to an increase 
of free drug in the tissues. The diffusion of free drug into the plasma 
compartment will produce equilibration of this displaced drug and there 
will be an increase of both free and bound concentrations in the plasma. 
As the plasma volume is relatively small for most drugs, the distribution 
of displaced drug into the plasma will be unable to buffer the impact of 
the increased pool of free drug in the body. Fer the majority of drugs, 
then, tissue binding displacement approximates to a reverse of the effects 
seen with plasma protein binding displacement. 
It is quite possible that a displacing agent may displace a 
primary drug from both plasma and tissue sites simultaneously. Such an 
interaction would certainly lead to an increased free drug concentration 
in the plasma. HO\1ever, until methods are developed for quantifying 
tissue binding and displacement, measurements of free and bound levels in 
plasma must serve as the sole tool for the examination of drug 
displacement interactions whether they take place in the plasma or in the 
tissues. 
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1.2.2 Disease States 
The plasma protein binding of drugs has been seen to be an 
important determinant that can affect the distribution, elimination and 
pharmacological activity of drugs. The extent of drug plasma protein 
binding may be altered by changes in protein concentration and distribution, 
pH, ionic strength and temperature, and by endogenous ligands and metabolic 
products. In a number of pathological conditions, drug levels may be 
affected by changes in one or more of these factors. As pointed out by 
Wande11 and Wi1cox-Thole (1983), the most life-threatening and clinically 
complex disease states are frequently those that exhibit the largest 
variation in protein binding. 
An assessment of the effect of diseases on plasma drug levels was 
compiled by Jusko and Gretch (1976). In a recent review Ti1lement et a1 
(1978) have examined the pathophysiological mechanisms which modify drug 
binding to plasma proteins and discussed the pharmacological consequences 
of a number of disease states. Some further developments will be 
considered in this section. Piafsky (1980) has summarized the effects 
of disease-induced changes in the plasma binding of basic drugs. The 
course of action of a drug is dependent upon the normal functioning of 
a number of organs which combine to absorb, distribute, metabolise and 
excrete the drug at a characteristic rate; Wi1son and Bromberg (1981) 
have reviewed the effects of a number of pathological conditions on drug 
pharmacokinetics. 
Hypoa1buminemia is characterized by a decrease in the plasma 
concentration of albumin. The extent of drug binding depends on the 
quantity of binding protein available and when this decreases so does the 
amount of bound drug. The phenomenon is important only for highly bound 
drugs with a low volume of distribution; these are usually weakly acidic 
drugs. Hypoa1buminemia is associated with severe stress or altered 
nutrition as well as with nephrosis, hepatitis, cirrhosis, cancers, 
gastrointestinal diseases, heart disease and hypothyroidism. 
Hypera1buminemia is so rare to be regarded as a result of dehydration 
(Peters,1975). Thus, variations in.plasma albumin levels are relatively 
narrow and if significant, almost al\~ays in 'the direction of decreasing 
concentT'ati on. 
Basic drugs bind to 1ipoproteins and (X,-acid glycoprotein as well 
as to albumin. The former show large fluctuations due to both physiological 
and pathological conditions a,-acid glycoprotein, the acute phase protein, 
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is raised above normal in a large number of conditions characterized by 
physiological stress, in response to inflammation such as seen in rheumatoid 
arthritis and other diseases, and in malignancy. Associated with these 
changes in binding protein both increases and decreases in the plasma 
protein of basic drugs have been recorded. 
The distribution of free and protein-bound drug in the body is 
illustrated in Figure 1.1. Distribution of bound drug clearly follows 
that of its carrier protein. In the case of albumin, plasma and 
interstitial fluid contain about 40% and 60% respectively of the total 
quantity in the body. The succession of equilibria between free and bound 
drug may be upset in a number of disease states in which there is knol!ln 
to be an increase in the concentration of albumin in the interstitial 
fluid at the expense of the plasma compartment. 
A change of pH is knovm to alter the protein binding of drugs 
(Newbould and Kilpatrick, 1960). The organ and tissue selectively of 
certain drugs may be partly due to pH-dependent differences in unbound 
concentration. Henry and co-workers (1981) have developed a model for 
the pH-dependence of drug-protein binding which suggests that acidosis and 
alkalosis could produce alterations in the duration and intensity of action 
of a wide variety of drugs. 
In some pathalogical conditions the reduced protein binding of 
drugs may be due to a structural modification of the carrier molecule. 
The role of physiological inhibitors of drug-protein binding, such as 
fatty acids and bilirubin, has already been considered: reduced protein 
binding in disease states may also be due to the existence of pathological 
binding inhibitors. The identification of the latter in uraemia is the 
focus of much current research. 
Uraemia is associated with a decreased protein binding of weakly 
acid drugs such as salicylate, warfarin and sulphonamides. The defect is 
related somewhat to a decrease in serum albumin levels but can not be 
accounted for by hypoalbuminemia alone (Reidenberg, 1976). Two major 
hypotheses have been offered to explain the reduced binding in uraemia. 
The first hypothesis that there may be alterations in the structure of 
serum proteins in uraemic patients is supported by the differences in amino 
acid compositions of purified normal and uraemic albumin (Boobis, 1977). 
The second hypothesis is that certain toxic metabolic products which are 
normally excreted by the kidneys in healthy individuals, accumulate in renal 
failure. These compounds would bind to albumin and interfere with the 
binding of weakly acidic drugs either by direct competition for binding 
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sites or by modifying the protein conformation (Sjoholm et al. 1976; 
Kober et al. 1979; Bowmer and Lindup. 19B2). This theory is supported 
by the fact that the binding defect is rapidly arrested by renal transplant 
and by active charcoal treatment of uraemic sera (Grafnetterova et al. 1979). 
The endogenous metabolites responsible for these binding defects have yet 
to be recovered. Very recently. however. Lichtenwalner et al (1981) have 
partially purified and characterized drug binding inhibitors extracted 
from u raemi c sera. When added to normal human serum these compounds were 
capa~le of inducing binding defects similar to those seen in uraemia. In 
addition. Schwertner and Hawthorne (1980) observed a fluorescent material 
in the serum of patients with chronic renal disease and established that 
the fluorescence is not attributable to albumin itself but to the binding 
of certain unidentified species. The chemical characterization of these 
agents is awaited. Calvo et al (1982) have investigated the binding of 
sulphisoxazole and diazepam in plasma samples from healthy and uraemic 
patients in an attempt to establish the effect of the disease on the binding 
of drugs to two distinct sites on albumin. 
While considerable attention has focused on the biochemical 
characterization of albumin from sufferers of chronic renal failure or 
uraemia. Itoh et al (1981) have used the fluorescent probe. ANS. to 
examine the ligand-binding properties of nephrotic albumin. 
The binding of acidic drugs is reduced in patients with chronic 
liver disease (Urien et al. 1981). This finding may be explained only 
partially by hypoa1buminemia (Jahnchen et al. 1981). Thus endogenous 
binding inhibitors may also be a factor in the decreased protein binding 
of drugs in liver disease (Koberet al. 1978). 
Although abnormal binding of L-tryptophan has been reported in 
patients with rheumatoid arthritis (McArthur et al. 1971). Wanwimo1ruk 
et al (1982) found that the protein binding of several. drugs is unaltered 
in patients with this disease. 
Fee1y et al (1981) examined the plasma protein binding of 
propranolol (basiC drug) and warfarin (acidic drug) in patients with 
thyroid disorders. Their results suggest that the binding of both acidic 
and basic drugs is altered by thyroid disease. 
1.2.3 Miscellaneous Factors 
There are a number of miscellaneous conditions which can alter 
the protein binding of drugs. They are included here for completeness and 
help to put into perspective the significance of plasma protein binding 
displacement interactions in determining free drug levels. 
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The plasma protein binding of drugs may be altered in pregnancy 
(Perucca and Crema, 1982; Perucca et al, 1981). This is hardly surprising 
because the normal human pregnancy is associated with considerable changes 
in the concentrations of plasma proteins, free fatty acids and possibly 
other endogenous substances which interfere with drug binding. 
McNamara et al (1980) have reported an apparent effect of tobacco 
smoking on drug binding to human serum proteins. Adir et al (1982) found 
that the plasma protein binding of an acidic drug decreased with age but 
the results could be explained partly by the lower albumin concentrations 
in elderly subjects. Wood and Wood (1981) have investigated age-related 
changes in a,-acid glycoprotein and related these to plasma drug binding 
in the ne,lborn infant. There may be sex-related differences in the plasma 
protein binding of certain drugs (Routledge et al, 1981). 
As stated previously, the bound drug concentration depends on 
the quantity of binding protein available. The latter may be dependent 
on 1utri~ional status (Varma, 1981). Stress, injury, alcohol and the 
acci~'i'r~lization to heat are known to decrease albumin producti on 
(Rothschild, 1973) and so could lead to a significant increase in free drug 
blood levels for highly bound drugs. Morrison et al (1979) have shown that 
the concentrations of a number of serum constituents, including albumin, 
vary in characteristic patterns during the course of the day. Levels of 
a,-acid glycoprotein have been reported to be raised after surgery, 
resulting in a reduction of the free fraction of basic drugs (Fremstad et 
al, 1976). 
1.3 The Location of Drug 8inding Sites in the Blood and Tissues 
1.3.1 The Partitioning of prugs Amongst Blood Components 
Before considering molecular aspects of the binding of drugs to 
plasma proteins, it is worth examining the physiological role of the 
proteins involved and the relative contributions they make to the binding 
of drugs in plasma. 
Many detailed reviews of the composition, structure and function 
of the plasma proteins have appeared (Neurath, 1965; Jonas, 1972; Putnam, 
1975) consequently only limited aspects will be covered in this section. 
Of the hundreds of proteins present in the plasma of healthy 
individuals only a few are kn~~n to be important in the binding of drugs. 
The best known example is human serum albumin (HSA). 
Serum albumin is the most abundant and the most extensively 
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studied protein in the blood. Approximately 60% of the total serum protein 
is albumin. While other·plasma proteins tend to have single, fairly specific 
functions, albumin appears to have several important physiological roles. 
It is the principal agent responsible for the osmotic pressure of the blood 
and hence contributes to the maintenance of the circulating fluid within 
the vascular system. Albumin has a major role in the binding and tr~port 
of long chain fatty acids, and in the binding and detoxification of 
unconjugated bilirubin. Although albumin binds thyroxine and numerous 
steroid hormones less tightly than do speCific binding proteins, it is 
present in larger quantities and so acts as a buffer when the primary 
binding proteins become saturated. Albumin can therefore stabilize the 
plasma concentrations of hormones and other endogenous ligands. The latter 
include tryptophan which is the only amino acid bound reversib1y to 
albumin (cysteine is able to bind cova1ent1y to the thio1 group of the 
protein), and calcium. The binding of the calcium ion constitutes a weak 
association but is important phYsiologically due to the abundance of 
albumin in the plasma. The minor nutritive role of albumin arises from 
its availability to cells through pinocytosis: it contributes about 5% of 
the amino acids used by peripheral tissues. Recent findings suggest that 
the biological function of albumin may also be associated with the regulation 
of prostaglandin synthesis in vivo (Saeed et a1, 1981). 
The physiological importance of serum albumin is reflected in the 
fact that the concentration of albumin in blood has been used as a major 
index in health and disease over the years. The normal level of HSA in the 
serum of healthy adults is 42g/1 with a range of 35-50g/1 (Peters, 1977). 
HONever, a stable serum albumin level depends upon an equilibrium between 
three processes: distribution, degredation and synthesis. 
As mentioned earlier, the albumin of the blood is involved in 
active exchange with that of the other body fluids. While equilibrium 
within the vascular pool is rapid, a sloN but constant extravascular 
exchange occurs such that di stri buti on equi 1 ibri urn between i ntravascu1 ar 
and extravascular pools is usually achieved in man within 7-10 days. At 
anyone time, however, only about 40% of the exchangeable albumin pool is 
located in the plasma. 
The normal half-life of circulating albumin is approximately 19 
days. This corresponds to a daily degredation of 14g. The breakdown of 
albumin follows first-order kinetics and is probably the result of continual 
uptake of droplets of circulating plasma into cells by pinocytosis. The 
free amino acids produced by complete digestion of the protein mix with the 
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amino acid pool of the tissues concerned before entering the circulating 
p:::. :~:·.::·:cr, the factors that regulate the degredation of serum proteins 
are unknown and no specific organ has been identified which is predominantly 
responsible for albumin breakdown. 
Albumin is synthesized almost exclusively by the liver. Of the many 
factors influencing albumin synthesis, the most important appears to be 
adequate nut\rition, or more specifica11y~ the supply of amino acids at the 
sites of synthesis. Albumin production increases very rapidly after each 
protein-containing meal. Nonetheless, negative feedback processes tend to 
regulate albumin synthesis. Thus, the circulating albumin level and the 
colloid osmotic pressure contribute to homeostasis •. ' Albumin synthesis is 
also affected by the total hormonal balance (Kernoff, 1971). It appears 
that albumin is synthesized as a precursor form called proa1bumin which 
contujns a small additional peptide segment (Quinn et a1 1975). Further 
information on the biosynthesis of albumin is contained in the revie\~ by 
Peters (1977). 
Aside from its physiological interactions with numerous 
endogenous 1igands, human serum albumin makes the predominant contribution 
to the plasma protein binding of drugs and other exogenous ligands 
including metals (Pedersen, 1981; Perrin, 1982; Lau et al, 1979), 
surfactants (Sukow et a1 1980), dyes (Meyer and Guttman, 1968), insecticides 
(Fang, 1980) and pesticides (Maliwal and Guthrie, 1983). On the other 
hand, in cases of severe albumin deficiency such as analbuminemia, other 
plasma proteins appear to compensate partly for the deficiency by serving 
a significant transport role for endogenous and exogenous 1igands 
(Frohlich et al, 1981). Nevertheless, Bridges and Wi1son (1973) have 
suggested that \~ith the exception of cytochrome P-450, albumin is probably 
unique in its capacity for binding 1igands of diverse chemical and physical 
properties. The physiochemical and structural properties of albumin which 
allow it to bind such a wide range of compounds are reviewed in the next 
section. . 
Human serum albumin is clearly not the only circulating plasma 
protein involved 1n drug binding. For a certain class of drugs, a,-acid 
glycoprotein and not albumin is the major binding protein in plasma. It 
is also well-known that some drugs can bind to 1ipoproteins. 
ai-acid glycoprotein (orosomucoid) is a globulin present in normal 
human plasma. The structure and properties of this protein have been 
reviewed in detail by Schmid (1975). From this report it is clear that 
a,-acid glycoprotein has several features which allow it to be 
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distinguished from the other plasma proteins. For example, it has a very 
high carbohydrate content amounting to about 55% of its weight. In fact 
the carbohydrate moiety of a,-acid glycoprotein accounts for about 10% 
of the protein bound carbohydrate of normal plasma. a,-acid glycoprotein 
exhibits a significant degree of homology with the immunoglobulins. 
Furthermore, Schmid et al (1973) have shown that there are multiple amino 
acid substitutions of a,-acid glycoprotein, a property shared as far as is 
known only by the immunoglobulins. 
a,-acid glycoprotein is synthesized in the liver.and the half-
life of this 1I'-globulin is about 5 days. Plasma levels of a,-acid 
glycoprotein are rather low showing a normal mean level of 90mg/100ml with 
a normal range of 55-~40mg/100ml (Putnam, 1975). However, as discussed 
in Section 1.2.2,· a,-acid glycoprotein is an acute phase reactant and 
increased blood levels are associated \~ith induced inflammation, pregnancy 
and various unrelated disease states including cancer, pneumonia and 
rheumatoid arthritis. In addition, normal individuals who undergo a major 
operation will also produce an increased plasma concentration of ai-acid 
glycoprotein. The physiological role of a,-acid glycoprotein remains to be 
elucidated, but the parameter common to the above states, namely cell 
proliferation, is kno~ to effect an increasing synthesis ofa,-acid 
glycoprotein in the liver. As this protein has been found to be homologous 
to the immunoglobulins, it is conceivable that higher concentrations are 
required to protect the increased cell population. Other observations 
pertaining to the possible biological function of a,-acid glycoprctein 
suggest that it may influence blood clotting, have a minor role in binding 
some steroids and be involved in the formation of striated collagen. 
The plasma lipoproteins constitute an extremely heterogeneous 
group of compounds and contain variable proportions of lipid, protein and 
carbohydrate. The protein content varies from as low as 2% in the 
c~omicrons to a high of only about 50% in the high density lipoprotein 
(HOl) class. 
0- The lipoproteins are normally separated into classes that are 
characterized by their flotation rates: c~lomicrons, very low density 
lipoproteins (VlOl), low density lipoproteins (lOl), high density 
lipoproteins (HOL), and very high density lipoproteins (VHOL). Since the 
interactions of the lipid and protein components are noncovalent and the 
classes are heterogeneous, the term molecul ar ~Ieight does not have true 
meaning. However, the majority of lipoproteins present in serum are in 
the range 200,000 to 10,000,000 daltons. 
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The major biological function of circulating lipoproteins is the 
transport of lipids. The complex lipoprotein system ensures the transport 
of a remarkably heterogeneous group of lipids which include unesterified 
fatty acids, mono-, di- and triglycerides, various phospholipids, 
cholesterol, and other minor components such as hydrocarbons and glycolipids 
(Scanu et al, 1975). The solubilization of otherwise water unsoluble 
substances by lipoproteins is the basis of many fundamental metabolic 
mechanisms occurring in vivo. 
Both the liver and intestinal mucosa are capable of serum 
lipoprotein synthesis. Normal serum lipoprotein concentrations range from 
about 200 to 700mg/100ml and are influenced by age, sex and diet 
(Romach et a1, 1981). 
The~, S and ~ globulins are an important group of binding proteins 
in serum. Several a and S globulin have a high affinity, but relatively 
low capacity, for a number of endogenous substances and chemically related 
synthetic compounds. For most drugs though, binding to these proteins is 
negligible. The metal containing globulins, transferrin and ceruloplasmin 
interact strongly with iron and copper respectively and have an essential 
biological function in the transport of these ions. Binding globulins 
have also been identified for other endogenous compounds induding 
corticosteroids, testosterone, oestradiol, progesterone, thyroxine and 
several vitamins. The plasma ~ globulins probably do not interact 
significantly with drugs except where they occur as specific antibodies 
to them. 
a -fetoprotein (AFP) is a serum protein made and secreted by the 
fetal liver and yolk sac of all mammals so far studied. The serum 
concentration of AFP decreases rapidly during fetal development to a 
residual level in adulthood but rises again in individuals with hepatomas 
or germ-cell tumours. Elevation of AFP levels is also observed in a 
variety of pathological conditions and in certain human fetal malformations 
such as neural tube defects. The exact function of AFP is unclear, 
although similar biological and PhYS~Chemica1 properties suggest that it 
may be the fetal counterpart of adult serum albumin. Recently, Law et al 
(1981) have shown that the amino acid sequence and primary structure of 
AFP reveals extensive homology to serum albumin. AFP is known to bind 
estradio1 (Grigorova et a1, 1980), but the drug-binding capability of this 
protein remains to be established; it is a prime candidate for future study. 
Having considered the major binding proteins in serum and 
examined their biological functions it is pertinent to discuss the manner 
in which bound drugs are distributed between the various serum components. 
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An appreciation of the ability of albumin to bind a large number 
of acidic and non-acidic drugs may be obtained from the comprehensive 
tabular summaries of Meyer and Guttman (1968) and Jusko and Gretch (1975). 
Numerous studies have demonstrated the high affinity binding of anionic 
drugs to HSA, and it is generally believed that at therapeutic levels of 
these drugs, albumin represents the major binding protein in plasma 
(Tillement et al, 1982). For the majority of drugs therefore, it appears 
that the binding to serum albumin is quantitatively by far the most 
important and often accounts for almost the entire drug binding in plasma. 
Recently, however, sufficient evidence has accumulated to suggest 
that the blood binding of basic (cationic) drugs differs from that of 
acidic compounds; while albumin is the major binding protein for the latter, 
many basic drugs exhibit only a moderate affinity for albumin and bind 
more avidly to other blood components such as ~-acid glycoprotein and 
1ipoproteins (Glasson et a1, 1979 Brinkschu1te et al, 1981 Romach et a1 
1981). Meu1dermans et a1 (1982) have considered the possible contribution 
of red blood cells as well as a.-acid glycoprotein and lipoproteins to the 
binding of basic drugs in blood. For cationic drugs the protein bound 
fraction in plasma is clearly a heterogeneous one. 
The widely held belief that albumin can account for almost all 
the anionic drug binding in plasma has, nonetheless, been challenged 
some\~hat by the recent findings of Urien et a1 (1982). These authors 
present evidence for the binding of certain acidic drugs to aa-acid 
glycoprotein. Although et, -acid glycoprotein is present in plasma in far 
lower concentrations than is human serum albumin, the association constants 
of some acidic drugs with ~ -acid glycoprotein are high enough to suggest 
that binding to ai-acid glycoprotein will contribute significantly to the 
plasma bound fraction of these drugs (Urien et al, 1982). 
Up to now, the binding of drugs to erythrocytes and other cell 
components appears to have received little attention. The ability of 
organic bases to penetrate and associate with red blood cells has been 
known for many years; more recently it has been shown that a number of 
basic drugs bind to red blood cell membranes and their contents (Piafsky, 
1980). Although the amount of bound drug is usually small, it should 
not be ignored and on occasion the binding to blood cells can even exceed 
that to plasma proteins (Ehrnebo et al, 1974). 
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1.3.2 Binding of Drugs to Tissues and Extravascular Proteins 
The binding of drugs to blood components has been extensively 
studied primarily because the blood is readily accesible to sampling, can 
be easily separated into its constituent macromolecules, and is amenable 
to quantitative analysis. Tissue binding studies have none of these 
advantages and so despite its clinical significance, the binding of drugs 
to tissue components has received only limited attention. Kurz and 
Fichtl (1983) have summarized the methodological problems associated 11ith 
tissue binding studies; thi's review also covers the current evidence for 
the binding of drugs to constituents of muscle, kidney, liver and lung 
tissue. 
60 to 65% of the exchangeable albumin pool is located in 
extraplasma sites, notably in the skin and muscle. Consequently, not only 
does albumin have a major role in the binding of drugs in the blood, but 
it is the principle drug binding protein in tissues. However, a number 
of other substances have been found to be involved with the uptake of 
drugs by tissues. For example, it appears that drug binding proteins in the 
cytoplasm of hepatocytes may hasten metabolism by increasing the amount of 
drug available to the enzyrres located tCMards the centre of the cells. 
Two hepatic cytoplasmic proteins called Y and Z proteins have been isolated 
and are knol'/O to bind a number of endogenous and exogenous substances. 
Y protein or ligandin has been shown to be a major determinant of the 
selective hepatic uptake of a number of small anions and may influence the 
flux of metabo1ites from the liver to the plasma or bile. Z protein 
appears to bind the fluorescent dye ANS (Sugiyama et a1, 1980). It is 
likely that a number of specific and nonspecific cellular binding proteins 
will be isolated and characterized in the future and this should lead to 
a better understanding of tissue-binding phenomena. 
Many drugs bind to microsomal components, particularly to 
cytochrome P450 (Bridges and Wi1son, 1976). A number of drugs whose 
structures are planar combine with DNA by intercalation between the base 
pai rs. Dabrowiak (19B3) has recently outlined methods which can be used 
to examine the specificity of drug-DNA interactions and includes a survey 
of the sequence speCifications of several small 1igands which interact 
with DNA. Some planar aromatic drugs are concentrated in the pigmented 
structures of the eye; melanin is probably responsible for thp binding of 
these drugs. The binding of drugs to lysozyme, one of the major proteins 
in human tears has been demonstrated by El Nimr et a1 (1981). Other tissue 
components which can bind drugs include calcified materials such as bone 
- 32 -
and teeth. 
;\ur LOll" Fi chtl (19B3) suggest that in general the binding of 
drugs to tissues is governed by similar mechanisms in all tissue and 
exhibits a lower degree of specificity than does plasma protein binding. 
1.4 Human Serum Albumin and the Nature of its Drug Binding Sites 
1.4.1 The Molecular Structure and Physiochemical Properties of HSA 
As the simplest plasma protein to prepare in a relatively pure form, 
albumin has been known for over a century. The term albumin was originally 
used to designate a group of plasma proteins with certain solubility 
characteristics. Serum proteins were separated into two fractions, 
albumin and globulin, according to solubility. With the advent of 
el~r+~n~~n~~~is in the 1940s, it was found that one electrophoretic 
fraction produced the most conspicuous peak and accounted for at least 
95% of the protein in the albumin fraction, whereas globulin turned out 
to be a highly complex mixture of proteins. The protein of this peak 
was called serum albumin (or plasma albumin). A detailed historical 
perspective of the development of methods for isolating and purifying serum 
albumin is included in the review by Peters (1975). 
Although purified preparations of albumin are now widely available, 
a microheterogeneity is present even in the albumin of a single donor. 
Polymorphism of a donor population is clearly not the cause. Removal of 
tightly bound fatty acids decreases but does not eliminate this 
microheterogeneity. Intramolecular disulphide bond interchange (Sogami 
et al, 1969) or the modification of circulating molecules such as 
acetylation of e: -amino groups by aspirin are more likely explanations for 
the observed heterogeneity. The drug or metabo1ite induced heterogeneity 
of albumin produces variants which have been called bisalbumins (Scheur1en, 
1955). There is no reason to suspect that the plasma of a normal 
individual contains albumin species differing in amino acid sequence, 
although very occasionally inherited albumin variants or alloalbumins have 
been detected in the serum of clinically healthy subjects (Giu1iani et a1, 
19B1). The inherent heterogeneity of albumin preparations and the variation 
between commercially available . samples helps to explain why many aspects 
of albumin structure remained obscure for so long. 
It is now firmly established that albumin is an example of a 
sim~le protein, that is, one consisting only of amino acid residues. 
Albumin alone among the major plasma proteins contains no carbo~ydrate. 
Fatty acids that are present are bound tightly but not covalent1y. The 
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amino acid compositions in terms of residues per molecule of albumin have 
btt" ':'~~ci·";jned for several mammalian albumins and show characteristic 
features. The high levels of glutamic and aspartic acids and lysine are 
consistent with the polarity of albumins. In comparison to most other 
proteins the cystine contents are high. whereas tryptophan. methionine. 
isoleucine and glycine levels are low. 
The major impetus for much recent work on albumin stems from the 
elucidation of the complete amino acid sequences of bovine and human serum 
albumins. These are the considerable achievements of Brown and co-workers 
(Brown. 1975; Behrens et al 1975). Meloun and co-workers (Meloun et al. 
1975). and others. Minor divergences have existed. but it now seems 
probable that the final sequence of the human protein i$ as shown in 
Figure 1.4. The primary structure deduced from the disuiphide bridging 
pattern was proposed by Brown (1974). The model produces a unique pattern 
of nine double loops held together by disulphide bridges (Figure 1.4). 
The existence of the independent double loops was confirmed by the 
isolation of various peptide fragments without rupturing disulphide bridges. 
It has been estimated that the secondary structure of human serum 
albumin contains 45 to 50% a helix (Sogami and Forster. 1968). about 15% 
S-pleated sheet (Reed et al. 1975). and the remainder random coil. 
McLachlan and Walker (1978) on the other hand have calculated probabilities 
of helix structure throughout the amino acid sequence of albumin and 
estimate that there is probably 75% or more of helix. and little. if any. 
S sheet. 
The tertiary structure of albumin is also a matter of some 
conjecture. According to hydrodynamic studies. bovine albumin at pH 5 to 
• 8 is a prolate ellipsoid with major and minor axes of 140 and 40A. Within 
this shell the tertiary structure is discernible only by inference. since 
X-ray crystallographic studies of the configuration of albumin are in their 
infancy. One can assume that strong associative forces between some of the 
loops of the peptide chain are responsible for the compact molecule 
observed at neutral pH. It is also likely that association of the loops 
forms globular regions or domains. A model showing a linear arrangement 
of such domains with transverse clefts has been proposed by Anderson and 
Weber (1969) in order to satisfy their observations on the polarity of the 
fluorescence of complexes with ANS. 
Peters (1975) has discussed the grouping of the double loops of 
the albumin peptide chain into domains. Arrangements are of necar;ity 
based on the rapid cleavage of the connecting link. 3-4. by trypsin and 
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FIGURE 1.4 Amino Acid Sequence and 9-Double-loop Structure of Human 
Serum A lbumi n 
Dotted lines signify a possible arrangement of the double 
loops of the peptide chain into domains. 
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by pepsin, and on the fact that loops 3 and 4 each have a net positive 
charge which would tend to repel one from the other. Loops 7-8-9 are 
suggested as a second domain; the long connecting link 6-7 is particularly 
susceptible to attack by both trysin and pepsin, and loop 7-8-9 can be 
isolated as an intact fragment which retains a fatty acid-binding site. 
The split between loop 6 and loop 5 rests on more tentative evidence -
the high net negative charges of loops 5 and 6 and the cleavage of link 
5-6 by pepsin at pH 3.7 and subtilisin at pH 9 in the presence of a 
denaturant. Under these conditions changes in charge distribution may 
have altered the protein structure. The final, tentative subdivision of 
the molecule is into domains of loops 1-2-3, 4-5, 6 and 7-8-9; the 
division between 4-5 and 6 is the least clearly defined of the three. 
Brown (1978) has put forward a slightly different model for the 
tertiary structure of albumin. In this case the albumin molecule is seen 
as consisting of three linearly arranged globular elements, or domains, of 
loops 1-2-3, 4-5-6, and 7-8-9. The strong homologies in the amino acid 
sequences of these domains has led Brown to propose that they 'form similar 
three-dimensional folding-patterns. It is suggested that each domain 
consists of six tl-helices (three double loops) forming a cylindrical 
structure; the albumin molecule is then visualized as an association of the 
three cylindrical domains. The suggestion that albumin is composed of 
three domains is supported by low angle X-ray scattering studies 
(Bloomfield, 1966). 
Other mammalian species and lower animals have proteins with 
similar structures and properties to those of HSA. The amino acid 
compositions of mammalian albumins exhibit many common features and these 
proteins tend to cross react serologically. Immunochemical relationships 
have helped to define evolutionary differences: work on the phylogenetic 
origins of albumin has been reviewed by Peters (1975). The repeating 
double loop structure of albumin and the presence of recurrent amino acid 
sequences in the different loops has led to proposed evolutionary pathways 
for albumins. (McLachlan and Walker, 1977). It appears that the modern 
protein probably descended from a primative albumin consisting of a single 
double-loop structure by a train of gene duplication and depletion. 
Despite their probable common ancestry, albumins from different 
species have been found to exhibit marked variations in their capacities 
for binding drugs (Genazzani and Pagnini, 1963; Seller et al, 1977). 
Albumin has been a model protein for physical chemists. A 
selection of the most important physiochemical data has been tabulated by 
Peters (1975). Steinhardt et al (1971) have reviewed the major differences 
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bet~Een the physical, chemical and spectroscopic properties of bovine and 
human serum albumins. It is possible to reconcile many of the properties 
of albumin with its amino acid sequence and structure. 
Albumin is characterized ~y its high solubility, total charg~, 
net negative charge, stability and flexibility, and by its ability to bind 
a diverse range of endoganous and exogenous ligands. The flexibility or 
'conformational adaptability' of the albumin molecule can be explained by 
the proposed loop-link pattern of Figure 1.4. 
The more than 200 posi ti ve and negative charges distributed over 
the molecule give albumin a hydrophilic character and contribute to its 
high solubility in aqueous media. The titraticn curve in the pH range 
2-12 can be closely reconstructed as a composite of the ionizab1e groups 
of the constituent amino acid residues. Albumin is a strong buffer at 
pH 4 and pH 10 but a weak buffer at pH 7. The isoionic point of HSA is 
near pH 5.2 and is close to the pH at which all basic groups are protonated 
and carboxyl groups are still negatively charged. Hence the isoionic point 
of albumin is also the pH of maximum total charge with about 100 positive 
and 100 negative charges. At plasma pH 7.4 albumin has a net negative 
charge of 18 but, as discussed in the next section, it can nevertheless 
interact strongly at this pH with anions as well as cations. 
In the pH range from 2 to 4, ultracentrifugation, viscosity and 
diffusion measurements indicate that the albumin molecule expands, becoming 
larger and more asymmetric. The helical structure decreases (Wa11evik, 
1973) and the molecule unfolds so that interior regions become accessible; 
ab cut 150 additional hydrogen atoms exc~ange D20 and more tyrosine residues 
becomp. exposed to the solvent. With exposure of hydrophobic regions, the 
molecule becomes less soluble in aqueous solutions. 
The hydrogen-ion dependent transitions in the acid pH range can 
be divided into'two regions, the exact limits being contingent upon 
temperature (Wa11evik, 1973). The major reversible change in the 
conformation of the albumin molecule which occurs between pH 3.8 and 5.0 
has been attributed by Foster (1960) to a transition from a normal or N 
form to a species with faster electrophoretic mobility called the F-form. 
The normal-fast, or N-F, transition represents an unfolding of the albumin 
molecule as the pH is reduced. The second stage of the transition is the 
acid expansion ~/hich occurs between pH 2.6 and 3.8. From about pH 2.0 to 
2.5 the albumin conformation is independent of pH and corresponds to the 
acid-expanded form of the molecule. The expansion of albumin in acid 
probably begins as a separation of domains such as those described above. 
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The full expansion of the molecule in highly acidic media can be pictured 
as a dissociation of individual loops of the peptide chain into a long 
viscous molecule. 
In the region of pH from 5 to 7 the albumin molecule does not seem 
to undergo major changes of conformation. A limited change, the neutra1-
base, or N-B, transformation takes place about pH 7 to 8 and is characterized 
by a small net loSs of a helical structure (Wa11evik, 1973). Kremer et al 
(1982) have described the effect of the N-B transition on the kinetics of 
the binding of warfarin to human serum albumin. 
On the alkaline side of neutrality, beginning about pH 9,.a less 
well-characterized isomerization has been detected by electrophoresis. 
A slo~1 process of aging takes place when albumin is stored in mildly 
alkaline solutiDns resulting in the A form (Nickel and Foster, 1971). 
The process is probably a rearrangement of intramolecular disulphide bonds, 
catalysed by the single, free sulphydryl group of the protein (Stroupe and 
Foster, 1973). A more extensive unfolding of the albumin molecule takes 
place in a narrow interval of pH between 11.2 and 12.0. 
In contrast to the pH-dependent transitions of HSA, the thermal 
unfolding of albumin appears to involve broad, continuous transitions with 
no detectable intermediate stages. Thermal transitions may represent the 
sum of simultaneous but more or less independent unfo1dings of different 
regions of the molecule (Wal1evik, 1973). 
The spectroscopic properties of albumin have been examined in 
detail by a number of authors (Steinhardt et al, 1971; Longworth, 1981: 
Waldmeyer et a1, 1982) and Dale (1975) has reviewed the more general 
aspects of protein luminescence. Ultraviolet absorption spectra of 
albumins are quantitatively similar to those of other simple proteins, but 
the absorption near 280nm is lower due to the low tryptophan content of 
albumins. Human albumin with one tryptophan has an absorptivity about 20% 
less than that of bovine albumin which has two. If albumin is excited at 
ab~ut 280nm, the fluorescence contains contributions from both tyrosine 
and tryptophan residues. The tryptophan fluorescence originates not only 
from direct excitation by the incident radiation but also from tryptophan 
residues which have been excited by radiation1ess energy transfer from 
tyrosine side chains. However, if the exciting wavelength is increased 
to between 295nm and 305nm, all of the tryptophan emission is the result 
of direct excitativn by the incident radiation; under these conditions 
tyrosine does not absorb radiation and so neither emits nor transfers energy. 
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The structural and physiochemical properties of HSA underline 
its urllqut! allility to bind and transport a diverse range of small molecules. 
Changes induced in the physical and chemical properties of albumin by the 
binding of small molecules provide a means for studying ligand-albumin 
interactions. Current theories concerning the major drug-binding sites on 
HSA are considered in the next section and experimental methods are 
reviewed in Section 1.5. 
1.4.2 The Location of the Major Drug-Binding Sites of HSA 
- Literally hundreds of in vitro studies have supplied information 
on the binding of drugs to human serum albumin. The purpose of this revie\~ 
is to examine the methodolgies employed, and to highlight some of the 
more recent attempts to rationalize the accumulated data in terms of 
the binding process at the molecular level. 
It is now generally accepted that there are only a small number 
of high affinity drug-binding sites on HSA (Meyer and Guttman, 1958). 
Many drugs appear to compete for common sites on the albumin molecule and 
much recent work has been concerned with the identification and classification 
of the specific drug binding sites. 
Two specific sites for acidic drugs have been characterized using 
fluorescent probe techniques by Sudlow et al (1975) and were designated 
sites I and 11. Site I is the ~Iarfarin binding site, and \~arfarin and 
5-dimethylaminonaphthalene 1 sulphonamide (DNSA) were used .as selective 
fluorescent probes for this binding site. Site II ~Ias labelled with the 
fluorescent probe dansylsarcosine. By observing the competitive 
displacement of these fluorescent probes, Sudlow et al (1975) were able to 
associate a number of drugs ~lith either one or both of the specific 
binding sites on HSA. 
In a similar manner MUller and Wollert (1975) used tritiated 
L-tryptophan as a marker for a single binding site on human serum albumin. 
Sudlow et al (1975) gave some evidence for a third drug-bindiny 
site on HSA but could not find a specific ligand for it. Sjaholm et al 
(1979) used \~arfarin and diazepam as markers for two specific drug-binding 
sites and proposed that digitoxin binds to a third high affinity site on 
albumin. 
Goya et al (1982) have synthesized a fluorescent probe which is 
displaced from its primary binding site on HSA by digitoxin. Furthermore, 
site 1 and site 11 drugs on the basis of Sudlow's classification do not 
significantly displace the fluorescent probe. The results of Goya et al 
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(1982) clearly support the suggestion of Sjeholm et al (1979) that the 
di\jlwxln binding site is independent of the drug binding sites I and II. 
Wanwimolruk and Birkett (1982) have demonstrated that the N-B 
transition of albumin provides a further distinction between site I and 
site 11 binding characteristics. The N-B transition of HSA involves a 
change in conformation at site I \~hich results in the increased binding of 
drugs and fluorescent probes at this site, whereas there is no corresponding 
effect on acidic drug binding at site 11. 
On the other hand, Bruderlein and Bernstein (1979) suggest that 
the distinctions betWeen sites I and 11 are not clear-cut. They used the 
fluorescent probes DNSA and dansylsarcosine to investigate the location of 
the L-tryptophan receptor site on HSA in relation to the established drug 
binding sites I and 11. Their observation that L-~ptophan has a single 
binding site on albumin but displaced both probes in an apparently 
competitive fashion led them to conclude that sites I and 11 may be 
overl apping. 
Based on a comprehensive survey of competitive binding results in 
the literature, Kragh-Hansen (1981) has proposed that there are at least 
six binding regions on the albumin molecule. A summary of the proposal is 
given in Table 1.1. It is suggested that binding region nunbers 1, 4 and 
probably 5 are very specific, \~hereas binding regions numbers 2, 3 and 6 
seem to be less specific and capable of high-affinity interactions with 
several different ligands. Although only one of these binding regions has 
been allocated to drugs, the author concedes that there are probably other 
important drug binding sites on the albumin molecule. However, in this 
revi ew (Kragh-Hansen, 1981) and in a subsequent paper (Kragh-Hansen, 1983), 
caution is stressed in the interpretation of competitive binding results. 
For example, before assignment of the high-affinity binding sites of two 
different ligands to the same binding region of the protein, it is 
essential to determine whether an apparent decrease in the binding of one 
of the ligands,caused by the simultaneous addition of the other ligand, is 
the result of direct competition or of some other effect: the latter may 
arise when conformational changes of the drug-albumin complex are induced 
by the binding of the second ligand to another region of the protein, or 
when, in a fluorimetric study, the fluorescence of a probe molecule is 
reduced through energy transfer to a second bound ligand. (Some further 
modulatory effects are considered later). Another complicating factor is 
that ligands are usually bound not only to one or two high affinity sites 
but to a greater number of low affinity binding sites. 
Binding Region or Site 
1 
2 
3 
4 
5 
6 
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Ligand Bound With High Affinity 
Long chain fatty acids 
L-thyroxi ne 
L- and D-tryptophan 
Octanoate 
Chlorazepate 
p-iodobenzoate 
Chl ori de ion 
Bil irubin 
Certain dyes (eg. phenolsulphonphthalein 
dyes) 
Iopanoate 
Cu2+ and N~+ ions 
Haemin 
Sali cyl ate 
Sulphaethidole 
Sulphathiazole 
Chlorpropamide 
To 1 butami de 
Indomethaci n 
TABLE 1.1 A Scheme for Binding Regions Located on Serum Albumin 
(From Kragh - Hansen, 1981;1983). 
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An important aspect of the characterization of specific binding 
sites on HSA is the identification of the amino acid residues which line 
the binding regions. This information is useful in testing the validity 
of the common site models derived from competitive binding studies, and 
leads to a better understanding of the structural requirements for the 
binding of ligands to specific regions of t~e albumin molecule. 
A recognized approach is to modify certain amino acid residues 
of the protein by reactive compounds and to compare the ligand binding 
properties of the modified and native albumin. Such studies can be 
supplemented by a sequence analysis to determine the position of the 
covalently attached modifier. Unfortunately, there are a number of inherent 
difficulties in the chemical modification technique. The reagent is 
seldom specific and so more than one kind of amino acid residue may be 
modified. Conformational changes are often induced in the protein molecule 
during the labelling procedure, although these can be minimized by a 
careful control of the experimental conditions. A specific labelling of 
t:,e hydrophobic amino acids of albumin (except for tryptophanyl and 
cysteinyl) has not been achieved but a knowledge of the amino acid 
sequence of the molecule may permit an assignment of the identity and 
positions of the hydrophobic residues in the vicinity of the binding regions. 
Since the finding that acetylsalicylic acid specifically acetylates only 
one ly&ine of HSA (Hawkins et al, 1968), many other amino acids of HSA have 
been more or less specifically modified, for example, the lone 
tryptophan residue (Fehske et al, 1978), the lone cysteine residue 
(Walker, 1976), the highly reactive tyrosine residue (Fehske et al, 1979) 
and lysine, histidine and arginine residues sensitive to different reagents. 
The binding of site specific ligands to the modified albumin derivatives 
clearly indicates whether or not the modified amino acid residues 
participate in the binding sites. 
Anot'ler approach is to cleave the albumin molecule into definite 
fragments using reagents such as cyanogen bromide, trypsin and pepsin. 
The binding of drugs to isolated fragments has been used to localize 
specific binding sites. Again, nowever, the secondary and tertiary 
structure of the fragments may differ from that of the same sequence in the 
native protein. Thus, it can be difficult to decide whether the failure 
to find binding to a particular fragment depends on the location of the 
binding site in another part of the molecule or on the destruction of the 
binding site due to conformational changes in the fragment under 
investigation. 
- 42 -
Perhaps the most advanced approach to localize a binding site 
might be to synthesize peptide analogues. Lakusta and Sarkar (1979) 
and Sankaranarayana Iyer et al (1978) have achieved this for the divalent 
metal ion binding site which is located at the amino terminus of HSA. As 
yet, no drug-binding sites have been constructed in this way. 
Despite the difficulties, biochemical techniques such as those 
outlined above, have supplied useful information on the structure and amino 
acid composition of drug-binding sites on HSA, and on the location of these 
sites within the secondary and tertiary structure of the protein. Much of 
the recent work has been summarized by Fehske et al (1981). 
Probably the best characterized binding site of HSA is the 
indole and benzodiazepine binding site (MUller and Wollert, 1979) called 
site II by Sudlow et al (1975). This site binds several indole derivatives 
and benzodiazepires with a high degree of structural specificity. The 
interaction of tryptophan with HSA is an outstanding example of stereospecific 
binding. Specific markers for this site are L-tryptophan (MUller and Wollert, 
1975), diazepam (SjBholm et al, 1979), dansylsarcosine (Sudlo\~ et al, 1975) 
and iopanoic acid (Mudge et al, 1978). Many other drugs of very different 
chemical structures also bind to the indole and benzodiazepine binding site 
with high affinity (SjBholm et al, 1979). 
Contradictory evidence exists for the localization of this specific 
binding site within the HSA molecule and for the amino acids involved. 
Since hydrophobic forces seem to be important for the binding of indoles 
and benzodiazepines, participation of lipophilic amino acid residues is 
very likely. Among the three lipophilic arorr,atic amino acid residues 
tryptophan, tyrosine and phenylalanine, the lone tryptophan residue was, 
until relatively recently, the most likely candidate as an important part 
of the indole binding site of HSA (Gambhir and McMenamy, 1973 Swaney and 
Klotz, 1970). However, using a specific modification by 2-hydroxy-5 
nitrobenzlbromide, Fehske et al (1978) have demonstrated that the lone 
tryptophan of HSA is not directly involved in the indole and benzodiazepine 
binding site. 
Fragw~nts of HSA have been investigated with respect to the 
position of the indole bindin~ site. The major locus f~r the indole 
binding site in HSA occurs in cyanogen bromide fragment C (residues 124-
298) as concl uded from the binding of L-tryptophan and di azepam (Garr,bhir 
and Mc~lenamy, 1973 Sj6holm and Ljungstedt, 1973). Part of the binding 
site may also be located in fragment A (residues 299-585) which binds both 
marker ligands, although to a much smaller extent than fragment C. The 
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third major cyanogen bromide fragment, called fragment B (residues 
1-123) does not bind L-tryptophan and diazepam. 
Within fragment C, His 146 and Lys 194 have been shown to be 
involved in the specific indole and benzodiazepine binding to HSA 
(Roosdorp et a1, 1977) the most important is probably Arg 145 (Fehske, 1981). 
It is interesting to note that the amino acid sequence in .the vicinity of 
His 146 and Arg 145 contains lipophilic residues (Tyr 138, 140, 148, 150) 
and cationic charged residues, which provides a favourable environment for 
the binding of small organic anions. 
Employing a selective chemical modification procedure, Fehske et a1 
(1979) tested the hypothesis that tyrosine residues participate in the 
specific indole binding site. A single highly reactive tyrosine residue of 
HSA was shown to be part of the indole and benzodiazepine binding site. 
Although the authors suggested that the highly reactive residue could be 
one of the four tyrosines in the vicinity of Arg 145, it is no\~ established 
that this tyrosine is Tyr 411 (Means and Wu, 1979 Fehske et a1, 1980) and 
so located within fragment A not fragment C. Sj~din et a1 (1977) isolated 
a trypsin-resistant fragment of HSA (residues 182-585) which retained 
diazepam binding properties. The highly reactive tyrosine (Tyr 411) and 
Lys 194 are located within this fragment, but His 141 and Arg 145 are not. 
The data are definitely not consistent with previous assumptions 
that the indole and benzodiazepine binding sites can be located on a single 
amino. acid sequence of the HSA primary structure. Rather it seems that 
sequences and amino acid residues of very different parts of the albumin 
primary structure are involved in this site. This is an agreement with the 
original hypothesis of Gambhir and McMenall',y, 1973 that thei·l'ldo1e binding 
site is located between fragments A and C as they exist in native albumin. 
Accordingly, the indole and benzodiazepine site must be finally formed by 
the HSA terti ary strutture. 
The location of the warfarin binding site,or site I of·HSA is, 
probably less well-defined than that of the indole and benzodiazepine binding 
site. From the work of Sjoho1m and Ljungstedt (1973), at least one part of 
the warfarin binding site seems to be located in fragment C (residues 124-
298). The only amino acid residue clearly involved in the warfarir, binding 
site is the lone tryptophan residue of HSA, trp 213 (Swaney and K10tz, 1970)·. 
The amino acid sequence in the neighbourhood of the lone tryp~ophan .is . 
striking in having a cluster of apolar residues. A1 a-Trp-A1a-Va1-A1a , 
bracketed by two cationic residues, Lys and Arg. Swaney and K10tz (1970) 
suggest that this is a particularly appropriate environment for interactions 
with a small organic anion. 
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r10dification of the lone tryptophan residue by two different 
rea!:len~, lidS been shown to reduce the binding of warfarin to its specific 
high-affinity binding site on HSA (Fehske et al, 1979). while the 
modi ficati on of tyros ine resi dues has very 1 i ttl e effect. The 1 ocati on of 
the tryptophan residue within the warfarin binding site has also been 
demonstrated by spectroscopic measurements (Chignell, 1970). 
In large contrast to the above findings are recent observations 
that the tryptophan modification do~s not affect the binding of 
phenylbutazone and azopropazone even though both of these drugs readily 
displace I,.'arfarin from its albumin binding sites. These observations have 
led Fehske et al (1982) to propose that the warfarin binding site is 
actually a larger binding area consisting of the overlapping subsites of 
warfarin and azopropazone. The lone tryptophan residue of HSA, previously 
estaOllsneo as part of the warfarin binding site, could be located in the 
non-overlapping part of the warfarin sUbsite so that its modification 
affects only the binding of drugs to the warfarin and not to the azopropazone 
subsite of this large binding area. In general, it appears that drugs 
interacting wi th one of the two subs i tes tlill di spl ace drugs bound to tile 
other subsite, although the degree of displacement for both sUbsites may 
vary considerably. 
Unfortunately the role of the tryptophan residue of human serum 
albumin is still not resolved. The latest work in this field (Sakamoto 
et al. 1983) suggests that the tryptophan residue of HSA lies in or near 
the indole and benzodiazepine binding site and not in the primary binding 
site of warfarin anc phenylbutazone. These findings are clearly at odds 
with those of Fehske and colleagues (1978 and 1982). 
The third specific drug binding site of HSA is the digitoxin 
binding site which is clearly independent of both sites I and 11 and binds 
only very fe\~ drugs (Sjtlholm et al, 1979). Little information is available 
about the location of this site. Neither the lone tryptophan nor the 
highly reactive tyrosine seem to be involved, although the modification 
of 9 out of 18 tyrosine residues strongly reduces the binding of 
digitoxin to this site (Fehske et a1, 1981). 
Although fatty acids are not drugs, a discussion of the fatty 
acid binding site will be included in this section; there is evidence to 
suggest that their binding is associated with a reduced or enhanced 
binding of drugs to HSA through both competitive displacement and allosteric 
mechanisms. However, the relationship of the fatty acid binding site to 
other specific binding sites on HSA is still not clear. 
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~'any observations have contributed to the assertion that serum 
alDUllnn Dlnds long and medium chain fatty acids at different sites (Kragh-
Hansen.1981). Demarkations seem to exist between unbranched fatty acids 
of 10 carbon atoms or less and those of 12 carbon atoms or more. Soltys 
and Hsia (1978) used a spin label probe for the bilirubin site and showed 
that fatty acids of chain length less than 10 carbon atoms competively 
displace the spin label from albumin while fatty acids of longer chain 
length enhance the binding of the label allosterically. These results 
support the hypothesis that serum albumin has two distinct sets of 
endogenous binding sites for fatty acids of different chain lengths. This 
phenomenon is of additional interest because fatty acids of different chain 
length appear to have different effects on the binding of drugs to HSA. 
Experimental evidence suggests that the high affinity binding site 
of long chain fatty acids is not identical with the binding sites of other 
organic ligands. but that long chain fatty acids can profoundly influence 
other ligand binding sites on the albumin molecule via allosteric 
mechanisms. Chakrabarti (1978) chose oleic acid as a representative 
long chain fatty acid and demonstrated a cooperative interaction between 
warfarin and the oleate ion for albumin binding. Similarly for site 11. 
the.other major drug binding site of albumin. Sj8din (1977) concludes 
that the displacement of bound diazepam by oleic acid occurs primarily 
through an allosteric mechanism. In contrast. Tstutsumi et al (1975) 
studied the binding of a benzodiazepine derivative to HSA in the presence 
of rather high molar concentrations of laurate over HSA and found a 
significant inhibitory effect on the binding which they suggested vias 
competi ti ve. 
Clearly different from the high affinity binding site of lon~ 
chain fatty acids is the high affinity binding site for medium chain fatty 
aCids. The primary binding site of fatty acids with 10 or fewer carbon 
atoms seems to be identical with the indole and benzodiazepine binding 
site of HSA (Koh and Means. 1979 Sollene and Means. 1979). 5-(dimethyl-
amino)naphthalene-l-sulphonic acid may be a useful fluorescent probe of 
the medium chain fatty acid binding site of serum albumins (Ooody et al. 
1982) • 
Brown et al (1922) have recently presented evidence for the 
existence of distinct albumin binding sites for shcrt chain fatty acids 
(7 or less carbon atoms) and medium chain fatty acids (8 or more carbon 
atoms). Moreover. from these preliminary results it appears that the 
short chain fatty acid site may lie in the same region as the warfarin/ 
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azopropazone binding area of HSA. 
Bilirubin is not a drug but it binds strongly to HSA and merits 
discussion because of its clinical importance (Brodersen, 1979). Althoug:, 
bilirubin has been shown to bind to a number of different fragments of 
HS.o. the evidence for the location of the hig~ affinity binding site is 
contradictory. While the bilirubin binding site is clearly independent 
of the diazepam binding site of HSA. that is, site 11 (Roosdorp et al, 
1977 i Brodersen et al, 1977), its relation to the warfarin binding site 
is not fully understood. Bilirubin reduces the binding of many drugs 
typical of the warfarin bindin~ site (SjBholm et al, 1979) but modification 
of the lone tryptophan of HSA does not affect the binding of bilirubin 
(Jacobsen, 1972). 
While important progress has been made recently concerning the 
possible location of the major ligand binding sites of the albumin molecule, 
the only site which is fully characterized is the metal ion binding site at 
the N-terminal end of the protein. For all other ligand binding sites the 
complete structure and location are not yet known. One reason why this is 
so may be related to the increasing evidence which suggests that quite 
different parts of the albumin primary structure are involved in the binding 
of organic ligands. Thus, it is questionable whether binding sites can be 
located only within one fragment of the HSA amino acid sequence. A more 
complete characterization of binding sites may well depend upon a better 
knowledge of the albumin tertiary structure. A second reason for the lack 
of knowledge about the location of albumin drug binding sites may be that 
some of the binding sites consist of several subsites. The expression 
'binding area' (Fehske et al, 1981) might be a better term for this type 
of binding site. The structure and location of the drug binding sites of 
HSA may therefore be more complicated than previously believed. 
1.4.3 Binding Forces, Structural Reguirements and Theoretical Aspects 
of the Binding of Drugs to HSA 
A fundamental question concerning drug-albumin interactions is the 
nature of t~e binding forces involved. The fact that anionic drugs are 
preferentially bound to HSA suggests some form of electrostatic interaction, 
and at one time the binding of drugs to albumin was attributed to a simple 
e 1 ectrostati c interacti on bet\~een the i oni c form of the drug and a cha rged 
group on the protein. More recent work suggests that while the initial 
attraction and specificity of orientation of a drug molecule towards its 
binding site on albumin may be an electrostatic interaction, it is probably 
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reinforced by hydrophobi c, van der Waa 1 s and hydrogen- bonding. 
Hansch et al (1965) examined the binding of a large number of 
compounds to bovine serum albumin and analysed the data in terms of the 
partition coefficients of the compounds between octanol and water. The 
authors of this much-cited study concluded that the binding \~as rather 
nonspecific and was best described as being due to hydrophobic bonding. 
Several attempts have been made to correlate the binding strengths 
of structurally related sulphonamides with their physiochemical properties. 
These and similar studies have aimed to uncover the nature and relative 
contributions of the binding forces involved in drug-albumin interactions 
and to illustrate the relationship between structural features and binding 
affinities. In an early study of the binding of sulphonamide drugs to 
Dovine serum albumin, i~origuichi et al (1968) concluded that electrostatic 
• forces dominate in the binding of acidic compounds to albumin. Agren et al 
(1971), on the other hand, demonstrated a direct correlation between the 
lipophilicity and albumin binding of 13 sulphonamides to HSA. Hsu et al 
• (1974) investigated the binding of 11 sulphonamide and 7 pen.cillin 
derivatives and showed that the binding affinities of these drugs were 
greatly affected by their side-chain substituents: the binding was enhanced 
by hydrophobic substituents and decreased by hydrophilic substituents on 
the parent molecule. 
Studies have been performed with other classes of drug and many 
are discussed in the papers by Bridges and Wilson (1976) and JuskQ and 
Gretch (1976). Since these reviews, Wojcikowski and Szlabowicz (1977) and 
Goto et al (1978) have shCl.'In that hydrophobic and, to a somewhat lesser 
degree, electrostatic forces are involved in the binding of sulphonylurea 
derivatives to HSA; Judis (1982) has demonstrated that the binding of 
phenol compounds to albumin primarily involves hydrophobic bonds, while 
Otagiri et al (1978) suggest that the bindin~ of four anionic drugs to HSA 
includes considerable contributions from van der l4aals forces and hydrogen-
be>nds. Whereas the vie\', that most of the energy of drug-albumin interactions 
is due to hydrophobic forces may be receiving increasing support, the above 
studies illustrate the problem of data interpretation when more than one 
potential binding force is involved. A recognised complication is that 
estimations of the thermodynamic contributions of hydrophobic groups to 
form a drug-protein complex may sometimes be obscured by the simultaneous 
contribution of the protein molecule due to 'conformational adaptivity' 
(see later). Thus, the relative contributions of electrostatic, 
hydrophobic and other forces to the binding process is still not fully 
establ ished. 
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Similarly, it is not possible to make accurate predictions about 
the albumin properties of a drug simply from a kno\~ledge of its structure. 
However, based on a diverse range of drugs some rough guidelines for the 
effects of substituents on drug-protein binding constants may be discerned. 
These have been summarized by Bridges and Wilson (1976) and include the rule 
that sUbstituents which cause an enhancement of hydrophobicity tend to 
increase binding. Since many drugs are small, aliphatic anions, the 
carboxylic fatty acids have been frequently used in albumin binding studies 
as they provide a convenient homologous series of ligands with similar 
charge but varying chain length and lipophilicity. Indeed chain length 
and hydrophobicity have been suggested as important "determinants of ligand-
albumin binding (Bird and Marshall, 1967). Structure-activity studies have 
shown linear relationships between lipophilicity (octanol/water partition) 
and albumin binding affinity for various ligands including the fatty acids 
(Hansch, 1968). Ho\~ever, the chain length of un branched fatty acids 
appears to affect the location of binding to the albumin molecule (Brown 
et al, 1982) and so binding affinity is not simply related to lipophilicity. 
The particular structural parameters which determine the 
selectivity of drugs for the major drug binding sites on HSA are not yet 
known. Some drugs (dicoumarol, indomethacin, tolbutamide, ethacrynic acid) 
can bind to both sites I and 11, and in certain cases apparently very 
small changes in the chemical structure of drugs can dramatically alter the 
site selectivity (Mudge et al, 1978). Nonetheless, Bruderlein and Bernstein 
(1979) have designated structural requirements for binding at each site. 
Drugs which bind to site II are all aromatic carboxylic acids which are 
largely ionized at physiological pH. The net negative charge is located 
on the COO- group, a\~ay from the nonpolar region. Drugs wl1ich bind to 
site I are also all aromatic acids with a delocalized negative charge 
generally at the centre of a large nonpolar molecule. 
Large numbers of different ligands can bind to albumin, but the 
binding is clearly not nonspecific. As already mentioned, the SUbstitution 
of 1 igands ~Iith relatively simple groups can cause profound changes in 
their binding properties. For example, iopanoate and iophenoxate, which 
differ only by the former having an amino group and the latter a hydroxyl 
group, are bound to different high affinity binding sites of HSA (Mudge 
et al, 1978). In some cases ligand binding to albumin is stereospecific. 
D-tryptophan binds t~ HSA with a binding constant about lOO-fold lower 
than that of L-tryptophan (McMenamY and OnCley, 1958). On the other hand, 
the affinities of d- and 1- warfarin are verr much alike (Brown et al, 
1977). Finally, isomeric compounds may not only have different affinities 
- 49 -
for binding albumin but may even bind to separate sites (Kragh-Hansen, 1981). 
The evidence presented in the previous section shows categorically 
that the actual number of high affinity binding sites of the HSA molecule 
is rather small. In fact only three major drug binding sites have been 
identified and one of these binds only a very limited number of compounds. 
Site I and site 11, on the other hand, are able to bind many drugs of very 
different chemical and parmaco10gica1 properties. The capacity to accommodate 
a wide range of structural forms must be reconciled \~ith the almost 
receptor-like specificity and even sterospecificity exhibited by these 
binding sites. The explanation for this apparent discrepancy may be the 
conformational adaptivity of the albumin binding sites. 
There is now increasing evidence that the binding of 1igands to 
HSA may induce small conformational changes in the environment of the 
binding sites (f4Uller and Wollert, 1979). The N-B transition is a well 
knO\~n pH-dependent conformational change in bovine and human serum albumins 
and may be affected by the binding of ions such as C1-, Ca2+ and !492+ as 
well as H+ (Van der Geisen and Wilting, 1983). Warfarin which has a much 
higher affinity for the B than for the N form can shift the conformational 
equilibrium of albumin to the B state (Janssen et a1, 1981). Ligands may 
therefore induce conformational changes in the albumin tertiary and 
quaternary structures. Lassman and Reitbrock (1982) suggest that the 
observed conformational c~anges in the HSA molecule after the binding of 
~,arfarin may be a necessary process in achieving the high affinity of 
albumin towards anionic drugs. In a study of the bindin~ of a series of 
long chain fatty acids to HSA, Ashbrook et al (1975) concluded that the 
selectivity that albumin contributes to the binding process may be due 
to varying degrees of conformational adaptivity of its binding site as 
the fatty acid increases in length. The reasons why the binding sites of 
HSA can adapt in some cases but not in others (for example, the enantiomers 
of tryptophan) CII"~ not knol1n. The increased stability of the albumin 
molecule when ligand; are reversib1y bound to it may be due to some 
conformational change of the protein (Gumpen et a1, 1979). 
Cooperative and antagonistic binding of 1igands to albumin are 
other manifestations of ligand-induced conformational changes. Weber 
(1975) has speculated that non-competitive mechanisms may more often be 
the rule than the exception in ligand-protein interactions. Madsen and 
E11is (1381) have recently proposed a cooperative mechanism for the 
displacement interaction between warfarin and phenylbutazone and suggest 
that a cooperative viewpoint of displacement phenomena will provide a more 
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stable fraJre"lork for further understanding than continuing amendments to 
tile common-slte model. 
The concept of conformational adaptivity of the albumin sites 
may parallel the allosteric transition theories of enzyme-activity 
modificati on (Koshland, 1958; Monod et al, 1963) and the mode of anti~en­
antibody interactions (Roitt, 1979). In order to account for its binding 
to a wide range of compounds though, a high, if not unique, conformational 
adaptivity must be attributed to HSA. 
Isotope exchange experiments reveal that proteins in solution are 
not static structures but molecules changing between different conformational 
states. The rates at \~hich hydrogen atoms in the protein exchange with 
those in aqueous solution depend upon their location in the molecule. 
Hydrogens on the protein surface readily exchange with de uteri urn in the 
solvent whereas hydrogens buried in the protein cannot exchange unless 
contact with t~e solvent is established. Such contact can only be brought 
about by relatively large-amplitude fluctuations, or 'breathing', of parts 
of the protein. There is evidence to sho\~ that albumin is able to change 
conformation by both large and small amplitude motions (Kragh-Hansen, 1981). 
Moreover, hydrogen exchanse measurements support the view that serum 
albumin is able to change conformation more readily than other proteins 
which do not share its ability to bind ligands with a high affinity. 
The existence of various conformational fluctuations of albumin 
with time constants di ffering by several orders of magnitude has been 
demonstrated (Kragh-Hansen, 1981). The large-amplitude motions probably 
occur at or close to the protein surface and may play an important role in 
ligand binding. However, many details of the conformational changes are 
unknO\~n. 
TI'fO theories have been proposed to explain the influence of ligand 
binding on the conformation of albumin. Firstly, albumin in solution may 
be envisaged not as a system of identical molecules but as a collection of 
isoJreric proteins of approximately equal energy in thermal equilibrium 
with each other (Karush, 1950). Addition of a ligand to the protein 
solution produces a preferential interaction between the ligand and the 
isomeric form of albumin which results in the most stable complex. This 
may be understood in terms of the symmetry or two-Site model of Monod 
et al (1965) which was used to explain the activation of enzymes by small 
~~lecules and required the existence of protein tautomeric forms in 
equilibrium but with different affinities for the ligand. 
Secondly, it is proposed that the albumin molecule has a high 
degree of flexibility or adaptability and during the binding process a 
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ligand molecule is able to modify the conformation of a binding region 
so that a greater congruence occurs between the ligand and the binding site. 
This is the theory of conformational adaptivity and is similar to the 
sequential or induced-fit model of Koshland et al (1966). A number of 
kinetic studies are in accordance with this idea. For example, Scheider 
(1979) has shol1n that the binding of oleate to HSA occurs in two steps. 
The first step is diffusion controlled and involves a nonspecific 
attachment of the ligand. The second step is rate limited by a negative 
entropy of activation and involves a rearrangement of the protein fatty-
acid conformation. 
Daniel and Weber (1956) studied the cooperative nature of the 
binding of ANS to bovine serum albumin. The authors concluded that the 
observed cooperative binding phenomenon could not result from equilibria 
of the simple type invoked by ~'onud et a1 (1955). Moreover, the results 
appeared to indicate the existence in the protein molecule of relaxation 
effects upon binding and dissociation of the ligand. Gibson and Levin 
(1977) have made important distinctions betl1een the t.10-state (Monod et 
a1, 1965) and induced-fit model (Karush et a1, 1966) for cooperative 
ligand binding. 
Suzukida et a1 (1983) have recently developed a method for 
measuring distances between several amino acid residues in HSA. It will 
be interesting to see how these distances are affected by the binding of 
various 1igands to the albumin molecule and to discover whether these 
changes are consistent vlith the induced-fit model. 
To conclude, there are clearly regions of the albumin molecule 
which can be regarded as drug binding sites and certain steric and 
structural requirements have to be satisfied by the ligand before high 
affinity binding can occur. Nevertheless, these binding regions exhibit 
a degree of adaptability which allows t~em to bind a wide range of 
chemical compounds. The degree of adaptabi1 ity is not unlimited, hO\1ever, 
as demonstrated by the specificity of albumin binding. 
1.5 A Review of Current Techniques Employed in the Study of Drug-Protein 
Binding 
The methods which can be used to investigate drug-protein binding 
cover a diverse range of chemical and physical techniques. Most of tile 
available methods have been applied to the study of the binding of drugs 
to human serum albumin. It is beyond the scope of this introduction to 
assess each approach in turn, although some of the more general aspects 
will be considered. 
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Bridges and Wi1son (1976) have identified twelve principal 
techniques and approximately twenty less commonly used methods for 
studying drug-protei n i nteracti ons. Bush and A 1vi n (1973) revi eVled the 
'classical' methods for estimating the levels of free and bound drug, 
namely dialysis, ultrafiltration and gel filtration. Physical methods for 
studying drug-protein binding, both spectroscopic and nonspectroscopic, 
have been examined in some detail by Chignell (1971). The same author 
has considered the ways in which fluorescence spectroscopy can be used 
to study the interactions of drugs with biological systems in general 
(Chignell, 1972). The review by Meyer and Guttman (1958) includes a 
discussion of the methods in use at that time. Enzymatic digestion and 
biochemical labelling techniques for investigating molecular aspects of 
the drug binding sites of HSA were considered in Section 1.4.2. 
Classical methods for estimating the degree of protein binding of 
a drug are based on the physical separation of the unbound drug from the 
drug-protein complex. The most widely used techniques are those of 
equilibrium dialysis, ultrafiltration and gel filtration. The main value 
of these methods lies in their direct quantitative application to the 
measurement of drug-protein binding since their use in deriving structural 
informaticn regarding the nature of the interaction is extremely limited. 
In practice it is important to ensure that the equilibrium between free 
and bound drug is not disturbed during the experimental runs and to 
determine the degree of non-specific absorption to the dialysis membrane, 
gel, or walls of the apparatus. An assessment of the strengths and 
weaknesses of the equilibrium dialysis approach is given in Chapter 5. 
A number of techniques have been developed from the classified 
methods and i nc 1 ude mi cro- and non-equi 1 i bri urn di a lysi s wlli ch requi re 
much shorter experimental times (Eisen, 1971; Colowick and Womack, 1969; 
Hiji et al 1978). Nonetheless equilibrium dialysis remains the most 
commonly used method for determining drug-protein binding in clinical 
pharmacokinetic studies • 
• Several chromatographic techniques have been adapted to the study 
of drug protein binding. Keresztes-Nagy et al (1972) compared the use of 
equilibrium dialysis and frontal analysis chromatography in the examination 
of salicylate binding to HSA. The immobilization of albumin by covalent 
coupling to agarose gel matrices has allowed Lagercrantz and co-workers 
(1979) and Nakano et al (1982) to employ continuous frontal affinity 
chromatography to investigate the binding of drugs to bovine and human serum 
albumins, respectively. Sebille et al (1978) have determined drug-protein 
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binding param~ters using high-performance liquid chromatogra~hy. 
ji,t! d~I..IVe techniques simply involve the physical separation of 
the bound and free drug. Subsequent to this separation there must be some 
measurement of the free or bound drug. It is normal practice to assay 
the former and the most widely used methods involve the use of radiolabelled 
drugs. In equilibrium dialysis experiments tracer amounts of radiolabelled 
drugs are added on either side of the dialysis membrane, but more usually 
on the buffer side. After dialysis has reached equilibrium the free 
fraction of the drug can be assessed from liquid scintillation 
measurements. Although this is a very sensitive and conceptually simple 
technique, Bjornssen et al (1981) have shown that radiochemical impurities 
can introduce large errors into the assay and suggest an extensive 
purification of radiolabels prior to dialysis. Hertl and Odstrchel (1982) 
recentiy patented a method for separating free ligand (including 
radiolabelled ligand) from radioactive breakdown products in the dialysate. 
The technique involves the use of an immobilized antibody specific for a 
given ligand. While this approach means that the extensive purification 
of radiolabels can be avoided, it still constitutes a rather complicated 
and costly adaptation of the basic concept of equilibrium dialysis. 
A somewhat different method for the classification and identification 
of drug-binding sites on HSA has recently been described by Kurono et al 
(1981) and Kurono and Ikeda (1982). It makes use of the observation that 
the binding of drugs to human serum albumin can inhibit the esterase-
like activity of the protein for the substrates p-nitrophenyl acetate and 
S-nitroaspi rin. 
Spectroscopic techniques such as ultraviolet and visible absorption 
spectroscopy, fluorescence spectroscopy, optical rotatory dispersion and 
circular dichroism, nuclear magnetic resonance and electron spin 
resonance are playing an increasingly important role in protein binding 
studies. Compared to the more classical methods of assessing drug-protein 
binding, spectroscopic techniques have several advantages. Since membranes 
and gels are not involved and measurements can be made rapidly, absorption 
pro':llems and concerns over the disturbance of equilibrium conditions are 
often minimized. Moreover,spectroscopic measurements can not only be 
used to measure the amounts of free and bound drug in a given system but 
can yield additional information on the nature of drug-protein interactions. 
The interpretation of nuclear magnetic resonance and electron 
spin resonance spectra tends to be rather difficult but they may reveal 
which group or part of a drug molecule is involved in the binding process 
(Jardetsky and Wade-Jardetsky, 1965). By recording electron spin resonance 
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spectra from enantiomeric labels, Hsia et al (1982) have examined the 
sk,cv,,,,, ... ;ficity of the bilirubin binding sites of HSA. 
Optical rotatory dispersion and circular dichroism may yield 
informaticn on the three-dimensional nature of the drug binding site. 
These techniques can also provide quantitative data, although the 
interpretation of spectra may not be straightforward. Ekman et al (1930) 
have recently used circular dichroism as an aid in the characterization 
of the indomethacin binding sites of HSA. 
When drugs bind to proteins their visible absorption spectra and 
those of the proteins often show marked changes. Since the degree of 
spectral change is usually proportional to the concentration of the drug-
protei n compl ex, thi s change may be used to measure the degree of drug 
binding to albumin. Spectral changes below 300nm are often small and are 
best observed by means of ultraviolet difference spectroscopy. 
Fluorescence spectroscopy is a particularly powerful and sensitive 
technique with which to examine the binding of drugs to HSA. The 
wavelengths of maximum excitation and emission, the quantum yield of 
fluorescence, the degree of polarisation and the fluorescence lifetime 
of a drug may be markedly affected when it binds to albumin. Changes in the 
fluorescence characteristics of the protein molecule may also be affected 
by the binding of a drug. Fluorescence measurements can provide 
quantitative information on the degree of binding and qualitative information 
concerning the environment of the drug binding site. Fluorescence energy 
transfer measurements may be used to determine the distances between the 
lone tryptophan residue of HSA and specific drug binding sites. 
A particularly important development which nas extended the use 
of fluorescence spectroscopy in albumin binding studies is the identification 
of site-specific 'probe' molecules. These include ANS (Dodd + Radda. 1959). 
L-kynurenine (Churchi ch. 1972). warfarin (Chignell. 1970). dansyl amino 
acids (Sudlow et al. 1975), 7 anilinocoumarin-4 acetic acid (Goya et al 
1982). and bilirubin. Fluorescent probes may be used to investigate the 
protein binding characteristics of a drug by measuring its ability to 
displace the probe molecule from albumin. Fluorescent probes can frequently 
be used over a wide concentration range and the displacement method has 
the particular virtue that it allows the assessment of the protein-binding 
properties of even those drugs which are intrinsically difficult to assay. 
A major part of this thesis is concerned with attempts to exploit this 
approach to the full. The possibility that a drug could alter the 
spectroscopic characteristics of a fluorescent probe via a modification of 
the protein conformation rather than by its direct displ acement from a 
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specific binding site is examined by comparing results with those of a 
more conventional method. 
The measurement of the thermodynamic parameters governing the 
bindiny of a drug to a protein can provide important information on the 
nature of the interaction at the molecular level. Most of the various 
separation and spectroscopic techniques mentioned above can be performed 
at different temperatures and so, with the aid of the van't Hoff equation, 
permit the calculation of entropy and entha1py changes for a given 
interaction. This is only rarely attempted in practice, an example bein~ 
the study of Whit1am et a1 (1979). On the other hand, calorimetric 
techniques allo\~ these parameters to be measured di rect1y. Otagiri et a1 
(1978) have used microca10rimetry to estimate thermodynamic parameters 
for the binding of four anionic drugs to HSA. They interpreted the 
results in terms of the relative contributions of hydrophobic, electrostatic, 
van der Waa1s and hydrogen-bonding to the binding process. A microca10ri-
metric method for the study of the competitive binding of ligands to HSA 
has been described by Coasso10 et al (1978). 
When spectroscopic methods are used in conjunction with stopped-
f1~~ or relaxation techniques, it is possible to study the kinetic 
parameters of drug-protein interactions. Lassman (1981) has used this 
approach to investigate the kinetics of the binding of warfarin to HSA. 
The binding process was followed by observing tha enhancement in warfarin 
fluorescence which occurs on binding of the drug to albumin. Lassman and 
Reitbrock (1982) have used this new technique to investigate the pH-
dependent binding kinetics of warfarin. These studies should lead to a 
better understanding of the binding process at the molecu1 ar level; the 
kinetic param:ters may also have important pharmacokinetic consequences. 
The classical separation techniques used in the study of drug-
protein binding tend to be rather tedious and time-consuming. 
Spectroscopic methods which do not involve any physical separation of the 
bound and free drug are more convenient to perform and are particularly 
suited to automation. A further aim of this study is to investigate the 
possibility of automating drug-protein binding studies. 
1.6 Molecular Fluorescence Spectroscopy 
The aim of this section is to cover some important theoretical 
and practical aspects of molecular fluorescence spectroscopy. Particular 
emphasis is placed on the effect of the molecular environment on f1uorescenca 
spectra: it is the extreme sensitivity of fluorescent probes 'to changes in 
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their environment which makes a study of the spectroscopic properties of these 
molecules so useful in drug-protein binding studies. 
There are a number of textbooks and reviews concerned with both 
the principles and the applications of fluorescence spectroscopy. Probably 
the best and most comprehensive of these are the works by Parker (1968). 
E~ling (1970). Winefordner et a1 (1972) and Guilbault (1973). Bowen and 
Wokes (1953). Becker (1969) and Simons (1371) have written important books 
on the theoretical aspects of luminescence. while Udenfriend (1962 and 
1969). White and Argauer (1970). and Gifford (1981) have discussed the use 
of f1uorimetric analysis in biochemistry and medicine. These publications 
contain further referenc~s to the extensive literature on fluorescence 
spectroscopy. 
1.6.1 lntroduction to Molecular Fluorescence 
Descriptions of the transitions which give rise to molecular 
fluorescence invariably include a simplified representation of the available 
molecular energy levels. Various excited state processes are described 
with reference to this simple diagram. It is convenient to do so. and since 
only limited information exists concerning the available energy states of 
individual molecules. it is usually necessary. Nevertheless an 
appreciation of the radiative and non-radiative transitions in excited 
molecules requires some further understanding of molecular structure. 
Without this. simplified diagrams can obscure important aspects of 
fluorescence. 
Those characteristics of molecular structure which are relevant 
to a discussion of fluorescence will be covered in this section. More 
detailed descriptions are given in standard textbooks such as that on 
molecular quantum mechanics by Atkins (1970). 
The molecular orbitals within a molecule are fo~ost i~ 
determining its chemical and spectroscopic properties. The electronic 
charge in a a bond is strongly localized between the nuclei it binds. 
Electronic repulsion. as well as the limitation of the Pauli exclusion 
principle. prevents the formation of more than one a bond'between any two 
atoms. Since the electrons involved in abonding are concentrated between 
the bonded atoms. they are held very tightly and a great deal of energy 
is required to promote these electrons to vacant molecular orbitals (see 
Fi gure l. 5). IT bonds are genera lly weaker than a bonds as the overl ap 
charge does not occur immediately between the nuclei. This means that IT 
electrons are freer to move \~ithin the molecule than are aelectrons. 
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So if several atoms are (J bonded in series and each has a p or d orbi tal 
wit:,;.:,,, correct spatial orientation to form a II bond with the others, 
a set of II bonds is formed whose electrons are spread over the entire 
series of atoms. The II bonds are therefore delocalized and in sorre cyclic 
organic molecules this delocalization extends over the whole molecule. 
Such aromatic compounds are of primary interest in molecular luminescence 
spectroscopy. 
The symmetri ca 1 nature of the (J bond about its axi s means that 
rotation is possible around such bonds. The II bond is symmetrical by 
reflection in its molecular plane but not with respect to rotation about 
the intramolecular axis. Hence rotation about a II bond destroys the 
parallelism needed for the overlap of its constituent p orbitals. Thus 
the double bond is in effect rigid and cannot rotate. Indeed II -systems 
are often to be found in extensive planar molecules. 
In systems containing II and n electrons the spectral features 
and chemical reactivity are sometimes assigned exclusively to these electrons. 
The localized (J electrons are regarded as providing a (J -bond fram~work 
relative to which the distribution of II electrons is discussed. This 
approach is called the II -approximation. It is not completely valid 
because the II charge on a certain atom can repel the (J cloud and vice 
versa. Moreover, in excited states there is usually an alteration in one 
or other of the charge density distributions which then affects other 
distributions. Hovlever, while it is wrong to treat the (J electrons and 
the nuclei as together establishing a rigid core, it is almost inevitable 
to do so and theories concerned \~ith II electrons alone have been very 
successful. This is due to two factors: the fundamental difference in 
symmetry betl~een (J and II electrons and the greater polarizability of the 
II electrons which allows them to respond more readily than do (J electrons 
to any disturbance or perturbation. For spectroscopic purposes, then, 
and within the limits of the II -approximation, the entirety of the 
molecular electronic structure can be seen as consisting of occupied II 
orbitals at 10l.'/est energy, the occupied n orbitals at slightly higher 
energy than the II electrons, and the unoccupied II * orbitals to which 
n or II electrons are promoted for the electronically excited states. 
This is shown in Figure 1.5. 
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FIGURE l.5 General1 zed IOOlecular-orbital energy diagram. 
The electronic spectra of IOOlecules are·complex and their 
interpretation merits a description of more than just the electronic 
energy levels. The energy associated with rotational transitions is 
usually less than that associated with vibrational transitions which in 
turn is less than associated with electronic transitions. Consequently, 
although it is possible to observe pure rotational spectra, when a 
vibration is excited in a molecule then so are rotational transitions. 
Similarly, electronic spectra do not involve purely electronic transitions, 
both vibrational and rotational transitions are excited. While the gross 
structure of electronic spectra can be described in terms of the available 
electronic energy levels, the widths of absorption bands and the position 
of maximum absorption depend strongly on the molecular vibrational and 
rotational energy levels. Vfbrational transitions have a particularly 
strong influence on the spectral properties of fluorescent molecules. 
The energy of a bond between two atoms changes if the nuclei 
are disturbed from their equilibrium positions. A number of functions 
have been put forward to describe the potential energy curves of vibrating 
molecules. These functions may be used in the Schrodinger equation to 
compute the quantis~d vibrational energy levels. The all~~edenergy levels 
may be represented as a series of horizontal lines on the potential energy 
curve. For molecules undergoing anharmonic oscillations, the quanti sed 
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energy levels are less well spread at high energies than at low. and 
vii.JI'Cli.iullai i.rdllsitions are governed by the selection rule !'\\! = .:!:.1 • .:!:.2 • .:!:.3 .... 
The vibrations of polyatomic molecules are complex and cannot be considered 
to be a property of individual bonds but must involve the entire molecule. 
While a detailed discussion of the possible vibrational modes is not merited. 
the role of molecular vibrations in governing the electronic spectra of 
various compounds \~ill be considered. 
The vibrational wavefunctions and probability density functions 
for an oscillating molecule can be used to calculate the probability of 
finding the vibrating nuclei at any distance from their equilibrium positions. 
For the lowest vibrational states the probability distribution function has 
a maximum at the centre of the vibration; higher vibrational states have a 
maximum pro~abi1ity near the turning points. A kno\~ledge of the most 
likeiy iocation of the vibrating nuclei in a particular energy state can be 
used to determine the probabil i ty of transi ti ons from one state to another. 
Of course these transition probabilities also depend upon the 
population of the available energy states. The intensity resulting from 
the transition of a molecule from some initial state of energy to a final 
state depends on the number of molecules that have the initial energy. 
If there are two energy levels from which transitions to a third are 
equally possible then the most intense spectral line will come from the 
level which initially had the greater population. The Boltzman distribution 
may be used to calculate the population of available levels. This asserts 
that at equilibrium the ratio of the numbers of molecules· in the states 
\~ith energi es Ei. and E~ is 
= exp 
n.l 
-4E 
kT 
where n. and n, are the numbers of molecules with energy EL and E, 
respectively. k is Boltzman1s constant. T is the absolute temperature. and 
AE:t.Ei. - Ej • When 4E is much less than kT. n, is negligible with 
respect to n,. At room temperature the energy difference betl'/een the fi rst 
excited molecular electronic state and the ground state is much greater 
than kT. Consequently. an absorption spectrum normally sh~~s transitions 
originating exclusively from molecules in their electronic ground states. 
Vibrational spectra of samples at room temperature can also usually be 
accounted for entirely in terms of transitions from the lowest vibrational 
states because the first vibrational excited state lies well above the ground 
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state and is only slightly populated. In constrast, for molecular 
r(j:;;':~v:-.:'~ levels the spacing is much smaller and even at room temperature 
many levels are populated. A rotational absorption spectrum contains 
lines due to transitions of molecules from a range of populated rotational 
levels. 
Like all molecular electronic spectra, fluorescence originates 
in the absorption of visible or ultraviolet radiation by molecules in their 
ground states. The conventional system for representing electronic 
transitions is one in which the upper state is written first and the lower 
second (Atkins, 1970). The direction of the arrow then indicates emission 
(A ~ X) or absorption (A ~ X). 
A transition between two stationary electronic states can be 
induced by radiation provided its frequency is (EJ - E:J.--1;' where EL and 
E~ are the energies of the states and h is Plank's constant. The frequencies 
at which electronic bands occur are determined by the energy separations 
bet\~een the ground state and the various excited levels. The electronic 
spectrum is normally divided into three regions: the visible between 400 
and 750nm, the near ultraviolet between 200 and 400nm and the far or 
vacuum ultraviolet bel~~ 200nm. 
Since a large input of energy is required to promote electrons 
involved in cr bonding to vacant molecular orbitals (see Figure 1.5), 
molecular electronic spectra concerning cr electron transitions occur \1ell 
into the vacuum ultraviolet and are not available to, or of interest in, 
conventional luminescence spectroscopy. IT electrons are not as tightly 
bound as cr electrons and so thei r e 1 ectroni c spectra occur at lower 
frequencies. For molecules with isolated multiple bonds, transitions 
involving IT electrons are on the borderline of the near ultraviolet and 
the vacuum ultraviolet. When two or more multiple bonds are conjugated, 
however, molecules contain delocalized IT electrons and have IT electron 
spectra in the near ultraviolet. Highly delocalized IT systems such as 
aromatic molecules have intense IT * + IT transitions ranging from the 
near ultraviolet for small molecules to the near infra red for large 
molecules. While the IT * + IT transition is often intense, it tends to 
reduce the strength of the bond because a binding electron is transferred 
to an anti boding orbital. Electron pairs in n orbitals, on the other hand, 
are unavailable for conventional covalent bonding but are potential 
contributors to the spectral features of molecules that possess them. 
In contrast to the narro\~ spectral lines of atoms, molecular 
electronic spectra usually appear as broad bands. This is because each 
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molecular electronic state is accompanied by a manifold of vibrational 
and rotational states. As mentioned earlier, to explain the shapes of 
molecular spectra, transitions that involve both the electronic and 
vibrational levels must be considered. These are often referred to as 
vibronic transitions. 
Electronic transitions in molecules occur very quickly. The tim~ 
required for a molecule to pass from the ground state to an electronically 
excited state upon absorption of a quantum of radiation is of the order of 
10-15s • In contrast, vibrational transitions that require rearrangement 
of the position of nuclei take about 10-12s• It is therefore reasonable 
to assume that electronic transitions occur so rapidly that the nuclear 
framevlork of a vibrating molecule remains unchanged. This is the basis of 
the Franck-Condon principle. 
The Franck-Condon principle is extremely helpful in predicting 
which vibrational transitions accompany the transitions between molecular 
electronic levels and in explaining the intensity with which each vibronic 
transition occurs. The qualitative application of this principle may be 
understood by reference to Figure 1.6 l'Ihich shows hypothetical potenti al 
energy curves for the ground and first excited electronic states of a 
diatomic molecule. The horizontal lines indicate the vibrational levels 
associ ated l'Ii th each e 1 ectroni c state and approximate probabil i ty dens ity 
functions are included. 
The variations of potential energy with respect to nuclear 
configuration may be similar in the ground and excited states (Figure 
1.6(a)). When an electronic transition occurs the molecule is excited to 
the state represented by the upper curve in Figure 1.6(a). Since the 
lowest vibrational level of the ground state is the most densely populated 
at room tem~erature, most transitions occur from this level. However, 
although there are no restrictions on the change in the vibrational quantum 
number during an electronic transition, the vibrational lines in a 
progression are not of the same intensity. According to the Franck-Condon 
principie, the nuclear coordinates remain constant during an electronic 
transition and so a vertical line has been dral'ln on the diagram to represent 
such a transition. In the vibrational ground state the most probable 
conformation of the nuclei when the transition occurs is that in which they 
are at their equilibrium positions. The lowest vibrational wavefunction 
has a maximum at this position. The vibrational transition may cut throug,l 
several vibrational levels of the excited electronic level. When the 
nuclear configuration is similar in the ground and excited electronic states, 
there is strong overlap between the v=O vibrational wavefunctions of the 
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exci ted ' 
state 
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el ectroni c ~~~~~~~?7"'"--
ground 'i 
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(a) (b) 
FIGURE 1.6 The Franck-Condon Principle and Vibronic Transitions 
Potential energy curves are shown for two electronic states 
of diatomic molecules with probable spectroscopic transitions. 
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electronic states and so the (O~O) transition is the most intense. 
Nevertheless transitions to other vibrational levels retain some proba~ility 
since although the nuclei are most likely to be located at or near their 
equilibrium displacement in the v=O state, a finite probability exists for 
them to be at the extremities of their vibration. Because the v=O 11avefunction 
is finite even for these nuclear configurations, overlap is quite possible 
with wavefunctions for other vibrational states. Of course, the (If-O), 
(2+-0) and other transitions are of lower intensity than the (D.-D) line. 
The (0.--0) transition normally defines the low frequency (high wavelength) 
limit of the absorption band. At high temperatures, though, other 
vibrational levels may be apprecially populated and radiation of longer 
wavelength than the (D.-D) line may be absorbed. 
Quite often the equilibrium nuclear configuration of the ground 
electronic state is considerably different from that of the electronically 
excited state. Indeed, the upper potential energy curve is usually displaced 
to the right of the lower curve, that is, to longer bond lengths .• This is 
so because an electronic transition often involves an increase in the 
antib('nding character of a bond. In these circum!tances the intensity of 
the vibronic transitions will differ from those in Figure 1.6(a). Vertical 
transitions may reveal that the most probable transition is nOl1 from tne 
lower v=O level to the upper v=3 state (Figure 1.6(b)). The upper state 
most probably reached depends on the displacement of the upper and lower 
potential energy curves. A lot of vibrational structure is indicative 
of considerable displ acement of the two states. 
In a molecule, electronic transitions are accompanied by changes 
in the rotational as 11ell as the vibrational states. Thus the precise 
wi dth of absorpti on bands and the pos ition of maxi TTUJm absorpti on depend on 
the structure caused by rotational as 11ell as vibrational transitions. 
However, molecules are most often studied in solutions at room tem~erature 
and as a result of intermolecular collisions the rotational structure is 
invariably blurred. In fact vibrational as well as rotational structure 
is lost from most molecular electronic spectra and the result is a broad 
band spectrum. 
Upon absorption of radiation of the correct frequency, a molecule 
can be excited to one of the vibrational levels of the electronically 
excited singlet states. There are several mechanisms by which the molecule 
can return to the ground state only one of which is fluorescence. The 
various mechanisms are illustrated in Figure 1.7. 
The radiationless relaxation processes - those that involve direct 
s. 
S, 
A 
s. 
FIGURE 1. 7 
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vibrational coupling or quantum mechanical tunne1ing between electronic 
stut~~, :;-;::! t~:~e due to thermal degredation of the vibrational and 
electronic levels through molecular collisions - are kno\~n as internal 
conversion. The probability of such processes occuring is extremely high; 
indeed radiative emissions other than .those from the first excited 
electronic state are extremely rare. The various mechanisms which 
constitute internal conversion are discussed below. 
The most common means by which excited molecules return to tile 
ground state is via thermal decay. If an excited molecule is subjected to 
frequent collisions with molecules in its environment - \~ith the solvent 
mo1cu1es if it is in solution - then the colliding species may act as an 
acceptor for the excess energy. In this manner excess vibrational energy 
may be dissipated with each collision removing a quantum of vibrational 
en'::f9.i. C.:.l1isions may also transfer the electronic energy of excited 
molecules into the vibrational modes of acceptor molecules in the 
environment. Water, for example, has widely spaced vibrational energy 
levels \~hich coincide with a range of typical electronic excitation energies. 
The energy may be distributed even more widely as the vibrational energy 
of the acceptor molecules is transferred by further collisions into the 
rotational and translational modes of the system. Through this relaxation 
prccess the excitation energy is degraded into heat as the absorbing 
molecule returns to the ground state. The lifetime of the excited 
electronic state depends on the eff&ciency of the transfer of energj into 
the vibrational modes of the neighbouring molecules. 
The proportion of the excitation energy lost by this co11isiona1 
process is difficult to determine. For some large molecules interactions 
of any kind with the solvent may be unnecessary for the decay from high to 
10\~ excited electronic states. The transition occurs not only in solution 
but in rigid media and in the gas phase where the nUnDer of collisions may 
be severely diminished or even zero. Indeed it has been shown that upon 
excitation into their second excited singlet states, naphthalene, 
anthracene and naphthacene exhibit radiation1ess conversion into the first 
excited singlet state under conditions where no collisions occur during 
the lifetime of the second excited singlet state (Watts and Strich1er, 1966). 
These observations suggest there must be other, intramolecular radiation1ess 
transitions in excited state molecules. 
The potential energy surfaces of two electronic states may cross 
and the higher vibraticna1 levels of the 10~ler electronic state overlap 
the lower vibrational levels of the higher electronic state. This means 
the nuclear configuration and energies of the two electronic states are 
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identical er very similar during a low level vibration of the upper and a 
hi~~ ~:,::~ vibration of the lower electronic state. Following a vibration 
in the upper electronic level, a high probability exists that in the next 
and succeeding vibraticns. the molecule will be vibrating in a manner 
appropriate to the lower level. The transient thermal equilibrium between 
the electronic states permits population of the lower state. This coupling 
of the neighbouring electronic states by a vibronic perturbation represents 
a breakdown of the Born-Oppenheimer approximation: the electronic states are 
not independent of the nuclear vibrations. 
If the vibrational levels of one electronic state do not overlap 
those of another but are separated only by a few vibrational quanta, a 
molecule in the upper electronic state may still convert to the lower by 
a tunnel ing mechani srn. Tunneling is permitted quantum IIl'!chani cally because 
the wave function characterizing a partic]e does not vanish at distances 
away from the most probable distribution but decreases asymptotically. 
So there is always some overlap of vibrational levels in different electronic 
states. The possibility of tunne1ing, and hence internal conversion, 
decreases as the difference in energy between the lower vibrational levels 
of the upper and the upper vibrational levels of the lower electronic state 
increases. 
If there is a considerable separation between an upper and a lower 
electronic energy level, direct vibrational coupling of the electronic 
states 11111 be impossible and tunne1ing highly improbable. Nonetheless, 
the probability of radiation1ess transitions between the closely-spaced 
higher electronic states is extremely great. Internal conversion is at 
least a thousand times more likely than 1s radiative emission from any 
excited singlet above the first excited singlet (Becker, 1969). However, 
as may be appreci ated from the lifetimes of the exci ted states shown in 
Figure 1.8, internal conversion from the lowest excited state to the ground 
state is often much slower than it is between the higher states. This is 
because the energy separation between the ground state and the first 
excited state is larger than between the higher electronic levels. Hence 
other processes, including fluorescence, can sometimes compete successfully 
11ith internal conversion for depopulation of the lol~est vibrational level 
of the first electronically excited state. Of course, in a molecule where 
there is significant overlap between the lower vibrational levels in the 
first excited state and the upper vibrational levels in the ground state, 
the fluorescence will be weak or absent. 
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FIGURE 1.8 Mean decay times for non-radiative and radiative transitions 
in excited state molecules. 
In general a radiative transition between electronic states is 
called luminescence. The term fluorescence is used when the upper and 
lower electronic states are of the same multiplicity. Fluorescence 
involves the spontaneous emission of a photon of visible or ultraviolet 
radiation. The emission of the radiation is spontaneous in the sense 
that it is not stimulated by incident photons of the same frequency. 
The mechani srn of spontaneous emi ss i on is such that it becomes very 
important only at high frequencies; the tirre required for a nucleus to 
reverse its magnetic moment in a magnetic field is astronomical. For 
molecular fluorescence the mean lifetime of the excited state is about 
10-8s• This is still quite long on a molecular scale since the excitation 
;'lS process takes only about 10 s. 
The frequency at \~hich fluorescence bands appear is proportional 
to the difference in energy between the ground state and the lowest, 
or very.exceptionally the second, excited singlet state. The shapes and 
intensiti es of the fl uorescence spectra are governed by the Franck- Con don 
principle which was discussed in connection with absorption spectra. 
Vertical transitions from the 10\~est vibrational level of the first 
electronically excited state terminate in anyone of a number of 
vibrational (and rotational) levels in the ground electronic state (Figure 
1.7). The result is a band spectrum. For molecules having identical 
nuclear configurations in the ground and first excited state, of the many 
poss ibl e vi broni c trans i ti ons, the one bet>,~een the v=O levels of the two 
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states ~Jill be the most probable. If, as is usual, the e1uilibrium nuclear 
confl gurati ons of the ground and excited states are s 1 i Jht1y different, 
the emission band maximum will correspond to the frequency of some other 
transition. Which one will depend on the amount of displacement bet\~=en 
the configurations. 
Since at room temperature virtually all the radiative transitions 
in fluorescence originate from the same (v=O) vibrational level of the 
lowest excited singlet state, the vibrational structure of the emission 
spectrum is characteristic of the ground state. Indeed, this provides 
a method for studying the vibrational structure of the ground state. On 
the other hand, the correspondi ng absorpti on spectruin ori ginates from the 
lowest vibrational level of the ground state and its vibrational structure 
is characteristic of the excited electronic states. It is not surprising, 
therefore, that there are many accounts in the literature of an a!Jproximate 
mirror-image relationship l:etween the absorption and emission bands. This 
is to be expected if the spacings between the vibrational levels, and if 
the equilibrium nuclear configurations are similar in the ground and 
excited states. The mirro~-image relationship should not be considered as 
general, however, since quite often considerable differences in the 
vibrational frequency and geometry of the two states can modifl this 
relationship. In addition, while a molecule may show a number of bands in 
its absorption spectrum, it \~il1 never have more than one fluorescence 
band. Absorption may occur from the ground state to a number of 
electronically excited levels: fluorescence normally only originates from 
the first excited singlet state and terminates in the ground state. Thus 
quinine sulphate has tllO absorption bands corresponding to (5,.+--5,,) and 
(5. ~S(l) but one emission band (5,-+50 ). 
In returning the excited molecule to the lowest vibrational level 
of the first electronically excited state, the dissipation of absorbed 
energy by internal conversion means that fluorescence occurs at a longer 
wavelength, that is at 10'.~er energy, than does absorption. The (0-40) 
transition of fluorescence is the hig/, frequency limit of fluorescence and 
the low frequency limit of absorption for the same electronic states 
(Figure 1.7). This implies that the fluorescence maximum always occurs 
at a lo.~er frequency, that is higher \'/ave1ength, than the corresponding 
absorption maximum. In fact this is nearly always so except, of course, 
when the 0-0 band is both the fluorescence and the absorption maximum. 
Even then the bulk of the fluorescence band is at lower frequency than 
the absorption band. As discussed previously, the absorption and emission 
band maxima are usually centred around some other than the 0--0 transition. 
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The absorption and fluorescence may then be well separated. The 
disp1a':'c;T,~nt to longer Navelength of the emission band maximum with respect 
to the excitation band maximum is constant for a given molecule. It is 
call!d the Stokes shift. 
Anti-Stokes fluorescence, the emission of radiation at a shorter 
wavelength than that of the existing radiation can only occur if thermal 
energy is added to the excited state or if the molecule has many highly 
~opulated vibrational levels. This type of fluorescenc~ is only OJserved 
in dilute gases at hig, tem~erature. Almost all fluorescence in solutions 
at ordinary temperatures is of the Stokes type. 
Inspection of Figure 1.7 shOlts that fluorescence must not only 
com~ete with internal conversion for depopulation of the various excited 
states, but with intersystem crossing to the triplet manifold. So far, 
the role of the triplet state in electronic transitions has not been 
consi dered. 
Molecules with an even number of spin-paired electrons have 
singlet electronic levels. The pairing means that t~= molecule as a whole 
has no set electronic magnetic rr~ent. If the spin of a single electron 
in such a molecule is reversed, there will be two unpaired electrons. The 
multiplicity is three and the electronic state is triplet. 
According to Hund's rule for atoms, electrons with parallel 
spins are lo\~er in energy than the corresponding pair with opposed spins. 
By analogy, a triplet state in a molecule will a1\~ays have lower energy 
than the corresponding singlet electronic state. This drop in energy to 
the triplet suggests another pathway by which the energy of an excited 
singlet state ,"ay be dissipated. However, electronic transitions bet'teen 
statps ef different multiplicity are forbidden. In practice the selection 
rule may break doo·,n to varyi ng degrees under the inf1 uence of certai n 
perturbations. These perturbations increase the extent of spin-orbital 
coupling in molecules and may bring about the electron spin reversal 
necessary for triplet formation. 
Even in the absence of perturbing species, some spin-orbital 
coupling occurs in almost all atoms. An electron has spin and so 
possesses a magnetic moment. An electron with orbital angular momentum 
is effectively a circulating current and so gives to a magnetic field \~ith 
a strength proportional to its angular momentum. Spin-orbital coupling 
occurs when the magnetic moment due to the spin of the electron interacts 
with the magnetic field of its orbital motion. This interaction means tilat 
some degree of intersystem crossing should occur in the excited states of 
practically all molecules. 
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For intersystem crossing to be effective, though, strong 
perturbations, such as those produced by heavy atoms, paramagnetic ions 
and heteroatoms, need to be present in the molecule or its immediate 
environment. These are discussed later. 
The possibility of intersystem cros~ing also depends on the 
overlap of the vibrational wavefunctions of the singlet and the 
corresponding, but slightly lo~'er, triplet electronic state. In fact, 
intersystem crossing may be considered to be a spin-forbidden internal 
conversion m~chanism. Intersystem crossing is normally only important 
bet\~een the first excited singlet and triplet levels. Intersystem crossing 
involving higher singlet and triplet electronic states is severely limited 
by the great rate of internal conversion between the more energetic singlets 
(see Figure 1.8). Even if some intersystem crossing results in the 
population of higher triplet levels, internal conversion amongst the 
triplet states is so rapid that only the lowest excited triplet is of 
interest in conventional spectroscopy. Internal conversion in the lm'/est 
excited triplet level continues until the ground vibrational level is 
reached (Fi gure 1.7). 
A radiative transition from the lowest vibrational hvel of the 
first excited triplet state to the electronic ground state is forbidden 
since it involves a change in multiplicity. The molecule may return to 
the ground state via the first excited singlet state if enough energy can 
be acquired from the envi ronment to raise it back to the region ~/here the 
first excited singlet and triplet levels cross. Under these conditions, 
the spectral distribution of the subsequently emitted radiation is the sa!i1~ 
as that produced by normal fluorescence but has a considerably longer 
lifetime. Such a transition is unlikely to occur, especially at lo\~ 
tem?eratures but when it does it is called delayed fluorescence. 
Although a forbidden transition, radiative emission may still 
occur from the lC\~est vibrational level of the first excited triplet to 
the ground singlet state. Since intersystem crossing has already arisen 
between 'the first excited singlet and triplet levels, a perturbaticn must 
be present that can mix the multiplicities and break the selection rule. 
In addition return to the first excited singlet from the lo\',er triplet is 
improbable. The emission of energy via a radiative transition from the 
triplet state must therefore retain some probability. This transition is 
kno'!tn as phosphorescence. 
Phosphorescence appears at a longer wavelensth than the exciting 
radiation, and since the triplet is lo\~er in energy than the corresponding 
Singlet state, it is also at a longer wavelength than the fluorescence 
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band of the molecule. The vibrational structure of the phosphorescence 
band is characteristic of the ground singlet state. The relative 
intensities of the individual vibronic transitions and so the shape of 
the band are again determined by Franck-Condon transitions. 
Since phosphorescence involves a change in multiplicity, th~ 
lifetime of t~e process is very much longer than that of fluorescence 
(Figure 1.8). Phosphorescence often continues to be emitted long after 
the excitation is withdrawn. Due to the long lifetir..e of the triplet 
state, phosphorescence must compete ~Iith physi ca1 and chemi ca 1 processes 
for deactivation of the 10'~est triplet state. Thus the triplet state maj 
parti ci pate in photochemi cal reacti cns rather than return to the ground 
state. This is the basis of photochemistry and explains why the tri~let 
state is more important than the singlet state in most photochemical 
reactions. In solution at room temperature the long-lived triplet state 
is very susceptible to non-radiative deactivation through co11isiona1 
processes. For this reason, phosphorescence is normally observed in rigid 
or non-viscous media at very low temperatures: 
The excitation of phosphorescence by the direct absorption of 
radiation from the ground state singlet to the excited triplet is extremely 
rare. Spin-orbital coupling and so intersystem crossing can only occur to 
any reaso~ab1e degree if there is a small energy differen'ce between the 
singlet and triplet states concerned. This is so for the excited singlet 
states and the corresponding excited triplet states. The probability of 
intersystem crossing between these levels is therefore very rruch greater 
than is the direct transition from the ground state singlet to the we1l-
removed first or higher excited triplet states. 
Figure 1.8 shows that intersystem crossing is still fast enough 
to compete with fluorescence and give triplet state occupation. In many 
circumstances the relative rates of the two processes may be altered to 
favour intersystem crossing with a consequent high or even total occupation 
of the triplet state and a resulting complete absence of fluorescence. 
Molecular fluorescence is therefore very sensitive to structural and 
environrrenta1 factors. 
1.6.2 The Effect of Molecular Structure on Fluorescence 
The first requirement for fluorescence is an absorbing structure. 
The greater the ability of a molecule to absorb radiation, the more 
* intense is likely to be its fluorescence. The n +.n. transitions in 
aromatic compounds are usually strongly allowed and many of these compounds 
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are highly fluorescent. 
n* +. 11 transitions in isolated carbon to carbon double bonds 
occur at about 180nm. When the double bonds are part of a conjugated 
system the absorption band is shifted to longer wavelengths; highly 
conjugated systems are often coloured. Aromatic compounds being cyclic 
conjugated systems show a similar effect; the larger the aromatic molecule 
the lower the frequency of any given absorption band. 
As in the case of absorption spectra, luminescence bands tend 
towards higher wavelengths as the size of the Tl system is increased. 
In addition, the intensity of the fluorescence often increases as the 
degree of conjugation increases. For a given number of aromatic rings, 
linear ring systems fluoresce at longer wavelengths than non1inear systems. 
For aromatic molecule containing carbonyl groups, and in 
heterocyc1ic compounds, n electrons are available for excitation into 11 * 
orbitals. 11 * .. n transitions, however, are much less intense than 
11 * +. 11 transitions. This is so because an important feature governing 
the intensities of electronic transitions is the spatial orientation of 
the orbitals between which transitions occur. In heterocyc1ic molecules 
such as pyridine, the ground state n orbitals are directed into the 
molecular plane whereas the 11 * orbitals are directed perpendicular to it. 
Consequently, there is poor overlap between the nand 11 * orbitals and 
II .. n transitions appear weakly with respect to 11 * +. n transitions. 
On this basis alone, aromatic carbonyl compounds and heteroatoms would be 
expected to be less strongly fluorescent than aromatic hydrocarbons. 
As noted in Figure 1.5, the energy of 11 * +. n absorption vlill 
usually be lower than the lowest 11* +II transition. Such transitional 
characteristics are due to the n orbitals in the ground state of the 
molecule being higher in energy than the occupied I1 orbitals. I1 * ~ n 
fluorescence should therefore occur at longer wavelength than IT * + IT 
fluorescence. This is not ahlays the case because, as discussed later, 
solvent-n electron interactions can alter the position of the fluorescence 
bands. 
In saturated hydrocarbons there are no IT -binding or nonbonding 
electrons and all electronic transitions must involve a electrons. All 
transitions involving a electrons require a large input of energy and 
bond dissociation may accompany absorption. The probability of 
fluorescence is low. Some saturated hydrocarbons do fluoresce, though 
emission is very weak. In a1iphatic carbonyl compounds 11 * +. n 
transitions can occur, but fluorescence intensities are again very low. 
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Some non-aromatic, but highly conjugated compounds are quite fluorescent 
du~ tu I.i,,:~ UI..(;urrence of 11 *+ 11 transitions. In general, however, the 
vast majority of intensely fluorescent compounds are aromatic. 
To explain the relation of molecular structure to fluorescence, 
it is insufficient sim~ly to consider those aspects of structure which 
make for strongly absorbing species. Following excitation. fluorescence 
must corr.pete wit~ a variety of other excited state processes. Structural 
features and functional groups that enhance internal conversion and 
intersystem crossing may substantially reduce. or perhaps totally prevent, 
the emission of fluorescence from evenly strongly absorbing molecules. 
Whether a molecule employs internal conversion or fluorescence 
to pass from a higher to a lower electronic state depends on the energy 
separation betl~een the t~o states and the number of vibrational levels 
aSSOClatea ~ti th each e 1 ectroni c state. The 1 atter property is important 
because it determines the probabil ity of vibrational overlap of the 
electronic states. If a molecule has a large number of modes of vibration 
then the vibrational levels of different electronic states are likely to 
overlap and internal conversion will be favoured. This method of 
dissipating the excitation energy explains \~hy fluorescence is only rarely 
exhibited by ali?hatic molecules and others that do not have rigid 
molecular skeletons. Such molecules posses many vibrational degrees of 
freedom. Aromati c mo1ecul es with thei r rig id ring structures are the 
class of compounds that most frequently show fluorescence. 
Since internal conversion between the first excited singlet and 
the ground electronic state is generally unimportant in aromatic 
hydrocarbons, the principle proces~ competing \~ith fluorescence in these 
compounds is intersystem crossing. The presence of a heteroatom in an 
aromatic molecule usually means that the lowest excited singlet state is 
an (n,1I *) singlet. Fluorescence rarely occurs from this state and if it 
does, it is extremely weak; indeed it is a hundred to a thousand times 
lower in intensity than 11*'" 11 fluorescence. As mentioned before. it is 
a consequence of the symnetry forbiddeness bet.~een the excited state and 
the ground state and means that the radiative lifetime of (n, 11 *) singlets 
tends to be considerably longer than those of (11 ,11*) singlets. 
Consequently, intersystem crossing can compete effectively with fluorescence 
for molecules whose lowest singlets are (n.II*). Moreover, energy 
differences between the first excited singlet and triplet states are 
frequently much larger for ( 11,11*) than for (n,1I *) excited states 
(Winefordner et a1, 1972; Guilbau1t, 1973). Since the probability of 
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intersystem crossing decreases as the energy separation of the states to 
b: ;;;;;;~~ ;~=:-c(:ses, the process is more likely to occur for heteroatomic 
molecules than it is for their hydrocarbon analogoues. Thus, greatly 
enhanced phosphorescence to fluorescence ratios are observed as a result 
of heteroatom sUbstitutions. 
Certain simple generalizations may be made concerning the 
effects of meta- and of ortho-, para-directing subst1tuents on the 
fluorescence of aromatic hydrocarbons. Ortho-, para-directing substituents 
often enhance fluorescence, whereas meta-directing sUbstituents tend to 
increase the extent of intersystem crossing and repress fluorescence 
(Guilbault, 1973). 
By providing strong perturbations, heavy atoms, paramagnetic 
ions and heteroatoms enhance 1ntersystem crossing through spin-orbit 
coupli;ig. Since the orbital angular morrentum of an electron is located 
at the nucleus, whereas the spin angular momentum is located roughly on the 
electronic orbital, the spin-orbital coupling is weak unless the electron 
has a high probability density near the nucleus. Generally, then, only 
atoms with high nuclear charge (heavy atoms) exhibit appreciable spin-
orbital coupling. Spin changes and hence intersystem crossing are readily 
brought abQut by the intense fields near to the nuclei of such atoms. 
Heavy atoms sUbstituents can increase the rate of singlet to triplet 
intersystem crossing and triplet to ground state phosphorescence. Thus, 
when the sUbstituent series F, Cl, Br, I is traversed for the 
halonaphthalenes, the ratio of the quantum yields of phosphorescence to 
fluorescence increases. 
Paramagentic ions may quench fluorescence by forming charge-
transfer cOIT';>lexes with potential fluorescers. The charge-transfer state 
may mix the multiplicities of the singlet fluorescer and the high spin 
paramagnetic species in th'e sarre way as spin-orbi tal coupl ing mixes the 
singlet and triplet states of the same molecule. Certain metallo-organic 
complexes contain paramagnetic ions. The strong inhomogenous magnetic 
field due to the paramagnetic ion is similar to that produced by a heavy 
atom and may likewise increase the chance of intersystem crossing. 
Another process which may have a profound effect on the 
fluorescent properties of a compound is intramolecular energy transfer. 
Molecules containing more than one separate aromatic ring system may 
exhibit this effect and it is particularly important in proteins. 
The commonest type of energy transfer is singlet-singlet 
transfer which involves a nOrlT'ally fluorescent donor whose excitation 
energy passes to an acceptor that mayor may not be fluorescent. For 
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energy to be transferred between different parts of the same molecule, 
Certaln spatial and steric requirements must be met and the emission 
spectrum of the donor must overlap the absorption sp~ctrum of the 
acceptor moiety (F8rster, 1951). The interaction is due to dipole-dipole 
coupling and does not involve the overlap of electronic orbitals. Energy 
transfer may therefore occur over relatively long distances up to about 
• 100 A. 
The proximity of absorbing residues in proteins means the 
conditions are highly favourable for resonance energy transfer. This 
process, often referred to as the Fllrster mechanism is seen to have a 
cons i derab le effect on prote in fluorescence. The intrinsi c f1 uorescence 
of proteins is due to the presence of aromatic amino acids. The aromatic 
residues phenylalanine, tyrosine and tryptophan fluoresce in water with 
emission band maxima at 282nm, 303nm and 348nm, respectively. However, 
the characteri s ti cs of protein fl uorescence are extremely dependent on 
the structure of the protein and so cannot be fully described by simply 
specifying the fluophors themselves. 
The fluorescence of phenylalanine is of very little importance 
in proteins due to its 10~1 quantum yield and efficient quenching by energy 
transfer to other chromophores. Class A proteins contain phenylalanine 
and tyrosine but no tryptophan. In these, pheny1a1inine fluorescence 
cannot normally be detected and the emission spectra are characteristic of 
tyrosine. Class B proteins contain tryptophan as well as phenylalanine and 
tyrosine. Usually the only fluorescence observed from class B proteins 
is that due to tryptophan. The absent or diminished tyrosine fluorescence 
in these proteins is probably due to energy transfer from tyrosine to 
tryptophan is feasible over the distances encountered in proteins. 
There are, nonetheless, several other mecllanisms by which 
tyrosine fluorescence may be quenched in proteins. These mechanisms may 
explain why the quantum yield of tyrosine is frequently so low in native 
proteins, even those containing no tryptophan. Due to the overlap of the 
absorption and emission spectra of tyrosine, whose maxima are centred at 
280nm and 303nm, respectively, energy transfer between tyrosine residues 
may occur. This process is known to happen and its existence makes it 
possible for a nonf1uorescent tyrosine to dissipate the energy of other 
residues. Thus it is believed that an ionized tyrosine residue can act 
as an effective quencher of the fluorescence of unionized tyrosines via 
energy transfer (Winefordner et a1, 1972). An iodinated, and hence non-
fluorescent, tyrosine may perform the same function. Tyrosine fluorescence 
quenching in proteins may also occur via peptide bonds and by hydrogen-
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bonded groups. 
Unlike tyrosine, h~~ever, tryptophan fluorescence in proteins 
may have fluorescence quantum yields lower, about the same, or even 
higher than that of the free amino acid. This illustrates clearly how 
the fluorescence of aromatic amino acid residues is very dependent on the 
structure of the protein in which they reside. Indeed, if a single protein 
contains more than one tryptophan residue, the fluorescence from each way 
not be identical. 
Much work has been performed over the last ten years in an attempt 
to understand the luminescence of proteins in relation to structure and 
conformation. The reviews of Chen (1973), Dale and Brand (1975) and Galley 
(1979) cover this field. 
1.6.3 The Effect of Molecular Environment on Fluorescence 
During electronic transitions, whether absorption or emission, 
the nuclei remain essentially stationary. This was the conclusion of 
the Franck-Condon principle. When a molecule in the ground state absorbs 
a photon it 1s promoted to a metastab1e excited state. This is the 
Franck-Condon excited state in which the molecular geometry and solvent 
configuration are those characteristic of the ground state. In solution 
at room temperature solvent reorientation follows within 10-12 to 10-11s of 
excitation and produces an equilibrium state in which the solvent 
configuration 1s optimal for the geometry and electronic distribution of 
the excited molecule. Relaxation of the solvent molecules will tend to 
lower the energy of the excited state: this is shown in Figure 1.9. Thus 
if emission of radiation occurs, it will be from the equilibrium excited 
state to a Franck-Condon ground state. Relaxation of the solvent cage will 
ta<e place again and return the molecule to the equi1ibriuw ground state. 
The energy differences between the Franck-Ccndon states and 
the equil ibrium states depend on the nature of the interaction between 
the solute molecule and the solvent. If the solvent and solute are such 
that one is polar and one is nonpo1ar, or both are nonpolar, there may be 
only a small energy difference between the Franck-Condon and the 
equilibrium states. Under these circumstances the 0-0 bond in absorption 
and emission may be expected to be coincident, or nearly so, since the 
energy change is similar. Often, however, especially when both solvent 
and solute are polar, the energy separating the Franck-Condon and 
equilibrium states is relatively large. The ground and excited states 
involved in absorption and fluorescence are then quite different. As a 
excitation 
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Franck-Condon excited state 
solvent 
re 1 axati on 
equilibrium excited state 
emission 
Franck-Condon ground state 
solvent relaxation 
__ --'-________ --"& equilibrium ground state 
FIGURE 1.9 The effect of solvent relaxation on the separation 
between excitation and emission frequencies. 
result, the 0-(1 bands in absorption and emission may be well separated. 
For transitions involving ( n, IT *) states a change in solvent 
polarity has a characteristic effect. The ground state n orbital is 
largely unaffected by the solvent polarity. On the other hand, the 
excited singlet state is more polar than the ground state and may drop 
substantially in energy. through electrostatic interaction with polar 
solvents. The greater the polarity of the solvent, the smaller is the 
energy difference between the highest occupied n orbital of the ground 
state and the excited states of the molecule. Hence, en , IT*) transitions 
are shifted to lower frequencies as the dielectric constant of the 
solvent increases. Generally, then, the transfer of a fluorescent dye 
from a nonpo1ar to a polar solvent results in a red shift in the 
fluorescence emission w~ximum. Since the excited state interacts more 
strongly with the solvent than does the ground state. the spectral shift 
is larger in fluorescence than it is in absorption. 
Direct evidence for solvent reorientation during the excited 
state lifetime of 2-p-to1uidinonaphtha1ene-6-su1phonate (TNS) and 1-ani1ino-
8-naphtha1ene sulphonate (ANS). both in viscous solvents and when absorbed 
to proteins has been obtained using the technique of nanosecond time-
resolved emission spectroscopy (Brand and Goh1ke. 1971). McC1ure and 
Ede1man (1966) have suggested that the increased interaction bet~lE!en the 
chromophore and the solvent which accompanies solvent relaxation produces 
a greater number of vibrational levels in the state resulting from 
emission. This would account for the increase in spectral bandwidth 
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observed in polar solvents. 
For transitions involving (n, n *) states, the effect of a polar 
solvent is generally more pronounced on the energy of the ground state n 
orbital than it is upon the excited state. The positive end of a solvent 
dipole exerts an attractive force on the n electrons in a solute molecule 
thereby lowering their potential energy. This has the effect of lowering 
the energy of the n orbitals relative to that of the norbitals. The n 
orbitals being more symmetrically bound by the molecule "as a whole do 
not experience the electrostatic interaction to a considerable extent. 
Although the energy of the excited (n, n *) singlet is lowered by solvent 
relaxation, the decrease in energy of the ground state nonbonded orbitals 
accompanying electrostatic interaction with the solvent is greater. Hence 
the more polar the solvent, the greater is the difference between the 
".hi,ghest occupied n orbitals in the ground state and the excited states of 
themolec'ule (n, 1[ *) transitions are shifted to higher frequency with 
increasing solvent polarity. In the limit, when the nonbonded pair enters 
into coordinate covalent bonding with the solvent, the energy of the n 
orbitals, which is transferred into a cr orbital, drops well below the 
energy of the occupied n orbitals and (n, n *) transitions are eliminated 
from the visible and near ultraviolet. 
The generalizations than n orbitals are higher in energy than 
the occupied n orbitals, and that (n, IT *) transiti ens always occur at 
lower frequencies than (IT , IT *) transitions in the same molecule therefore 
needs some qualification. In polar solvents (n, IT *) transitions are 
shifted to higher frequencies (shorter wavelengths), whereas (IT , IT *) 
transitions move to lower frequencies (longer wavelengths). If a solvent 
becomes polar enough, the (n , IT *) transitions may actually overtake the 
(n, rr *) transitions and become the lowest energy band in the spectrum. 
The effect of solvent polarity on the quantum yield of fluorescence 
is even more dramatic than the effect on the emission maxima. In 
molecules where the (n, rr *) state is the lowest excited singlet, 
fluorescence is rare and extremely weak when it does occur. As discussed 
in Section 1.6.2 this is a consequence of the symmetry forbideness of 
the transition between the exci ted state and the ground state. Phosphorescence 
is usually the most important emission in such molecules. However, 
because (n, IT *) and (rr , IT *) singlet states are often close together, 
they may be reversed in energy rel ative to one another by a change of 
solvent. An example is quinidine where ~ie lowest excited singlet is 
(n, rr *) in nonpolar solvents and (IT , n *) in polar solvents. The 
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interchange effects the probability of intersystem crossing to the triplet 
ana may nave dramatic consequences on the relative intensities of 
fluorescence and phosphorescence. Thus the fluorescence of quinidine is 
30 times greater in ethanol than in benzene, and 30 times greater in water 
than in ethanol. 
Ve~ often, however. the fluorescence of a molecule may be 
quenched as the solvent polarity increases. Since in polar solvents the 
separation between the ground state and the (11, 11 *) state is decreased, 
internal conversion to the ground state may be enhanced from both the 
lowest excited singlet and triplet states. Luminescence is quenched, 
and both the fluorescence and phosphorescence lifetimes are decreased, 
although the effect on the fluorescence 1 ifetime is usually greater. 
A further explanation for quenching in polar solvents involves 
the enhancement of intersystem crossing. It is to be expected that the. 
dipole moment of the triplet state is less than that of the first excited 
singlet state (Jackson and Porter, 1961). In polar solvents, then, solvent 
reorientation may considerably decrease the separation of the first excited 
singlet and triplet states facilitating intersystem crossing and thereby 
quenching fluorescence. Seliskar and Brand (1971a)have used this mechanism 
to explain the low quantum yield of the N-arylaminonaphthalenesulphonates 
in liquid polar solvents. Additional evidence for solvent relaxation 
during the first excited singlet lifetime of N-(p-to1y1)-2-aminonaphtha1ene-
6-su1phonate has been obtained by Brand and Goh1ke (1971). 
The arguments developed above may suggest plausible mechanisms 
to ex~lain the spectroscopic properties of fluorescent probes of protein 
structure. These molecules fluoresce intensely when bound to proteins 
or when dissolved in nonpo1ar solvents, but have low Quantum yields of 
fluorescence in aqueous solutions. Studies of ANS in a variety of solvents 
(Stryer, 1965) have supported thl' concept that observed changes in the 
fluorescence quantum yield, emission maximum and emission band width are 
related to the polarity of the environment around the fluorescent species 
and that these molecules can serve as probes for hydrophobic sites on 
proteins. Turner and Brand (1968) have also studied the fluorescence of 
N-ary1aminonaphtha1enesu1phonates in different solvents in an attempt to 
quantify the relationship between polarity and fluorescence characteristics. 
The effect of solvent environment on the fluorescence of these compounds 
is discussed further in the review of Brand and Gohlke (1972). 
EnVironmentally sensitive fluorescent probes usually contain two 
groups. an electron donor and an electron acceptor, attached to an aromatic 
ring system. A red shift of the emission maximum with increasing polarity 
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of the solvent environment is dependent upon a large increase in dipole 
mOIll:fI ~ 111 we fl uorescent state over that of the ground state. So, other 
things being equal, the greatest effects may be expected when the electron 
donor and acceptor groups are as far apart as possible in the parent 
molecule. With this in mind, Weber and Farris (1979) have described the 
synthesis, characterization and interesting spectroscopic properties of 
6-propionyl-2-(dimethylamino) naphthalene (PRODAN), a compound that 
fulfills the above conditions. Following the same principles, Prendergast 
and co-workers (1983) have recently synthesized a polarity-sensitive 
fluorescent probe which selectively labels thiol groups in proteins. 
Other factors may influence the spectroscopic properties of 
fluorescent molecules. For example, the fluorescence spectra of most 
aromatic compounds containing acidic or basic functional groups are very 
sensit1ve to alterations in the pH of the solvent. The ionizable groups 
can exist in solution at various stages of dissociation depending on the 
hydrogen ion concentration. Moreover, because ionization of the acidic 
or basic groups produces a considerable change in the electronic structure 
of the molecules which contain them, pH changes may affect both absorption 
and fluorescence. The ionized and unionized forms may be regarded as 
separate species each ~ith their own spectral characteristics. 
Hydrogen-bonding with the solvent can have profound effects on 
the spectra of luminescent solutes. Hydrogen-bonding may involve the 
ground or excited states of a molecule. In the former case both the 
absorption and fluorescence spectra may be affected. When hydrogen-bonding 
occurs after eXCitation, only the emission will be perturbed by the 
interaction. It has been seen hON the luminescence of a molecule is 
highly dependent on whether the lowest excited singlet or triplet states 
are (n, IT *) or ( IT, If *) states. In hydroxyl ic solvents the ( IT, IT *) 
states are shifted to lower energies, while the (n, IT *) singlets increase 
in energy. It is possible for a molecule whose lowest singlet is (n, IT *) 
in nonpolar media to be (IT, IT *) in hydrogen-bonding solvents. This is 
the case with some aromatic carbonyl compounds which are very weakly 
fluorescent in aprotic solvents and highly fluorescent in hydrogen-bonding 
solutions. 
Many compounds exhibit a blue shift in their fluorescence spectra 
when the temperature is lowered and the solvent becomes more viscous. The 
increase in the energy of low temperature fluorescence compared to that 
at room temperature is due to the fact that the low temperature emission 
arises from a Franck-Condon state. At room temperature the solvent 
molecules reorientate themselves around the electronically excited solute 
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molecules in about 10-11s. Since the lifetime of fluorescent states is 
abc~t ~8-8s, room temperature fluorescence is never observed from the 
Franck-Condon state. Nevertheless, if the temperature is lowered 
sufficiently, the time required for reorientation of the solvent may be 
greater than the lifetime of the excited state and emission from the 
Franck-Condon state may be observed. 
The low temperature blue shift in fluorescence is, in fact, 
an effect of viscosity rather than temperature. A similar blue shift in 
room temperature fluorescence can be obtained for compounds embedded in 
rigid matrices. Thus t~e importance of solvent relaxation is supported 
by the finding that the fluorescence of TNS in ice resembles that in 
organic solvents (Seliskar and Brand, 1971a). Although the dye is 
surrounded by polar molecules in ice, they are not free to relax during 
the lifetime of the excited state. Similarly, the emission maximum of TNS 
in glycerol is temperature dependent (Seliskar and Brand, 1971b), shifting 
to the red (lower energy) with increasing temperature. Not surprisingly, 
at about 3000 K where the relaxation time of glycerol is similar to the 
fluorescence lifetimes of N-arylaminonaphthalenesulphonates, the emission 
spectrum of TNS is particularly temperature-sensitive. 
The rates of radiationless decay of electronically excited 
molecules in solution are also temperature dependent. The probability of 
deactivation of the excitation energy through collisions of the excited 
species with the solvent, or with other solute molecules, rises as the 
temperature of the medium increases. In fact the long lifetime of 
phosphorescence makes it so susceptible to competition from radiationless 
processes that this type of emission is not normally obtained in solution 
at room temperature. It is usually necessary to employ rigid media at 
very low temperatures in order to detect phosphorescence. Similarly 
fluorescence intensi ties increase at low temperatures. Moreover, 
luminescence spectra in rigid media at low temperatures often show well-
resolved vibrational structure. In solution at room temperature such 
structu~ is lost due to collisional processes. 
The effect of temperature is clearly complex due to the separate 
temperature dependent factors of diffusion, intramolecular energy 
conversion, excited state processes such as hydrogen-bonding with the 
solvent, and the effect of temperature on equilibria in solution. 
Important spectroscopic characteristics including th!! quantum 
yield of fluorescence, may show a concentration-dependence. At low 
concentrations, the fluorescence intensity of a given solute may increase 
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linearly with concentration. At high concentrations the fluorescence may 
reach a maximum and even decrease with further increases in concentration. 
Several processes may be responsible for this 'concentration quenching.' 
The low frequency tail of the absorption spectrum of a solute 
may overlap the high frequency end of its fluorescence spectrum. The 
fluorescence emitted by an excited state molecule may therefore be 
reabsorbed by a ground state molecule of the same solute. The magnitude 
of the effect increases with rising solute concentration. The self-
absorptive process can appreciably distort the shape of the emission band. 
Many ground state aromatic molecules may form dimers or 
aggregates in particu1 ar solvents. The tendency to form dimers increases 
at high concentrations, and if the dimer is less fluorescent than the 
monomer, the overall fluorescence will be quenched. It is also possible 
for an electronically excited molecule to form an excited dimer, or excimer, 
with a ground state molecule of the same solute. So, in some cases, as 
the solute concentration is increases a gradual dissapearance of the initial 
fluorescence and the appearance of a new spectrum is observed. 
Dimer and excimer formation can also occur between different 
solute molecules. When a complex forms between a luminescent species and 
a quencher, an excimer of mixed character is produced and the process is 
called co11isiona1 quenching. It occurs at~or near the diffusion 
controlled rate and is strongly dependent upon the viscosity of the medium. 
Co11isiona1 quenching is normally rendered negligible by adjusting the 
solution so that no solute is present at a concentration greater than 
about 10-3M. Many quenching reactions involve specific interactions between 
the f1uophor and a quenching agent. For example, heavy atoms in a solvent 
may quench the fluorescence of a solute molecule by increasing Singlet to 
triplet intersystem crossing and phosphorescence when the solute interacts 
with the solvent sheath. 
Intermolecular energy transfer provides another pathway by 
which the emission of a f1uophor may be quenched in solution. Intermolecular 
energy transfer may be significant for high concentrations of donor and 
acceptor molecules but diminishes with dilution of the solution. This is 
so because with dilution the average intermolecular distance may increase 
beyond the range of dipole-dipole coupling. When two absorbing species are 
combined into a single molecule, the probability of energy transfer, 
which is then an intramolecular process, increases enormously. If the 
conbination is such that the two parts of the molecule are within the 
range of dipole-dipole coupling, then the phenomenon of energy transfer 
will always be observed even in very dilute solutions. 
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It has been seen how simple self-absorption can effect the 
emission spectrum of a fluorescent compound. When other compounds are 
present in solution which absorb a significant proportion of the excitation 
or fluorescence radiation, the observed fluorescence may be diminished by 
what is kno~tn as an inner-filter effect. The non-specific trivial 
attenuation of the exciting or emitted beam is usually significant only if 
the concentration of an interfering species is sufficiently large for its 
absorbance to be greater than about 0.005. 
1.6.4 Practical Aspects of Fluorescence Spectroscopy 
For dilute solutions the intensity of therluorescence emission 
is directly proportional to the concentration of the fluorescent species. 
In concentrated solutions the linear relationship between f1uophor 
concentration and fluorescence intensity may break down because of inner-
fil ter effects or concentration-dependent self-quenching mechanisms. 
The quantity of fluorescence which is emitted by a sample is 
dependent on the intensity of the absorbed radiation multiplied by the 
quantum efficiency of fluorescence. So for any given concentration of 
ana1yte, the strength of the measured fluorescence signal may be increased 
simply by raising the level of the exciting radiation. Powerful light 
sources are therefore used in fluorimetry to ensure good sensitivity. 
Very intense sources, hOlo/ever, may produce photodecomposition of the sample. 
In absorpti ometry the si gna 1 s whi ch are measured are often 1 arger than 
those detected in fluorimetry; th~ intensity of the radiation emitted by 
a molecule is less than that which is absorbed. Nevertheless, for many 
organic compounds, luminescence methods are considerably more sensitive 
than absorptiometric procedures. This may be explained in terms of the 
manner in which the signals are measured. 
In absorptiometry the detector must distinguish a small difference 
between two large signals, each of which may contain an appreciable noise 
level. On the other hand, in fluorimetry the detector need only measure 
a small signal against a zero, or perhaps, very small background noise. 
This is feasible because fluorescence is emitted in all directions and the 
detector may be positioned at an angle to the incident beam. Thus the 
sensitivity of fluorimetry is often 10 to 1000 times greater than that of 
absorpti ometri c methods. 
In contrast, curvature of the analytical curves at high 
concentrations is a more severe problem in fluorimetry than it is in 
absorption spectroscopy. Consequently, absorptiometry is generally the 
preferred technique for high and intermediate concentrations of absorbers. 
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Apart from their greater sensitivity, luminescence methods have 
another useful quality. This is their high selectivity. Many molecules 
that absorb radiation have no emission spectra. Thus there are inherently 
fewer interferences I'men a luminescence rather than an absorptiometric 
method is employed. In addition another parameter may be used to enhance 
selectivity. In luminescence measurements both excitation and emission 
wavelengths can be selected to minimize interferences whereas in 
absorptiometrj only the wavelength of absorption is variable. 
Phosphorescence may be even more selective than fluorescence since 
phosphorescence decay times offer an additional parameter for differentiating 
between two phosphorescent species. This forms the basis of time-resolved 
phosphorimetry. Recently, however, techniques have become available for 
performing analysis using time-resolved fluorimetry. 
Larger bandwidths are possible in phosphorimetry than in fluorimetry 
because scattering problems are essentially nonexistent' in the former but 
relatively severe in the latter. Consequently the sensitivity of 
phosphorescence methods is often greater than for fluorescence methods. 
The disadvantage of phosphorimetry is that it is far more complicated 
experimentally than either fluorimetry or absorptiometry. 
As a result of Franck-Condon considerations, absorption 
spectroscopy can yield information on only the average ground state of 
molecules which absorb light. Only solvent mo1ecu1es:which are immediately 
adjacent to the absorbing species can affect its absorption spectrum. 
Thus absorption spectroscopy is not sensitive to molecular dynamics. In 
contrast, fluorescence spectroscopic parameters are sensitive functions of 
dynamic proce>ses which occur during the lifetime of the excited state and 
these processes can involve other molecules which are over 10nm away from 
the f1uorphor at the moment of excitation. The lifetime of fluorescence 
emissions (10- 7 to 10-9s) is a long time relative to the motions of small 
molecules in fluid solution, and it is a time span which is comparable to 
the rotational diffusion of proteins and membrane-bound fluorescent probes. 
Thus fluorescence spectroscopy can reveal the dynamic properties of proteins, 
membranes and nucleic acids on the nanosecond timesca1e (LakoNicz, 1980; 
Horie et al, 1~82). 
A block diagram showing the essential components of a typical 
fluorimeter or spectrof1uorimeter is given in Figure 1.10. The source of 
the exciting radiation is usually provided by an arc lam~. A shutter is 
included in the incident light path so that irradiation of the sample can be 
restricted to the period of measurement. The desired wavelength region of 
excitation may be selected by means of the excitation monochromator. 
SOllRCE SHUTTER 
I 
I 
SLIT 
I 
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MONOCHROMATOR (OR FILTER) 
SAMPLE 
COMPARTMENT 
EMISSION 
MONOCHROMATOR (OR FILTER) 
DETECTOR 
FIGURE 1.10 Major Components of an Instrument for Measuring Fluorescence. 
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Fluorescence is emitted by the sample in all directions but only a portion 
oi ";'" ,,",i~sion is sampled by the detection system at some angle, usually 
900 , from the axis of the exciting beam. The detection system consists of 
an emission monochromator which selects the wavelength region of the 
fluorescence emission to be measured; a photomultiplier which converts the 
fluorescence radiation into an electrical signal; and the am;>lifier-readout 
system. The latter amplifies and processes the electrical signal as 
required and displays it in a convenient form. Often one or more choppers 
are placed in the light paths in an attempt to decrease the effect of signal 
noise. The simpler instruments use optical filters in place of 
f'lonochromators and are called fi 1 ter fluorimeters. The more versatile 
spectrofluorimeters employ grating or prism monochromators. The term 'photo' 
sometimes appears in the naming of luminescence instrumentation and 
implies photoelectric detection of the emitted radiation. 
Equipment should provide reasonably high spectral resolution, 
sensitivity and signal-to-noise ratio over the desired wavelengths of 
excitation and emission. Spectral resolution. is a function of the design 
and adjustment of the monochromator system, or, in filter instruments, the 
choice of filters. Most noise arises from the radiation source, the detector 
and to a lesser degree, the amplifier-readout system. 
A spectrofluorimeter is capable of scanning the wavelength 
spectrum continuously and usually automatically. A fluorimeter is always 
a manual instrument best suited for measurements at fixed wavelengths, a 
change in filter being required each time the wavelength is altered. The 
spectrofluorimeter, having two monochromators, can therefore measure both 
excitation spectra in which the intensity of the fluorescence band is 
recorded as a function of the wavelength of the exciting light, and emission 
spectra in which the fluorescence intensity is measured as a function of 
the emission wavelength for a fixed wavelength of excitation. For analytical 
purposes th~ emission spectrum is normally used, although it is standard 
practice to run an excitation spectrum to select the optimum excitation 
wave 1 eng th. 
The intensity of the radiation source and the response ef the 
detector are both \1avelength dependent. Hence, the exact shapes of the 
recorded excitation and emission spectra will rely upon the pr~cise 
characteristics of the instrument used to make the measurerrents. The spectra, 
termed apparent or uncorrected spectra, may be grossly distorted versions 
of the true spectra. It is pOSSible, however, to make allowances for the 
source and detector characteristics and to generate true, that is, 
corrected spectra (Parker and Rees. 1960). 
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There are also a number of problems associated with the 
application of fluorimetry to quantitative analysis. Light scattering 
in particular may seriously limit the sensitivity and reproducibility of 
a fluorescence assay. Rayleigh scattering is commonly encountered in 
fluorimetry and occurs at the same wavelength as the incident radiation. 
This type of elastic scattering takes place in all directions with respect 
to the incident radiation and has a relatively symmetrical intensity 
distribution. The intensity of the Rayleigh scattering, however, varies as 
the inverse fourth power of the wavelength of the incident radiation and 
so becomes increasingly significant at short wavelengths. 
For Rayleigh scattering to occur the scattering centres must have 
dimensions much smaller than the wavelength of the incident radiation and 
be distributed in a medium of refractive index different from their own. 
Thus, in measuring the fluorescence of solutions, Rayleigh scattering is 
often observed from both solvent and solute molecules. 
Light scattering may also arise from particles in the colloidal 
range of sizes, where the particulate matter has dimensions greater than 
a tenth but less than about one and a half times the \~avelength of the 
incident radiation. This is Tyndall scattering. In contrast to Rayleigh 
scattering, the characteristic intensity pattern for large particle 
scattering is predominantly in the forward direction. Indeed, for very 
large particles only well-defined refracted and reflected beams remain. 
In general, then, light scattering is relatively non-specific 
and may be exhibited by· sample containers, optical surfaces and dust 
particles, as well as by the solvent and solute molecules of the sample. 
So while electronic excitation is a selective process and produces 
relatively few excited molecules, light scattering may occur from a large 
proportion of the molecules in solution. 
Rayleigh-Tyndall scattering may be a problem in fluorimetry 
especially when ahsorption and fluorescence peaks are close together and 
when the intensity of fluorescence is low compared to the intensity of the 
. 
exciting radiation. The effects of scattered radiation may be diminished 
by narrowing monochromator slit widths on both the excitation and emission 
side or by introducing a secondary cut-off filter. With spectrofluorimeters 
it is sometimes worthwhile to reduce the overlap of scattered and 
fluorescence peaks by lowering the wavelength of excitation and/or 
increasing the wavelength at which the fluorescence is measured. The 
geometry of the cell and cell holder may greatly influence the amount of 
scattered radiation incident on the detector; thus, it is common practice 
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to measure the emitted radiation at right angles to the exciting beaw.. 
An effect related to Rayleigh scattering may also give rise to 
spectral interferences in the measurement of fluorescence. Raman 
scatter is observed from many pure solvents. Raman bands are displaced 
by a fixed frequency from the incident radiation irrespective of the 
wavelength of excitation. This displacement arises because during the 
Rayleigh scattering process some of the incident energy may be abstracted 
and converted into vibrational or rotational energy. As a result of the 
inelastic process, the radiation that is scattered has a correspondingly 
lower energy than the incident radiation and is called the Stokes Raman 
band. On the other hand, a small proportion of the molecules encountered 
by the incident radiation will already be in higher vibrational and 
rotational energy states and may contribute this extra energy to the 
scattered photcns. This leads to scattered radiation of higher energy 
than the incident beam and it is termed anti-Stokes Raman scatter. The 
difference in frequency between the Raman bands and the exciting radiation 
is characteristic of the irradiated molecule and corresponds with certain 
vibrational and rotational frequencies of that molecule. The Raman 
bands are usually much fainter than the corresponding Rayleigh scatter 
peak. Of the the t.IO types of Raman band, the longer wavelength satelite 
is by far the more intense. 
Raman scatter is of primary concern in fluorimetry \~hen it occurs 
in the same region of the spectrum as a fluorescence peak. Although 
usually sharper than fluorescent bands, when monochromator slits are 
narrower Raman peaks can be mistaken for part of the analyte spectrum. 
When it occurs at a slightly shorter wavelength than fluorescence, 
troublesome Raman scatter may be minimized by the use of a suitable emission 
cut-off filter which removes all wavelengths below and including the Raman 
band. A better separation of the Raman and fluorescence peaks is 
achieved in a spectrofl uorimeter '1hen the excitat ion wave length is lowered. 
This produces a corresponding shift in the Raman peak to a shorter 
wavelength, but since the wavelength of fluorescence is independent of the 
wavelength of excitation, the fluorescence becomes separated from the Raw.an 
scatter. 
Both Rayleigh-Tyndall and Raman scatter differ from fluorescence 
in their degree of polarization and can be removed from fluorescence 
spectra by the proper use of polarizers. Thus, although they may 
diminish the measured signal somewhat, polarized filters may increase the 
sensitivity of fluorimetry for certain quantitative analyses (Lim et al, 1978). 
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Another practical problem encountered in analytical fluorimetry is 
the well-known inner-filter effect. Although it has no influence on the 
primary process of emission from excited state molecules, it may lead to 
a serious reduction in the intensity of the observed fluorescence through 
absorption of the excitation or emission radiation within the sample itself. 
The phenomenon is responsible for the distortion of otherwise linear 
calibration plots of observed fluorescence intensity versus concentration. 
Since inner-filter effects operate through the absorption of radiation 
within the sample, the distortion of analytical curves becomes more marked 
at high concentrations of fluophor where the absorption is high. As a 
self-absorption process, the effect is clearly dependent on the light paths 
through the sample and can be controlled experimentally by a suitable 
adjustment of the sample cell geometry. Absorption may be reduced by 
minimising the path-length through the sample for both the excitation and 
emission beams. This is commonly achieved by placing the cell excentrically 
~!ithin the sample compartment and allowing the incident or- emitted radiation 
to pass through only a portion of the sample cell. For highly concentrated 
solutions it is possible to increase the linear concentration range by the 
use of microcuvettes. 
Front-surface illumination of samples in fluorimetry has been 
employed in attempts to minimise the problems of inner-filter effects. 
Unfortunately the application of this technique is often limited by 
difficulties associated with light scattering and background fluorescence. 
Methods for the correction of fluorescence measurements for inner-filter 
effects have been described by Mertens and K!gi (1979) and Christmann et al 
(1980). Due to the temperature sensitivity of fluorescence, it may be 
necessa~y to ensure that the sample is maintained at a constant temperature 
prior to measurement. For accurate work thermostated cell holders may be 
required. 
A final practical consideration concerns the stabilization of 
the recorded fluorescence intensities. Even with fixed instrumental 
settings the recorded signal may vary with time. This variation is normally 
dUe to instrumental drift and necessitates the use of stable fluorescent 
standards in quantitative analysis. The standards are used to detect and 
monitor changes in the instrumental response. 
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1.7 Mathematical Models and the Graphical Representation of 
Binding Data 
As discussed in Section 1.5, many studies are concerned with 
drug-protein systems at equilibrium and with the determination of the 
degree of binding as a function of the composition of the sample. This 
is so because in principle it is possible to determine the number of 
classes of binding sites, the number of sites in each class, and the 
affinity constant of each class from estimations of the free and bound 
fraction of the ligand. In practice, however, the analysis of binding 
data is a fundamental problem and the focus of much. current research. 
Clearly, the model which best describes the collected data 
must be sought. It is preferable if the model is an accurate reflection 
of a real biochemical or biophysical process, but it may simply be a 
mathematical tool for interpolating data. There should be sufficient 
experimental data to generate precise estimates of the parameters of the 
model. Within the constraints of the model, efforts should be made to 
interpret these parameters in physiochemical terms such as those 
described above. The aim of this section is to discuss the theory and 
application of some mathematical models of drug-protein binding. 
Consider the general case of the completely reversible 
association of a ligand A with n unoccupied, prexisting sites of a 
macromolecule P, each site being capable of interacting with the ligand. 
Assume initially that activities are equal to concentrations and all sites 
interact independently with the ligand A. The kinetic reaction for an 
individual binding site is described by 
k 
P + A --l. PA 
Tt 
and can be characterized by the differential equation 
d [PAl 
dt 
= kIp] rA] - k' [PAl 
where [ J denotes mol ar concentrati on; and k and k' are the rate constants 
of the forward and reverse reactions. At equilibrium d~~AJ= 0 and the 
intrinsic microscopic association constant is 
k [PA] 
= k' = IPl rAJ 
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Kt in this case is also called the apparent association constant or the 
Statchard association constant. The fraction of occupied sites is 
[PA] 
r; = [r.] + [PA] = 
where r, and [A] are the variables that are usually measured. This equation 
also defines the probability that a ligand binds to a given site. 
Since it is assumed that all the binding sites are independent 
and equivalent, the probabilities may be summed over the n sites to obtain 
the average number of molecules bound, 
(1.1) 
If there are m classes of sites, all of which are independent 
but UQt equivalent then for each class i having ni sites with an apparent 
association constant ki' equation 1.1 can be generalized so that 
m 
r " L or 
i=1 
r = + 
n. k. [A] 
(1.2) 
l+k. [A] 
This is called the generalized Scatchard model (Scatchard, 1949) and 
assumes that the binding of a drug molecule at one site does not influence 
the binding at another site. This model has been applied very widely tc 
calculate the classical binding parameter n" kL and mL' 
The difficulty with the Scatchard model is that a number of the 
fundamental assumptions used in its formulation are open to question. 
For example, the Scatchard analysis assumes that all of the binding sites 
exist initially and compete independently for available 1igands. This is 
inconsistent with observations that the binding of certain organic 1igands 
to albumin produces conformational changes in which binding sites are 
altered or formed (see Section 1.4.3). In the case of ionized drugs, a 
modification of binding may arise when there is a resultant overall change 
in the electrostatic environment of the protein which affects the binding 
.' 
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of further drug molecules. 
:-i'vi'" ii theoretical viewpoint, the stepwise multiple equi1ibria 
model is the most satisfactory theory on which to base the analysis of 
drug-protein binding data. The binding of a ligand to a macromolecule that 
contains no subunits can be described as a sequence of n stepwise 
equilibrium reactions (K10tz, 1953) where 
k, [PAJ 
P + A -..:>. PA, ..-- K, = 
k' [p] [A} , 
k~ [PAJ 
PA,+ A --'> PAa. ..--- K& = [PAJ [A] k.: 
PA •• , + A PA" K" = (1.3) 
This model does not presuppose the existence of n fixed sites, but only 
that n associations of a ligand to a macromolecule can OCCUr sequential1y. 
Clearly such a model is not based upon the assumption that the 'sites' 
bind independently. In fact, additional sites can be created or eliminated 
by the process of binding to an existing site. Thus the model can 
incorporate cooperative binding effects. 
Since the number of moles of bound ligand equals the number 
of moles of PA, plus twice the number of moles of PA , and so on, the 
weighted average of the numrer of ligands bound per mole of macromolecule 
can be written as 
IPAJ + 2 [PAJ +.. ..,.+ [PAJ 
r ;: [pJ + [PAJ +[PAJ + .•... + [PAJ 
Thus in view of equation (1.3) 
r = 
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or 
~ n 
K.[AJ + 2K, K ... [AJ + ...... -+ n (Ko Ka, ... K.,) [A] 
r = 
1 + K, [AJ + K, Ka.t A J\ ..... + (K, Ka,·. 'K,,) [A]" (1.4) 
This is the generalized equation for the extent of binding according to the 
theory of multiple equilibria (Klotz, 1953). 
The Scatchard model and the sequential equilibria model appear to 
be quite different. The classical thermodynamic analysis of binding 
(Klotz, 1946; Klotz, 1953), which forms the basis of-the stepwise multiple 
equi1ibria model, does not depend on any recognition of specific sites. 
The stepwi se bi ndi ng cons tants so obtai ned express the equi 1i bri a in 
purely stoichiometric terms and may have no meaning as actual site-binding 
constants (Klotz, 1983). It has long been acknowledged, nonetheless, 
that the stoichiometric (also known as macroscopic or classical) binding 
constants must be related to the site (or microscopic) binving constants 
for certain systems. General relationships between stoichiometric and site 
binding constants have been described for a multisite system by Fletcher 
et a1 (1970). Using these relationships, and supposing that n sites 
prexist and that all of these n sites have the same intrinsic microscopic 
association constants, it can be shown that the general stepwise equilibria 
model, equation 1.4, contains the Scatchard model, that is equation 1.2, 
as a special case (F1etcher et al, 1970; 1973; Klotz, 1953). 
Despite the fact that most laboratories have easy access to 
computing facilities, the graphical representation of binding data has lost 
none of its appeal. The earliest approach to the plotting of protein 
binding data was the adsorption method by Freudlich (1907) and Langmuir 
(1917) where r is plotted against [A]. This approach is unsatisfactory 
since curved plots result and large changes in binding at high drug:protein 
ratios result in only a small alteration in curvature. The most commonly 
used representations employ various linear transformations of equation 1.1: 
three examples are shown below. 
1 1 1 1 
-r = nk [Aj +-I n (1.5), the double-reciprocal plot (Klotz,1946); 
w=- 1 [A] +_1_ r n nk, (1 .6), (Kl otz, 1953); 
r 
-k r + k, n 
--= [A] 
, (1.7), the Scatchard plot (Scatchard, 1953). 
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The graphical equivalents of equations (1.5), (1.6) and (1.7) are shown 
in Figure 1.11 (a), (b), and (c) respectively, and are particularly useful 
when fitting equation 1.1 to experimental data. Some less frequently 
used graphical representations are discussed by Bridges and Wilson (1976). 
Equation (1.1) applies only to a single class of independent 
binding sites with the same intrinsic binding constant. When there are 
two or more independent classes of sites, or interacting sites, the 
functions represented by the coordinates in Figure 1.11 will no longer 
give linear graphs. It may still be possible to determine the limiting 
slopes and intercepts on the coordinate axes for the curves but the 
relation of these graphical parameters to the site binding constants is 
not what seems to be commonly assumed on intuitive grounds. The general 
expressions for the graphical parameters have been derived by Klotz and 
Hunston (1971), nevertheless the widespread misinterpretation of curved 
binding plots still pervades the literature on drug-protein binding. 
Norby et al (19BO) reviewed 50 publications which contained various errors 
of graphical construction: many authors continue to use incorrect methods 
to estimate binding constants. Some of the more common mistakes are 
discussed below. 
In a large number of studies authors have based their conclusions 
on insufficient and sometimes rather imprecise data. Straight line graphs 
have been fitted by eye or by least-squares methods to a few scattered 
points covering only a small fraction of the binding isotherm. The number 
of binding sites and the apparent association constants have been derived 
from the intercepts on the axes. Unfortunately, to obtain proper estirrates 
of the bindi~g constants, reliable measurements must be available over 
an extensive range of ligand concentrations. Klotz (1982) has recently 
pointed out the problems of calculating the total number of binding sites 
from Scatchard plots and suggested that it is better to estimate this 
parameter from a semilogarithmic plot of bound ligand concentration versus 
the logarithm of free ligand concentration; the advantage of the 
semilogarithmic plot is that interpretation of the characteristic sigmoidal 
curve matches it imperative to take measurements over a wide range of ligand 
concentration. A particular problem encountered with the interpretation 
of curved Scatchard plots was highlighted by the survey of Norby et al 
(1980): many authors appeared to have preconceived ideas urging them to 
obtain limiting intercepts corresponding to whole numbers on the abscissa. 
Since the intercept on the abscissa represents an n-value only in extreme 
cases (Klotz and Hunston, 1971), the dangers of subjective influencies on 
(a) 
-k 
(b) 
(c) 
r 
/fA] 
1 ~ 
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FIGURE 1.11 Graphical Representation of Three Commonly Used Linear 
Transformations of the Binding Equation for a Single Si te 
or a Single Class of Sites. 
The slopes and intercepts of the straight lines are indicated. 
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the decomposition of the plot are clear. 
r·lanual procedures have been developed for fitting the parameters 
of the Scatchard model to sets of experimental data when more than one class 
of binding sites exi st (Rosenthal, 1967; Pennock, 197.3). Although 
theoretically sound, the manual graphical methods for determining binding 
parameters in complex systems are tedious and rather subjective. Fletcher 
et al (1973) have used a computerized method for accomplishing a least 
squares fit of the generalized Scatchard model to experimental data. A 
flexible curve-fitting program which uses a nonlinear least squares 
procedure has been developed by Munson and Robard (1980) to analyse the 
results of ligand binding studies; the analysis is based, in part, on the 
theoretical considerations of Feldman (1972). The report of Feldman (1972) 
includes graphical methods for the estimation of binding parameters from 
the Scatchard curve in those cases where the curve reduces to a 
hyperbolic form, and computational methods for fitting parameters to 
experimental data from more complex ligand-binding systems. 
Although it is possible to resolve non-linear Scatchard plots 
into tNO or more independent components by fitting the generalized Scatchard 
model (equation 1.2) to the data, the curvature of the binding plots may 
be due to cooperative interactions rather than to the presence of several 
classes of independent binding sites. In these circumstances, the 
assumptions inherent in the Scatchard model have been violated and the 
Scatchard constants derived from the curve-fitting procedure are not 
meaningful as binding constants. Thus, the mechanism of the binding 
process need not necessarily satisfy the Scatchard assumptions even though 
the data are adequately fitted by the Scatchard model. 
The slope of a Scatchard plot of the data may, however, reveal 
useful information about the form of the binding model that should be 
chosen for fitting the data. It can be sho\~n that the slope of the 
Scatchard plot is always negative (Fletcher et al, 1973), that is, the 
data on ,the Scatchard plot must have an everywhere negative slope if this 
model is to be fitted. Therefore, if the Scatchard plot of the data has 
a slope that is non-negative over any range of its values, only the step\~ise 
form of the model can be applied. On a plot of ~ versus r, a positive 
slope signifies that as ligand binds to the macromolecule the probability 
of more ligand binding increases: this is the phenomenon of positive 
cooperativity, an allosteric effect on the binding process. Jose and 
Larralde (1982) have presented a qualitative graphical analysis of the 
sensitivity of the Scatchard plot to site-site interactions based on a 
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computerized simulation of the stepwise binding model of Klotz (1953). They 
have shown th at Scatchard plots may aqui re ve ry unusual shapes wi th 
several inflection points when there is a mixture of positive and negative 
intramolecular interactions. 
Since the stepwise model is completely general and applies to all 
mUltiple equilibrium reactions, even when a variety of cooperative effects 
are present, it is an extremely powerful theory on which to base the 
analysis of drug-protein binding data. However, when n is greater than 
2 in equation 1.4, fitting this equation by means of a non-linear curve-
fitting procedure requires reliable starting estimates for the 
stoichiometric binding constants. Fletcher and co-workers (1970; 1973) 
have proposed a practical means for fitting binding data to the stepwise 
equilbria model. An initial indication of the nature of the binding can 
be obtained from the Scatchard plot of the data. If the data indicate an 
everywhere negative slope, the results can be fitted to the generalized 
Scatchard model. This does not imply that the assumptions in the 
generalized Scatchard model are satisfied but only that it can not be 
distinguished from the stepwise model at this point. The mathematical 
equivalence of the stepwise and Scatchard models means that approximate 
values of the stoichiometric binding constants can be derived from tile 
parameters of the Scatchard model. These estimates are then refined by 
a least-squares fitting procedure which analyses the data in terms of the 
stepwise equilibria constants. Whenever the Scatchard model is not 
applicable, for example when the Scatchard plot has a positive slope in some 
region, the starting estimates of the stiochiometric binding constants 
must be obtained by trial and error or from other independent information. 
Altheugh the step\~ise multiple equilibria model is mere general 
than the independent-site model (the basis of the Scatchard plot), in 
that no a priori assumptions are made about the existence or nature of the 
binding sites, the amount of physical insight that can be obtained from the 
stepwise equilibrium constants is limited. Furthermore, whenever the 
assumptions of the Scatchard model are not violated, the microscopic 
(or site) binding constants represent the true association constants. 
Monot et al (1983) have considered difficulties in applying the 
Scatchard model of ligand binding to proteins. The problems encountered in 
applying the stepwise equilibria model are as formidable. A practical 
limitation associated with the use of these models stems from the large 
numbers of parameters they contain. A great deal of highly accurated 
experimental data is required to estimate the values of even a small number 
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of the binding parameters. It is often meaningless to fit anything more 
co'"pi i .. ai.t:'; i.:,cin a two-site Scatchard model to a set of data; this model 
contains four unknCMns n, , nu k,and k~. Monot et a1 (1983) propose 
other models \~ith only two parameters, but despite the simplification they 
bring to curve-fitting, these models are primarily mathematical tools and 
offer no insight into the binding process. 
It can be argued that thp Scatchard plot, the double-reciprocal 
plot and the like are of limited value in representing drug displacement 
interactions since they display only one drug and can be potentiaHy 
misleading. When both drugs are present at approximately the same 
concentration and both occupy a substantial fraction of the available 
binding sites, then the mutual displacement of each drug should be 
considered. Aarons et a1 (1979) have proposed that a superior method of 
anaiysin!;J cirug displacement interactions is in terms of the stepwise 
equi1ibria model and discusses the considerable numerical problems 
associated with thp. fitting of this kind of model to experimental results. 
Interpretation of the significance of the stepwise equi1ibriuffi constants 
may also be difficult. The same authcrs have experimented with a different 
kind of representation of drug displacemp.nt interactions. This involves 
a three dimensional plot in which the abscissa are the total concentrations 
of the two drugs and the ordinate is the unbound concentration of either 
drug (Aarons et a1, 1979). As pointed out by Rowland (1980), when there 
are ffiore than two species interacting at a common binding site, a 
quantitative interpretation of the underlying events is virtually 
impossible. 
There clearly remain several theoretical and practical difficulties 
associated with the analysis of drug-protein binding data. The limitations 
of the different models of analysis must be appreciated if binding 
experiments are not to be misinterpreted. 
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CHAPTER 2 
Materials and Standard Experimental Methods 
This chapter describes the basic procedures which were followed 
repeatedly during the practical work. More specific and non-routine methods 
are discussed fully in later chapters. 
2.1 Chemicals 
2.1.1 Source and Pretreatment 
Human serum albumin. or HSA. of 100% electrophoretic purity was 
purchased from Hoechst. No attempt was made to remove fatty acids from the 
commercial preparation. 
Warfarin. phenylbutazone. ethacrynic acid. 2-p-(ch10rophenoxy)-2-
methyl propionic acid (CPMP). and the sulphonamide drugs sulphisoxazole. 
sulphamerazine. sulphadiazine. sulphapyridine and su1phisomidine were 
produced by the Sigma Chemical Company and f1ufenamic acid by Parke. Davis 
and Co. They were used without further purification. 
The ammonium salt of 8-ani1ino-l-naphthalene sulphonic acid (ANS) 
was obtained from Sigma Chemical Co. It was purified by several 
recrysta11izations from saturated magnesium chloride solutions following the 
procedure used by Dodd and Radda (1969). The green crystals of the magnesium 
salt. (C16 H12 N S03)zMg. 2 H20. were dried in an oven at 1100C for 24 hours 
to yield the stock reagent (see Figure 2.1 for chemical structural formulae). 
Quinine sulphate and Tris. that is. Tris-(hydroxymethyl)-methy1amine. 
were manufactured by B.D.H. Chemicals Ltd. Aristar grade Tris was used in 
fluorimetry. Other laboratory reagents were of analytical grade. 
2.1.2 Preparation of Solutions 
Unless otherwise stated. solutions were made up in O.lM Tris-HC1 
buffer at pH 7.40. The buffer was prepared using good quality double-distilled 
water that had been collected in glass. The pH was adjusted with a small 
quantity of concentrated hydrochloric acid. Those drugs having low water-
solubi1ities were first dissolved in small volumes of ethanol or O.lM 
sodium hydroxide before making up to the required concentrations in the 
aqueous buffer. To avoid frothing of the solution and a possible denaturation 
of the protein. albumin was carefully dissolved in the buffer with little 
or no stirring. 
Quinine sUlphate solutions were produced in O.OSM sulphuric acid. 
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FIGURE 2.1 Chemical Structural Formulae of Drugs and Fluorescent Probes 
used in this Study. 
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2.1.3 Determination of Concentrations 
For quantitative work it was necessary to control the concentrations 
of reagents in the standard solutions as accurately as possible. 
After heating in a vacuum oven and reweighing at hourly intervals, 
all the commercial drug samples were found to contain less than 1% water 
by weight. Accordingly, solution concentrations could be deduced from 
accurate measurements of dry-weights. As a safeguard the water-content of 
powdered stock samples was checked periodically. 
Routine determination of HSA was achieved by measuring the 
absorbance of solutions at 280nm and using an extinction coefficient, 
E l~m = 5.30 (Chigne11 1969a);a molecular weight of 66.500 (Me10un et a1 
1975) was used to calculate the corresponding molar concentrations. 
2.1.4 Storage of Chemicals 
All chemicals were stored as recommended by the manufactures. Thus 
for sulphisoxazole the instruction "store dark and desiccated at 0.50C" was 
adhered to. 
Whenever possible solutions were stored in the dark. To minimize 
bacterial contaminations all solutions containing Tris-HC1 buffer were kept 
at 40C and used as soon after preparation as possible. If, despite the 
precautions, solutions became cloudy through bacterial growth they were 
immediately discarded. This avoided the necessity of adding preservatives 
such as sodium azide or thiomerca1. 
Serum samples were separated into convenient volumes and stored 
neat at -40C. Dilutions were made up as required. 
2.2 Instrumentation 
Absorbance spectra were run on a Pye Unicam SP8000 Ultraviolet 
Recording Spectrophotometer. This instrument was used for qualitative 
purposes only. 
Quantitative absorbance readings at fixed wavelengths were produced 
with a Pye Unicam SP600 UV Spectrophotometer. Unless otherwise stated, 
matched 1cm x 1cm silica cells were used to contain sample and reference 
solutions. 
Fluorescence intensity measurements were obtained at preselected 
settings of the excitation and emission monochromators on a Baird-Atomic 
F1uoripoint Spectrof1uorimeter fitted with manual wavelength controls. 
F1 uorescence exci tati on and emissi on spectra \'/ere generated us ing a Bai rd-
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Atomic F1uoricord instrument. This machine has an automatic wavelength 
drive. 
A Perkin E1mer MPF44B Fluorescence Spectrophotometer with a 
differential corrected spectra unit attachment, the DCSU-2, was employed 
to measure fluorescence intensities at fixed wavelengths and to produce 
corrected and uncorrected excitation and emission spectra. This versatile 
instrument was also used for the recording of synchronous and derivative 
spectra. 
For certain fluorescence titrations it was desirable to minimize 
temperature fluctuations within the sample solutions. This necessitated 
the acquisition of a thermostatically controlled water-bath, a combined 
temperature-block and cell holder capable of installation into the 
fluorimeter cell compartment, and a reliable water pump. Water from the 
bath was pumped through the temperature-block and cell holder, and efficient 
heat-exchange between the circulating water and the fluorimeter cell walls 
meant that the sample solution could be easily maintained at a constant 
temperature. 
The fluorimeter cells were a matched pair of 1cm x 1cm silica cells 
(Spectrosi1 Code Q Type 3, Chem1ab Instruments ltd) with a low absorbance 
in the ultra-violet region. 
Buffer pH was adjusted with the aid of the Ell 7050 (Electronic 
Instruments ltd) or the PHM 64 Research pH Meter (Radiometer ltd). 
Other equipment, notably that designed or modified to perform 
specific tasks, is described in the appropriate sections of the thesis. 
2.3 Spectrophotometric Measurements 
Absorption spectra and absorbance valves at fixed wavelengths were 
produced by standard procedures. As is common practice in spectrophotometry, 
reference solutions contained eve~thing in the sample except the analyte. 
In most cases this simply meant using a diluent buffer as the reference. 
Sample a~d reference solutions were always equilibrated at room temperature 
prior to insertion in the spectrophotometer. They were inspected before and 
after measurement to ensure bubbles were not adhering to the cell surfaces. 
For any substance the wavelength of maximum absorption could be 
determined by running a spectrum. Whenever possible this peak wavelength 
was chosen for quantitative measurements of absorbance. Basic theoretical 
considerations reveal why this is the most suitable choice. 
Close to the absorption peak, the absorbance of the sample varies 
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little with the wavelength. This is in contrast to other regions of the 
spectrum where the absorption curve is steep. Using the absorption maximum 
as the analytical wavelength minimizes the effect any irreproducibility or 
error in the wavelength setting may have on the precision or accuracy of 
the absorbance measurement. 
Another obvious justification for taking readings at the maximum 
in the absorption spectrum is that the highest available sensitivity can 
normally be achieved at this wavelength. Furthermore, this procedure 
minimizes apparent deviations from Beer's law when the incident radiation 
is of a wide bandwidth (Olsen, 1975). 
Having decided on a suitable wavelength for'quantitative work, it 
became necessary to define a sensible range over which absorbance values could 
be accurately determined. In this context it is worthwhile to consider the 
Beer-Lambert law. 
The Beer-Lambert law may be expressed as: 
10910 (Io/I) = A = ecl (2.1) 
10 and I are the intensities of the incident and transmitted light 
respectively, and 10910 (Io/I) is defined as the absorbance A. C is the 
concentration of the absorbing species and e is the molar absorptivity 
(the absorbance of a lM solution in a lcm cell). If Equation (2.1) is used 
to find the concentration of the absorbing species, and assuming the 
Beer-Lambert flow is applicable, then the maximum precision in the 
determination of c must correspond to the maximum precision in A. 
Random errors associated with the measurement of absorption impose 
a limit on the degree of precision attainable. At low absorbances the 
instrument must discern a small difference between two large signals both 
of which includes an appreciable noise level. At high absorbances, where 
only a small amount of radiation is incident on the detector, a high 
amplification gain is required and an accurate measurement of the 
transmitted intensity is unlikely. So the range over which accurate 
absorbance values may be generated has well-defined upper and lower limits. 
If the error in measuring the intensity of the transmitted radiation 
is constant over the operating range, differentiation of Equation (2.1) allows 
the relative error in the absorbance reading to be calculated. As expected, 
the error function, which is sometimes called the Twyman-Lothian curve, 
passes through a minimum. The absorbance corresponding to the minimum error 
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is found by differentiating the Beer-Lambert equation again and setting the 
Se':'"",'; ":CI ivo.i.ive equal to zero. As it transpires. the minimum relative 
error occurs at an absorbance of 0.434. More significantly. the error 
function helps to define the useful range for taking absorbance measurements; 
outside the interval 0.2 to 0.7 absorbance units. readings are subject to 
rapidly increasing errors. A further discussion of the precision of 
spectrophotometric measurements is presented by Gridgeman (1952). 
The Beer-Lambert law was used in the determination of unknown 
sample concentrations. Steps were taken to ensure absorbance measurements 
were made under conditions conducive to attaining maximum or near maximum 
precision. Two approaches were used. In the first. linear calibration plots 
were produced from measurements taken on solutions of known concentration. 
Unknown solutions were subsequently determined by recording sample absorbances 
and reading the corresponding concentrations off the calibration plots. The 
second approach made use of published absorptivity values. In the routine 
determination of HSA. for example. absorbance measurements were taken at 
280nm and transformed into albumin concentrations by means of the accepted 
El~m value. 
In all quantitative work sample absorbances were adjusted to lie 
within the optimum range as defined in the preceeding theory. To determine 
solutions of high concentrations it was necessary to take accurate dilutions 
of the sample until the absorbance reading fell within the required limits. 
For very dilute samples. on the other hand. the absorbance of a suitably 
concentrated stock solution was first determined. This solution could then 
be diluted to the required strength. 
An allowance was made for slight differences in the transmission 
properties of the absorption cells. With one cell containing the reference 
solution and the other acting as the sample cell. the absorbance of the 
sample solution was measured several times. The mean A. and the standard 
deviation a. were calculated for these results. The roles of the cells 
were then reversed. That is, the cell that had contained the sample 
solution was thoroughly rinsed and used to hold the reference solution. while 
the former reference cell was washed and filled with sample solution. Values 
for the sample absorbance were obtained again. and the mean A2 and standard 
deviation 0 of several measurements recorded. Writing A = (Al + A2)/2 and 
1 1 • _ 
a = I ( 02 + a2 ) allowed the calculatlon of A. the absorbance corrected for 
cell-mismatching. and if required, enabled the corresponding standard 
de vi ati on ·a to be reported. 
Large differences between Al and A2 were viewed with suspicion as 
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they suggested at least one of the cells was dirty. In such circumstances 
ce i i~ wtm:! cleaned and measurements retaken. When coeffi cients of vari ati on 
were calculated from a they were typically 1.5% or less. 
2.4 Fluorescence Measurements 
2.4.1 Uncorrected Spectra 
Excitation and emission spectra were produced by scanning excitation 
monochromators at fixed wavelengths of emission. and by scanning emission 
monochromators at fixed wavelengths of excitation. respectively. Both 
types of spectra were run on Baird-Atomic F1uoricordand Perkin-E1mer MPF44B 
spectrof1uorimeters. In all cases the fluorescence was detected at right 
angles to the incident radiation. 
The following paragraphs outline the main steps taken in the 
production of fluorescence spectra. 
All solutions were allowed to equilibrate at room temperature 
before transferring to the fluorimeter cells. If air bubbles formed on the 
cell surfaces. they were removed. Strict temperature control of sample 
solutions was unnecessary except when quantitative measurements of spectral 
intensities were required. 
Since the presence in solution of materials which absorb a 
significant proportion of the exciting or fluorescent radiation will diminish 
the observed fluorescence by an inner-filter effect. the concentrations of 
such substances and of the fluorescent species itself were maintained at 
levels corresponding to a low absorbance at the wavelengths of interest. 
Consequently. prior to recording a fluorescence spectrum, it often proved 
worthwhile to examine the absorption characteristics of a sample. 
After allowing a suitable warm-up time to elapse, the correct 
focusing and alignment of the lamp was assured. This was essential if a 
reasonable level of irradiation of the sample were to be achieved. 
Notwithstanding this. significant adjustments to the Perkin-E1mer lamp 
settings were seldom called for. 
To obtain reasonable spectra a suitable selection of the instrumental 
parameters was required. The most important parameters were those governed 
by the slit-width, time constant. scan speed and gain controls. 
General guidelines exist which are helpful in deciding the 
settings to use. A choice of monochromator slit widths may be partially 
determined by the type of spectrum being recorded. that is, whether it be 
an excitation or an emission spectrum. To obtain the desired resolution. 
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excitation spectra should be recorded with a sufficiently narrow excitation 
monochromator slit width; the emission monochromator slit may be wider, 
though, in order to give the intensity required for a good signa1-to-noise 
ratio. Conversely, emission spectra may be recorded with a narrow emission 
monochromator slit width and a wider excitation monochromator slit width. 
On the other hand, if high resolution is not required, wide slit widths may 
be used for both monochromators. In general though, the minimum slit widths 
consistent with acceptable signa1-to-noise ratios were sought. 
A poor choice of response times and scan speeds may result in gross 
distortions of recorded spectra. Fluorescence excitation and emission 
spectra are usually obtained by scanning the appropriate monochromator 
wavelength drive at a constant rate and recording the emission signal versus 
time. 
The response time is an indication of how quickly the output, pen 
position, needle recording, etc., follows changes in the input signal, be 
it current or voltage. A system with a short response time faithfully displays 
rapid changes in the input signal, whereas a system with a long response time 
smooths out and perhaps attenuates input signal changes. As a rule, random 
noise in the output of an analytical system may be reduced by increasing 
the response time. However, there is a limit to which the response time may 
be profitably increased. Excessively long response times may distort 
fluorescence spectral peaks and blur out details of fine structure. A 
similar effect arises with fast scan speeds, or a combination of fast scan 
speeds and long response times. The optimum scan speed obviously depends 
on the choice of response time and on the structure of the spectrum. 
The time constant is a measure of the response time of an instrument. 
It is the time taken for a signal to decay to lIe of its initial value. For 
faithful spectral reproduction the time allowed for a signal to change 
full-scale should be at least five time constants. So, with a O.ls time 
constant the signal should change in O.Ss or longer. For a scan speed of 
4nm s-l this amounts to a 2nm change • 
• A time constant of 0.3s and a scan speed of 2nm s-l were found 
suitable for most purposes. In fact, only in the derivative mode was 
spectral distortion a problem. 
Having selected appropriate slit widths, time constant, and scan 
speed, the photomultiplier gain was adjusted so that the peak signal in the 
spectrum was of a convenient magnitude, say 80% of full scale. If at the 
maximum gain only a small fluorescence signal could be obtained with the 
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chosen slit widths, or if the signal-to-noise ratio was unacceptably low, 
the SiltS were widened. Should this cause an appreciable loss in resolution 
.. 
or, indeed, fail to generate a large enough signal, the concentration or 
composition of the sample was adjusted. 
For each sample, the instrumental settings involved in the 
production of fluorescence spectra were invariably reported alongside the 
chart record. 
Sample solutions were only irradiated during the relatively short 
periods required to measure the spectra. At all other times the shutter 
was kept closed. This was an attempt to minimize photodecomposition of 
samples. 
Immediately after use, cells were cleaned by washing thoroughly in 
tap water and then rinsing in distilled water. Synthetic detergents were 
avoided whenever possible as many of these agents are known to be 
intrinsically fluorescent (Udenfriend, 1962). Occasionally deposits of 
protein or other substances formed on the walls of the cuvettes and had to 
be removed with nitric acid. After such treatment, the cells were carefully 
washed in the usual manner. Rather than leaving to soak in distilled water, 
the clean cells were dried in air. The disadvantage of the former procedure 
was that after a few days microorganisms became apparent in the soaking 
sol uti on. 
2.4.2 Corrected Spectra 
Similar considerations applied to the production of both corrected 
and uncorrected spectra. However, to generate corrected, or true spectra, 
it was necessa~ to make allowances for the source and detector 
characteristics of the fluorimeter. 
Interfaced with the MPF44B fluorimeter, the DCSU-2 microprocessor 
unit permitted corrected spectra to be produced automatically. Before 
running a corrected spectrum, the DSCU-2 unit had to be programmed as 
outlined in the manufacturers handbook. This involved the use of a 
Rhodamine B standard which enabled correction factors to be calculated and 
stored in the microprocessor unit every O.2nm over the specified range. 
Corrected excitation or emission spectra could be generated simply by 
selecting the appropriate mode on the DCSU-2 unit and running the spectrum 
in the usual manner. 
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2.4.3 Emission Intensities 
Quantitative measurements of fluorescence intensity were made at 
fixed wavelengths of excitation and emission on standard solutions of 
known concentrations. These standards were dilutions of an accurately 
produced stock solution. The results were expressed as calibration plots 
of fluorescence intensity versus concentration for various fluorescent 
species. They were used to determine the unknown analyte concentrations 
in different sample solutions. In so doing. the sample and standard 
fluorescences were measured under identical conditions. 
The choice of instrumental settings in the recording of fluorescence 
intensities was largely guided by an inspection of the relevant excitation 
and emission spectra. For a given sample. the highest sensitivity. and 
hence the lowest limit of detection. are normally achieved when the 
observed signal is a maximum. So. for analytical work the peak wavelengths 
in the fluorescence excitation and emission spectra are the obvious ones 
to employ. Moreover. as in absorption spectroscopy. using the maximum in 
the excitation and emission spectra tends to minimize the effects of any 
errors in the wavelength settings. 
Unfortunately. however. complications may arise in fluorimetry; 
the sensitivity and reproducibility of a fluorescence assay may be 
diminished by interferences due to scattered radiation. Not surprisingly 
therefore. further considerations are often necessary if optimal wavelength 
settings are to be achieved. 
Most scattered radiation has the same wavelength as that of the 
exciting beam. If there is only a small Stoke's shift between the 
fluorescence excitation and emission maxima. Rayleigh-Tyndall scattering 
from the sample may interfere with the measurement of fluorescence. Under 
these conditions. of course. scattering from cell surfaces. optics and 
slits will tend to aggravate the problem. 
To avoid collecting scattered radiation together with the sample 
fluoresc~nce. it may be necessary to select narrow monochromator slit widths 
or to employ a suitable cut-off filter. Both techniques were used in the 
practical work. 
As suggested previously. however. it is often feasible to reduce 
the overlap of scattered and fluorescence radiation by an adjustment of the 
wavelength settings. Lowering the wavelength of excitation produces a 
corresponding shift in the location of the Rayleigh-Tyndall scatter. At 
the same time. though. such an operation has no effect on the position of 
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the fluorescence band. Consequently, selecting a shorter wavelength for 
excitation tends to improve the resolution of scatter and fluorescence 
peaks. Measuring the fluorescence at a longer wavelength than that of 
maximum emission may similarly reduce the effects of scatter. So although 
the recorded signal is greatest when the monochromators are set at the 
wavelengths of maximum excitation and emission, lowering the wavelength of 
excitation, or increasing the wavelength of emission, or doing both these 
operations, may actually increase the sensitivity of an assay. Hence, the 
monochromator settings used in the measurement of fluorescence intensities 
did not necessarily correspond exactly to the peak wavelengths in the 
excitation and emission spectra. 
Raman scattering, which is a physical property of the pure solvent, 
could be readily distinguished from fluorescence because ·Raman peaks are 
always at a fixed frequency difference from the incident radiation 
irrespective of the wavelength of excitation. Although usually of very low 
intensity, Raman scattering can nonetheless be a problem when small 
fluorescence signals are to be measured. Fortunately, should the Raman 
band of the solvent coincide with the fluorescence emission from the sample, 
separation can again be achieved by changing the exciting wavelength to a 
lower value, when the Raman band will be similarly displaced. Since the 
wavelength of fluorescence is independent of the exciting wavelength, this 
method allows the fluorescence to be separated from the Raman scatter. 
In practice it was often helpful if the position of Raman peaks 
could be predicted, or at least identified, for any wavelength of excitation. 
The problem demanded that a shift in frequency be related to a shift in 
wavelength, and so required differentiation of the relationship, 
=1. c/v where and v are the wavelength 
and frequency of the radiation, respectively, and c is the speed of light. 
This gave: 
that is, d" 
2 
= -Alc dv (2.2) 
The negative sign in Equation (2.2) signifies that a decrease in 
frequency (negative dv) corresponds to an increase in wavelength {positive d~. 
Since c is a constant, knowing the fixed frequency shift dv between 
the Raman band and the exciting radiation allows the equivalent wavelength 
displacement d" to be determined for any excitation wavelength.". The Raman 
peak will be located at (" + d A) • A correspondi ng anti -Stoke I s Raman band 
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will be centred at the wavelength (~-dA) but is normally of low intensity 
all"; ""YW"Y ";u.,l> not interfere with the measurement of fluorescence. 
Aqueous buffers were invariably used as solvents in fluorimetry. 
The three modes of vibration in the water molecule are all Raman-active 
but only the symmetrical stretch gives a strong Raman band. The value of 
dv. corresponding to this band was used in Equation (2.1) along with the 
proposed wavelength of excitation to predict the location of the Raman peak. 
Such simple calculations proved useful in the interpretation of spectra; 
moreover, for quantitative work, they indicated how suitable instrumental 
parameters could be chosen to separate fluorescence emissions and Raman 
scatter peaks. 
In the absence of interfering species, resolution of the fluorescence 
and scattered radiation resulted in low blank signals. The minimization 
of biank signais is always desirable since the subtraction of a large blank 
signal from an only slightly larger blank plus sample signal is extremely 
prone to error. 
Theoretically, the blank solution should contain everything in the 
sample except the ana1yte. In most cases true blank solutions were available. 
For example, if the emission intensity of a fluorescent probe was to be 
measured when protein-bound, a blank solution could be prepared in which 
the protein concentration, buffer ionic strength and pH were identical to 
those in the sample solution. 
The blank and sample fluorescences were measured with the same 
instrumental settings and under the same experimental conditions. The blank 
value was subtracted from the sample fluorescence. Although the blank 
fluorescence. sometimes called the background fluorescence, was usually 
extremely small, suitable blanks were invariably prepared and sample readings 
blank-corrected at all times. 
As well as minimizing the effects of Raman and Ray1eigh-Tynda11 
scatter, it is important to check the purity of solvents if low fluorescence 
blanks are to be maintained. Thus. "Aristar" grade Tris and good quality 
double-distilled water were used in the preparation of buffer solutions. A 
less expensive batch of Tris was found to give an unacceptably high background 
emission. The water was always collected and stored in glass rather than in 
plastic vessels; organic additives and plasticizers have been known to leach 
out of plastic containers and into solution where they may interfere with 
spectroscopic measurements. Even if non-fluorescent, these contaminants can 
act as quenchers. 
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Similarly, all glassware used in fluorimetry was thoroughly washed 
i~ w,t~r tn remove traces of impurities such as chromic acid and detergents 
which may have an intrinsic fluorescence. 
The growth of microorganisms in buffer or sample solutions was seen 
to result in higher blank values, presumably through an increase in the 
amount of light scattered. To overcome this, solutions made up in buffer 
were always stored at 40C and discarded at the first signs of contamination. 
For accurate fluorescence work control over certain environmental 
factors was of great importance. In all quantitative experiments the 
temperature of sample solutions was maintained at 230C ~ 0.2oC using the 
apparatus described in Section 2.2. Strict temperature regulation was 
necessary for two reasons. Firstly, the fluorescence of a sample of constant 
composition could be varied simply by altering the temperature. This was 
not unexpected, since as discussed in Section 1.6.3 the quantum yields of 
many substances are temperature-sensitive. However, the second need for 
temperature control lay in the nature of the specific system under 
investigation. When a drug interacts with a protein, the equlibrium between 
the bound and unbound fractions is dependent on the temperature. So even if 
the total amounts of protein and drug are fixed, temperature changes can 
alter the composition of a sample as measured by the ratio of bound to 
unbound drug. Consequently, shifts in the solution temperature could not 
be tolerated if further complications in the interpretation of fluorescence 
data were to be avoided. 
Another factor carefully monitored was the sample pH. This was 
necessary since relatively small changes in pH can sometimes have pronounced 
effects on the intensity and spectral characteristics exhibited by a sample. 
Of equal relevance to this work is the fact that interactions between small 
molecules and proteins are sensitive to changes in pH. Presumably, this 
sensitivity is a result of structural perturbations. At all times, therefore, 
buffers were made up accurately and the pH carefully adjusted to 7.40. 
Subsequent to sample preparation, and having chosen the instrumental 
conditions, the actual reporting of measured fluorescence intensities needed 
some attention. Due to fluctuations in instrumental variables such as lamp 
intensity and photomultiplier sensitivity, it is normally impossible to 
obtain the same readings on a fluorimeter from one day to the next. In fact 
measurements may differ from hour to hour. This means that if precise 
quantitative fluorescence readings are to be recorded, some standardization 
of the equipment is required. A solution of a stable fluophor Of known 
concentration may be used to maintain the instrument at a given sensitivity. 
Adjustments are best accomplished by varying the amplifier gain or 
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photomultiplier voltage rather than the monochromator band widths. On the other 
hand, gradual changes in the instrumental sensitivity may be tolerated if 
the sample fluorescence is always measured with respect to the emission of 
the stable reference solution. 
One of the most widely accepted fluorescence standards is quinine 
sulphate. Solutions of quinine sulphate in 0.05M sulphuric acid were 
always used when quantitative fluorescence measurements were required. 
Nevertheless, as with all other standards, there are certain limitations on 
the application of this substance in fluorimetry which are worthy of 
consideration. 
Quinine sulphate undergoes decomposition at· very low concentrations. 
Bowen and Wokes (1953) reported that whereas quinine sulphate solutions 
containing 10-6g/ml or more are unaffected by prolonged irradiation, solutions 
of 2 x 10-Hg/ml or less deteriorate under continued exposure to ultra-violet 
light. It is apparent that decomposition of reference standards can lead to 
serious errors in the measurement of fluorescence. To minimize such errors, 
the concentrations of quinine sulphate reference solutions were normally 
10-6g/ ml or above, and stock solutions were always stored in the dark. 
Aside from the problem of photodecomposition, there is another good 
reason for avoiding very low concentrations of quinine sulphate. If adsorption 
of the solute on to glass surfaces is appreciable, then the effect will 
become more pronounced as solutions are diluted. Gradual removal of the 
fluorescent species from solution would produce an unacceptable decrease in 
the reference signal. 
Whenever the sample fluorescence was measured with respect to the 
emission of a reference solution,.it was preferable if the two signals to be 
compared were of a similar magnitude. This could be achieved by adjusting 
the strength of the reference solution but bearing in mind, of course, the 
above constraints on the concentration to use. If the sample and reference 
measurements differed by a factor of ten or more, then unduly small pen or 
needle deflections corresponding to either the sample or reference 
fluorescence would have to be monitored and large errors of measurement 
introduced. So for calibration plots extending over a wide range of 
fluorescence intensities, several reference solutions of differing 
concentrations were required. 
Reference solutions are normally only useful .for substances which 
fluoresce in the same region of the spectrum. Fortunately, quinine sulphate, 
with its wavelengths of maximum excitation and emission at 350nm and 450nm 
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respectively, was particularly suitable for our purposes and no other 
fluorescent standards were needed. 
Once instrumental drift had been allowed for, the values of the 
observed fluorescence intensities could be used to generate the calibration 
plots of fluorescence versus ana1yte concentration, mentioned at the 
beginning of this section. When these plots were extended over a wide 
concentration range, they showed a non-linear response. This was a result 
of inner-filter effects, the origins of which have been discussed in 
Section 1.6.4. Attempts were made to correct for these and in so doing 
to construct the more useful linear transformations. 
2.5 Computational Methods 
Routine calculations and the statistical analysis of certain results 
were performed with a Casio Fx-80 hand-held calculator. When more 
complicated proceSSing of data was necessary, computer programs were devised. 
These were written in FORTRAN IV and all routines were run on an IBM 1900 
computer using the card input and 1ineprinter output facilities. 
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CHAPTER 3 
Development of a Homogeneous Fluorescence Assay for the Accurate 
Determination of Protein Binding Constants 
3.1 Introduction 
The clinical importance of the interactions between drugs and 
plasma proteins is well established. In particular, the degree binding of a 
drug to HSA may limit its availability:to the receptor sites and excretory. 
systems. Consequently, the affinity of a drug for binding albumin can have 
a profound influence on its biological activity and half-life. It is not 
surprising, then, that the strength of such an interaction, which is 
usually expressed as an apparent association constant, is an important 
parameter to determine. 
An argument which was developed further in Chapter 1 concerned the 
displacement of drugs from plasma binding sites. It was seen how harmful 
side-effects may arise when several active drugs compete for a similar 
class of binding sites on albumin. Experimental evidence suggests that 
there are only a small number of high affinity drug binding sites on HSA. 
It would be useful if individual sites could be characterized more 
completely as this might help to identify potential drug interactions 
based on displacement and redistribution. 
A major aim of this study was to develop simple and reliable methods 
for investigating drug-protein binding in vitro. At first, particular 
attention was paid to the application of fluorescence techniques to the 
determination of binding constants. The work with fluorescent pro::'es 
formed a basis from which to examine the properties of separate sites on 
albumin. 
Prior to 1977 fluorescence spectroscopy had already been widely 
used to study the binding of drugs and other small molecules to the plasma 
proteins. Much of this work has been reviewed by Chignel1 (1974) and Wilson 
and Bridges (1976). An early objective of this project was to search the 
literature and find out whether accurate procedures were available for 
quantifying the interactions between fluorescent probes and albumin. It 
soon became clear, however, that it would be extremely difficult to repeat 
and assess a standard protocol from the literature. There were two main 
reasons for this. 
Firstly, the reporting of experimental procedures often gave too 
1 i ttle detail for the work to be reproduced faithfully. Approxi mati ons \~ere 
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frequently introduced to simplify calculations of the concentrations of 
protein-bound and unbound fluorescent probe. These were sometimes 
difficult to justify especially \~hen the full experimental conditions \~ent 
unreported. 
Secondly, and perhaps more importantly, the results of binding 
experiments were commonly misinter~reted. Even though binding data were 
generally expressed in a similar form - usually as a Scatchard plot, the 
methods of extracting binding constants from the results took many courses. 
The literature contains numerous examples in ~/hich linear binding plots 
have been constructed on the basis of insufficient data covering only a 
fraction of the binding isotherm. Even more frequently, however, curved 
Scatchard plots have been produced but the authors have simply 
extrapolated apparently linear portions of the curves and translated the 
intercepts on the axes dire~tly into binding constants. The use of these 
constructions is unfounded, and the complex relationship between the 
intercepts and the site binding constants is rarely acknoNledged. A 
further discussion of the problems encountered with the decomposition 
of binding curves is presented 1n Section 1.7. 
Due to the lack of a suitable procedure in the literature, a new 
method was devised for measuring binding constants for the interactions 
between fluorescent probes and proteins. 
In general, if a fixed concentration of protein is taken, and if 
different amounts of ligand are added in a titration, then the strength 
of any ligand-protein interaction may be estimated from measurements of 
the quantities of bound and unbound ligand at each point in the titration. 
Some method must be provided for determining the bound and 
unbound fractions. If the ligand under consideration is a fluorescent 
probe, its distinctive spectroscopic property provides a means of 
achieving this goal through a simple, homogeneous assay. In other words, 
the enhancement of the observed fluorescent intensity and the concomitant 
shift in the wavelength of maximum emission which accompany binding of the 
fluorescent probe to the protein permit a spectrosccpic resolution of the 
bound and unbound fractions of the probe without recourse to their physical 
separation. 
By definition, resolution will be perfect only when the 
fluorescence intensity observed at the wavelength of maximum emission 
of the bound probe fluorescence originates entirely from this species and 
contains no contribution whatever from the unbound fraction, while the 
fluorescence recorded at the wavelength of maximum emission of the unbound 
fraction includes none of that due to the bound probe. Even if there is a 
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considerable wavelength shift on binding to the protein, the weak 
fiuu''''''''"L'' of the unbound probe is likely to be masked by the high 
wavelength edge of the bound probe fluorescence. On the other hand, if 
enhancement of the emitted intensity is extremely large when the probe 
binds protein, the signal associated with the bound fraction is unlikely 
to be perturbed to an appreciable degree by the much weaker fluorescerce 
of the unbound probe. Measurements of the fluorescence intensity at the 
11avelength of maximum emission of the bound probe fluorescence may then 
be rel&ted directly to the concentration of bound probe and assuming the 
total concentration is known, the free fraction may be determined by 
subtraction. 
In reality, however, the prohe molecule Ni" have an intrinsic 
fluorescence in aqueous solution, albeit one of a relatively low quantum 
YlelG. At high probe:protein ratios where a large proportion of the 
binding sites are saturated, the unbound fraction of the probe will 
predominate. Under these circumstances the fluorescence emitted by the 
high concentration of unbound probe may be quite appreciable and it 110uld 
be difficult to justify neglecting its effect on the signal measured at the 
Navelength of emission of the bound probe fluorescence unless tile two 
srectral peaks 11ere completely resolved. Moreover, whether the wavelength 
shift on binding protein is large or small, it is highly probable that 
the unbound probe will be capable of reducing the fluorescence observed 
from the bound species by an inner-filter mechanism. The effect is 
largely dependent on absorption of radiation by the unbound fraction at 
the wavelength of excitation of the bound probe fluorescence and this is 
why it can be a problem even when the difference betl~een the fluorescence 
emission pea~s of the bound and unbound probe is large. As a result, 
a simple correlation between the measured fluorescence intensity and the 
concentration of bound probe is unlikely to hold in the presence of 
varying amounts of unbound probe. Since the relative proportions ef bound 
and unbound ligand will change continuously during a binding titration, 
care must be taken if fluorescence intensity measurements are to be 
correctly interpreted in terms of the degree of binding of a fluorescent 
probe to a protein. 
The binding of two fluorescent molecules to HSA has been examined 
in detail. At fi rs t attenti on focused on the anti coagul ant wa rfarin. As 
well as being a commonly administered drug, warfarin is fluorescent and 
is known to exhibit a significant change in its spectral properties on 
binding to proteins (Chignell, 1970). Figure 3.1 shows how the fluorescence 
of this molecule is enhanced when it binds to human serum albumin. The 
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FIGURE 3.1 Corrected emission spectra of bound and free warfarin 
illustrating fluorescence enhancement. Wavelengths of 
excitation 320nm. 
(a) 7.1 x 10-6M warfarin in O.lM Tris/HCl buffer pH 7.4 
containing 5 x lo-5M human serum albumin. 
(b) 7.1 x 10-6M warfarin in O.lM Tris/HCl buffer pH 7.4. 
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concomitant blue shift in the emission maximum and the reduction of the 
ba~~~·:~:!th. a~ illustrated in Figure 3.2. 
In terms of the criteria discussed previously, however, warfarin 
is far from being an ideal fluorescent probe. Its quantum yield in free 
solution is quite appreci~ble and the wavelength shift on binding to 
albumin is too small to allo~1 for a proper resolution of the peaks which 
correspond to the bound and unbound species. Indeed on bindin9 to HSA, 
the fluorescence intensity observed at the wavelength of maximum emission 
is only about thirteen times that of the unbound probe at the same 
wavelength. If a sample contains protein-bound and unbound warfarin in 
equilibrium, any attempt to correlate the fluorescence intensity at 375nm 
with the concentration of bound probe will have to recognize potential 
interferences from the free fraction. This observation emphasizes the 
need to characterize the fluorescence of the probe in free solution as well 
as the fluorescence of the protein-bound species. 
The second fluorescent molecule to be considered was the dye ANS. 
The dramatic enhancement of the fluorescence which accompanies binding of 
this probe to HSA is shown in Figure 3.3. Figure 3.4 illustrates how 
the wavelength of maximum emission is shifted to the blue by about 75nm 
when ANS binds albumin. Once again a narrowing of the emission band 
accom~anies removal of the fluorescent probe from an aqueous environment. 
It should be emphasized that a much higher gain was used to record the 
fluorescence of the unbound probe in Figure 3.4. 
The excitation spectra of warfarin and ANS are i.ncluded in 
Figure 3.5. They have been recorded alongside the emission band of HSA 
to demonstrate the potential for resonance energy transfer between the 
protein and the fluorescent probes which bind to it. Figures 3.6 and 3.7 
show hovl both warfarin and ANS quench the fluorescence of HSA by 
resonance energy transfer. The bound species of the fluorescent probes 
can act as acceptor molecules for the albumin fluorescence because their 
excitation bands overlap the emission wavelengths of the protein (Figure 
3.5). ·Energy transfer between HSA and ANS is further illustrated in 
Figure 3.B which is an excitation spectrum of bound ANS. The appearance 
of a strong excitation peak at about 2BOnm is evidence that the 
fluorescence recorded at 475nm is sensitized by the transfer of energy 
from albumin as well as by direct excitation of the bound probe 
fluorescence at 375nm. 
The gross changes in the fluorescence spectrum of ANS which 
accompany its binding to HSA make this a relatively simple system to 
study. In marked contrast to warfarin, when ANS is used as a fluorescent 
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FIGURE 3.2 Corrected emission spectra of bound and free warfarin 
illustrating differences in peak maxima and spectral 
bandwidths. Wavelengths of excitation 320nm. 
(a) 8 x 10-7M warfarin in O.lM Tris/HCl buffer pH 7.4 
containing 5 x 10-6M human serum albumin. 
(b) 1 x 10-5M warfarin in O.lM Tris/HCl buffer pH 7.4. 
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(b) 
500 Wave 1 ength 600nm 
Corrected emission spectra of bound and free ANS 
illustrating fluorescence enhancement. Wavelengths 
of excitation 375nm. 
(a) 5 x 10-7M ANS in O.lM Tris/HCl buffer pH 7.4 
containing 1.5 x 10-5M human serum albumin. 
(b) 5 x 10-7M ANS in O.lM Tris/HCl buffer pH 7.4. 
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FIGURE 3.4 Corrected emission spectra of bound and free ANS illustrating 
differences in peak maxima and spectral bandwidths. 
Wavelengths of excitation 375nm. 
(a) 5 x 10-7M ANS in O.lM Tris/HCl buffer pH 7.4 containing 
1.5 x lO-5M human serum albumin. (b) 4 x. 1O-5M ANS in O.lM Tris/HCl buffer pH 7.4. 
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FIGURE 3.5 
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(a) Corrected excitation spectrum of 5 x lO-5M warfarin in 
0.1M Tris/HCl buffer pH 7.4. Wavelength of emission 390nm. 
(b) Corrected emission spectrum of 5 x lO-5M HSA in 0.1M 
Tris/HCl buffer pH 7.4. Wavelength of e~itation 294nm. 
(c) Corrected excitation spectrum of 2 x lO-~5 ANS in 0.1M 
Tris/HCl buffer pH 7.4 containing 2 x 10- M HSA. 
Wavelength of emission 460nm. 
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FIGURE 3.6 Emission spectra of human serum albumin illustrating resonance 
energy transfer to acceptor molecule (warfarin). Wavelengths 
of excitatign 290nm. (al 5 x 10- M HSA in 0.1M Tris/HCl buffer pH 7.4. (b 5x lO-~ HSA in O.lM Tris/HC1 buffer pH 7.4 containing 
1.5 x 10-6M warfarin. 
(cl 5 x lo-5M HSA in O.lM Tris/HC1 buffer pH 7.4 containing 
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FIGURE 3.7 Corrected emission spectra of human serum albumin illustrating 
resonance energy transfer to acceptor molecule (ANS). 
Wavelengthssof excitation 28Snm. (a) 2 x 10- M HSA in O.lM Tris/HCl buffer pH 7.4. 
(b) 2 x 10-5M HSA in O.lM Tris/HCl buffer pH 7.4 containing 
2 x 10-6M ANS. 
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FIGURE 3.8 Corrected excitation spectrym of albumin-boung ANS. Wavelength 
of emission 46Snm. 2 x 10-5M HSA and 2 x 10- M ANS in O.lM 
Tris/HCl buffer pH 7.4. 
Pe~k 1 Excitation of albumin (Inten~e fluorescence measured 
at 465nm is due to resonance energy transfer to bound AN~ 
Peak 2 Direct excitation of bound ANS. 
Peak 3 Rayleigh scatter peak. 
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probe it is possible to take a reading with the monochromators set at 
the wavelengths of excitation and emission of the bound probe fluorescence 
and, to be sure of collecting virtually no spurious signal from any ANS 
~Ihich is in free solution. However, the unbound fraction is still able 
to i nte rfere wi th the measurement of the bound probe fl uorescence through 
an inner-filter effect. Once again it will be necessary to quantify a 
spectroscopic property of the unbound probe when examining bindins; to HSA. 
To produce accurate binding constants for both high and 10\1 
affinity sites on a macromolecule it is important that the ligand 
concentration is varied over as wide a range as possible. In a 
fluorescence assay this means examining the intensity of the radiation 
emitted by protein-bound and unbound probe at both high and low 
concentrati ons. The experimental procedures used to generate the 
required information are described in the next section. 
3.2 The Characterization of Probe Fluorescence 
The work outlined in this section provided the basis on which to 
establish an analysis of subsequent binding curves. The role of these 
experiments in the overall scheme is illustrated in the flow diagram of 
Figure 3.9. 
3.2.1 Production of a Calibration Curve for Unbound Probe 
The intensity of the radiation emitted by the unbound probe was 
quantified by measuring the fluorescence from samples consisting of 
various concentrations of the probe dissolved in the assay buffer, O. 1 ,~ 
Tris/HCl pH 7.40. 
To prepare samples of the correct composition, microlitre 
quantities of a suitably concentrated stock solution of the probe were 
added to a fluorimeter cell containing a measured volume of the assay 
buffer - usually 3ml. Thorough mixing was achieved by stirring the 
solution with the needle of the microlitre syringe. The sample remained 
in the fluorimeter during the titration and its temperature was normally 
maintained at 230C Z 0.20C by means of the thermostated cell holder. 
The excitation and emission monochromators were set at or very 
close to the wavelengths of maximum excitation and emission of the bound 
probe fluorescence. As far as warfarin was concerned, this meant an 
excitation wavelength of 320nm, and an emission wavelength of 375nm. 
When ANS was under examination, the corresponding settings were 375nm 
and 460nm. Spectra such as those in Figures 3. I, 3.3 and 3.5 were 
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he 1 pful when choos i n9 the monochromator setti ngs. 
Solutions of quinine sulphate were used to maintain the 
fluori~eter at a given sensitivity. This procedure ensured that 
instrumental drift could have no effect on the recorded fluorescence 
intensities. 
The signal detected wit~ only buffer in the fluorimeter cell 
provided a blank value which could be subtracted fro", the intensities 
obtained in the presence of fluorescent probe. Blank and samph 
fluorescence intensities were determimed under identical experimental 
conditi ons. 
To calculate the concentration of probe at each point in the 
titration, an allowance had to be made for the sample dilution brought 
about by the repeated addition of small quantities of stock solution to 
thp. fixpd volume of buffer. The blank-corrected fluorescence intensities 
could then be plotted against probe concentration in the form of a 
calibration curve. A typical example is shown in Figure 3.10. It way be 
regarded as a 'standard curve' and used to determine the concentration 
of an unknown sample. 
As described above, a range of probe concentrations could be 
introduced into the fluorimeter cell by making serial additions of a 
concentrated stock solution to a measured volume of buffer. Although this 
method gave satisfactory results, it was quite susceptible to experimental 
error. This susceptibility may be appreciated from Figure 3. 11(a) which 
shows how the sample concentration at any point is made up of 
contributions from all the previous additions. Since an imprecision in 
one pipettin9 step affects all the subsequent points in the titration 
curve, there is a likelihood of accumulating unacceptably large 
experimental errors in the samples of high concentration. 
A second method of sample preparati on was examined and found to 
have certain advantages. Thus, in later experiments a slightly less 
concentrated stock solution was taken and a number of separate dilutions 
prepared outside the fluorimeter cell. This is illustrated in Figure 
3.11 (b). Comparing the ne~1 scheme \>Iith that which involved serial 
additions (Figure 3.11(a)), it is obvious that the number of pipetting 
steps associated with each point in the titration may be reduced by 
preparing dilutions independently of one another. An error in dispensing 
one volume of reagent will now affect only a single point in the 
titration curve and there is no tendency to produce increasingly inaccurate 
samples as the concentration is raised. 
When solutions were made up separately they had to be introduced 
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FIGURE 3.10 Calibration Curve for Unbound Fluorescent Probe (Warfarin) 
o Measured fluorescence intensities from samples containing 
warfarin in O.lM Tris/HC1 buffer pH 7.4. 
A Fluorescence intensities corrected for inner filter effects 
by determining the molar absorptivities of free warfarin at 
the wavelengths of excitation and emission and incorporating 
these values in Equation 3.5. 
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Solution (A) O.lM Tris/HC1 pH 7.40 containing 10-~ Probe. 
Solution (B) O.lM Tris/He1 pH 7.40. 
(a) 
Sample Preparation NO.Pipetting 
No. Steps 
1 (20\l1 20\l1 )(A)+3.0m1 (B) 2 
2 (20\l1+20\l1 40\l1 )(A)+3.0m1 (B) 3 
3 (20 \l1 +20\l1 +20 \l1 60\l1 )(A)+3.0m1 (B) 4 
I I I I 
I I I I 
I I I I 
I I I I 12 (100 \l1 + ••• +20\l1 +20\l1 1.0m1) (A)+3. Om1 (B) 13 
(b) 
Sample Preparation No.Pipetting 
No. Steps 
1 2O\l1(A) + 2. 98m1 (B) 2 
2 40\l1 (A) + 2.96m1(B) 2 
3 6O\l1(A) + 2.94m1(B) 2 
I I I I I I I I 
I I I I I I I I 12 1.0m1(A) + 2.00m1(B) 2 
FIGURE 3.11 Scheme Showing Methods for Sample Preparation. 
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into the fluorimeter one after the other. This meant the fluorimeter 
cells had to be rinsed with the solution of next highest concentration 
between each measurement. However, the need to stir samples was removed 
and it \~as no longer necessary to make allowances for sample dilution 
when plotting results. 
Due to its poor solubility in aqueous solution, it \'laS necessary 
to dissolve warfarin in a small quantity of ethanol or O;lM sodium 
hydroxide prior to making it up in the required volume of buffer and using 
as a stock solution. To demonstrate any effects these solvents may have 
had on the fluorescence of the probe, fUrther experiments ~Iere required. 
These involved the addition of solvent to buffer solutions containing 
appro~riate concentration of warfarin. Any alterations in the observed 
fluorescence were noted. 
As it turned out, neither ethanol nor sodium hydroxide had any 
significant effect on the fluorescence of warfarin in free solution. This 
was true over the entire range of solvent concentrations which had been 
encountered in t:le fluorescence titrations. Consequently, the cal ibration 
curves requi red no sol vent-correcti on. 
3.2.2 Production of a Calibration Curve for Bound Probe 
Two separate titrations were required before fluorescence 
intensity measurements could be translated into moles of bound probe. 
Both sets of results were recorded at the sarre temperature and with 
similar instrumental settings. As usual, the monochromators were adjusted 
to the wavelengths of maximum excitation and emission of the bound probe 
fl uorescence. 
The first of the two titrations entailed measurin9 the 
fluorescence intensity emitted by a fixed amount of probe in HSA solutions 
of increasing concentration. In these 'reverse titrations' the albumin 
concentration was raised until the probe fluorescence intensity reached a 
limiting maximum independent of further increases in the protein strength. 
Background contributions to the measured signals were accounted for by 
running blanks. Since the blanks were designed to include everything in 
the sample except the analyte, bound fluorescent probe in this case, they 
comprised a series of solutions containing increasing quantities of albumin. 
At each point in the reverse titration, therefore, it was possible to 
subtract scattered light and residual protein fluorescence from the total 
signal. However it must be emphasized that the background signals were 
small compared to the intense fluorescence emitted by the bound probe. 
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The results were plotted as illustrated in Figure 3.12. The 
attainment of a maximum fluorescence intensity at high protein:probe 
ratios suggested that all the existing probe mclecules had become bound 
to albumin. Under these conditions it seemed reasonable to assume that the 
blank-corrected signal was due entirely to the fluorescence of bound 
probe, there being no unbound fraction to complicate matters. 
Armed with information from the reverse titration, it was 
possible to devise a second titration in which the probe binding sites 
remained saturated with HSA. Tbroughout these experiments it was the 
albumin concentration which was held constant, or nearly so, while the 
amount of fluorescent probe in each sample was allowed to vary. In 
practice this meant selecting an appropriate concentration of albumin and 
dispensing a convenient volume of solution, say 3ml, into the fluorimeter 
cell. Small quantities of a stock solution of fluorescent probe were then 
added from a mi crosyringe the ti p of which was used to sti r the mi xture. 
As with the unbound probe titration, this method of dispensing reagents 
was later modified so that samples of the required composition could be 
made up individually before inserting into the fluorimeter cell. 
Whichever the method of sample preparation, titrations were 
carefully designed so that the final probe concentration was still low 
enough for there to be an excess of binding sites on the protein molecules 
in soluti on. 
In this type of titration a constant background fluorescence 
intensity was subtracted from each of the recorded values. This signal 
was determined by taking the appropriate albumin solution and measuring 
the emission, again with the monochromators set at the wavelengths of 
maximum excitation and emissicn of the bound probe fluorescence, but doing 
so before any fluorescent probe had been added. The blank-corrected 
fluorescence intensity measurements were then plotted against the known 
concentration of probe in each sample. Due to the design of the experiment, 
this provided a calibration plot of fluorescence intensity versus bound 
probe concentration. 
In simple terms, the calibration plot could be regarded as a 
standard curve for use in the determination of the concentrations of 
albumin-bound fluorescent probe in unknown samples. However, it \~ould 
only be feasible to assay an unknown sample if it contained no fluorescent 
probe in free solution, or if it did, provided the fluorescence of the 
unbound species was negligible compared to the total signal. Obviously 
the fi rs t of these two provi sos dras ti ca lly 1 imits the appl i cation of 
the calibration plot to a very narrow class of samples. On the. other hand, 
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FIGURE 3.12 Reverse Titration for ANS 
ANS concentration 10-6M• An allowance was made for the 
small inner-filter effect of HSA. 
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FIGURE 3.13 Calibration Curve for Bound Fluorescent Probe (Warfarin) 
o Measured fluorescence intensities from samples 
containing war!arin in O.lM Tris/HCl buffer pH 7.4 
containing 10- M HSA • 
... Fluorescence intensities corrected for inner-filter effects 
by measuri n~ l!1ol ar absorptfvi ties of bound warfarin, and 
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if the fluorescence of a probe is enhanced a great many times on binding 
~1h"-'~, tip ~f>cond proviso is satisfied and a calibration curve of the 
type shown in Figure 3.13 can be used to determine the concentrations of 
bound probe in a sample which also contains fluorescent probe in free 
solution. 
In practice, though, measurement of the signal from the bound 
fraction may be complicated by the presence of the unbound species even 
if the latter is virtually non-fluorescent. This was mentioned in 
section 3.1. Nevertheless, the calibration plot of fluorescence intensity 
versus bound probe concentration will be seen to play a central role when 
determining the strength of the interaction between the probe and HSA. 
Zierler demonstrated in 1977 how the method outlined above for 
converting fluorescence intensity measurements into moles of bound 
fll1r.r~hnr is much preferable to the most cOl1'l11only used approach which 
involves an interpretation of the intercept of a plot of reciprocal 
fluorescence intensity of probe versus reciprocal protein concentration. 
In the graphical procedure, efforts to relate the fluorescence intensity 
to the concentration of bound ligand through a certain coefficient, always 
lead to an overestimate of the desired value (Zierler, 1977). 
Additional experiments were performed in an attempt to identify 
how critical it was to control certain of the experimental variables. For 
example, the effect that a change in temperature has on the fluorescence 
intensity observed from a sample containing warfarin bound to HSA was 
monitored. The results are shl'\'ln in Table 3.1. The reduction in t;,e 
intensity of the fluorescence emitted by the bound probe which accompanies 
an increase in telll'erature is quite marked. Although the sensitivity 
of fluorescence spectra to changes in temperature has already been 
discussed in Section 1.6, these results emphasize the importance of 
maintaining strict temperature control when producing data for the protein-
bound fraction of the probe. 
Vari ations in the ionic strength of the assay buffer were found 
to have a.less well-defined effect on the emission intensities. This may 
be appreciated from an inspection of the results in Table 3.2. Although 
small variations in the buffer strength appeared to be of little 
consequence, Tris/HCl buffer were always made up accurately to a 
concentration of O.lM. 
The effects of ethanol and O.lM sodium hydroxide on the intensity 
of the fluorescence emitted by warfarin were also examined when the probe 
was bound to albumin. The results are analysed in the next section. 
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TEMPERATURE OBSERVEO TEMPERATURE OBSERVED 
·C FLUORESCENCE ·C FLUORESCENCE 
14.0 B5.5 22.6 73.4 
16.0 B1.5 22.8 73.3 
1B.0 77.3 23.0 73.1 
20.0 75.5 23.2 73.1 
21.0 74.6 23.4 72.B 
21.5 74.0 23.6 72.7 
22.0 73.8 23.9 72.9 
22.5 73.5 28.0 67.5 
TABLE 3.1 The Effect of Temperature on the Fluorescence of Albumin-
Bound Warfarin. 
Overall decrease in fluorescegce is about 1.5% per ·C. 
Samgle composition: 1.7 x 10- M warfarin and 1.0 x 
10-~ human serum albumin in O.lM Tris/HCl buffer (pH 7.4 
at 20·C). 
Concentration of Observed 
Tris/HCl Buffer (M) Fluorescence Intensity 
0.10 21.1 
0.11 21.4 
0.14 21.3 
0.17 20.7 
0.24 21.3 
0.31 22.0 
0.43 22.6 
0.68 22.9 
TABLE 3.2 The Effect of Buffer Ionic Strength on the Sample 
Fluorescence. 
Sample : 8 x 10-6M warfarin and 5 x 10-~ human 
serum albumin in Tris/HCl buffer. 
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Samples were tested to see if they had been properly mixed. 
Sa~l es prepared by the usual methods were subjected to further agitation 
using the tip of a microsyringe. No change in the recorded fluorescence 
intensities could be detected. Hence the rather peculiar phenorrenon 
observed by Ko1b and Weber (1975) namely, that stirring alters the 
results of a fluorescence binding titration, could not be reproduced 
and would appear to be an artefact. 
The results suggest that provided reasonable regard is paid to 
experimental detail, the intensity of the signal emitted by a fluorescent 
probe may be quantified over a wide concentration range for the a1bumin-
bound. as well as the unbound species. 
3.2.3 A Detailed Examination of the Calibration Plots 
To make proper use of the information contained in the calibration 
plots, due regard had to be paid to inner-filter, solvent and dilution 
effects. 
It was a simple matter to make allowances for dilution of the 
sample. The effect arose only in titrations which required serial 
additions of one reagent to a fixed volume of another. Knowing the 
volumes involved, it was very easy to calculate the true concentrations 
of the sample components at each stage in the titration. For those 
experiments where samples were made up to tbe required concentrations 
separately and then measured one after the other in the fluorimeter, 
there were no dilution effects to consider and the results could be 
plotted directly. 
Allowances for solvent effects were slightly more complicated. 
As mentioned earlier, it was necessary to dissolve warfarin in a small 
quantity of ethanol or O. HI sodium hydroxide prior to diluting in buffer. 
Neither solvent appeared to have any effect whatsoever on the fluorescence 
emitted by the unbound fraction of the probe. However, ethanol had a 
cons derab1e influence on the fluorescence of \'!arfarin when it was bound 
to HSA (see Figure 3.14). The signal observed from the bound probe in 
the presence of ethanol was found to fit an empirical equation of the 
form 
(3.1) 
where 1 and m are constants, and c is the concentration of ethanol. 
Using the values of 1 and m in Figure 3.14 provided an adequate 
means of correcting the bound probe calibration curve for solvent effects 
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c (Microlitres of ethanol per 3ml of sample) 
FIGURE 3.14 The Effect of Ethanol on the Fluorescence of Albumin-
Bound Warfarin. 
Equation of solid line is FM = 100 exp (-0.025c+3.86xlO- 4c2). 
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over a sufficiently wide range of ethanol concentrations. 
It is obvious that during a titration in which increasing 
amounts of warfarin are added to HSA, the concentration of ethanol will 
also rise as it too is present in the stock probe solution. At the end 
of a titration sufficient ethanol may have accumulated to produce a 
considerable change in the recorded signal. Decreases of up to 15% have 
been observed. Consequently, it would seem advisable to avoid this solvent 
whenever possible, even though its perturbing effects can be suitably 
described in terms of Equation 3.1. Ethanol is known to denature proteins 
and the observed attenuation of the fluorescence emitted by the bound 
fracticn could be due, at least partially, to an alteration of the binding 
site geometry and a displacement of bound fluorescent probe. 
0.111 sodium hydroxide appeared to have no effect on the signal 
detected from the bound fraction of warfarin. 
Regardless of whether corrections have been necessary for solvent 
or dilution effects, the calibration plots of observed fluorescence 
intensity versus analyte concentration were invariably non-linear. As 
illustrated in Figures 3.10 and 3.13 this was so for both the protein-
bound and unbound fractions of the fluorescent probes. Curvature of the 
plots became more pronounced at high concentrations. The effects were 
consistent with an inner-filter mechanism, the origins of which have been 
discussed in Section 1.6. Attempts were made to correct the experimental 
data for the apparent inner-filter effects. Two approaches were used and 
both depended on very similar theoretical descriptions of the self-
absorptive process. 
Consider a fluorescent molecule or conjugate at some position 
()(,'Y,) in a fluorimeter cell. As illustrated in Figure 3.15, x, represents 
the depth of sample solution through which the exciting radiation must 
pass before it impinges on the fluorphor. Similarly, y, corresponds to th1! 
depth of solution through which the emitted beam passes before emergin~ 
from the sample cell in the direction of the detector. 
The intensity of the exciting radiation at any point in the 
fluorimeter cell depends upon the incident beam intensity attenuated by 
the absorption which has already taken place in the sample solution. This 
is best summarized in the Beer-Lambert law, 
loo .!2. 
-10 I 
= abc 
Where 10 is the intensity of the incident beam, I is the intensity of the 
- 136 -
radiation after the beam has passed through a depth b of solution, c is 
thp rnnrpntr~tion of the absorbing species and a is the molar absorbtivity 
of the sample. This expression may be rewritten in the form, 
I = 10 exp (-2.303 abc) 
Thus after travelling a distance x, into the sample solution, the radiation 
which remains and is capable of exciting fluorescence has an intensity 
10 exp (-2.303 a,x,c), where a is the molar absorbtivity of the sample at 
the wavelength of excitation. If there are no other absorbing species in 
the sample, c may be taken as the concentration of fluorphor. In the 
absence of an inner-filter effect, that is when a, = 0 the intensity of the 
incident radiation is clearly 10 at every point in the sample. This means 
that for points at a depth x, into the sample, the radiation available to 
excite fl uorescence in the presence and absence of i nner-fi 1 ter effects 
differs by the factor exp (-2.303 a, x, c). Accordingly, if the intensity 
of the fluorescence emitted in the direction of the detector by a molecule 
centred at x, is labelled f in the presence of an inner-filter effect, and 
fo in the absence of an inner-filter effect, then 
f = fo exp (-2.303 a,x,c) 
Before reaching the detector, however, the radiation emitted by 
the fluorescent species may be further attenuated by self-absorption. 
This arises when the sample itself absorbs at the wavelength of emission. 
Consequently, if the fluorescence passes through a depth of solution ~ 
before emerging from the sample cell in the direction of the detector, 
the signal which .is finally measured will depend on the intensity of the 
radiation emitted by the fluorescent molecule modified by a second 
absorption term. That is, 
fm = .fo exp (-2.303 a,x.c) exp (-2.303 a&Yo c) 
or 
fm = fo exp (-2.303(a,x,+ a&~) c) (3.2) 
where fm is the fluorescence intensity measured outside the sample cell 
and originating at (x, ' 1,), and a .. is the molar absorbtivity at the 
wavelength of emission. Again it has been assumed that no other absorbing 
molecules are present apart from the fluorescent species. 
c represents the concentration of fluorphor in the sample. 
Once more, then, 
Under these 
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conditions it is reasonable to ex~ect that aLis considerably smaller 
th~:-: =-,. .".ft::r all, the fluorphor must absorb strongly at the wavelength 
of excitation for its fluorescence to be observed. 
So far the signal from just one fluorescent molecule has been 
considered. If there were n such molecules in solution, each \lith 
coordinates (x .. Yd, the intensity of the fluorescence that ~Iould be 
observed from the total population is given by 
n 
Fm = t:l fo exp (-2.303 (a, xi. + a.y~ )c) (3.3) 
In order to translate Equation 3.3 into a form which may be 
applied in practice, it is necessary to devise some method of carrying out 
the required summation. In Appendix A it is shown that if the conditions 
are those prevailing in a standard fluorimeter, the approximation that 
Fm = Fo exp (-2.303 (a,x + a .. y)c) (3.4) 
is an extremely close one. The terms x and y represent the mean values of 
the positions of the fluorescent molecules within the sam~le cell and are 
defined by, x =l~l ~i. and y =t~l *. Fo is the fluorescence intensity that 
would be registered if the sample exhibited no inner-filter effect. The 
error in the inner-filter correction factor is likely to be less than 1% 
when the above approximation is used (see Appendix A). 
The first of the methods employed in the determination of inner-
filter effects needed estimates of x and y. As far as could be ascertained 
by inspection, a reasonable assumption was that the irradiated portion of 
the sample was disposed symmetrically about the vertical axis of t~e 
fluorimeter cell. Such an arrangement is the one shoNn in Figure 3.16. 
Under these conditions the average path lengths of the excitation and 
emission beams are equal. Moreover, since a lcm cell was used, x and y 
were both taken to be 0.5cm. This allowed Equation 3.4 to be simplified to 
Fm = Fo exp (-2.303 (at ~ a~)c) (3.5) 
When expressed in this form, the equation could be used to correct the 
fluorescence calibration plots for inner-filter effects. The only 
requirement was the prOVision of values of a,and a~. 
It should be noted that changes in the absorption as wcll as the 
fluorescence spectrum of a ligand may accompany binding to a macromolecule. 
Consequently determinations of a,and aL~18re necessary for both the protein-
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FIGURE 3.15 Diagram of Fluorescent Molecule at Some Position 
(x,. Y, ) in a Fluorimeter Cell. 
ENTRANCE 
SLITS 
8 
,--
SOURCE r ~=:-~,:.:~.-~-~:~···~--:I-_~'~ , ~~- -
y, 
.-'.'~I+ 
1-
f ~ 
I 
! I \ I 
1 I i \ \ 
I I! ' \ I 
I 
11 ; \ i 
11 ! ~T H , f r! I : I 
UNDETECTED 
.-- .-- RADIATION 
EXIT 
SLITS 
FIGURE-3.16 Diagram Showing a Central Symmetric. Irradiated Portion 
of a Fluorimeter Cell. 
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bound and unbound fractions of the fluorescent probes. 
For a fluorescent probe in free solution, several estimates of a, 
and a,were obtained by taking absorbance measurements on buffer solutions 
containing increasing concentrations of the probe. In each case, absorbance 
readings were recorded at two \~avelengths. These corresponded to the 
excitation and emission monochromator settings used in the appropriate 
fluorescence titration. Kno~ling the concentrations of probe in each sample, 
it was an easy matter to find values of a,and a~from the absorbance 
measurements. The mean experimental values of a,and a,were calculated. 
Equipped with these it was possible to use Equation 3.5 to correct observed 
fluorescence intensities for inner-filter effects. All that was necessary 
~'as to compound the I,:easured signals Fm with the corresponding concentrations 
of unbound probe, c. The 'corrected' intensities Fo wereplotted against 
concentration to yield the inner-filter corrected calibration plot. 
A typical example is shown in Figure 3.10. It is clearly linear 
over a wide concentrated range. 
For albumin-bound fluorescent probe, absorbance measurements were 
again made on samples containing increasing quantities of the probe, but 
in these experiments a fi xed concentration of a lbumi n was present. The 
actual amount of HSA had been determined from a reverse titration, as 
described previously, and contained sufficient binding sites to accommodate 
all the probe molecules. As usual, absorbance measurerrents were recorded 
at the "'avelengths of excitation and emissicn of the bound probe 
fl uorescence. In thi s case, though, the protein absorbance had to be 
subtracted from the totals before determinins a, and a~. Determinations were 
made with a number of concentrations of the bound probe. Mean values of a, 
and aLwere calculated from the results and along with Equation 3.5 they 
were sufficient to correct intensity measurements for the inner-filter 
effect of the bound probe itself. However, since albumin absorbs radiation 
in the appropriate region of the spectrum, it was shown to be capable of 
reducin~ the intensity of the fluorescence observed from the bound probe 
by a secend inner-filter effect. (This was particularly noticeable when 
warfarin was being studied). To account for this effect, and in so doing to 
render the points in a plot of 'corrected' fluorescence intensity versus 
bound probe concentration independent of the protein strength, a,and a. 
were found for HSA. These values \~ere used in an expanded version of 
Equation 3.5, as described belo\~. 
In the theory presented previously it had been assumed that the only 
absorbing species in the sample solution was the fluorescent molecule under 
examination. The assumption allrn~ed the derivation of Equation 3.4 to be 
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explained in a reasonably simple manner. Moreover it was valid as far as 
samples containing fluorescent probe in free solution were concerned. 
Nevertheless in experiments where there are two or more absorbing species 
in the sample solution. it becomes necessary to expand the exponential term 
in Equation 3.5 to include the molar absorbtivities and concentrations of 
each component. So. in general. if any number of absorbing species are 
present the expression takes the form. 
+ (a, (r~ + a. (r) c
r
}) (3.6) 
where c" ca. • ..... cr are the concentrations of the individual constituents 
and a.(l). a, (2) ...... a, (r) and aL (1). a .. (2) ...... a .. (r) represent the 
corresponding molar absorbtivities at the wavelengths of excitation and 
emission. respectively. 
To account for the inner-filter effects of both albumin and bound 
probe, the appropriate version of Equation 3.6 included terms for two 
absorbing species. As menti oned p revi ously, in titrati ons where increas ing 
volumes of a stock solution of fluorescent probe were added to a solution of 
albumin in the fluorimeter cell. the protein concentration became somewhat 
diluted. Consequently. the inner-filter effect of the albumin was not 
exactly the same at each point in the titration. This was accounted. for by 
calculating anew the concentration of HSA after each addition of fluorescent 
probe. Where samples had been prepared separately and the albumin 
concentration maintained at a steady level. the corresponding inner-filter 
correction ~'as a constant factor over the whole range of the titration. 
The calibration plot of bound probe concentration versus 
fluorescence intensity which is shown in Figure 3.13 was corrected for 
self-absorptive effects in the manner described. The calculated fluorescence 
intensities (.) are those which would be observed from the specified 
concentrations of albumin-bound warfarin if neither protein nor probe 
exhibited an inner-filter effect. Again. the I corrected I calibration plot 
is linear over a wide range of concentrations. 
In contrast to the bound probe titrations,.the so-called Ireverse 
titrations' contained fixed concentrations of fluorescent probe in the 
presence of increasing quantities of albumin. A reverse titration curve of 
observed fluorescence intensity versus protein concentration is shown in 
Figure 3.12. To prevent the points in this titration curve falling again 
at high protein concentrations an allowance was made for the increasing 
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inner-filter effect of the albumin. Of course the correction in this 
instance was different at each pOint in the titration, being a function 
of the protein concentration. However it must be admitted that this 
adjustment for inner-filter effects was somewhat cosmetic; the intention 
of the reverse titration was simply· to indicate the minimum protein 
concentration required to bind essentially all of a certain quantity of 
fluorescent probe. This information could be gleaned almost as easily from 
the uncorrected curve as from the results which had been corrected for 
inner-filter effects. 
Although the procedure described above was highly successful in 
correcting experimental data for inner-filter effects,. a method was 
developed subsequently which performed the same function but dispensed with 
the need to measure the molar absorbtivities of samples at the wavelengths 
of excitation and emission of the bound probe fluorescence. As well as 
cutting down on the amount of experimental work, it soon became clear that 
the revised procedure had important theoretical advantages. In particular, 
no assumption were required regarding the cell orientation or the path 
of the light beam through the sample. As a result, a more generally 
applicable procedure for the correction of inner-filter effects could be 
formulated. 
Before describing the neN method, it is worth considering some 
weakne;ses in the present approach. As the error in aSSUming;,gle(i<i + Yt) 
= n e(x + y) has been shown to be negligible under most experimental 
conditions, 
Fm = Fo exp (-2.303 (a,x + a~) c) (3.4) 
is a very close approximation to the general equation (3.3). Nevertheless, 
it may be difficult to determine x and y. In the method described above 
it Has assumed that x = y = 0.5cm. However Equation 3.4 does not require 
that x and y be equal, and in some experimental arrangements they are 
specifically designed not to be so. The equation is valid whatever portion 
of the sample solution is measured, be it in the centre or the corner of 
the fluorimeter cell, or at some intermediate location. Since no 
restrictions were placed on the position of the fluorescent molecule 
originally considered, the analysis is three-dimensional in the sense that 
the incident beam and the direction of the emitted radiation need not lie 
in the same horizontal phase. That is, the possibility that some of the 
fluorescent radiation can pass at a slight angle up or down into the solution 
and still be detected has not been discounted. Likewise, there is no 
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requirement that the incident and emitted beams have to be arranged exactly 
perpenolcu"lar in the fluorimeter. Any estimates of the values of if: and Y 
must therefore include a number of assumptions about the experimental set-up 
and in so doing will restrict the generality of Equations 3.3 and 3.4. 
The need to measure a,and a~for each absorbing species in the sample 
is also undesirable. Errors in determining these values may adversely 
affect the accuracy of the original correction procedure. 
The revised method was nonetheless based on the same theoretical 
description of the inner-filter effect that led to Equations 3.3 and 3.4. 
It is clear from these expressions that the measured fluorescence intensity 
is dependent on some exponential function of the distances travelled by 
the exciting and emitted beams on passing through the sample. For a 
homogeneous sample solution these distances may be approximated very close 
to the mean values x and y or, if necessary, more complex functions can be 
used (see Appendix A). However they are formulated, the value of these 
functions depends solely on the geometry of the chosen experimental 
arrangement provided," of course, the safillle is uni forn:. Furthermore, if 
the sample is of constant composition, and as long as the Beer-Lambert 
law holds, a,and a~are independent of concentration. Under these 
" circumstances the term (a, x + ~y), or its more complicated equivalent, 
is a constant and 
Fm = Fo exp (-kc) (3.7) 
where k = 2.303 (a,x + a~Y). If Equation 3.7 holds true for a set of 
measurements over a certain concentration range, it may be possible to 
deduce a value of k from the results and in so doing to make an allOl~ance 
for i nner-fil ter effects. 
For completeness, it is worth considering how a background 
fluorescence signal would fit into Equation 3.7. As described before, 
background intensities are those emitted by the sample in the absence of 
fluorescent probe. Now addition of fluorescent probe produces an inner-
filter effect in exactly the same manner as Fo is. The total signal which 
wi 11 be detected is therefore, 
Fm = Fo exp (-kc) + FS exp (-kc) = (Fo + FS) exp (-kc) 
Of course, in the trivial case where there is no inner-filter effect (k = 0), 
the observed signal is simply the sum of the background fluorescence and the 
signal emitted by the fluorescent probe. From the last equation, 
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Fo = Fm exp (kc) - Fa 
and the inner-filter corrected fluorescence intensity for unit concentration 
of the probe is given by 
FE = F~c = ~ {Fm exp (kc) - Fa} (3.8) 
This is simply another way of expressing FE' the term which was defined 
earlier as the gradient of a plot of the 'corrected' fluorescence intensity 
versus probe concentration. 
Since the fluorescence intensities Fm and Fa, and the concentration 
c are known for each point in a titration, the last equation provides a means 
of determining the optimum value of k for any set of results. Ideally, FE 
should be constant over all values of c. In practice, of course, 
experimental error ensures that even if compensation for inner-filter 
effects is perfectly adequate, slightly different values of FE will be 
obtained with each data point. Nevertheless, the best value of k may be 
defined as the one which produces the minimum variation in FE over. the 
entire range of the experiment. 
The procedure was to test a trial value of k in Equation 3.8. 
Usually, a reasonable estimate of the 'true' value could be made, although 
in reality it would be possible to start with any estimate of k, however 
inaccurate. The initial estimate of k was used in Equation 3.8 along with 
the experimental va1u~s of c, Fm and Fa to complete a set of answers for 
FE" The number of values obtained for FE was equal to the number of samples 
measured during the titration. Typically 15 measurements were made. From 
the set of values of FE, the mean and standard deviation were calculated. 
If the initial estimate of k were far removed from the actual 
value, FE would vary widely over the entire range of the titration. On the 
one hand, as increasing sample concentration were considered an 
underestimation of k would generate successively lower answers for FE. 
Conversely, an overestimation of k would produce successively higher answers 
for FE as one traversed the calibration curve. These cases are illustrated 
in Figure 3.17. 
Nevertheless, by adjusting the estimate of k in a systematic 
fashion, a set of values of FE could be found for which the standard deviation 
was a minimum. The value of k which corresponded to this minimum was then 
taken to be the optimum one for the data. The procedure may be appreciated 
from the results in Table 3.3. The mean of the set of values of FE with the 
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FIGURE 3.17 Illustration of Over- and Under-Estimations of k on 
Calibration Plots. 
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k 'F. sd n 
0.0056 0.9501 0.04300 14 
0.0057 0.9614 0.03683 14 
0.0058 0.9728 0.03145 14 
0.0059 0.9845 0.02757 14 
0.00598 0.9939 0.02618 14 
0.00599 0.9951 0.026143 14 
0.00600* 0.9963 0.026135 14 
0.00601 0.9975 0.02616 1·14 
0.00602 0.9987 0.02622 14 
0.0061 1.0084 0.02781 14 
0.0062 1.0207 0.03237 14 
TABLE 3.3 The Optimization of k from Experimental Data. 
k - inner filter correction factor (trial values) 
FE - the mean of the val ues of FE obtai ned for each of the n 
data points when the appropriate value of k is used in 
Equation 3.8 
sd - the standard deviation of the set of FE values associated 
with a particular value of k 
* The optimum value of k for this set of data (the corresponding sd is a 
minimum) • 
Experimental results were obtained by measuring the fluorescence emitted 
by samples containing ANS in O.lM Tris/Hel buffer, pH 7.4. 
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minimum standard deviation was calculated and used to construct the best 
straight line through the inner-filter corrected flucrescence intensities. 
From Equation 3.8, the equation of this line is simply Fo = c FE' In the 
example shown in Figure 3.18, the best straight line through the inner-
filter corrected intensities has a gradient FE of 1.00(! 0.03) x 104 M-1, 
where the figure in brackets is the standard deviation of FE across the 
curve. 
Having obtained suitable values for k and FE it is possible to 
construct a curve representing the fluorescence intensities which would be 
measured experimentally in the presence of the estimated inner-filter 
effects over a range of sample concentrations. If the background fluorescence 
is subtracted from each measurement, the curve may be defined as 
Fm = Fm - FB = (cFE + FB) exp (-kc) - FB 
which 1s just a restatement of Equation 3.8. In Figure 3.18 the theorectical 
curve can be seen to fit the experimental points over a wide concentration 
range. This lends support to the original statement that inner-filter 
effects are instrumental in distorting the linearity of calibration plots 
of fluorescence intensity versus concentration and that this distortion can 
be described adequately by a simple exponential function containing a 
constant k times the f1uorphor concentration. 
The results depicted in Figure 3.18 were obtained by measuring the 
fluorescence emitted from ANS in free solution. The only inner-filter 
effect was that of the unbound probe itself. Now, as explained before, it 
is necessary to consider inner-filter effects from two sources when 
interpreting the radiation emitted by protein-bound fluorescent probe. 
Consequently an extended version of Equation 3.7 is required. This expression 
is analogous to Equation 3.6 and in its most general form may be written as 
Fm = Fo exp (- {k,c,+ k~c .. + ••••• + k. Cr ) (3.9) 
where k, , k .. , k~ are the values of k for each absorbing species in the 
sample, and c" ca' •••••• c~ are the corresponding concentrations. 
Returning to the specific case of the bound probe fluorescence, 
the appropriate version of Equation 3.9 included terms for two absorbing 
species. Estimates of these terms were deduced separately from an 
examination of the result of the two titrations involved in the production 
of the calibration plot. 
A value of k was found for HSA by considering the results of a 
FIGURE 3.18 
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effects by determining the optimum value of k using 
Equation 3.B. 
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'reverse titration'. At a certain stage in the titration sufficient 
albumin wiii be present to accommodate all the fluorescent probe in the 
sample. Since there is no more fluorescent probe to be bound, the signal 
emitted by the sample will have reached a limiting maximum which is 
independent of further increases in the protein concentration. However, 
the observed fluorescence intensity will normally start to fall again 
as more albumin is added because the latter exerts an inner-filter effect. 
A suitable allowance for the inner-filter effect of HSA must remove this 
anomaly so that the corrected fluorescence intensities are virtually 
constant at high protein concentrations. 
As all the constituents in the reverse titration were invariant 
apart from the protein concentration, it was feasible to use an expression 
of the form shown in Equation 3.8 to determine the optimum value of k for 
albumin. In this instance FE represented the 'corrected' fluorescence 
intensity attributable to unit concentration of the bound probe, and c was 
the concentration of HSA. The optimum value of k was defined as that which 
gave the minimum variation in FE for each concentration of HSA above the 
critical level necessary to accommodate all the fluorescent probe. 
Likewise, the second titration used in the production of a 
calibration plot of fluorescence intensity versus bound probe concentration 
involved only one variable. This was the concentration of bound 
fluorescent probe. Accordingly, it was possible to determine a value of k 
for the bound probe by taking the experimental results and applying 
Equation 3.8 in the normal manner. 
Combining the estimates of k for the bound fluorescent probe and 
the albumin in the way shOfln in Equation 3.9 made it practicable to 
produce a plot of 'corrected' fluorescence intensity versus bound probe 
concentration whose values were independent of the protein concentration. 
An example is shown in Figure 3.19. Here the magnitude of FE, which 
corresponds to the gradient of the straight line calibration plot, is much 
larger than that obtained for the same probe in free solution (Figure 3.18). 
Indeed, the gradients differ by a factor of more than two thousand. This 
is another ill ustrati on of the f1 uorescence enhancement whi ch accompani es 
the binding of ANS to HSA. 
The procedure of optimizing the value of k from the observed 
fluorescence intensities is easily computerized. Consequently an appraisal 
of the 'goodness of fit' betl~een experiment and theory is readily 
available and can be used in the analysiS of errors. This approach has 
other advantages over the previously described method for estimating inner-
filter effects which are worth considering. No estimates of x and y are 
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required as the method is independent of the geometry of the light path 
througn tne sampie. In fact, inner filter corrections are possible even if 
the sample cell arrangement is unknown. Having performed a fluorescence 
titration, there 1s no need for further experiments to measure a,and a~. 
This offers a saving in reagents as well as time, and reduces the level of 
experimental error. 
A slight disadvantage of simply optimizing k to produce a 
mathematical fit to the data is that the correction procedure is not as 
physically plausible as is a direct measurement of the variables responsible 
for the inner-filter effect. Of course, if the assumptions about the 
geometry of the 1 i ght path through the samp1 e are correct and provi di ng a, 
and aaare measured accurately, then the two methods of inner-filter 
correction will give identical results. 
As shown in Figures 3.18 and 3.19, once account had been taken of 
solvent, dilution and inner-filter effects, it was possible to express the 
concentrations of bound and unbound probe as linear functions of fluorescence 
intensity. When in this form, the information provided the means to 
determine the degree of binding of a fluorescent probe to a protein over a 
wide concentration range. 
3.3 The Production of Data for Binding Curves 
The procedure was to take a convenient concentration of albumin, 
add various quantities of the probe and record the fluorescence emitted by 
the sample. The problem was to deconvolute the observed fluorescence 
intensities in terms of the separate contributions from the bound and 
unbound fractions of the ligand. By making use of the results of the 
previous section it was possible to achieve this and in so doing to 
determine the degree of binding of the fluorescent probe to HSA. 
3.3.1 Practical Aspects of Binding Titrations 
Initially, titrations were performed in the fluorimeter cell by 
adding micro1itre volumes of a stock solution of probe to a known quantity 
of albumin. Samples were stirred with the tip of the microsyringe u5ed to 
dispense the fluorescent probe. Measurements of the fluorescence intensity 
were recorded with the same wavelength settings and under exactly the same 
experimental conditions as were employed in the generation of the 
corresponding calibration plots. As these procedures and conditions have 
been described already, they will not be repeated here. 
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Titrations were also carried out in which a series of samples of 
the requi red composition \~ere prepared outsi de the fluorimeter. The 
advantages of this form of sample preparation have been discussed in 
Section 3.2.1. Fluorescence intensities were recorded in the usual manner. 
3.3.2 The Analysis of the Results of Binding Titrations 
The results consisted of a series of fluorescence intensity 
measurements, Fm. Each measurement corresponded to a certain total 
concentration of fluorescent probe, CT, the strength of the protein being 
constant or nearly so. 
At each stage in the binding titration the concentrations of bound 
and unbound probe were in thermodynamic equilibrium. Since it is axiomatic 
that the bound probe fluorescence is far more intense than that of an 
equivalent quantity in free solution, the measured fluorescence intensity 
at any point in the titration was a unique function of the degree of binding. 
Thus, in the absence of i nner-fi lter effects and background si gna ls. 
(3.10) 
where Fm is the measured fluorescence, CB and Cu are the concentrations of 
bound and unbound fluorescent probe; and FEB and FEu are the intrinsic 
fluorescence factors of bound and free fluorescent probe, respectively. 
Values for FEB and FEu were available from the work of the previous sections. 
Furthermore. 
CT = CB + Cu (3.11) 
where CT is the total concentration of fluorescent probe added to the 
system. Now, Equations 3.10 and 3.11 constitute two simultaneous equations 
containing two unknowns, Cu and CB. In its simplest form, therefore, the 
problem of finding levels of bound and free ligand reduces to the solution 
of two sfmultaneous equations. Unfortunately, the observed fluorescence 
will nearly always be attenuated by inner-filter effects due to bound probe, 
free probe and protein, and may contain a contribution from albumin. These 
additional factors must be taken into consideration when analysing the 
results of a binding titration. An iterative computer procedure, FLUORB, 
was developed to perform this function. 
Descriptions of the signals attributable to free and albumin-bound 
fluorescent probe were fed into the memory of the computer. As outl ined 
previously, FE' the fluorescence intensity corrected for inner-filter and 
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other effects, was available for unit concentrations of bound and unbound 
probe from the gradients of the respective linear calibration plots. For 
convenience, the reciprocal values were employed. Thus, the labels FTDBC 
and FTDFC were given to the terms capable of converting corrected 
fluorescence intensities into concentrations of bound and unbound fluorescent 
probe. To provide a better description of the results obtained under normal 
experimental conditions, inner-filter correction factors for albumin, and 
for bound and unbound fluorescent probe were introduced in turn as AP, AB 
and AF. These factors were the values of the expressions 2.303 (a.; a,) or 
k covered in Section 3.2.3. If applicable more information concerning 
dilution and solvent effects VIas presented to the computer program. 
Where necessary FLUORB had to be modified slightly to make 
allowances for sample dilution. In this form the program was able to 
calculate the total concentrations of both fluorescent probe and albumin 
at each point in the titration by taking regard of the slight increase in 
sample volume following each addition of the stock reagent. To account for 
solvent effects, the program had to be adapted still further. These 
relatively simple modifications are not shown in the listing in Figure 3.20. 
Once the computer contained a description of the fluorescence 
intensity emitted by a wide range of concentrations of bound and unbound 
probe, it was programmed to accept the results of a binding titration. The 
process may be followed in lines 51-53 of Figure 3.20 where values of DC(I) 
the total concentration of probe in each sample, are fed in alongside the 
corresponding measured fluorescence intensities, EXF(I). 
Sufficient information was then held in the memory to permit a 
calculation of the concentrations of the bound and unbound fractions of the 
probe at each point in the binding titration. However the complex nature 
of the calculation meant that an iterative solution was required. 
Before commencing the iteration, an assumption had to be introduced 
in to the program. This made for rather an obvious statement. It concluded 
that the bound fraction of the probe was responsible for the major part of 
the observed fluorescence intensity over all concentrations. The assumption 
meant that an initial, approximate value for the bound probe concentration 
coul d be found at any point in the ti trati on di rectly from the recorded 
fluorescence intensity EXF(I). Although not strictly true, especially at 
high probe:protein ratios, the assumption provided a means by which the 
iterati ve procedure could be initiated in a simple and convenient fashion. 
Thus in line 57 the initial estimate of the corrected emission intensity 
of the bound fraction CDBF(I) is set equal to the measured fluorescence 
signal EXF(I) for the sample under consideration. As will become clear 
0050 C 
0051 
0052 
0053 
0054 
0055 C 
0056 
0057 
0058 
0059 
0060 
0061 
0062 
0063 
0064 
0065 
0055 
0067 
0068 
0069 
0070 
0071 
0072 
0073 
0074 
0075 
0076 
0077 C 
0078 
0079 
0080 
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READ IN EXPERIMENTAL DATA 
DO 1 1=1,100 
READ(l,102,END=2)DC(I),EXF(I) 
102 FORMAT(2F10.5) 
1 CONTINUE 
BEGIN ITERATION TO GENERATE DATA SATISFYING INPUT VALUE, EXF(I) 
2 DO 7 I=l,N 
CDBF( I) =EXF (I) 
3DB(I)=CDBF(I)*FTDBC 
DF(I)=DC(I)-DB(I) 
CDFF ( I) =DF ( I) /FTDFC 
UDBF( I) =CDBF( I )*EXP( -(AB*DB( I ))-(AF*DF( I) )-(AP*PCONCN)) 
UDFF(I)=CDFF(I)*EXP(-(AB*DB(I))-(AF*DF(I))-(AP*PCONCN)) 
X=EXF(I)-(UDBF(I)+UDFF(I)) 
Y=-X 
IF(X.GE.0.001) GO TO 6 
IF(Y.GE.0.001) GO TO 6 
IF(X.LE.0.001.AND.Y.LE.0.001) GO TO 4 
4 R(I)=DB(I)/PCONCN 
RONDF(I)=R(I)/DF(I) 
RINVS( I)=l/R( I) 
DFINVS(I)=l/DF(I) 
DFONR(I)=DF(I)/R(I) 
WRITE(2,103)DC(I),DB(I),R(I),RONDF(I),RINVS(I),DFINVS(I), 
1DFONR(I ),DF( I) 
103 FORMAT(4(4X,F8.4,2X,F8.4)) 
GO TO 7 
ADJUST ESTIMATE OF CDBF 
6 CDBF( I)=CDBF( I)+1.5*X 
GO TO 3 
7 CONTINUE 
FIGURE 3.20 Listing of a Segment of FLUORB 
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shortly, the validity of this statement is irrelevant to the proper 
functlonlng of the program. 
A first approximation to the concentration of bound probe OB(l) 
is determined from COBF(l) using the conversion factor FTOBC (see line 58). 
OF(l), the concentrati on of probe now supposedly remaining in free sol ution 
is found simply by subtracting OB(l) from the total concentr.ation of 
fluorescent probe in the sample. In conjunction with FTOFC, OF(l) is used 
to obtain COFF(l) which represents the corrected fluorescence intensity 
associated with this first estimate of the concentration of unbound probe. 
The calculation is shown in line 59. The values COBF(l) and COFF(l) are 
stored in the computer. 
As well as having acess to the protein concentration, PCONCN, 
the program now contains estimates of the protein-bound and unbound probe 
concentrations. The way forward is clear. The signal that would be 
observed under normal experimental conditions from a sample of the proposed 
composition must be computed and compared with the value actually recorded. 
If the two quantities are in agreement, then the estimates of the concentrations 
of the bound and unbound fractions may be taken to be close to those 
existing in the sample. 
The next step, therefore, is to modify the corrected fluorescence 
intensity due to the bound fraction, COBF(l), so that account is made for 
solvent, dilution, inner-filter or other experimental artefacts. As 
described previously, however, experiments were usually designed so that 
only inner-filter phenomena were worthy of consi deration. Line 61 shows 
how the inner-filter effects of the three absorbing species in the sample 
may be accounted for and how the uncorrected fluorescence intensity, 
UOBF(l), is determined from COBF(l). Of course, the concentrations of the 
bound and unbound probe to use in this equation are the initial estimates, 
OB(l) and OF(l), since these make up the sample composition currently under 
test. At the same time and in a similar manner, it is possible to use 
COFF(l) to compute the fluorescence intensity that would be observed 
experimentally from the unbound fraction in the presence of these inner-
filter effects. Thus UOFF(l) is calculated in line 62 of the program. 
The quantities UOBF(l) and UOFF(l) are summed to give the total 
fluorescence intensity which would be measured with the hypothetical sample 
of composition OF(l), OB(l), PCONCN. The result is compared with the 
experimental value EXF.(l) in line 63. Unless the two terms agree within 
certain limits which are set closer together than the minimum intensity 
change detectable by the fluorimeter, 
COBF(l) in the appropriate direction. 
the program adjusts the value of 
This adjustment may be followed 
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in lines 63-66 and 78-79. The new value of CDBF(l) allows fresh estimates 
of the concentrations of bound and free fluorescent probe to be generated. 
Fluorescent intensi ti es are computed again and the results compared l'lith 
EXF(l). If necessary. CDBF(l) is adjusted for a second time and the cycle 
repeated once more. It is possible that a large number of cycles may be 
required before the statement in line 67 is satisfied. Fortunately. however. 
the oscillating iterative procedure incorporated into the program is very 
efficient and it can quickly reveal the sample composition responsible for 
the observed fluorescence intensity. 
Once this has been achieved for one data point. the next value of 
(DC(I). EXF(I)) say (DC(2). EXF(2)) may be processed. Before doing so. 
though. the computer is instructed to take the concentrations of the bound 
and unbound probe it has just determined and. along with the protein 
concentration. to present the results in a form suitable for constructing 
binding plots. These representations are discussed in the next section and 
some experimental data are presented. 
3.4 The Presentation of Results 
The most common method for presenting the results of an in vitro 
binding studY is in terms of one of the linearization procedures described 
in Chapter 1. Examples of these linear transforms are the Scatchard Plot 
r/Cu v. r (Scatchard. 1949). the double-reciprocal plot of l/r v. l/Cu 
(Klotz. 1946) and the plot CU/ r v. Cu (Klotz. 1953) in which Cu represents 
the concentration of unbound ligand. and r is the ratio of the concentration 
of bound ligand CB to the total concentration of protein (or other 
macromolecule) Cp. Since the parameters of these binding equations are 
simple functions of the total protein concentration and the concentrations 
of bound and unbound ligand. it proved quite straightforward to instruct the 
program FLUORB to generate numerical output for binding curves. The only 
requirement was that the concentrations of the three species should be 
combined in the appropriate manner. The relevant equations are given in 
lines 68;73 of the program. 
A subroutine was available which allowed data to be represented 
graphically on the lineprinter. This program was used in conjunction with 
FLUORB to illustrate the results of a binding titration in the form of the 
three plots described above. 
The binding of warfarin to HSA has been studied. The results of 
one experiment are shown in Tables 3.4(a)-(c) and Figures 3.21-3.23. In 
this example. inner-filter correction factors were determined from 
absorbance measurements taken at the wavelengths of maximum excitation and 
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SUMMARY OF DATA 
DC DB R RONDF RINVS DFINVS DFONR OF 
0.4194 0.3446 0.0675 0;9032 14. Blll 13.376B 1.1072 0.0748 
0.8385 0.6610 O. 1295 0.7295 7.7207 5.6299 1.3714 0.1776 
1.2577 0.9482 0.1858 0.6002 5.3816 3.2302 1.6661 0.3096 
1.6767 1.2308 0.2412 0.5410 4.1452 2.2425 1.8485 0.4459 
2.0955 1.5033 0.2947 0.4976 . 3.3931 1.6885 2.0095 0.5922 
2.5142 1.7652 0.3461 0.4621 2.8891 1.3352 2.1639 0.7490 
3.3512 2.2498 0.4413 0.4007 2.2661 0.9080 2.4958 1. 1 014 
4.1876 2.6629 0.5225 0.3427 1. 9139 0.6559 2.9181 1.5245 
5.0234 3.0338 0.5955 0.2993 1.6794 0.5026 3.3413 1.9895 
5.8587 3.3830 0.5542 0.2583 1.5055 0.4039 3.7273 2.4757 
6.5934 3.6358 0.7141 0.2335 1.4004 0.3271 4.2818 3.0575 
7.5276 3.8977 0.7658 0.2110 1.3059 0.2755 . 4.7403 3.6299 
8.3512 4.1435 0.8143 0.1931 1.2280 0.2371 5.1795 4.2178 
10.0258 4.5955 0.9038 0.1664 1.1065 0.1841 6.0094 5.4312 
12.5210 4.9965 0.9835 0.1307 1. 0167 0.1329 7.6499 7.5245 
15.5671 5.5558 1.0955 0.0986 0.9128 0.0900 10.1425 11.1113 
20.7994 5.9112 1.1675 0.0786 0.8565 0.0672 12.7520 14.8883 
24.9)81 6.2274 1.2320 0.0559 0.8117 0.0535 15.1708 18.5907 
41.2579 7.0378 1.4015 0.0410 0.7135 0.0292 24.4152 34.2201 
51.3837 7.5842 1.5428 0.0287 0.6482 0.0186 34.8065 53.5995 
81.1848 8.6743 1.7558 0.0242 0.5595 0.0138 41.2987 72.5105 
119.8443 11.1555 2.2945 0.0211 0.4358 0.0092 47.3558 108.5878 
(a) (b) (c) 
TABLE 3.4 The Data of One Binding Experiment as Represented by the 
Program FLUORB 
DC - total concentration of warfarin (10-6M) 
DB - concentration of bound warfarin (10-6M) 
OF - concentration of free warfarin (10-6M) 
R - DB/PCONCN where PCONCN is the total protein 
concentration; in this experiment albumin 
concentration was 5.10 x 10-5M. 
RONDF - R/DF (106M-1) 
RINVS - l/R 
DFINVS - l/DF (106/11-1) 
DFONR - DF/R (10-5M) 
Data presented in form of 
(a) Scatchard plot (Scatchard. 1949) 
ib~ Double reciprocal plot (K1otz. 1945) 
c K10tz plot (Klotz. 1953) 
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0.4 
0.2 
o 0.5 1.0 1.5 2.0 
R 
FIGURE 3.21 Scatchard Plot Representing the Binding of Warfarin to HSA. 
12.5 
10.0 
7.5 
5.0 
2.5 
o 2.5 5.0 7.5 
l/oF (xl06M-l ) 
FIGURE 3.22 Double Reciprocal Plot Representing the Binding of 
Warfarin to HSA. 
DF /R (1 0-6M) 
FIGURE 3.23 of/R Versus OF Plot Representing the Binding of Warfarin to HSA. 
NB. The three graphs on this page were produced from the 
same set of binding data. . . 
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emission of fluorescence. Dilution effects were considered but solvent 
corrc:::~:1~ were unnecessary as the stock solution of warfarin contained 
only a small volume of O.lM NaOH. The units of concentration are lO-6 r1 • 
A comparison of the three representations of the binding data 
shows how the plots of '/r v. llCu and CUlr v. Cu tend to compress the 
results to one end of the graphs, while the experimental pOints in the 
Scatchard Plot are more evenly spaced. The rather cumbersome way in which 
the parameters of the first two transorms vary can also be appreciated by 
inspecting the numerical data in Tables 3.4(b) and 3.4(c). There is a 
temptation to draw straight lines through the points in the Klotz Plots, 
especially if the values obtained at the lowest probe:protein ratios are 
omitted. Misinterpretation of the Scatchard Plot is less easy. Furthermore, 
Meyer and Guttman (1968) believe the double reciprocal plot to be less widely 
accepted than the Scatchard representation on account of its tendency to 
underemphasize the results obtained at low ligand:protein ratios. These 
are the results whi ch are frequently the most relevant in vi vo. 
Although all three portrayals of the binding data contained the 
same information, albeit in slightly different forms, it was concluded that 
the Scatchard Plot was the easiest to work with. 
Now, linear plots will be obtained with the functions represented 
by the coordinates in Figures 3.21~3.23 only if a single class of binding 
sites is involved, each site being totally independent of the others. It is 
obvious from the results that the interaction between HSA and warfarin 
entails more than a single class of non-interacting sites. 
Likewise, the curved Scatchard Plot in Figure 3.24 suggests that 
the binding of albumin to the fluorescent dye ANS is also complicated'by 
the existence of either different classes of sites or interacting sites. 
In this experiment inner-filter factors were deduced directly from the 
calibration plots as outlined previously. There were no solvent or dilution 
effects to consider. 
In Chapter 1 it was seen how the slopes and intercepts of linear 
binding plots may be used to determine the number of independent binding 
sites and the apparent association constants. With non-linear binding 
curves, which are symptomatic of more complicated interactions, Klotz and 
Hunston (1971) have shown that no simple relationship exists between the 
slopes and intercepts of these graphs and the binding constants. Under 
these circumstances it is necessary to employ curve-fitting procedures if 
anything like accurate values are required for the binding constants. 
Rosenthal (1967) has proposed a graphical method for the presentation and 
determination of binding parameters from the Scatchard plots of systems 
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n, = 0.785 
k, = 4.21 x 106M-l 
5.0 
n& = 2.72 
k:a. = 0.234 x 106rfl 
4.0 
3.0 
2.0 
1.0 
o 1.0 2.0 3.0 R 
FIGURE 3.24 A Scatchard Plot Representing the Binding of ANS to HSA. 
The curve and the binding constants were derived from the 
experimental data with the aid of the NKFIT routine. 
Error bars were computed as described in the text. 
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which involve one or more non-interacting binding sites. This method 
inc,,,rl<>< • trial and error procedure which has to be continued until a 
specified match to the experimental curve is found. Based on this ap~roach" 
Pennock (1973) has devised a simple mechanical calculator which may be used 
to aid in the extraction of binding parameters from experimentally determined I 
Scatchard Plots. However, these and other manual methods suffer from their 
complexity and tediousness. Furthermore, a subjective decision has to be 
~de concerning the best fit to the data. 
To overcome some of these problems, a computerized curve-fitting 
procedure was developed which allowed for the routine analysis of binding 
data. The method provided a means of extracting quantitative information 
from the results of a binding titration. Its main features are discussed 
in the next section. 
3.5 The Calculation of Binding Constants from Experimental Data 
A computer program was written to analyse the results of a binding 
titrati on in terms of a two-si te binding equati on: 
R(I) = n,k,OF(I) 
1 + k. OF (I) 
+ 
n. k .. OF (I ) 
1 + k~OF(I) (3.12) 
where R(I) 
OF(!) 
- moles of fluorescent probe bound per mole of protein. 
- concentration of free (ie. unbound) probe. 
n,,!la. - the number of binding sites in each class. 
k" k. the apparent association constants for these sites. 
and I = 1, N where N is the number of experimental observations. 
The program NKFIT finds the values of n, • k, • n .. , and k .. whi ch 
best satisfy Equation 3.12 for a complete set of values (R(I), OF{!). As 
previously described, R(I) and OF(I) may be deduced from the experimental 
data with the aid of FLUORB. A segment of the NKFIT routine is shown in 
Figure 3.25 and the following summary of its operation may be understood 
with reference to this listing. 
By varying the binding constants n, , k" n. and k .. in a systematic 
fashion and reading in a series of OF{I) values,it is possible for the 
program to produce several thousand sets of results for R(I) from Equation 
3.10. These are stored as the variable RR(I) in line 93. Each set of 
RR( I) values corresponds to a parti cul ar value of the parameters n" k" 
n&and k .. , while each member of the set is also related to a certain value 
of OF (1) • 
0043 
0044 
0045 
0046 
0047 C 
0048 
0049 
0050 
0051 
0052 
0053 
0054 
0055 
0056 
0057 
0058 
0059 
0060 
0061 
0062 
0063 
0064 
0065 
0066 
0067 
0068 C 
0069 
0070 
0071 
0072 
0073 
0074 
0075 
0076 
0077 
0078 
0079 
0080 
0081 
0082 
0083 
0084 
0085 C 
0086 
0087 
0088 
0089 
0090 
0091 
0092 
0093 
0094 
0095 
0096 
0097 
R( 1)=0.0 
RONOF(I)=O.O 
RFITOF(I )=0.0 
17 CONTINUE 
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READ IN SETS OF INPUT DATA. 
DO 7 I=l,NOATA 
REAO(l,101,ENO=16) R(I),OF(I) 
101 FORMAT(F9,4,F10,4) 
7 CONTINUE 
16 DO 1 K=I,NI 
ONEN(K)=O.O 
DO 1 L=l,NI 
TWON(L)=O.O 
DO 1 M=l,NI 
KONE(M)=O.O 
DO 1 N=l,NI 
KTWO(N)=O.O 
SUMSQ(K,L,M,N)=O.O 
1 CONTINUE 
DO 2 1=1,101 
RFIT( 1)=0.0 
ERROR( 1)=0.0 
PRCENT( 1)=0.0 
RR( I )=0.0 
2 CONTINUE 
GENERATE A SERIES OF TRIAL VALUES 
DO 3 K=l,NI 
AK=K 
ONEN(K)=TONEN+(AK-1.0)*STEP/5.0 
3 CONTINUE 
DO 4 L=l,NI 
AL=L 
TWON(L)=TTWON+(AL-1.0)*STEP/5.0 
4 CONTINUE 
DO 5 M=l,NI 
AM=M 
KONE(M)=TKON+(AM-1.0)*STEP 
5 CONTINUE 
DO 6 N=l,NI 
AN=N 
KTWO(N)=TKTWO+(AN-1.0)*STEP/2.5 
6 CONTINUE 
CALCULATE SETS OF RR USING ALL COMBINATIONS OF TRIAL VALUES 
CFMIN=SUMSQ(l,l,l,l) 
8 DO 11 K=I,NI 
DO 11 L=l,NI 
DO 11 M=l,NI 
DO 11 N=l,NI 
SSQ=O.O 
DO 9 I=l,NOATA 
RR(I)=(ONEN(K)*KONE(M)*OF(I»/(I+KONE(M)*OF(I»+ 
l(TWON(L)*KTWO(N)*OF(I»/(l+KTWO(N)*OF(I» 
OIFF=(RR(I)-R(I)/R(I) 
IF(OIFF.LT.O.O) GO TO 77 
GO TO 9 
0098 
0099 
0100 
0101 
0102 C 
0103 
0104 
0105 
0106 
0107 
0108 
0109 
0110 
0111 
0112 
0113 
0114 C 
0115 
0116 
0117 
0118 
0119 
0120 
0121 
0122 
0123 
0124 
0125 
0126 
0127 
0128 
0129 
0130 
0131 
0132 
0133 
0134 
0135 
0136 
0137 
0138 
0139 
0140 
0141 
0142 
0143 
0144 
0145 
0146 
0147 
0148 
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77 DIFF=-DIFF 
9 SSQ=SSQ+DIFF 
SUMSQ(K,L,M,N)=SSQ 
11 CONTINUE 
FIND MINIMUM VALUE OF SUMSQ,CFMIN. 
CFMIN=SUMSQ(l,l,l,l) 
DO 10 K=l,NI 
DO 10 L=l,NI 
DO 10 M=l,NI 
DO 10 N=l,NI 
IF(K*L*M*N.EQ.1) GO TO 10 
IF(SUMSQ(K,L,M,N).LT.CFMIN) GO TO 15 
GO TO 10 
15 CFMIN=SUMSQ(K,L,M,N) 
10 CONTINUE 
FMIN=CFMIN/NDATA*100.0 
SEARCH OUT VALUES OF ONEN,TWON,KONE,&KTWO WHICH GIVE CFMIN. 
IW=O 
DO 12 K=l,NI 
IW=IW+1 
IX=O 
DO 12 L=l,NI 
IX=IX+1 
IY=O 
DO 12 M=l,NI 
IY=IY+1 
IZ=O 
DO 12 N=l,NI 
IZ= IZ+ 1 
IF(ABS(CFMIN-SUMSQ(K,L,M,N».LT.0.00000001) GO TO 13 
12 CONTINUE 
13 TONEN=ONEN(IW)-STEP/5.0 
TKONE=KONE(IV)-STEP 
TTWON=TWON(IX)-STEP/5.0 
TKTWO=KTWO(IZ)-STEP/2.5 
NCOUNT=NCOUNT+1 
IF(NCOUNT.GE.5) GO TO 18 
ANI=NI 
STEP=STEP/(ANI/2.0) 
NI-NI+1 
GO TO 16 
18 WRITE( 2 ,102) ONEN( IW),KONE(IV), TWON(IX ),KTWO(IZ), I W, IX, IY , 
IZ,FMIN 
l,STEP 
102 FORMAT(11X,6HONEN =,F8.5/11X,6HKONE =,F8.5/11X,6HTWON =, 
F8.5/11X,6 
1HKTWO =,F8.5/11X,4HIW =,I4/11X,4HIX =,I4/11X,4HIY =,I4/11X, 
4HIZ =, 
1I4/11X,26HAVERAGE PERCENTAGE ERROR =,F10.6/11X,12HFINAL 
STEP =,F10 
1.7///l 
WRITE(2,103) 
103 FORMAT( 75H OF R RFIT ER 
1ROR PRCENT) 
SUMERR=O.O 
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0149 DO 14 I=l,NDATA 
0150 RFIT(I)=(ONEN(IW)*KONE(IY)*DF(I»/(l+KONE(IY)*DF(I) 
0151 1 )+(TWON(IX)*KTWO(IZ)*DF(I»/(l+KTWO(IZ)*DF(I) 
0152 1) 
0153 ERROR(I)=R(I)-RFIT(I) 
0154 PRCENT(I)=((R(I)-RFIT(I)/R(I)*100.0 
0155 RONDF(I)=R(I)/DF(I) 
0156 RFITDF (I) =RFIT( I) /DF(I) 
0157 SUMERR=SUMERR+(ERROR(I)*ERROR(I» 
0158 WRITE(2,104) DF(I),R(I),RFIT(I),ERROR(I),PRCENT(I) 
0159 104 FORMAT(5(F15.5» 
0160 14 CONTINUE 
0161 WRITE(2,107) SUMERR 
0162 107 FORMAT(11X,26HSUM OF SQUARES OF ERRORS =,F10.7) 
0163 STOP 
0164 END 
SUMMARY OF DATA 
ONEN = 0.78476 
. KONE = 4.21429 
TWON = 2.72571 
KTWO = 0.23429 
IW = 8 
IX = 8 
IY = 3 
IZ = 4 
AVERAGE PERCENTAGE ERROR = 3.993513 
FINAL STEP = 0.0047619 
0.01880 
0.03120 
0.05570 
0.07430 
0.10460 
0.16020 
0.20240 
0.28240 
0.34910 
0.40610 
0.66040 
0.60930 
1.00030 
1.65760 
2.37420 
4.91160 
8.14480 
12.20220 
16.55600 
25.74010 
35.29540 
45.21050 
65.13730 
84.60000 
0.08340 
0.12440 
0.16280 
0.20250 
0.30530 
0.40250 
0.50260 
0.59450 
0.68930 
0.78620 
0.94940 
0.96050 
1.09380 
1.38750 
1.66830 
2.20700 
2.59360 
2.79980 
2.94110 
3.11960 
3.21690 
3.23550 
3.25150 
3.36910 
0.06956 
0.11097 
0.18430 
0.23377 
0.30530 
0.41489 
0.48465 
0.59559 
0.67328 
0.73214 
0.94254 
0.90529 
1.15180 
1.44893 
1.68770 
2.20696 
2.55101 
2.78914 
2.94071 
3.11561 
3.21117 
3.27124 
3.34000 
3.37737 
+0.01384 
+0.01343 
-0.02150 
-0.03127 
+0.00000 
-0.01239 
+0.01795 
-0.00109 
+0.01602 
+0.05406 
+0.00686 
+0.05521 
-0.05800 
-0.06143 
-0.01940 
+0.00004 
+0.04259 
+0.01066 
+0.00039 
+0.00399 
+0.00573 
-0.03574 
-0.08850 
-0.00827 
SUM OF SQUARES OF ERRORS = 0.0272319 
FIGURE 3.25 Segment of NKFIT 
+16.58984 
+10.79273 
-13.20808 
-15.44044 
+0.00141 
-3.07716 
+3.57207 
-0.18336 
+2.32431 
+6.87647 
+0.72206 
+5.74761 
-5.30287 
-4.42745 
-1.16270 
+0.00185 
+1.64203 
+0.38061 
+0.01339 
+0.12786 
+0.17799 
-1.10477 
-2.72189 
-0.24537 
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If the binding constants are allowed to vary over a wide range, 
many of t~e sets of results that are computed for RR(I) will be very 
different from the experimental set R(I). NKFIT is instructed to search 
through all the sets of RR(I) values it has generated and to find the one 
which best fits the input data. The values of n" k" naand ka which are 
responsible for producing this best fit are located and displayed oM the 
lineprinter under the labels ONEN, KONE, TWON and KTWO, respectively. These 
may be seen in the output presented in Figure 3.25. Once identified, these 
binding constants are used in Equation 3.12 along with the OF(I) values 
obtai ned by experiment to regenerate the corresponding R( I) terms. The 
latter are printed under the heading RFIT and for ease of comparison, they 
are listed alongside the R(I) values which were determined directly from 
the binding titration. The absolute and percentage differences between 
RFIT(I) and R(I) are presented under the titles ERROR and PReENT, 
respecti ve ly. 
To start the analysis, however, the program demands that initial 
trial values for the binding constants are read in. Fortunately, these do 
not have to be close to the 'true' values, although, of course, the time 
taken to construct a reasonable fit to the ex~erimental data will be reduced 
if good trial values are available. Normally, inspection of the Scatchard 
Plot suggests reasonable initial estimates of the binding constants. 
Flexibility is maintained in the program by allowing the user to specify 
the intervals by wbich the trial values are to be varied and the range 
over which they are to extend. These parameters may be controlled separately 
for each binding constant. 
To make the program more efficient, an iteration may be directed to 
ensure that the interval between the consecutive trial values becomes 
smaller as the fit to the experimental data gets better. This means that 
the most suitable binding constants can be specified very closely. For 
instance, in the example shown in Figure 3.25, which uses data from the 
Scatchard Plot of Figure 3.24, n,= 0.785(0.001), k,= 4.214(0.005), n.= 2.726 
(0.001), k.= 0.234(0.002) where the figures in brackets represent the final 
intervals between the last trial values to be tested. So, as far as NKFIT 
is concerned, the best fit to these results is achieved for some value of 
n, defi ned by the 1 imits 0.784::: n,:O. 786. likewi se, the other parameters may 
be spec ifi ed. 
Clearly, the program must be given some criterion by which it can 
determine the best fit to the experimental data. For all trial values of the 
binding constants it is possible to calculate the differences between the 
computed values RR(I) and the corresponding experimental quantities R(I). 
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As shown in line 95 of the routine, these differences may be expressed in 
te!'"'~ ';>T ":h" f,.~cti(lna1 'errors' inherent in the estimates RR(I), The 
criterion of best fit is that the sum of the magnitudes of these errors 
should be a minimum. The fitting procedure is therefore analogous to a 
'least squares' method. As explained previously, the binding constants 
which are responsible for minimizing the defined error function are sought 
by the computer and eventually presented on the lineprinter. 
In most cases it was possible to achieve a very good fit to the 
experimental data using the two-site model of Equation 3.12. An example 
is shown in Figure 3.26. The solid line was constructed from the optimum 
values of n., k" n~ and k~ determined by the NKFIT program. The results 
appear to fit the mathematical model within the limits of experimental 
error. (These errors are discussed in the next section)." 
Al though the curve-fi tting procedure seemed to work qui te 
satisfactorily, it is worth pOinting out that a limited variation in the 
binding constants about the optimum values may have only a small effect on 
the goodness of the fit to the experimental data. In other words, the 
9uantities defined as 'SUM OF SQUARES OF ERRORS' and 'AVERAGE PERCENTAGE 
ERROR' may indicate that a reasonable fit to the results can be obtained 
over a restricted range of values of the binding constants, the fit perhaps 
being more sensitive to one binding parameter than to another. This 
behaviour would suggest that models based on three or more binding sites 
are likely to become increasingly difficult to interpret as several sets of 
possibly quite disparate binding constants may satisfy the input data to 
very similar degrees. No attempt was made to fit results to models more 
complicated than the two-site equation. 
To determine if there is a systematic departure of the data points 
from the fitted curve, one may inspect the signs of the residuals (see 
results under ERROR heading in Figure 3.25) and ascertain whether there is 
an element of nonrandomness in their sequence. One sort of non randomness is 
suggested by having too few runs (or sign changes). Thus + + + + - - - - -
+ + + + i-s a sequence of signs which seems-nonrandom because it has too fe~1 
runs, three in this case. The theoretical distribution of the number of 
runs in a sequence has been calculated by Bennett and Franklin (1954) 
assuming that each sign is an independent random event. If required, this 
test could be applied to the present program. However, a visual inspection 
of the signs of the residuals was found to be adequate for recognizing 
systematic deviations between the data and the fitted binding curves. 
Some effort was invested in finding an analytical solution to the 
determination of binding constants rather than using the trial-and-error 
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FIGURE 3.26 A Scatchard Plot Representing the Binding of Warfarin to HSA. 
Th€ curve and binding constants were derived from the 
experimental data with the aid of the NKFIT routine. 
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curve fitting procedure described above. Again only a two-site equation 
was consi dered. Since there are four unknol"ns. n •• k,. n ... and k .... at least 
four pairs of experimental values OF(I). R(I) are required to furnish 
answers for all the binding constants. NormalJy. considerably more data is 
available than the minimum just specified. Each pair OF(I). R(I) refers to 
a particular point in the binding titration. For a complete titration. 
then. the results associated with any four of the points may be abstracted 
and used to generate an estimate of n, • n .... k, and k .... Labelling one such 
set of results OF(O). R(O); OF(l). R(l); OF(2). R(2); and OF(3). R(3). 
a 11 OIlS the following equations to be formulated: 
R(O) = n, k, OF(O} + ilL k ... OF(O} (3.13) 
l+k,OF(O) l+k ... OF(O} 
n, k, OF (1 ) n .. k~OF(l} (3.14) R( 1 } = + 
l+k,OF(l} l+k ... OF(l} 
n. k, OF(2) n ... k2 OF(2} (3.15) R(2 ) = + 
1+k,OF(2} 1+k .. OF(2} 
n,k,OF(3) n .. k...OF(3} (3.16) R( 3} = + 
1+k I OF(3} l+k ... OF (3) 
Solutions are required for the binding constants n,. k,. n ... k .... in terms 
of the measured quantities OF(O). OF(l}. OF(2). OF(3). R(O}. R(l). R(2}. 
R(3}. 
From Equation 3.13 it should be possible to derive an expression 
for k,which is some function of the ether variables. that is 
k, = F (n, • nO., k2:; OF(O). R(O}} 
Similarly. from Equation 3.14 
k ... = F (n,. n .... kIt OF(l). R(1}} 
If the expression for k,is incorporated into the last statement. then k ... 
may be written in the form 
ka = F (n,. nL • OF(O). R(O}, OF(1}. R(1}} 
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From Equation 3.15 
nit = F (n, • k, • k •• DF(2). R(2)) 
and substituting in the descriptions of k,and k~gives 
nO. = F (n,DF(O). R(O). DF(l). R(l). DF(2). R(2)) 
Finally. rearranging Equation 3.16 allows n,to be described by the 
functi on 
n, = F (n ... k" k~, DF(3), R(3)) 
Inserting the appropriate expressions for n2. • k, and k~ into this 
statement means that n, can be written in terms of the experimental data 
alone: 
n, = F(DF(O). R(O). DF(l), R(l). DF(2). R(2). DF(3), R(3)) 
An estimate of n, is then available from the results of a binding titration. 
The remaining constants n ... k .. and k. are determined in sequence using the 
previous expressions. There are obviously several equivalent ways of 
solVing the simultaneous equations (3.13-3.16). The route given here is 
just one example. 
Unfortunately, when this procedure was followed it soon generated 
quadratic equations. Solutions to these functions were unmanageab1y long 
and included numerous terms raised to high powers. Moreover, it soon became 
clear that even if the solutions v/ere much simpler. the analysis would still 
be complicated by the method of feeding in the results. Although any four 
points in the binding titration could be used to find n., k" n .. and ko.. 
estimates of the binding constants would be applicable over the whole ran~e 
of the experiments only if all possible permutations of the input data 
were considered and some mean of the estimates produced. 
The unavoidable conclusion from this aspect of the work is that 
a curve-fitting procedure offers the best method of extracting accurate 
binding constants from the experimental data. The NKFIT program is more 
convenient than manual means of curve-fitting and, as shown in Figure 3.26 
and 3.24. the intractions of warfarin and ANS with HSA appear to be· 
consistent with a t,./O-site binding equation. 
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3.6 The Analysis of Errors 
?ubiished association constants for drug-protein interactions are 
often in very poor agreement. To assess the accuracy of the results produced 
in this study, it proved useful to examine the errors generated in each 
stage of the procedure. Those ~!hich were critical could be identified and 
suitable methods of improvement suggested. 
Assuminy temperature, pH and buffer ionic strength did not vary 
from sample to sample, the main sources of error would appear to be those 
associated with the measurement and correction of fluorescence intensities, 
and with the dispensing of reagents. 
Since the ~uality of the final binding data ·depends ultimately 
on the accuracy of the calibration curves, these will be considered first. 
It is reasonable to assume that stock solutions can be made up 
accurateiy. However, as seen in Section 3.2.1, serial additions of a 
concentrated stock solution during a titration may eventually lead to the 
accumulation of quite large errors. As a remedy, the number of pipetting 
steps connected with each point in the titration vias reduced by preparing 
each dilution independently of all others. Nevertheless, every sample 
would still differ very slightly from its intended composition due to 
pipetting errors. 
The effects of instrumental drift were minimized by comparing 
sample fluorescence intensities with those emitted by quinine sulphate 
solutions. Unfortunately, there is a limit to how accurately the instrument 
can be read and at low fluorphor concentrations where a high photomultiplier 
gain is necessary, the noise-level may make it im~ossible to determine 
accurate fluorescence intens~ties. Consequently, the imprecision inherent 
in the measurement of the fluorescence must be compounded with the errors 
in dispensing reagents to define the limits of accuracy of the calibration 
plots. 
A tlli rd factor to consi der is the correcti on of the observed 
intensities for inner-filter effects. In very dilute samples ,·/here 
absorption of radiation by the probe is insignificant, corrections for inner-
filter effects lIill be vanishingly small. As a result, at the low 
concentration end of the calibration plots the measured and corrected 
fluorescence intensities are very similar and errors in estimating the 
inner-filter correction factors a.and a~have only a marginal effect on the 
. magnitude of the corrected values. On the other hand, when enough 
fluorescent probe is present to absorb a significant proportion of the 
incident radiation, inner-filter effects may be quite large and errors in 
their estimation can result in the production of highly erroneous corrected 
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fluorescence intensities. 
Having recognized the three major sources of error involved in 
setting up calibration plots of corrected fluorescence intensity versus 
probe concentration, it is worth considering how each manifests itself. 
An estimate of the magnitude of the different errors may then be possible. 
Errors in the preparation of samples and in the measurement of 
fluorescence appear as a random scatter of data points about the calibration 
curves. As shown in Figures 3.10 and 3.13, this scatter may be observed 
with both corrected and uncorrected calibration plots. 
One way of estimating the magnitude of the errors associated with 
sample preparation and intensity measurement is to make up a number of 
samples to supposedly the same concentrati on and take several measurements 
on each. The spread of the results may be used to judge the precision 
obtainable over a range of sample concentrations. 
Another way of obtaining an estimate of these errors is to 
consider the inner-filter corrected calibration plots. In Section 3.2.3 
it was shown how the optimum value of the inner-filter correction factor k 
\'Iou1d be defined as that which gave the minimum variation in FE across the 
calibration plot. Obviously, if there were no errors in measuring the 
fluorescence intensity or in dispensing the reagents, and providing Equation 
3.8 were truly applicable, the appropriate value of FE would be a constant 
over the entire calibration range. In practice, of course, the different 
values of FE are scattered about some mean and the degree of scatter 
provides an estimate of the experimental preCision. A typical spread of 
values is illustrated in Table 3.5. 
Aside from the random errors inherent in the results, a poor 
estimation of the inner-filter phenomenon will appear as a systematic 
deviation of the corrected fluorescence intensities from a linear 
calibration plot. When the inner-filter correction is derived from the 
measurements of sample absorbance at the wavelengths of fluorescence 
excitation and emission, some estimate of the accuracy of the allowance 
can be obtained from an investigation of the errors included in the 
absorbance readings. On the other hand, if the effect is accounted for 
by optimizing the inner-filter correction factor k and producing the best 
straight line through the data, no absorbance measurements are involved. 
The error in this procedure has to be estimated from the fluorescence 
intensity readings alone. 
As described in Section 3.2.3, Equation 3.8 was employed to find 
the value of k which resulted in the minimum variation of FE across the 
calibration plot. The mean of the least variable set of FE values was 
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'c FM Fo FE 
10 16.4 9.55 0.955 
20 25.0 20.28 1.014 
30 31.8 30. 18 1.005 
40 36.9 39.05 0.977 
50 42.9 50.07 1.001 
60 49.9 63.69 1.061 
80 53.4 78.42 0.980 
100 60.4 102.2 1.022 
120 60.6 115.6 0.972 
140 62.8 137.7 0.984 
160 64.1 159.5 0.997 
200 61.3 195.5 0.978 
240 58.4 238.4 0.993 
320 48.5 322.7 1.008 
TABLE 3.5 The Variaticn in the Gradient of the Linear, Corrected 
Calibration Plot at Each Point in a Titration when the 
Optimum Value of k is used. 
c the concentration of ANS in O.lM Tris/Hel buffer, 
pH 7.4 (l0-6M) 
the measured fluorescence intensity 
the inner-filter corrected fluorescence intensity, 
where 
Fo = FM exp (kc) - Fa and 
Fa = 7.9, k = 0.00600 (see Table 3.3) 
the gradient of the linear inner-filter corrected 
calibration plot, where FE = FO/e 
From the above results FE = 0.995 (sd = 0.026). 
- 171 -
calculated and used to construct the best linear fit to the corrected 
flu~!"::::~:;: intensity measurements. NO~I a rearrangement of Equation 3.B 
gives the follol'!ing expression for k. 
Since c, Fm and Fa are known quantities, this expression provides a means of 
calculating the value of k required to transpose each experimental point in 
the titration curve on to the linear calibration plot of gradient FE' This 
is illustrated in Table 3.6 using the data shown in Figure 3. lB. As 
expected, the mean value of k is simply that used inEquation 3.B to 
determine FE in the first place. However, a study of the. variation in k 
across the calibration curve is useful in assessing how precisely this 
parameter can be defined by experiment. 
In dilute solutions the inner-filter effect is very small and may 
be difficult to detect. The task of measuring k under such conditions is 
made \~orse by the fact that the fractional error in a recording of the 
fluorescence intensity increases as the sample concentration is lowered. 
Fortunately, as mentioned above, errors in determining the inner-filter 
effects of dilute samples are of little consequence. Accordingly, a 
'\~eight~d' average of the imprecision in k was found by eliminating the 
results obtained in very dilute solutions (say exp (-kc)~1.05) and 
calculating the standard deviation of the remaining experimental values. 
For simplicity, an average value was also reported for the 
inaccuracy associated with dispensing the reagents and recording the 
fluorescence intensities. The lowest quantity of probe included in the 
calibration curves was well above the detection limit of the assay. Thus 
the error in FE ~/as held more or less constant over the range of concentrations 
examined. The variation in the estimates obtained for FE at each point in 
the titration \~as used to define an average experimental error, dFE (see 
Table 3.5). 
Once reasonable estimates were available for the inaccuracies 
inherent in the calibration plots, it was possible to consider their effect 
on the interpretation of subsequent binding titrations. 
The computer program FLUORa considers inner-filter effects arising 
from bound and unbound flUorescent probe and from albumin. So line 61 of 
the program may be expressed as, 
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C FM k 
30 31.8 0.00574 
40 36.9 0.00642 
50 42.9 0.00591 
60 49.9 0.00506 
80 53.4 0.00619 
100 60.4 0.00577 
120 60.6 0.00619 
140 62.8 0.00609 
160 64.1 0.00600 
200 61.3 0.00609 
240 58.4 0.00601 
320 48.5 0.00696 
TABLE 3.6 The Value of k Required to Transpose Each Data 
Point on to the Linear Calibration Plot. 
c - the concentration of ANS in O.lM Tris/HCl 
buffer, pH 7.4 (10-6M) 
FM - the measured fluorescence intensity 
k - inner-filter correction factor required to 
. transpose individual data points on to 
linear calibration plot; 
1 rE FE + F~ 
k = C ln \. FM -:; where 
FB = 7.9 and FE = 0.996 
From the results k = 0.00600 (sd = 0.0003). 
- 173 -
where FM is the observed fluorescence intensity. Fo is the inner-filter 
corrected intensity. kb. ku and kp are the inner-filter factors for bound 
and unbound fluorescent probe and for albumin., and cb' Cu and cp are the 
concentrations of the corresponding absorbing species. The uncertainty 
in the inner-filter corrected fluorescence intensity may be related to the 
uncertainties in the experimentally determined parameters kb. ku. kp and 
FM by a partial differentiation of the previous equation. Thus. after 
simplification 
IdFol 
,·!here IdFol. IdFMI. Idkbl. Idkul and Idkpl are the absolute errors in Fo. 
FM' kb. ku and kp• respectively. 
At any stage during a binding titration. therefore. the fractional 
error in the calculated inner-fi 1ter corrected fluorescence depends on the 
fractional error in the experimentally measured sample fluorescence. It 
also depends on the absolute errors in each of the estimates of the inner-
filter factors multiplied by the concentrations of the corresponding 
absorbing species. 
Now as long as the sample concentration is within the calibrated 
range, that is. the observed fluorescence is well above the experimental 
detection limit. the fractional error in FM must be similar to that incurred 
in measuring fluorescence intensities for the appropriate calibration plots. 
Since the greater part of the sample fluorescence is due to emission from 
the bound probe. it is reasonable to equate IdFMj/FM withldF~FE where the 
latter refers to the bound probe calibration curve. So. 
(3.17) 
In practice. albumin is present at a fixed concentration and 
usually absorbs only a small amount·of radiation at the wavelengths of 
excitation and emission of the bound probe fluorescence. Consequently. 
the value of Cp Idkpl is normally insignificant compared to the other terms 
on the right-hand side of Equation 3.17. However. since the uncertainties 
in measuring the inner-filter effects of the bound and unbound fractions 
are almost undoubtedly different. the accuracy with whi ch the observed 
fluorescence can be corrected will vary depending on the degree of protein 
binding in the sample under investigation. In other words. as I dkb 1=Fldkul 
in Equation 3.17. (Cb Idkbl + Cu Idkul) will change in a non-linear 
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fashion across the binding curve. (Had Idkbl and Idkul been equal, the term 
cb I dk ::,\ ... '=" I dku I would have been a linear function of the total probe 
concentration). Nevertheless, since both cb and Cu get larger as more probe 
is added to the albumin, IdFol will always increase as the total 
concentration of probe rise~9 
It is worth considering the errors in measuring the inner-filter 
factors of the bound and unbound fractions in more detail. At low probe: 
protein ratios most of the probe will be bound to albumin. Under these 
conditions, allO',~ance for the extremely small inner-filter effect of the 
unbound probe will certainly be unimportant. In fact, at this end of the 
binding curve, unless the sample contains large quantities of protein, it 
is likely that the bound probe concentration ~ll also be too low to exhibit 
an appreciable inner-filter effect. The corrected fluorescence Fo will 
hardly be different from the signal that is measured in practice but any 
small errors in allowing for inner-fi lter effects will be due almost 
entirely to uncertainties in providing for the bound probe absorption. 
On the other hand, at high probe:protein ratios, there may be 
sufficient fluorescent probe - both bound and unbound - to generate an 
appreciable inner-filter effect. However, many of the binding sites on 
albumin will be occupied at high protein:probe ratios and the greater 
fraction of the ligand will be in free solution. Thus errors in 
characterizing the inner-filter effect of the unbound species will become 
of greater significance as the total probe concentration increases. Indeed, 
determination of this parameter will likely prove to be the limiting factor 
in a fluorimetric assay of the lo~affinity binding sites on H5A. 
Having considered the experimental errors associated with an 
estimation of Fo, the next step is to examine how information is extracted 
from this term. FLUORB retains a value of that part of the inner-filter 
corrected signal which is attributable to albumin-bound fluorescent probe. 
The program uses this value to derive an estimate for the bound probe 
concentration. As shown in line 58, this derivation is very simple because 
the inner-filter corrected fluorescence intensity is directly proportional 
to the fluophor concentration. That is, 
and using partial differentiation, IdcBI 
cB 
= 
IdFOI 
Fo 
+ 
The fractional error in Fo has already been described as a function of the 
uncertainties in the experimental determinants (see Equation 3.17). 50 
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an overall expression for the error in the e~timated bound probe 
conc~~t~~ticn is 
WE! 2-- + FE (3.18) 
For completeness, another term would have to be included in this 
equation. It arises because the iterative procedure in FLUORB has to 
consider the contribution that the unbound probe makes to the total sample 
fluorescence. At high probe:protein ratios there may be sufficient probe 
in free solution to exhibit an appreciable fluorescence. It is conceivable 
that errors in estimating this signal could lead to uncertainties in 
determining cS. However, it can be shown that the inclusion of an 
additional term in Equation 3.18 is unwarranted. The uncertainty in 
measuring the fluorescence of the unbound fraction would have to be very 
high, while, at the same time, the enhancement in the probe fluor~scence 
on binding to albumin would have to be low. In addition, the unbound probe 
would need to be present in such high concentrations that uncertainties in 
determining the inner-filter effect would have already become unacceptable. 
At any point in the binding titration, the error in the estimate of 
the unbound fraction may be equated with that in the bound fraction. This 
is so because Cu is found simply by subtracting the bound probe 
concentration, CB from the total concentration, CT (see line 59). It is 
reasonable to assume that the error in CT is very small compared to the 
error in cS, so I dcul~ I dcS I. 
Finally, the imprecision in the value obtained for the albumin 
concentration may be determined by taking repeated absorbance measurements 
on a stock solution and reporting the spread of the results. In practice, 
the coefficient of variation of the absorbance readings was quite low -
0.8% being a typical value. 
Having assessed the experimental errors associated with the estimates 
of cS, Cu and cS, it was possible to examine their influence on the shape 
of the subsequent binding curves. This was quite straightforward as the 
parameters of the binding curves were simple functions of the total protein 
concentration and the equilibrium concentrations of hound and unbound ligand. 
The process is illustrated for the Scatchard plot of r versus r/cu. 
r = cS / / cp 
.. I~I = I dcS I + 
r CS 
I~I 
dp (3.19 ) 
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The fractional error in r is equal to the sum of the fractional errors 
inherent ln the calculation of the bound probe and total protein 
concentrations. During the course of most binding experiments only the 
ligand concentration is varied. Consequently, the second term on the 
right-hand side of Equation 3.19 will be the same for all points on the 
binding curve. In general, cS cannot be determined to the same degree of 
accuracy irrespecti ve of the total 1 i gand concentrati on. So Idcsl wi 11 
cS 
change across the binding curve. Above a certain ligand concentration, 
Equation 3.18 may be used to describe this variation for the fluorimetric 
assay and suggests that as r gets bigger so does the fractional errorl~rl 
(see Figure 3.24). As explained before, the problem lies in calculating 
inner-filter effects at high concentrations of fluorescent probe. At very 
low concentrati ons, however, a 1 ack of sens i ti vi ty wou1 d precl ude a proper 
measurement of the sample fluorescence, Equation 3.1B would be inapplicable 
and the error in r would rise again. 
The other parameter in the 5catchard analysis is 
:·1 dCu) 1= 
and I d~~u) I 
, --
= 
,/cu 
r 
Cu = 
1 
cpcu 
I dcS I 
CS 
I dCBI + .lldcul +~ I dcp I 
cpcus cucp" 
+ I dcu I + Idcpl 
Cu cp 
(3.20) 
(3.21) 
Equation 3.20 is a general expression to describe how the uncertainty in 
/,cu can be related to the experimental errors. For the procedure outlined 
in this Chapter, the uncertainties in estimating the bound and unbound 
1i gand concentra ti ons are equal, and because CT = Cs + cu, a speci a 1 case of 
Equation.3.21 is appropriate. Thus, 
= + (3.22 ) 
At low probe:protein ratios, most of the fluorescent probe is bound tc 
albumin and only a small fraction of the ligand remains in free solution. 
Under these conditions, Equation 3.22 sho\~s that the fractional error in 
r/ cu will increase without bounds. That is, d.(%u)~ 00 as Cu ~ o. 
(Ycu) 
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This explains the long error bars associated with the high values of ~cu 
in tlgures j.24 and 3.26. 
At the other end of the Scatchard Plot. the total ligand 
concentration may be sufficient to ensure that a high proportion of the 
fluorescent probe exists in free solution. In this context. Equation 3.22 
can be used to demonstrate that as the total ligand concentration is raised. 
the fractional error in ~u will fall until it approaches that in r. 
Thus. as Cu~ CT. 
d(~) I dCB I + Idcpl = I~I 
Cu ~-cB cp r (:J 
The marked decrease in the vertical error bars at high concentrations of 
fluorescent probe is apparent in Figures 3.24 and 3.26. 
The general expressions 3.20 and 3.21 can be used to explain the 
limitations inherent in any examination of ligand-protein binding - whatever 
the methodology. When investigating binding to high affinity sites. 
cB »cu and the limiting factor turns out to be the inaccuracy in measuring 
the unbound fraction. To minimize this error. it would be preferable if 
the assay ~~re one which measured cu directly. However the same equations 
shO\~ that in a stucIY of binding to low affinity sites. where cB :::::-::::cu. the 
uncertainty in determining the concentration of the protein-bound ligand is 
critical. It appears likely. therefore. that no one system will be ideally 
suited to an investigation of both high and low affinity binding sites. 
In order to apply the error functions described in this Section. 
an updated version of the FLUORB program was prepared. It computed the 
uncertainties in the parameters of the Scatchard plot using actual 
experimental data. Equation 3.18 was required to establish the error in the 
estimated bound probe concentration at any point in the titration. As 
mentioned before. this expression was also used to describe the uncertainty 
in the corresponding value for the unbound probe. The uncertainties in r 
and ~cu were found from Equations 3.19 and 3.22. The values of dku. dkb. 
dkp• dFE and dcp were fed in to the program as required. 
A typical distribution of errors 1s presented for a Scatchard plot 
representing the binding of ANS to HSA. The variability of the results 
of repeated experiments has been found'to agree broadly with those 
suggested by the error bars in Figure 3.24. 
The production of these error profiles has certain practical 
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applications. The uncertainty associated with each pOint in the curve 
allows the suitability, or otherwise, of a set of binding constants to be 
appreciated. For example, the solid ltne in Figure 3.24 is constructed from 
the values of n. , k. , n,t..k.shown and appears to fit the data to within the 
Hmi ts of experimental error. 
r40re importantly, perhaps, the error profile emphasi zes the 
limitations and scope of the present assay. The limitations are clear. 
The unbound fraction is measured indirectly - it is defined as the difference 
between the bound and the total ligand concentrations. At low probe: 
protein ratios most of the probe is in the bound fraction. NON because the 
absolute errors in the estimations of the bound and unbound fractions tend 
to be very similar, when CB'>'>cu a small percentage error in the estimate 
of cB will be translated into a very large percentage error in the estimate 
of cu. Consequently, the procedure is not ideally suited to the 
measurement of binding to high affinity sites. This is manifested in the 
large errors in ~cu at low concentrations of fluorescent probe. Likewise, 
the assay is of limited use when considering very high ligand concentrations. 
The problem here is in allowing for large inner-filter effects. The 
considerable errors in r at high probe concentrations are indicative of this 
limitation. However, restrictions at this end of the curve are usually 
unimportant because binding to low affinity sites on albumin is of less 
practical significance. 
Nevertheless, an investigation of the distribution of errors has 
shown that the procedure is capable of producing accurate binding data over 
a very wide range of ligand concentrations. This should be borne in mind 
when conSidering the other attributes of the assay; no separation of the 
bound and unbound fractions is required; the experiments are simple to 
perform: and although processing of the results is quite complicated, the 
procedure is easily computerized. 
3.7 Oerivate and Synchronous Fluorescence Spectroscopy in the Resolution 
of'Spectral Contributions from Bound and Free Fluorescent Probes 
The purpose of the work described in this section is to identify 
suitable methods for differentiating more completely between the spectral 
contributions of free and protein-bound fluorescent probes. Once 
identified, such methods may lead to a simplified procedure for constructing 
binding isotherms. For example, the iterative procedure discussed in 
Section 3.3 could be avoided if there were complete discrimination between 
the free and bound emission peaks. Furthermore, a truly independent 
measure of free and bound 1 igand woul d extend the working range of most 
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binding assays. 
Two techniques were employed to amplify the differences between the 
emission bands of bound and free fluorescent probes. However, it should be 
noted that while ANS was used to examine the feasibility of applying 
synchronous and derivative fluorescence spectroscopy to a study of protein 
binding, the practical necessity to discriminate between the very weak 
fl uorescence of the free probe and the intense fluorescence of the bound 
species would rarely arise. The same is not true for warfarin, of course, 
because the fluorescence of the unbound form can constitute a slgnificant 
proportion of the total signal observed from a sample containing both bound 
and free fluorescent probe. 
Deri va ti ve spectroscopy can be useful in resol vi ng spectral overl ap 
and enhancing the fine structure of most types of spectra. The technique 
consists of calculating the first, second or higher order of a spectrum 
with respect to wavelength and plotting the derivative rather than the 
spectrum itself. The result is an increase in structure that is generally 
paid for by a decrease in the signal-ta-noise ratio. 
Wavelength derivatives may be produced by electronic differentiation 
or wavelength modulation. Wavelength modulation coupled with a lock-in 
amplifier produces an output signal which is proportional to the derivative 
of intensity with respect to wavelength. An electronic signal differentiator 
produces an output signal which is proportional to the derivative with 
respect to time and uses this to simulate derivatives with respect to 
wavelength. Although wavelength ~odulation may be capable of giving 
superior signal-to-noise ratios in derivative absorption spectrometry, the 
same is not true in luminescence spectrometry where both derivative methods 
give similar signal-to-noise ratios (Green and O'Haver, 1974). Electronic 
differentiation is simpler and less expensive than wavelength modulation, 
it does not require a lock-in amplifier or any modification of the 
fluorimeter optics, and can generate the zeroth, first or other derivative 
time spectra simultaneously. However, the electronic method demands that 
the scan rate 1s not only constant but reproducible from scan to scan, 
whereas the wave length modul ati on does not suffer from ei ther of these 
limitations. 
In this study derivative spectra were generated electronically. 
The technique employed is similar to that used with dual-wavelength 
spectroscopy (Porro, 1972), where a wavelength offset of up to several 
nanometers between the two optical channels produces an intensity difference 
which 1s essentially equivalent to the first derivative. With the DCSU-2 
unit, however, differentiation is achieved electronically, rather than 
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optically, through data storage and computation. 
There are two main advantages of plotting the derivative of a 
spectral curve. Firstly, the derivative technique can be useful for 
resolving bands that are too close to be resolved in the original spectrum. 
The enhancement of resolution increases with derivative order but depends 
on band shape. Thus two Gaussian bands of equal height and width are just 
resolved in zeroth order, second derivative and fourth derivative spectra 
when their separations divided by their full width at half maximum is 0.85, 
0.63 and 0.52, respectively (Cahill, 1980). 
The second general effect of plotting the derivative of a spectrum 
is a discrimination in favour of its sharper features. Consequently, the 
influence of a broad background signal on a spectral peak may be reduced ~y 
taking the first or higher derivative. Again, discrimination against the 
broadpr band increases with derivative order (Cahill, 1980). 
Fell (1978) has demonstrated the practical advantages of second 
derivative ultraviolet-visible spectrophotometry for the quantitative assay 
of drugs in formulation mixtures. Green and O'Haver (1974) suggest that 
derivative techniques may be especially useful in luminescence spectrometry 
because of the rather cOlllllon occurrence of fluorescence background and band 
overlap problems in quantitative fluorimetric analysis. 
When calculating derivatives from initial spectra, a suitable 
compromise must always be sought between the fidelity with which the 
derivative is calculated and the signal-to-noise ratio. This is so because 
noise, even when small, contains by far the sharpest features of a real 
spectrum. Noise will increasingly dominate the derivative spectrum as the 
derivative order is increased. The decrease in the signa.l-to-noise ratio 
can be controlled to a large degree by averaging the derivative calculation 
over a wavelength regien that is large compared to the noise structure. 
This lowers the derivative signal as well as the noise level but discriminates 
against the latter. However, as this wavelength range is increased, the 
derivative becomes more and more distorted. The consequence of a finite 
wavelength range is therefore a decrease in the derivative signal and a 
decrease in resolution. 
In general the optimum values of derivative order and wavelength 
range must be determined experimentally for each application. The 
attainment of an undistorted derivative is not a useful goal. The best 
compromise between acceptable spectral distortion and sufficiently high 
signal-to-noise ratios should be sought. 
The first and second derivative modes of the Differential Corrected 
Spectra Unit-2 (DCSU-2) offer three choices of wavelength ranges which can 
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be used in calculating alogarithms (Di Cesare and Porro, 1978). These are 
2nm, 5nm and 10nm. The lo~rest selection, 2nm, is obviously used where 
resolution is necessary and signal-to-noise ratio can be sacrificed, while 
the highest selection, 10nm, results in the greatest signal-to-noise levels 
but a minimum resolution. When examining the emission spectrum of warfarin 
the presence of HSA, a wavelength range of 5nm gave an unacceptably noisy 
signal in the first derivative: an even higher noise level was observed with 
the second derivative mode. A satisfactory noise level was obtained for the 
second derivative spectrum when a 10nm wavelength offset was employed. 
Figure 3.2 shows corrected emission spectra for warfarin both in 
free solution and in a sample containing a high molar excess of albumin. 
Thus Figure 3.2(b) represents the fluorescence emission spectrum of un bound 
warfarin. At an albumin warfarin ratio of 10:1 essentially all of the 
drug is bound to protein: moreover, since the fluorescence of a 5 x 10-5M 
solution of HSA is negligible under the specified conditions, spectrum 3.2~) 
is representative of the emission of the bound form of warfarin. The blue 
shift in the fluorescence of warfarin on binding to albumin is clear: the 
emission maximum of the bound form is at 376nm compared to 385nm for the 
unbound species. The unbound form of the drug also appears to have a slightly 
broader emission peak - a full width at half maximum of 78nm, as opposed to 
one of 67nm for the bound form. 
Figure 3.27 shows the second derivatives of the spectra of Figure 3.2. 
As expected, the fluorescence of the unbound probe in the second derivative 
is shifted to a longer wavelength and its features are broader than those 
of the bound species. It appears that differences in the emission spectra 
of the bound and unbound forms of the drug are amplified in going from the 
zeroth order to the second derivative. Unfortunately, the increase in 
discrimination between the two spectra is insufficient for their complete 
resolution. Far too much overlap remains between the emission spectra of 
free and bound warfarin to allow one form to be determined in the presence 
of the other even with the use of derivative spectroscopy. 
In comparison to warfarin a much greater blue shift accompanies the 
binding of ANS to human serum albumin. (The relevant spectral parameters 
are summarized in Table 3.7). By definition, a large separation in the 
emission maxima should facilitate a resolution of the bound and free 
fractions. However, the problem of resolving the spectra of the free and 
bound forms of ANS lies in the relative intensities of the emission peaks. 
The fluorescence of the bound species is so much more intense than the 
fluorescence of the free form that the latter tends to be obscured by the 
long wavelength tail of the former even though the emission maxima are 
SECOND DERIVATIVE OF 
FLUORESCENCE INTENSITY 
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FIGURE 3.27 Derivative Spectra of Bound and Free Warfarin. 
Wavelengths of excitation 320nm. 
(a) Sample containing 5x10-6U warfarin and 5x10-5M HSA in 
O.lM Tris/HC1 pH 7.4. Scale expansion x 2. 
(b) Sample containing 5xlO-6M warfarin in O.lM Tris/HC1 pH 7.4. 
Scale expansion x 10. 
The second derivative spectrum of a sample containing 5x10- 5M 
HSA was not significantly different from zero over this 
wave length range. 
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Stokes ).ex ).em Shift FWHM 
Species (nm) (nm) (nm) (nm) 
Warfarin bound 320 380 60 70 free 320 390 70 78 
ANS bound 380 475 95 90 free 380 530 150 150 
. 
Human serum albumin 280 340 60 75 
TABLE 3.7 A Summary of the Major Features of the Fluorescence 
Spectra of Human Serum Albumin, Warfarin and ANS. 
).ex wavelength of maximum excitation of fluorescence. ).em wavelength of maximum emission of fluorescence. 
FWHM full width at half maximum intensity of the 
emission band. 
- 184 -
serarated by some 60nm. Derivative spectroscopy was incapable of producing 
a dbl./';llIifldtion between the weak fluorescence due to unbound ANS and the 
intense fluorescence of the bound species at shorter wavelength. Because 
of its ability to narrow spectral band widths. synchronous fluorescence 
spectroscopy was viewed as a potential solution to the problem. 
The idea of synchronous excitation of fluorescence emission spectra 
was first suggested by Lloyd in 1971. The method provides a means of 
increasing the sensitivity of luminescence spectrometry. Its application 
to the resolution of the spectra of bound and free fluorescent probes is 
examined below. 
In conventional fluorescence spectroscopy, an emission spectrum can 
be generated by scanning the emission wavelength while the, fluorescent 
compound is excited at a fixed wavelength. An excitation spectrum can be 
obtained by scanning the excitation wavelength while the emission is measured 
at a given wavelength •. A third possibility consists of varying 
simultaneously, or synchronously. both the wavelengths of excitation and 
emission while maintaining a constant wavelength interval ~A between them. 
The result is often called a synchronously excited emission spectrum. 
although since it can be considered as an emission or as an excitation 
spectrum, Vo-Dinh (1978) simply refers to it as a synchronous signal or 
a sync~ronous spectrum. All three terms will be used interchangeably 
in this section. 
The synchronous scanning of both excitation and emission 
monochromators can greatly simplify complex fluorescence spectra because 
the fluorescence contributed by each component is restricted to that 
excited at wavelengths synchronously trailing the recorded emission by a 
fixed value. A signal is only observed with the synchronous technique when 
~A matches the interval between an absorption band and the corresponding 
emission band. If it is possible to select a particular ~A which matches 
one unique pair of absorption and emission bands. the synchronous spectrum 
will show only a single peak. In order to have a situation where an interval 
~A can be found to match solely one pair of excitation and emission bands, 
it is necessary that the emission and excitation spectra consist of bands 
which are not separated by similar wavelength intervals. 
Lloyd and Evett (1977) have shown how the characteristics of 
synchronous spectra can be derived quantitavely from the characteristics of 
the corresponding fixed excitation and emission spectra. An important 
attribute of synchronous ly exci ted emi ss i on spectra is thei r much reduced 
peak half-widths relative to the excitation and emission spectra from which 
they originate. This band-narrowing effect is a consequence of the 
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multiplication of two intensity distribution functions - those of the 
excitation and emission spectra - which increase and/or decrease 
simultaneously. The capacity to modify the spectral band width for 
individual components in a mixture is an outstanding feature of the 
synchronous technique; it leads to a reduction in spectral overlap and an 
improvement in resolution. 
Corrected excitation and emission spectra for the bound and free 
forms of warfarin are recorded in figure 3.28. The corresponding spectra 
for ANS are shown in figure 3.29. figure 3.30 includes corrected excitation 
and emission spectra of HSA. The positions of the excitation and emission 
maxima of these species are summarized in Table 3.7. 
from the data it is clear that the excitation and emission bands 
of warfarin are separated by roughly similar intervals when the ligand is 
in free solution and when it is bound to HSA. Moreover. the emission spectra 
of bound and free warfarin are broad peaks of comparable band-widths. 
Consequently. it was not possible to find an interval ~A which would match 
just one of the two pairs of excitation and emission b.ands. Peaks due to 
the bound and free form of the fluorescent probe were not resolved in 
synchronously excited emission spectra over a wide range of AA values even 
when monochromator slits of only 2nm were used. Although of limited 
significance. it is worth stating that the synchronous spectrum of HSA could 
be readily distinguished from the signals attributable to the bound 
fluorescent probes for values of ~A ranging from 30nm to 60nm. 
When ANS is considered. however. it is obvious that an interval 
can be found which matches just the excitation and emission bands of either 
bound or free fluorescent probe. A synchronous spectrum of ANS in free 
solution is shown in figure 3.31. The constant wavelength interval is 140nm 
and the band maximum is centred at an excitation wavelength of 380nm and 
an emission wavelength of 520nm. A synchronous spectrum of albumin-bound 
ANS is sho~1!1 in figure 3.32. In this case ~A is 100nm. The band maximum 
corresponds to an emission wavelength of 475nmj there is no contribution 
from the'protein in this region of the synchronous spectrum. It is 
interesting to note the quenching of the albumin fluorescence at 370nm 
(wavelength of excitation 270nm) by energy transfer to the bound fluorescent 
probe (figure 3.32). Figure 3.33 illustrates the differences between t:le 
conventional and synchronous fluorescence spectra of albumin bound ANS. 
The narrowing of the band widths of the synchronous signal relative to the 
conventional emission spectrum is clear: the full widths at half maximum 
intensi ties for the synchronous and conventional spectra are 53nm and 83nm. 
respectively. Particular attention should be paid to the marked reduction 
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FIGURE 3.31 
WAVELENGTH 
Synchronously Excited Emission Spect~m of N~S in 
Free Solution. Sample contained 10-1M ANS in O.lM 
Tris/HCl buffer pH 7.4 • 
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FIGURE 3.32 
WAVELENGTH 
Synchronously Excited Emission Spectrum of Bound ANS. 
Sample contained 2xlO-6M ANS and 2xlO-SM HSA in O.lM 
Tris/HCl buffer pH 7.4. 
The ratio of the gain settings ·used in Figures 3.31 
and 3.32 was 10:1. . . 
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FIGURE 3.33 A Comparison of Conventional and Synchronous Fluorescence 
Spectra of Albumin-Bound ANS. 
(a} Synchro~ous1y ex§ited emission soectrum of sample 
containing 2x10- M ANS and 2x10-5M HSA in O.lM Tris/HC1 
buffer pH 7.4. 8A = 100nm. 
Full width at half maximum 53nm. 
(b) Conventional emission spectrum of same sample. 
Wavelength of excitation 375nm. 
Full width at half maximum B3nm. 
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in the long wavelength tail of the spectral band on going from the 
convl:u.iuUdi t.O the synchronous mode. Compared to the normal emission 
spectrum, the fluorescence of the bound probe in the region of 520nm is 
about six times lower in the synchronous spectrum. Thus, overlap between 
the spectra of bound and free ANS m~ be significantly reduced by employing 
the synchronous excitation of fluorescence emission rather than running 
normal emission spectra. 
Unfortunately, it was not possible to extend the synchronous 
technique to the separate measurement of free and bound levels of ANS in 
samples containing both species. As mentioned before, the fluorescence 
intensity of ANS in free solution is so weak that even a small contribution 
from the bound probe in the region of 520nm makes quantitation impossible. 
While synchronous scanning of excitation and emission monochromators 
certainiy reduced the problem of spectral interference, it was insufficient 
to totally eliminate the effect. 
From the results presented in this section, it is possible to 
predi ct under what ci rcums tances the deri vati ve and synchronous techni ques 
Nou1d be of most value. This is made easy by the fact that the fluorescent 
probes used in this investigation have quite different characteristics. 
Warfarin exhibits only a moderate enhancement in its fluorescence intensity 
on binding to HSA. Similarly the wavelength of maximum emission and the 
emission bandwidth are altered only slightly ~men the probe binds to 
albumin. Although derivative techniques can amplify differences between the 
emission spectra of the free and bound species, complete resolution of the 
peaks is not possible. Synchronous spectroscopy is also of limited use as 
far as warfarin is concerned because the Stokes shifts of the free and bound 
forms are so similar. In contrast to warfarin, the fluorescence intensity 
emitted by ANS increases dramatically on binding to albumin. Moreover, the 
wavelength of maximum emission is transferred to a much shorter wavelength. 
The problem here lies in discrimination between the weak fluorescence of the 
free forms of ANS and the intense fluorescence of the bound form. While 
synchronous scanning of the excitation and emission monochromators reduces 
the spectral band widths, complete resolution of the two signals is still 
not feasible. 
It is clear that the class of fluorescent probes which would 
benefit most from derivative and synchronous techniques would exhibit 
moderate shifts in the wavelengths of maximum emission on binding to 
albumin, possibly intermediate between those of warfarin and ANS but 
probably similar to that of ANS, and increases in the intensity of 
fluorescence on binding to albumin more akin to that of warfarin than ANS. 
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APPENDIX A 
The purpose of this appendix is to demonstrate that t,e 
approximation 
n 
r fo exp (-2.303(a, xi. + a~yi.) c) '" Fo exp (-2.303(a, x + atY)c) 
i. = 1 
holds true under specified conditions. 
By way of an introduction,.and in order to simplify the 
mathematics, the hypothesis 
n 
r exp (x;.) '" 
1.=1 
n exp [nr 
i.= 1 
~LJ (A.l ) 
will be tested. 
eX, 1 ~ . .. = + x,+ x~+ x,+ ••••• + 2S,.. + ..••• 
~. Jt r! 
eX& 1 •• r = + XL + X.a. + Xs + ••••• + !,& + .•••. 
2\ '!! r! 
eXn 1 .. 3 + •..•. = + x.,+ ~+ ~+ .•... + X 
2! 3! r! 
n 
. _ r 
t=l 
eXL = eX, + ex~+ ••••• + eXn = n + (X + X + + X ) + , ~ ...... n 
fx~+ x!+ ..... + x~ + fx~+ x~+ ..... + X~ + ..... + (X~+ !~+ ..... + P + ..... \f! I! 2i) 'J! J: 3;) \{! r! rJ 
n 
" r 
\. =1 
X· e 10 = n (1 + ~ + x"+ 'X. + .•.•• + i.-+ ..... 
I! 3! r: 
(A.2) 
h - ( ) -z. (.... L) ~I ere X = X,+ X.+ ..... + Xn , X = X,+ X .. + ..... + Xn ' 
n n 
x~ = (x7+ x:+ ••••• + x~) , etc. 
n 
n 
X,. = r 
i.= 1 
xr-
~ 
n ,etc. 
n xi. 
That is. x = .. - x" 
" n' i. = 1 
... . 
Now 1 + X + X + X + .•.•• + x + ••••• 
'21 3! Ft 
n 
= r 
\= 1 n , 
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.. ~ .. 
= n (1 + X + X + X + ••••• +x + •••• ) 
, '2"! '!! r!' 
(A. 3) • .&. n e 
The first two terms on the right-hand sides of Equations A.2 and A.3 are 
identi cal and 
~ r 
(~? X ) + ••••• + ex"· x ) 
3! r! 
(A.4) 
If the original approximation (Equation A.1) is to 'be acceptable. ~ must 
be small compared to n 
" x' • ., e 
i.= 1 
The conditions necessary to minimize fJ. may be appreciated by taking 
Equation A.4 and examining the terms in brackets. The first term may be 
rewri tten in the form 
~ 
n (XL. X ) = .&. (x, - x) + XL (x .. - x) + .2 (x.J- x) + ••••• + x ... (x r - x) + ••••• 
2! 2! 2! 2! 2! 
a The individual components 2l (x~· x) may be positive or negative depending 
(A.S) 
on whether XL is larger or smaller than the mean of the series. To minimize 
the function. however. the different values x.shou1d be as near to x as 
possible. that is (x;.- x) should tend to zero. 
The other functions in Equation A.4 may be expanded in a similar 
fashion. Again. if these terms are to be small, the variability of the 
series x,should be low. 
·The statement n 
!: 
;'=1 
may be tested using an appropriate practical example. Consider a number 
of fluorescent molecules situated within a fluorimeter cell. Suppose a 
central portion of the sample is being irradiated (see Figure A.Ha)) and 
the molecules under examination are at depths of 0.25.0.30.0.35 •••••••• 
0.75cm. So the approximation in Equation A.1 is under trial for the 
series xi= 0.25. 0.30. 0.35 ••••••• 0.75. Therefore n = 11. x = 0.5 and 
( a) - 192 - (b) 
••••••••••• 
0.25 0.45 , 
• 0.30 0.46 , 
0.35 0.47 
• • 0.40 
• 
0.48 
• 0.45 
• 
0.49 
• 0.50 0.50 
• a.ss 0.51 ~ • 0.60 
• 
0.52 
• 0.65 0.53 
• • 0.70 0.54 , ) 
0.75 0.55 
• 
A % = 1.2% A% = 0.05% 
( c) (d) 
......... 
0.85 10.25 
• 
, 
0.86 10.26 
• • 0.87 10.27 
• 0.88 10.28 
• • 0.89 10.29 
• • 0.90 10.30 
• 
, 
0.91 10.31 , , 
0.92 10.32 
• • 0.93 
• 
10.33 
• 0.94 10.34 , 
• 0.95 10.35 
• • A% = 0.05% FIGURE A.1 A% = 0.05% 
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n ~ pX. = eO.25 + eO•3 + ••••• + eO•75 = l8.3634 
t =1 
n 
/;. = ~ 
~.] 
= 11 eO. 5 = 18.1359 
r ~ Xi.] 
eX. _ nJ=l n = 0.2275 
'\.=1 r ~ xJ 
The percentage error in using the approximation n e~=l nJ instead of 
~ eXj. is [1:,/ ~ eX.] x 100%. In this case the error is small - about 1.2%. 
i=l '\.=1 
The series may be used to check the validity of Equation A.4 with 
x=0.5, X"= 0.275, x'= 0.1011125, etc. Evaluating the terms on the right-
hand side of the equation gives 
/;. = 0.1375 + 0.06875 + 0.01770 + 0.00312 + 0.00043 + ••••• = 0.2275 
which agrees with the previous 
[ ~ Xi.] 
and ne ;'=1 n. 
n 
resu1 t for the di fference between ~ eX;' 
i=l 
For a sample cell in which the irradiated portion is more restri~ted, 
the approximation becomes even.better. An example is .shown in Figure A.1(b) 
where the fluorescent molcu1es under consideration a~ located at 0.45, 
0.46, 0.47, ••• 0.55cm. The error in assuming that ~ eX~ can be replaced qv 
~ x~ [ 
n ] 1..=1 
n e 1.=1 n is only 0.05%. Since the variation about the mean displacement 
is low, such a small discrepancy is only to be predicted (see Equation A.5). 
Moreover, the magnitude of I:, % is independent of the exact position of the 
volume under consideration. This is demonstrated in Figures A.1(c) and 
A.1(d); as long as the spread of x~ is constant, the percentage error 
associated with the approximation is invariant. 
The analysis may be extended to sho\~that 
n 
~ 
1. =1 
exp (x\. + y~) " n [
n Xi. n y_] 
exp ~ n + I: -
;'=1 ;'=1 n 
under certain conditions. Thus, 
= n exp (x + y) (A.6) 
(x + y)' + ..... } 
r! 
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2! 3! 
where (x + y) " ((xi" y,) + (xa.+ y.J + ••••• + (xn + ¥,)) • 
n 
... ... (x + y'f" ((XI + y,) +(x ... + yJ + ••••• (x"+ ~)j. 
n 
(A.7) 
n {l + (x + y) + (x + y-t + 
2! 
( - -)~ . (- 'VIr } ~ + .•••• + X + y, + .•• 
3! r! 
(A.8) 
The first two terms on the right-hand ~ides of Equations A.7 and A.B 
are identical because (x +y) = ((x,+y,) + (x .. +~ + ••••• + (X,.+Yn)) = 
n 
(X,+ x .. + ••••• + x ... ) + (Y. + y .. + ••••• + y") = (x + y) 
n n 
n 
:. 6" 1.~1 e(X" + yJ - n e(X + y) = n {( (X+"Y)"- (x + y)) + 
2! 
((x:tj)l_ (x+y)) + ••••• + ((X"'+Y)",- (x+y)) + •••• } (A.9) 
31 r! 
be small 
If the approximation of Equation A.6 is to be acceptable, 6 must 
compared to n ·(x;+ vI 
E e ' "11. 
i." 1 
The fi rst term in Equation A. 9 Wli ch contributes to 6 may be rl'wri tten 
as 
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n J(X+'YY'- (x + YlJ = (x,+ .x) «x,- x) + (y, - Y)}+ ( 
l. 2! 2! 
[(x .. - x) + (~- Y)} + ..... + (x.. + ~ [(x"- x) + (y,,- Y)} 
2! 
x .. + ~) 
2l 
(A. 10) 
If this term is to be a minimum, the values x.and y~shou1d vary as little as 
possible from x and Y,respective1y. The same criterion can be sho~ to be 
true for the other terms in Equation A.9. 
It is now possible to consider a variable which is defined by two 
parameters. For example, suppose x~and YLrepresent the excitation and 
emission path lengths appropriate to a fluorescent molecule at some position 
(xi., yi) within a sample cell. Furthermore, suppose that;n the irradiated 
portion of the sample solution, molecules are located at points represented 
by the coordinates, 
l 
x· 
.. 
Yt 
123 
0.45 0.45 0.45 
0.45 0.5 0.55 
4 5 6 7 8 9 
0.5 0.5 0.5 0.55 0.55 0.55 
0.45 0.5 0.55 0.45 0.5 0.55 
This arrangement is shown diagrammatically in Figure A. 2(a). So, 
n ~ e(Xi+ YU = eO•9 + eO•95 + ••••• + el •l = 24.5053 
t. =1 
9 e(x + Y) = 9 e1•O = 24.4645 
.. /::,. = 0.0408 
The percentage error in using n e(x + Y) instead of ~ e(x~+ yJ is 0.17% 
... =1 
in this example. When the results are fed into Equation A. 9. 
/::,. = 0.015 + 0.015 + 0.00751 + 0.00251 + 0.00063 + 0.00013 + •••• 
= 0.0408 
as above. 
Figures A. 2(b) and A. 2(c) show how the error in assuming the 
validity of the approximation is independent of the absolute values (x~, y~) 
for constant variations about the means. However, when larger volumes of 
the sample solution are considered, variation of the coordinates (x~+ yJ is 
increased and the approximation becomes less accurate. This is illustrated 
(a) 
;55 50 
• .45 
(c) 
.15 10 r' .05 l 1 
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0.50 
0.55 
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••• 
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, 
• 
A % =0.17% 
••• 
••• 
••• 
0.05 
-+ 
~O 
~ 
!J. % = 0.17% 
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(b) 
(d) 
FIGURE A.2 
0.85 
0.90 
0.95 
/). % = 0.17% 
• • 
• • 
• • 
0.25 • 
0.50 ) 
0.75 
!J. % = 4.1% 
• 
• 
• 
• 
••• 
••• 
••• 
, 
, 
) 
90 •95 
.85' 
.75 
.50 
.25 
1 
; n Figure A. 2(d) 
It has been 
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n 
shown how E 
\..= 1 
exp (xL + yJ '" n exp (x + Y) under 
the appropriate experimental conditions. Since the terms f o• c. a,and a, 
defined in the main text are independent of xl-and YI. •. the following 
statement must be true: 
n 
FM = E fo exp (-2.303 (a, x~ + aLy;.) c) '" n fo exp (-2.303 (a, x + as)c) 
'-=1 
:. FM '" Fo exp (-2.303 (a,x + a ... Y) c) as required. 
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CHAPTER 4 
The Application of Fluorescent Probes to a Study of Drug Binding Sites 
on Serum Proteins 
4.1 Introduction 
The development of methods for measuring the binding of fluorescent 
probes to HSA provided the basis from which to examine the drug-binding 
properties of specific sites on the albumin molecule. The procedures 
described in Chapter 3 were used to determine the concentrations of bound and 
unbound fluorescent probe in the presence and absence of potential competitor 
drugs. The degree of probe displacement so obtained was interpreted in terms 
of the affinity of the competing 1igands for binding to albumin. 
Evidence from Sud10w et a1 (1975) that warfarin and ANS bind to 
separate sites on albumin suggested that these compounds might serve as probes 
for different regions of the protein structure. Thus a number of non-
fluorescent drugs were selected and tested for their ability to displace both 
warfarin and ANS. The first drug to be considered was phenylbutazone. 
PhenYlbutazone is an anti-inflammatory agent and is extensively 
bound to albumin (Burns et al. 1953). The interaction between this drug and 
warfarin is phenomeno1ogica11y well established and its potentially 
disasterous clinical consequences are generally appreciated (O'Rei11y. 1967). 
Agge1er et a1 (1967) have demonstrated the interaction in humans. As 
reported in the present chapter. an attempt was made to establish the degree 
of competition between phenylbutazone and warfarin for binding sites on 
albumin. The significance of this competitive binding process in the overall 
mechanism of the drug interaction is discussed. 
The ability of the sulphonamide group of drugs to displace 
fluorescent probes from albumin was investigated. This group provided a series 
of structurally similar compounds which could be screened for the presence 
of common features associated with strong binding to particular sites on 
albumin. The binding properties of some other drugs were also examined. 
While there is experimental evidence to suggest that albumin plays 
a major role in the binding of acidic drugs in human plasma (Ti11ement et al. 
1981). the possibility of interactions between these drugs and other serum 
proteins should not be overlooked. With this possibility in mind. and in 
order to establish the wider applicability of the method. a number of 
experiments were performed using whole serum. 
- 199 -
4.2 The Inf1 uence of Competitor Drugs on Probe Bi ndi ng Curves 
A procedure for studying the binding of fluorescent probes to HSA 
has already been described. and was discussed with regard to the subsequent 
generation of binding curves and constants. An obvious extension of this 
approach lay in a consideration of the effect of other 1igands on the binding 
curves and affinity constants of the fluorescent probes. The purpose of the 
following paragraphs is to show how this was achieved for warfarin. 
4.2.1 Practical Considerations 
Before commencing the binding experiments it was necessary to check 
whether potential competitors had any effects on the analytical signal -
that is, the bound probe f1uorescence,.other than those arising from direct 
displacement interactions. 
Of the drugs selected for examination, none had a detectable 
fluorescence at the wavelength used to assay the bound fraction of warfarin. 
Thus on addition of the ligands, there were no spurious signals to complicate 
an assessment of the probe binding. 
In general, the exci tati on peak of warfarin was centred at a 
considerably longer wavelength than the absorption maxima of the competing 
1igands. Figure 4.1 illustrates this for a number of cases. From their 
ultraviolet absorption spectra. it is quite clear why phenylbutazone and 
2-p-(ch10rophenoxy)-2-methy1 propionic acid (CPMP) should be incapable of 
reducing the intensity of the recorded signal by a simple absorptive process. 
Likewise, however. the need to make allowances for the small inner-filter 
effects associated with the overlap of the long wavelength tail of the 
absorption spectra of certain sulphonamides and the excitation peak of warfarin 
can be equally well-appreciated. Somewhat larger corrections were required 
for sulphapyridine and f1ufenamic acid as these compounds absorb rather well 
around 320nm. 
So when warfarin is used as a probe for albumin binding sites, there 
are two distinct mechanisms by which addition of a second ligand can affect 
a reduction in the measured Signal. Firstly by a competitive or non-
competitive displacement of the fluorescent probe from its binding sites. 
Secondly by a trivial inner-fi lter effect. As either, or both of these 
mechanisms may operate to lower the observed fluorescence, it is imperative 
to distinguish between the two phenomena. 
An evaluation of competitor inner-filter effects was feasible by 
the adaptation of some of the procedures described in Chapter 3. One 
Absorbance 
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0.7 
- 200 - Absorbance 
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FIGURE 4.1 Absorption Spectra for Several Drugs and their Relation to the 
Excitation Peak of Warfarin at 320nm. 
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possibility was to determine the absorbance of each competitor at the 
wavelengths of excitation and emission of the bound probe fluorescence. The 
results could be used in conjunction with Equation 3.5 to correct the 
measured fluorescence intensity for losses due to absorption. For most of 
the drugs under examination however, this procedure meant that spectrophoto-
metric readings had to be taken at wavelengths which were far removed from 
the main absorption peaks. Although not always of great consequence, this 
did tend to reduce the reliability of some of the results. 
Due to its increased sensitivity, and because there are a number of 
theoretical as well as practical reasons for estimating inner-filter effects 
by a f1uorimetric rather than a spectrophotometric method (see Section 3.2.3), 
the following procedure was routinely applied to competitive binding studies. 
The potential competitor was 'titrated into a solution containing 
the fluorescent probe in free solution, but the monochromators were set at 
the wavelengths used to determine the bound probe fluorescence. Any changes 
in the emission intensity were recorded. According to Equation 3.4, a 
decrease in the observed fluorescence must be proportional to exp -2.303 
(a, x+ a .. Y)c where, in this instance, a, and a...are the molar absorbances 
of the competitor at the wavelengths of excitation and emission respectively, 
c is the competitor concentration, and x and y represent the mean path 
lengths of the excitation and emission beams. This factor may be simplified 
to exp - k c where k = 2.303 (a,x + aaY). So, 
Fm = Fo exp (-k c) and 
k = * 1n (~) (4.1) 
where Fm and Fo are the fluorescent intensities observed in the presence 
and in the absence of competitor, respectively. 
By adding known concentrations c of the ligand of interest and 
noting the corresponding fluorescence intensity Fm it was possible to make 
several determinations of the inner-filter correction factor, k. The 
results obtained for su1phisomidine are typical. They are presented in 
Table 4.1. The mean experimental values of the correction factors for 
several other sulphonamides are included in Table 4.2. 
Once it became feasible to distinguish inner--filter from 
displacement effects, the production of probe binding curves in the presence 
of any competitor was quite straightforward. A convenient concentration of 
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SM Concentration Observed Fluorescence Inner-Filter Corre~tion 
--_c: .• , (Arbitrary Units) lA '" ""I Factor, k(xlO- ) 
0.00 11.25 
-3.28 10.75 6.03 
6.54 10.20 7.32 
9.80 9.65 6.80 
13.04 9.25 6.52 
19.50 8.25 6.91 
25.91 7.55 6.68 
32.29 6.95 6.48 
44.91 6.00 6.08 
63.55 4.60 6.11 
TABLE 4.1 
Ninp rl<>t<>nninations of the inner-5filter factor, k for sulph1somidine (511). Warfarin concentration 4.2 x 10- M. Diluent buffer was O.lM 
Tris/Hel pH 7.4. Wavelengths of fluorescence excitation and emission 
were 320nm and 375nm, respectively. 
Mean value of k = 6.55 x 10-4 
standard deviation = 0.433 x 10-4 
coefficient of variation = 6.6% 
Drug 
Sulphapyridine 
Sulphisomidine 
Sulphamerazine 
Sulphadiazine 
Sulphisoxazole 
TABLE 4.2 
kxlO-4 
45.61 
6.55 
5.83 
2.90 
0.67 
Mean values of k for some sulphonamide drugs. 
Experimental conditions as described in Table 4.1. 
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a potential competitor was added to an albumin solution before titrating 
the riuorescent probe. The program FLUORB was instructed to take account 
of competitor inner-filter effects before estimating the concentrations of 
albumin-bound and unbound fluorescent probe at each point in the titration. 
In practice, the main requirement was simply the provision of an appropriate 
inner-filter correction factor and a notification of the competitor 
concentration. Binding curves and constants were constructed with the aid 
of the usual computer programs. Alterations in the capacity of HSA to bind 
the fluorescent probe were revealed as changes in curve shape and 
modifications of binding constants. 
4.2.2 Results and Observations 
The effect of phenylbutazone on the binding of warfarin to HSA is 
illustrated in the Scatchal"d plots of Figure 4.2. There is clearly a 
dramatic reduction in the capacity of albumin for binding warfarin when 
phenylbutazone is present. The phenomenon is particularly noticeable at 
low probe-to-protein ratios when a very large proportion of the fluorescent 
probe appears to be displaced from its binding sites. At high warfarin 
concentrations the effect of phenylbutazone is less· marked. These observations 
may be further appreciated by a study of the changes in the absolute bound 
probe concentrations shown in Table 4.3. 
The similarity in the values of n, and n .. obtained in the presence 
and absence of phenylbutazone (Table 4.4) suggests that this compound does 
not alter the number of warfarin binding sites on albumin. Coupled with 
the shapes of the corresponding binding curves, this provides an indication 
of common binding sites on albumin for phenylbutazone and warfarin. As may 
be expected, the dOl-inward displacement of the Scatchard plot of warfarin 
on addition of phenylbutazone is reflected in a large reduction in k •• 
HOI!Iever, the values of k .. obtained at different competitor concentrations are 
little changed and suggest that the binding of warfarin to low affinity, or 
secondary', sites on albumin is virtually unaffected by the incorporation of 
phenylbutazone. From these results it seems that while phenylbutazone and 
warfarin share high affinity sites on HSA, competition for secondary 
binding sites is of little or no consequence. 
However, extreme caution must be exercised at this stage. As 
pointed out in Section 1.7, the mechanism of the binding process need not 
necessarily satisfy the Scatchard assumptions even though the data are 
adequately fitted by the Scatchard model. The interpretation given above 
5-"OF (xl05 M- l ) 
0"4 
• 
,... ............. . 
o 
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FIGURE 4.2 The Effect of Phenylbutazone on the Binding 
of Warfarin to HSA. 
Concentration of hurran serum albumin 
9.9 x 1O-6H 
• No competitor. 
Range of warSarin concentration 1.3 x 10-6M 
to 8.0 x 10- M. 6 
.. Phenylbutazone concentration 8.3 x 10- M.
8r Range of warSarin concentration 8.0 x 10- ~ 
to 5.7 x 10- M. -5 
• Phenylbutazone concentrati on 3.3 x 10 M. st.. 
Range of warfarin concentration 8.0 x 10-~ 
to 8.0 x 1O-5M. 
• • 
2-0 
R 
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TABLE 4.3 
The data used to construct the plots shown in Figure 4.2. Results from 
fluorescence'titrations were processed using the FLUORB program. DC, DB 
and OF are the cOlcentrations of total, bound and free fluorescent probe, 
respectively. R is the bound probe concentration divided by the total 
protein concentration. ROMlF is R divided by OF.' The total HSA 
concentration in these experiments was 9.9 x lO-6M• 
(a) No Competitor 
DC DB OF R RONDF 
xlO-6M xlO-6M xlO-6M xl06M-l 
,1.2530 0.9788 0.2742 0.0988 0.3603 
1.6704 1.2839 0.3866 0.1296 0.3353 
2.0877 1.5950 0.4927 0.1611 0.3269 
4.1719 3.0043 1.1675 0.3036 0.2601 
4.5883 3.276B 1.3115 0.3312 0.2525 
5.0046 3.6315 1.3731 0.3671 0.2674 
5.4207 3.8573 1.5634 0.3900 0.2495 
5.8367 4.1661 1.6706 0.4213 0.2522 
6.2526 4.3816 1.8710 0.4432 0.2369 
6.6684 4.6414 2.0270 0.4695 0.2316 
7.4994 5.0937 2.4057 0.5155 0.2143 
8.3279 5.5007 2.8292 0.5568 0.1968 
9.1598 5.9014 3.2584 0.5976 0.1834 
9.9892 6.7389 3.6504 0.6421 0.1759 
10.8181 6.6142 4.2039 0.6702 0.1594 
11.6464 7.0124 4.6340 0.7108 0.1534 
12.4741 7.4018 5.0723 0.7505 0.1480 
14.1280 7.8139 6.3141 0.7929 0.1256 
16.6046 8.5462 8.0584 0.8680 0.1077 
20.7215 9.4692 11.2522 0.9634 0.0856 
24.8248 10.2332 14.5916 1.0428 0.0715 
28.9145 10.9393 17.9752 1.1166 0.0621 
32.9908 11.5572 21.4336 1.1816 0.0551 
41.1033 12.2961 28.8072 1.2613 0.0438 
49.1627 12.5380 36.6247 1.2903 0.0352 
57.1697 13.4602 43.7095 1.3898 0.0318 
65.1247 14.0967 51.0280 1.4602 0.0286 
80.8806 14.7685 66.1122 1.5397 0.0233 
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TABLE 4.3 (continued) 
(b) B.3 x 10-6M Phenylbutazone 
DC DB OF R 
x10-6M x10-6M x10-6M 
0.0834 0.0348 0.0486 0.0035 
0.2086 0.0916 0.1170 0.0092 
0.4171 0.1837 0.2334 0.0185 
0.6256 0.2855 0.3401 0.0288 
0.8341 0.3798 0.4543 0.0383 
1.0425 0.4750 0.5676 0.0479 
1.2509 0.5885 0.6625 0.0594 
1.6676 0.7751 0.8925 0.0783 
2.0842 0.9479 1.1363 0.0957 
2.5006 1.1063 1.3944 O. 1117 
2.9169 1.2678 1.6491 0.1281 
3.3331 1.4416 1.8914 0.1456 
3.7491 1.6099 2.1392 0.1627 
4.1650 1.7626 2.4023 0.1781 
4.5807 1.9182 2.6625 0.1939 
4.9963 2.0677 2.9286 0.2090 
5.8271 2.3658 3.4613 0.2393 
6.6573 2.6554 4.0019 0.2686 
7.4870 2.7267 4.7603 0.2759 
8.3161 3.2678 5.1082 0.3247 
9.1447 3.4792 5.6655 0.3523 
9.9727 3.7186 6.2541 0.3767 
10.8002 3.9667 6.8335 0.4020 
11.6271 4.1801 7.4470 0.4237 
12.4535 4.4014 8.0521 0.4463 
13.2793 4.8306 8.6487 0.4697 
14.1046 4.8683 9.2362 0.4940 
14.9293 5.0791 9.8502 0.5155 
16.5772 5.4865 11.0907 0.5572 
18.2229 5.8849 12.3380 0.5981 
20.6873 6.4546 14.2327 0.6567 
22.3275 6.8942 15.4334 0.7018 
24.7839 7.3329 17.4510 0.7472 
28.8669 8.1370 20.7300 0.8306 
32.9366 8.8618 24.0748 0.9060 
36.9930 9.4687 27.5243 0.9697 
41.0360 10.0343 31.0017 1.0293 
49.0825 11.1869 37.8956 1.1513 
57.0767 12.1596 44.9171 1.2555 
RONDF 
xl 0611\-1 
0.0724 
0.0790 
0.0794 
0.0847 
0.0844 
0.0845 
0.0897 
0.0877 
0.0842 
0.0801 
0.0777 
0.0770 
0.0760 
0.0742 
0.0728 
O. 0714 
0.0691 
0.0671 
0.0580 
0.0636 
0.0622 
0.0602 
0.0588 
0.0569 
0.0554 
0.0543 
0.0535 
0.0523 
0.0502 
0.0485 
0.0461 
0.0455 
0.0428 
0.0401 
0.0376 
0.0352 
0.0332 
0.0304 
0.0280 
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TABLE 4.3 (continued) 
(c) 3.3 x 10-5M phe'l)'lblltazone 
DC DB OF R 
li:10"6M x10-6M xl0-6M 
0.0830 0.0265 0.0565 0.0027 
0.2075 0.0661 0.1414 0.0067 
0.4150 0.0906 0.3245 0.0091 
0.8300 0.1834 0.6465 0.0185 
1.0374 0.2176 0.8197 0.0220 
1.2447 0.2694 0.9753 0.0272 
1.6594 0.3399 1.3195 0.0343 
2.0739 0.4294 1.6445 0.0434 
2.4882 0.5208 1. 9674 0.0526 
2.9024 0.5874 2.3151 0.0593 
3.3165 0.6824 2.6341 0.0689 
4.1445 0.8143 3.3300 0.0823 
4.9715 0.9612 4.0103 0.0972 
5.7982 1.1241 4.6741 0.1137 
6.6243 1. 3132 5.3111 0.1328 
7.4499 1.5004 5.9495 0.1518 
8.2749 1.6547 6.6202 0.1675 
9.0994 1.8155 7.2839 0.1838 
9.9234 1.9622 7.9612 0.1988 
10.7468 2.0831 8.6637 0.2111 
11.5696 2.2200 9.3496 0.2250 
12.3919 2.3734 10.0186 0.2407 
13.2137 2.5219 10.6918 0.2558 
14.0349 2.6760 11.3589 0.2715 
14.8556 2.8359 12.0197 0.2878 
16.4954 3.1635 13.3319 0.3213 
18.9510 3.6834 15.2676 0.3745 
20.5854 3.9594 16.6260 0.4028 
22.2176 4.2559 17.9617 0.4333 
24.6620 4.6997 19.9623 0.4789 
28.7252 5.5174 23.2078 0.5632 
32.7752 6.0829 26.6922 0.6219 
36.8119 6.8158 29.9961 0.6980 
40.8355 7.3171 33.5185 0.7506 
48.8435 8.7336 40.1099 0.8988 
56.7997 10.0439 46.7558 1.0370 
64.7045 10.8226 53.8819 1.1211 
72.5585 11.6515 60.9071 1.2108 
80.3622 12.1736 68.1886 1.2692 
RONDF 
x106M- 1 
0.0473 
0.0472 
0.0282 
0.0286 
0.0268 
0.0279 
0.0260 
.. 0.0264 
0.0267 
0.0256 
0.0262 
0.0247 
0.0242 
0.0243 
0.0250 
0.0255 
0.0253 
0.0252 
0.0250 
0.0244 
0.0241 
0.0240 
0.0239 
0.0239 
0.0239 
0.0241 
0.0245 
0.0242 
0.0241 
0.0240 
0.0243 
0.0233 
0.0233 
0.0224 
0.0224 
0.0222 
0.0208 
0.0199 
0.0186 
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TABLE 4.4 
Estimated binding constants for the interaction between warfarin and HSA: 
the effect of phenylbutazone on these values. 
Binding constants were derived from the data presented in Table 4.3 with 
the aid of the NKFIT program 
Phenylbutazone Concn. nl kl n,. k,f. 
x 1O-6M X 105M-l x 10 M- l 
0.0 0.96 3.86 1.04 0.20 
8.3 0.89 0.59 1.23 0.19 
33.1 0.85 0.21 0.95 0.22 
... 
TABLE 4.5 
Estimated binding constants for the interaction between lI'arfarin and HSA: 
the effect of sulphisoxazole on these values. 
Binding constants were derived from the data presented in Figure 4.3 with 
the aid of the NKFIT program. 
Sulphisoxazole Con en. nl kl n,.. k,. 
x 10:"5M x 105M-l x 105M-l 
0.0 0.84 5.34 1.06 0.26 
9.8 0.92 1.51 1.06 0.20 
48.8 0.85 0.39 1.20 0.09 
- 209 -
is therefore a tentative one. and is only reliable within the limits of 
the twu-~ite Scatchard equation. 
It is important to record that during the course of this work the 
observed fluorescence intensity was shown to be independent of the order in 
which warfarin and phenylbutazone were added to the albumin. The most 
obvious. and the most reasonable explanation must be that the binding of 
these ligands to HSA is totally reversible. 
Like phenylbutazone. sulphisoxazole has a very noticeable effect 
on the bindi ng of warfarin to HSA. Fi gure 4.3 illustrates thi.s for two 
concentrations of sulphisoxazole, in experiments where the probe concentration 
is varied approximately two hundred-fold. Although the quantities of 
competitor drug are larger in this case, sulphisoxazole evidently resembles 
phenylbutazone in that it, too, produces a downward displacement of the 
warfarin binding curve. 
The degree to which sulphisoxazole displaces warfarin from albumin 
binding is reflected in the binding constants presented in Table 4.5. Tbese 
values were determined with the aid of the NKFlTprogram and clearly provide 
an excellent fit to the experimental curves of Figure 4.3. In the presence 
of this sulphonamide drug, the values of n,and n&are sufficiently close to 
those obtained with no competitor to suggest that within the limits of the 
binding model. warfarin and sulphisoxazole compete for identical sites on 
human serum albumin. Furthermore. while the undoubted reduction in k, 
demonstrates a marked increase in the affinity of HSA to bind warfarin at 
the primary, high affinity site, it would appear from the values of k&that 
sulphisoxazole also competes, albeit less avidly, for secondary binding 
sites on albumin. 
Four other sulphonamide drugs were examined for their ability to 
displace warfarin from its albumin binding sites. According to the Scatchard 
plots of Figure 4.4, sulphisomidine and suphamerazine have only a very 
small effect on the binding of warfarin to human serum albumin. Likewise, 
the results presented in Figure 4.5 suggest that sulphapyridine and 
sulphadiazine bind very weakly, if at all. to the warfarin sites on albumin. 
Using data from the experiments involving sulphapyridine and 
sulphadiazine. the apparent association constants for the interaction 
between warfarin and albumin were derived with the aid of the NKFIT program. 
As shown in Table 4.6 these values are very similar to those obtained in 
the absence of competitor and confirm that sulphapyridine and sulphadiazine 
have only minimal effects on the binding of warfarin to HSA. 
()o4 
0·2 
o 
• ... 
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FIGURE 4.3 The Effect of Sulphisoxazole on the Binding 
of Warfarin to HSA. 
Concentra6ion of human serum albumin 5.0 x 10- r~ . 
• No competitor.·· 7 
Range of warSarin concentration 4.2 x 10- M 
to 8. 1 x 10- M. . . _ 4 
• Sulphisoxazole concentration 1.0 x 10 M' 7 Range of warfarin concentration 4.2 x 10- M 
to 8.0 x 10-SM. . 
• Sulphisoxazole concentration 5.0 x 1O-4M. 
Range of warfarin concentration 4.1 x 10-7M 
to 6.0 x 10-SM. 
Solid lines represent the best fit to the data 
points and were found with the aid of NKFIT. 
.. • 
1·0 R 2·0 
004 
o 
0·2 
o 
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FIGURE 4.4 The Effect of Sulphisomidine and Sulphamerazine 
on the Binding of Warfarin to HSA. 
Concentra6ion of hUman serum albumin 5.0 x 10- M. 
• No competitor. 
Range of warfarin concentrati on 4.2 x 1O-7M 
to B.l x 1O-5M. 
A Sulph1somidine concentration 1.0 x lO-4M. 
Range of wartarin concentration 4.2 x 10-7H 
to B.O x 10- ~1. -4 
• Sulphamerazine concentration 1.0 x 10 t1. 
Range of warfarin concentration 4.2 x 10-7M 
to 6.1 x 10-5M. 
The lower solid line represents the best fit 
to data obtained in the presence of sulphisomidine 
and was constructed with the aid of NKFIT. 
1·0 2·0 
R 
(}4 
o 
0·2 
o 
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FIGURE 4.5 The Effects of Sulphapyridine and Sulphadiazine 
on the Binding of Warfarin to HSA. 
Concentration of human serum albumin 
5.0 x 1O-6M • 
• No competitor. -7 
Range of warfarin concentration 4.2 x 10 M 
to 8.1 x 1O-5M •. 
o Sulphapyridine concentration 1.0 x 1O- 4r1'
7 Range of war~arin concentration 4.1 x 10- M 
to 6.1 x 10- M. . 4 
6 Sulphadiazine concentration 1.0 x 10- M. 
Range of warfarin concentration 2.0 x 10-6M 
to 6.1 x 1O-5M. . 
The lower solid line represents the best fit to 
the data obtained in the presence of sulphapyridine 
and was constructed \~ith the aid of NKFIT. 
1'0 R 
2·0 
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TABLE 4.6 
Estimated binding constants for the interaction between warfarin and HSA: 
the effect of sulphisomidine and sulphapyridine on these values. 
Binding constants were derived from the data presented in Figures 4.4 and 
4.5 with the aid of the NKFIT program. 
Drug/Concentrati on n. k. n2- ka. 
x 105M-l x 105M-l 
No Competi tor 0.84 5.34 1.06 0.26 
1.0 x 10-4M sulphisomidine 0.81 4.92 1.13 0.20 
1.0 x 10 4M sulphapyridine 0.B8 4.67 1.15 0.18 
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So far results describing the inhibitory effects of competitor 
drugs on tne Dinding of warfarin to HSA have been summarized in terms of 
the ability of each competitor to reduce the association constants of the 
probe-protein interaction. Now in theory, it should be possible to process 
the same experimental results but this time to determine association constants 
for the competitors. Klotz et al (1948) have published equations to 
describe the competition bet~een two ligands for identical protein binding 
sites. Using this paper the following relationship was derived: 
n [p] ka [OF] - ka [oF] [oB] - [OS] kb = -7-~":":'::-~~-:--:'-=:';'--':"-""-~~:-----::-'::' le] ka[bF'] - n [p] ka[OF] +ka[OFj [osJi- [os1 
x ka IDF] 
[OS] (4.2) 
where kb is the association constant for the competitor, ka is the 
associ ati on constant for the probe, [OF] and [OS] are concentrati ons of 
free and bound probe, respectively; (pJ is the total protein concentration, 
[C) the total competitor concentration, and n is the number of binding sites. 
The model used by Klotz et al (1948) assumes that the two ligands 
compete for a single class of binding sites. Since warfarin binds to at 
least two different sites on HSA, the Klctz model is too simple to provide 
a full description of its displacement by another ligand. However, at low 
probe to protein ratios most of the warfarin molecules will bind to the 
primary, high affinity site on albumin. Under these conditions the 
assumptions inherent in Equation 4.2 may be acceptable. 
An approximate assod ation constant was obtained for phenylbutazone 
using data from Table 4.3. Only estimates of bound and free warfarin 
obtained at low total probe concentrations were considered. When these 
results were fitted in to Equation 4.2 along with the appropriated binding 
constants,· kb turned out to be about 106 M- l • Data from Figure 4.3 was 
processed in a similar manner to yield a measure of the affinity of 
sulphisoxazole for the major warfarin binding site on albumin. kb for this 
drug was approximately 104 Mrl. 
Although the estimated association constant for phenylbutazone 
may be slightly high (ElbarY et al. 1982). the observation that it has a 
greater affinity than warfarin for the same class of sites on HSA agrees 
with the work of Solomon et al (1968). The association constant obtained 
for sulphisoxazole is also comparable with the literature. Hsu et al (1974). 
for example. 
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4.3 A Rapid Method for the Characterization of Drug Binding Sites on 
,,;uUlllin and in Whole Serum 
Producing complete binding curves in the assessment of 
competitive binding phenomena is clearly a very useful exercise, but it can 
be rather time-consuming. To test large numbers of drugs for binding 
specific sites on albumin, more rapid procedures were devised. In their 
simplest form, these procedures involved the addition of potential 
competitors to a sample containing fluorescent probe and HSA. A reduction 
in the intensity of the recorded signal was taken as evidence for the 
competiti ve di splacement of bound fl uorescent probe. _-
Of course, to allow for a fuller characterization of the displacement 
interactions-, it was necessary to have stricter control over the conditions 
of the experiments. Thus, the albumin concentration I_~as normally fixed at 
about 5 x 10-6M and the quantity of fluorescent probe was kept low so that 
binding was mainly to high affinity sites. After each addition of 
competitor, the fluorescence was measured with monochromators set at the 
excitation and emission wavelengths of the bound probe. Standard procedures 
were employed to account for light absorption by the competitor, and when 
more detailed information was required,_the results were analysed with the 
aid of the FLUORB computer program. Processing the data in this way made 
it possible to report the quantity of fluorescent probe displaced after each 
addition of competitor. 
The results presented in Table 4.7 demonstrate the ability of a 
number of ligands to displace warfarin from its binding sites on HSA. They 
are expressed graphically in Figures 4.6 and 4.7 over two ranges of 
competitor concentration. 
Although the experimental points lie on smooth curves, the shape 
of these curves varies markedly from one competitor to the next. For 
example, Figure 4.6 shows that warfarin is very readily displaced from its 
binding sites by phenylbutazone. On the other hand,.of the three 
sulphonamides examined, only sulphisoxazole appears to produce a 
significant reduction in the bound probe fraction. These observations agree 
with those of the previous section (Figures 4.2 to 4.5). Figure 4.6 also 
demonstrates that while flufenamic acid competes very strongly for warfarin 
binding sites and CPMP very weakly, ethacrynic acid has an affinity which 
is intermediate. 
The results in Figure 4.7 have been extended to include higher 
concentrations of the competitors. They help to illustrate the huge-
variations in the gradients of the experimental curves and so emphasize the 
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TABLE 4.7 
Results illustrating the competitive displacement of warfarin from HSA 
by increasing concentrations of a number of drugs. DC and D3 are the 
concentrations of bound and free fluorescent probe. respectively. The 
percentage of fluorescent probe bound to HSA is given by %B = DB/DC x 
100%. Resul ts from experimental fl uorescence titrations ;were processed 
using the FLUORB comput~r program. The concentration of HSA was 
approximately 4.7 x 10- M in all samples. 
(a) Phenylbutazone 
Phel1YJ butazone DC DB %B 
Concn xlO-6M xlO-6M 
xlO-6M 
0.00 0.833 0.556 66.8 
0.83 0.832 0.493 59.2 
1.67 0.831 0.431 51.9 
3.33 0.830 0.333 40.1 
6.64 0.827 0.211 25.5 
16.43 0.819 0.092 11.2 
32.32 0.806 0.060 7.5 
47.71 0.793 0.043 5.4 
(b) Sulphisoxazole 
Sulphisoxazole DC DB %B 
congn xlO-6M xl0-6M 
xlO- M 
0.00 0.833 0.581 " 69.8 
4.17 0.832 0.547 65.7 
8.33 0.831 0.527 63.4 
16.64 0.830 0.480 "57.9 
41. 40 0.825 0.382 46.3 
82.11 0.819 0.289 35.3 
161.6 0.806 0.193 24.0 
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TABLE 4.7 (Contd) 
(c) Sulphamerazine 
Su1phamerazme DC DB %B 
Concn x10-6M x10-6M 
x10-5M 
0.00 0.840 0.545 64.9 
16.68 0.838 0.529 63.1 
33.31 0.837 0.505 60.4 
615.39 0.834 0.482 57.8 
164.4 0.826 0.439 53.2 
323.4 0.812 0.387 47.S 
(d) Sulphisomidine 
Sulphisomidine DC 03 %B 
Con~n xl0-6M xl0-6M 
xl 0- ~1 
0.00 0.840 0.588 70.0 
16.67 0.838 0.568 67.7 
33.44 0.837 0.552 65.9 
66.66 0.834 0.542 65.0 
165.0 0.826 0.512 62.0 
324.7 0.812 0.477 58.7 
(e) Flufenamic Acid 
Flufenamic Acid DC DB %B 
Con/in xl0-6M xl0·6M 
xl0- M 
0.00 0.840 0.571 68.0 
1.67 0.838 0.537 64.1 
3.33 0.837 0.502 60.0 
6.64 0.834 0.393 47.1 
16.43 0.826 0.161 19.4 
32.32 0.812 0.048 5.9 
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TABLE 4.7 (Contd) 
(f) Ethacrynic Acid 
Eth ac ryni c Aci d DC DB %B 
Con~n xl0-6M xl0-6M 
xl0- M 
0.00 0.834 0.529 63.5 
1.67 0.833 0.491 59.0 
3.34 0.831 0.472 56.7 
6.65 0.828 0.438 52.8 
16.47 0.820 0.361 44.0 
32.40 0.807 0.261 32.3 
(9) 2-(p-ch1 orophenoxy)-2. methyl proprionic acid (CPMP) 
CPMP Con~ntration DC DB %8 
x10 M x10-~ xl0-6M 
0.00 0.834 0.589 70.6 
3.35 0.831 0.589 70.8 
16.52 0.820 0.554 67.5 
32.50 0.807 0.509 63.1 
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FIGURE 4.6 The Effect of a Number of Drugs on the Degree of Binding 
of Warfarin to HSA • 
• Phenylbutazone, ... Sulphisoxazole, 0 Sulphisomidine, 
o Flufenamic Acid, A Ethacrynic Acid, 0 CPt~P, .Sulpham:razine. 
Initial total conoentrations of warfarin were 8.3 x lO-7M• 
The concentration of human serum albumin was 4.8 x lO-6M• 
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COt1PETITOR CONCN (x 1O-6M) 
FIGURE 4.7 The Effect of a Number of Drugs on the Degree of Binding 
of Warfarin to HSA over an Extended Concentration Range • 
• Phenyl butazone. .. Su1 phi soxazo le •• Su1phamerazi ne. 
o Su1phisomidine. 
Initial total concentrations of warfarin were 8.3 x 10
6
-
7M. 
The concentration of human serum albumin was 4.8 x 10- M. 
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underlying differences in the abilities of the various competitors to 
dh ... ~ cl ... " ~vund fluorescent probe. The i ni ti a 1 gradi ents of the curves for 
phenylbutazone and sulphisomidine differ by a factor of sixty five. 
Continuing the results to include higher concentrations of the competitors 
also allows for a better classification of ligands which bind only weakly 
to the probe binding sites. Thus the results in Figure 4.7 suggest that 
sulphamerazine has a slightly higher affinity for the warfarin binding sites 
than does sulphisomidine. 
Unfortunately, the displacement of warfarin by ANS was not 
susceptible to assessment by the normal fluorimetric procedure. Although a 
marked reduction in the sample fluorescence at 375nm accompanied the addition 
of ANS to a solution containing warfarin and albumin, the decrease in the 
recorded signal could not be related directly to a competitive displacement 
interaction. The problem appeared to lie with the occurrence of resonance 
energy transfer from warfarin to ANS. There were two reasons for supposing 
this to be so. Firstly, both fluorescent probes had been shown to bind 
strongly to HSA (see Chapter 3). When attached to the albumin molecule it 
is highly likely that their mean separation would be within the range 
normally available to the energy transfer process •. The maximum distance 
over which energy transfer can take place is generally accepted to be about 
70A (Fllrster, 1951). 
The second important point to note was the fact that the fl uorescence 
emission spectrum of warfarin overlaps the excitation spectrum of ANS. This 
may be appreciated from a study of the spectrum shown in Section 3.1. 
Indeed, the two bands appear to have their maxima at virtually the same 
wavelength. This clearly makes for a very efficient transfer of energy. 
An experiment was performed to confirm that the observed effects 
were the result of resonance energy transfer rather than displacement 
phenomena. A sample solution containing warfarin and HSA was prepared. As 
usual, the bound probe fluorescence was excited at 320nm. The addition of 
ANS to this sample produced an obvious decrease in· the warfarin fluorescence 
centred at 385nm (see Figure 4.8). Tests showed that this decrease was far 
too large to be the result of a si!llple inner-filter mechanism. Furthermore, 
when the same wavelength of excitation was used and warfarin added to a 
solution containing ANS and HSA, there was a noticeable increase in the 
intensity of the ANS flUorescence at 475nm. The effect is shown in the 
corrected spectra of Figure 4.9. Enhancement of the ANS fluorescence could 
not be demonstrated in the absence of HSA and must have been due to a short 
range energy transfer process. 
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FIGURE 4.8 The Decrease in the Fluorescence of Albumin-Bound Warfarin 
on Addition of ANS. 
Corrected emission spectra recorded with an excitation 
wavelength of 320nm. Warfarjn concentration 1.33 x 10-6M• 
HSA concentration 4.31 x 10-6M. 
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FIGURE 4.9 The Increase in the Fluorescence of Albumin-Bound ANS on 
Addition of Warfarin. 
Corrected emission spectra recorded with an excitation 
wavelength of 320nm. The enhanced ANS fluorescence centred 
at 475nm is due to resonance energy tra9sfer with warfarin 
as donor. ANS concentration 6.77 x 10- M, HSA concentration 
4.31 x 10-6M. 
(ba) No warfari9 () 3.34 x 10-7M warfarin (c) 6.67 x 10-6M warfarin (d) 1.33 x 10- M warfarin 
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Since the excitation and emission spectra of ANS are centred at 
longer wavelengths than those of warfarin, studies concerned with the 
displacement of ANS were not complicated by inner-filter or energy transfer 
processes. 
A number of drugs were examined for their ability to influence the 
binding of ANS to albumin. The effects of increasing concentrations of 
several of these potential competitors are shown in Figure 4.10. CPMP, 
ethacrynic acid and flufenamic acid in particular compete quite strongly 
with ANS. Phenylbutazone displaces very little fluorescent probe and warfarin 
practically none at all. In fact the last result suggests that ANS and 
warfarin bind to completely different sites on the albumin molecule. To 
emphasize the point, the primary binding sites of warfarin and ANS were 
labelled sites I and 11 respectively. This is in line with the notation 
of Sudlow et al (1975). 
An inspection of the data in Figures 4.6 and 4.10 reveals that 
flufenamic acid is able to displace both ANS and warfarin from their albumin 
binding sites. To a slightly lesser degree this is also true of ethacrynic 
acid. A further set of experiments were devised to test the contention that 
these two ligands compete for both ANS and warfarin binding sites on albumin. 
In these experiments two different ligands were ~ntroduced into a 
sample containing HSA and ANS. The first was one which bound preferentially 
to site I on albumin so even after adding a large quantity of it to the 
sample, only a very small proportion of the fluorescent probe would be 
displaced from site 11. The second ligand was supposed to bind to both sites 
I and 11. As such, it was expected to compete with ANS at site II and with the 
first ligand at site I. 
From measurements of the fluorescence intensity at 470nm it was 
possible to calculate the concentrations of bound and unbound probe at each 
stage in the procedure. Results for one experiments are presented in Table 
4.8. They show the degree to which ANS was displaced when flufenamic acid 
was added to a sample containing HSA, ANS and sulphisoxazole. 
Table 4.9 is a summary of the results of several experiments of this 
kind. As demonstrated on previous occasions it is clear that flufenamic 
acid displaces ANS from albumin binding sites. However, Table·4.9 also 
illustrates a definite enhancement of this effect in the presence of a 
number of drugs. 
Intensification of the competition between flufenamic acid and 
ANS may be explained in a fairly simple manner. The drugs listed in Table 4.9 
appear to bind to site I on albumin (see Figure 4.6). So, supposedly, does 
% BOUND 
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COMPETITOR CONCN (x 1O-6M) 
FIGURE 4.10 The Effect of a Number of Drugs on the Degree of Binding 
of ANS to HSA • 
• Warfarin. c Flufenamic Acid •• Phenylbutazone. 
~ Ethacrynic Acid. <> CPMP. 
Initial total concentrations of ANS were 3.3 x 10-6M• 
The concentration of human serum albumin was 4.8 x 10-6M• 
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TABLE 4.8 
The displacement of ANS from HSA by f1ufenamic acid in the presence of 
sulphisoxazole. The bound pro~e fluorescence was measured with 
excitation and emission monochromators set at 375nm and 470nm, 
respectively. The albumin concentration ~'as 5.0 x 10-6M. Results 
were analysed using FLUORB. DC, DB and OF are the concentrations of 
total, bound and unbound ANS. % displacement is the percentage of bound 
fluorescent probe displaced on addition of f1ufenamic acid to a sample 
of ANS, HSA and sulphisoxazole. 
Sulphisoxazole F1ufenami c Acid 
DC DB OF Concentration % 
x10-6M x10-6M x10·6M 
Concent~ati on 
x10- M x10-6!1 . Disp1acem~nt 
3.35 3.31 0.04 0.04 0.00 
-
3.29 3.18 0.11 1.64 0.00 
-
3.29 2.75 0.54 1.64 1.64 13.76 
3.28 2.38 0.90 1.63 3.27 24.90 
TABLE 4.9 
The displacement of ANS from HSA by f1ufenamic acid in the presence of 
a number of 1igands. Experimental conditions and nomenclature as in 
Table 4.8. 
RATIO is defined as, 
percentage of bound AtJS displaced by f1ufenamic acid in the presence 
of the named second drug 
percentage of bound ANS displaced by the same concentration of 
f1ufenamic acid only 
Concn.of f1uf~namic Second Concentration Of~ % 
acid x 10- M Drug Second Drug x 10· Di sp 1 acement 
1.66 
-
-
7.23 
1.64 SM 1.64 7.95 
1.64 SMZ 1.64 8.75 
1.54 SF 1.64 13.76 
1.65 PB 1.64 14.23 
1. 61 WF 1.61 16.06 
3.32 
- - 13.68 3.28 S'l 1.64 15.87 
3.28 sr~Z 1.63 17.25 
3.27 SF 1.63 24.90 
3.28 PB 1.64 25.08 
3.23 UF 1.61 30.19 
SM - su1phisomidine SMZ·- sulphamerazine SF· sulphisoxazole 
PB .• phenylbutazone WF - warfarin 
RATIO 
1.00 
1. 10 
1.21 
1.90 
1.97 
2.22 
1.00 
1. 16 
1.26 
1.82 
1.83 
2.21 
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flufena~iic acid. Competition for binding between flufenamic acid and one 
of tne otner drugs will result in the mutual displacement of both ligands 
to a degree which depends firstly on their relative binding affinities for 
this class of sites and secondly on their concentrations. Hence, in the 
presence of a drug which binds to site I, the resultant shift in equilibrium 
means that more flufenamic acid is free to compete with the ANS bound at 
site 11. The concentration of the bound fluorescent probe is then diminished 
still further due to the enhanced competitive interaction. Since thjs 
increase in the capacity of flufenamic acid to displace ANS depends in the 
first instance on the ability of the site I drug to compete with flufenamic 
acid, those drugs with the highest site I binding affinities may be expected 
to produce the largest elevation in the concentration of unbound probe. 
From Table 4.9 this is seen to be so. The drugs, ranked in decreasing order 
of their ability to affect the binding of ANS to HSA in the presence of 
flufenamic acid, are warfarin::> phenylbutazone:> sulphisoxazole»sulphamerazine 
>sulphisomidine. This ranking reflects the site·I binding strengths of 
these ligands as demonstrated by their tendency to displace warfarin from 
albumin (Figures 4.6 and 4.7). 
Although it binds very avidly to site I, mediati on of phenylbutazone 
in the displacement of ANS by flufenamic acid appears to be somewhat less 
than expected. This is probably due to the fact that phenylbutazone can 
also bind to site 11 albeit very weakly (see Figure 4.10). Competition 
between phenylbutazone and flufenamic acid at both site I and 11 would ~an 
that more complicated equilibria prevail with this combination of drugs than 
with the others in Table 4.9. Nonetheless, the results of these experiments 
are unequivocal and are consistent with binding of flufenamic acid to both 
sites I and 1I. 
The displacement processes involving flufenamic acid, ANS and the 
other ligands were reversible. That is, for a fixed total concentration of 
ANS, the amount which remained bound to albumin was independent of the order 
in which the other reagents were added. 
Competitive binding involving ANS and ethacynic acid was also 
examined in more detail. The results in Table 4.10 show how the presence 
of warfarin and sulphisomidine influence the displacement of ANS by 
ehtacrynic acid. Intensification of the displacement effect was obviously 
much greater with warfarin than with sulphisomidine. This was so for each 
of three concentrations of ethacrynic acid and further emphasized the 
difference in the affinities of the drugs for site I. The results were also 
consistent with binding of ethacrynic acid to both site I and site 11 :.on 
albumin. 
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TABLE 4.10 
The displacement of ANS from HSA by ethacrynic acid in the presence o~ 
sulphisomidine and warfarin. The albumin concentration was 4.9 x 10- M. 
% displacement is the percentage of bound fluorescent probe displaced 
on addition of ethacrynic acid to a sample of ANS, HSA and second drug. 
RATIO is defined as, 
percentage of bound ANS displaced by ethacrynic acid in the presence 
of the named second drug 
percentage of bound ANS displaced by the same concentration of 
Concn of etbacrynic 
aci d, x 1O-6M 
1.66 
1.64 
1.64 
3.32 
3.27 
3.27 
16.40 
16.14 
16.14 
sr4 - su1phisoT"idine 
WF - warfarin 
ethacrynic acid . 
Second Concentra ti on of % RATIO 
Drug Second 2rug, Displacement 
x 10- M 
.. 
- 11.11 1.00 
SM 1.64 11.62 1.04 
WF 1.64 13.01 1.17 
- -
20.72 1.00 
SM 1.64 20.44 0.99 
WF 1.63 26.12 1.26 
- -
32.64 1.00 
SM 1.62 32.23 0.99 
WF 1.61 43.30 1.32 
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A comparison of Tables 4.9 and 4.10 shows that similar concentrations 
of warfarin and su1phisomidine have a greater influence on the displacement 
of ANS by f1ufenamic acid than they have on the displacement of ~~S by 
ethacrynic acid. This is a consequence of the·different affinities of 
ethacrynic acid and f1ufenamic acid for sites I and II. 
So far. only the displacement of fluorescent probes from binding 
sites on HSA has been reported. However. experiments were also performed 
using whole serum. 10m1 volumes of blood were taken from three healthy adult 
male volunteers. The blood was allowed to stand at room temperature for 
several hours until clotting was complete. The clots were removed and the 
samples spun at 4000rpm for 30 minutes. The supernatants were decanted and 
centrifuged again. 2m1 a1iquots of the clear sera were stored at _200e. 
Small volumes of serum (sample 1) were thawed and diluted lOO-fold 
in Tris/He1 buffer O.lM pH 7.40. The displacement of ANS from its serum 
binding sites was investigated by monitoring the probe fluorescence in the 
absence and in the presence of various competitor drugs. An ANS concentration 
of 5 x 10-5H was used in these studies. The reagent concentrations were such 
that the serum background fluorescence was extremely small - just 0.14% of 
the signal recorded in the absence of competitor. Some results are presenteri 
in Table 4.11 (a). The low serum fluorescence contributed to the attainment 
of a high precision. Very similar results were obtained when a second serum 
sample was used (see Table 4.11 (b) ). 
By way of a comparision. Table 4.12 shows the extent to which ANS 
is displaced from albumin. rather than from serum binding sites. With the 
concentration of albumin set at 5.0 x 10-5H. the results suggest that 
f1ufenamic acid and ethacrynic acid displace ANS slightly more readily in 
this medium than in diluted whole serum. However. the HSA concentration in 
serum sample 1 was determined by the standard method of e1ectroimmunodiffusion 
and found to be 5.72 x 10-5M. that is. 44.5g/1. This figure lies within 
the generally accepted 'normal' range of 35-50g/1 (Peters, 1977). When 
values of bound probe concentration/HSA concentration were calculated for 
ANS in the presence of f1ufenamic acid and ethacrynic acid in the diluted 
serum and in the albumin solution. the earlier discrepancies disappeared. 
This was not so for su1phisomidine, though. While it may compete only very 
weakly with ANS. su1phisomidine appears to displace a significantly larger 
proportion of the bound probe in the diluted serum than in a solution 
containing a similar concentration of albumin. 
Experiments were also performed to examine the displacement of 
warfarin from its serum binding sites. As before, a lOO-fold dilution of 
(a) 
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TABLE 4.11 
Displacement of ANS in human serum by a number of ligands. Serum 
sample I was diluted 100.fold in O.lM Tris/HCl pH 7.40. The ANS 
concentration was 5.0 x 10-bM. Figures in brackets (s) were 
calcul ated from 
s = Js" + so. I .. 
where $,and s.refer to the standard deviations of the fluorescence 
intensities obtained in the prescence and in the absence of 
competitor. 
Drug Concentsati on % Displacement 
xlO- M of bound·ANS 
Flufanamic Acid 5.0 40.22 (0.16) 
Flufenamic Acid 5.0 41.60 (0.21) 
Ethacryni c Aci d 5.0 26.84 (0.14) 
Ethacrynic Acid 5.0 28.71 (0.21 ) 
CPMP 5.0 17.50 (0.15) 
Warfarin 5.0 7.58 (0.21) 
Sul phi soxazo le 5.0 2.84 (0.12) 
Sulphisomidine 5.0 2.53(0.12) 
Sulphi somi dine 5.0 2.58 (0.23) 
(b) Displacement of ANS in human serum. Serum sample 11 was 
diluted lOO-fold in O.lM Tris/HCl pH 7.40. The ANS concentration 
was 5.0 x 10-6M. 
Drug Concentrati on % Displacement 
xlO- 5M of bound ANS 
F1ufenamic Acid 5.0 40.74 (0.12) 
Ethacryni c Aci d 5.0 28.86 (0.20) 
Sulphisoxazole 5.0 1.73 (0.20) 
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TABLE 4.12 
Displacement of ANS from aJbumin binding sites. The concnetrations of 
HSA and ANS were 6.0 x 10- M and 5.0 x 10-6M, respectively. Figures in 
brackets were calculated from the standard deviations of the fluorescence 
intensities obtained in the prescence and in the absence of competitor. 
Drug Concent§ati on % Displacement 
xlO- M of bound ANS 
Flufenami c ACid 5.0 44.04 (O.20) 
Ethacrynic Acid 5.0 33.11 (O.11 ) 
Sulphisomidine 5.0 0.75 (O. 14) 
TABLE 4.13 
Displacement of warfarin from HSA and serum binding sites. Figures in 
brackets were derived from the standard deviations of the fluorescence 
intensities obtained in the presence and in the absence of competitor. 
Serum sample I was diluted ~OO-fold in O.lM Tris/Hel pH 7.40. The HSA 
concentration was 6.7 x 10- M. 
Drug Concent§ati on % Displacement of bound warfarin 
xlO- M Serum Sample I HSA 
Sulpharrerazine 1.0 6.16 (O.87) 5.71 (O.53) 
CP~1P 1.0 6.28 (O.59) 6.02 (O.50) 
Sulphisomidine 1.0 11.46 (0;66) 5.55 (O.53) 
Sulphisoxazole 1.0 7.39 (O. 64) 8.26 (O.59) 
Etha cryn i c Ac i d 1.0 29.26 (O.62) 26.47 (O.52) 
Fl'ufenami c Acid 1.0 26.13 (O.65) 27.24 (O.96) 
Phenylbutazone 1.0 60.78 (O. 60) 55.96 (O.50) 
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serum sample 1 was employed and the results compared with those obtained in 
1 . -6 so utlons of 6.7 x 10 M HSA. The serum background fluorescence was about 
11% of the total signal observed in the absence of competitor. The 
corresponding figure for the albumin fluorescence was about 5.5%. Inner-
filter effects were considered for each competitor drug and the normal 
allowances made. Except for flufenamic acid, the necessary corrections were 
very small - about 1%, or less. 
An examination of the results in Table 4.13 shows that there is a 
good correliltion between the ability of sulphamerazine, CPMP, sulphisoxazole, 
ethacrynic acid, flufenamic acid and phenylbutazone to displace warfarin 
from binding sites in human serum and in HSA preparations where the albumin 
concentrations are similar. However, under these experimental conditions 
sulphisomidine appears to displace twice as much warfarin in whole serum 
as it does in a solution of HSA. 
4.4 Discussion of Methods and Results 
Some general features of the procedures described in this chapter 
are worthy of further consideration. Positive aspects include the capacity 
to study binding over a wide range of ligand concentrations; the ability to 
examine the binding properties of non-fluorescent drugs which may be 
difficult to assay directly; and the potential to apply the methods to 
almost any ligand/fluorescent probe combination: these points are discussed 
separately in the following paragraphs. Possible limitations are covered 
later. 
The binding of fluorescent probes to albumin was expressed most 
conveniently in the form of Scatchard plots. The ability to extend these 
plots over a wide range of probe concentrations is extremely important, 
particularly if the effect of adding potential competitors is to be assessed. 
Now the series of curves shown in Figures 4.2 and 4.3 were obtained in the 
presence of phenylbutazone and sulphisoxazole, respectively. The curves are 
clearly 6f a simil ar shape and tend tCMards common intercepts on the R axes. 
This concurrence is reflected in the corresponding values derived using 
the curve-fitting procedure. Unfortunately, in the past many studies have 
not been extended to low values of R /DF. Aarons et al (1979) have shown 
that this practice can lead to an apparent decrease in the values of the 
intercepts on the R axis in the presence of increasing concentrations of 
competitor. The problem is particularly severe if the Scatchard plots are 
curved when the effect may be wrongly assigned to a decrease in the number of 
binding sites available to the fluorescent probe. Because the present method 
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allows measurements to be taken at low as well as high R IDF values. it is 
much harder to misinterpret the results. Thus an inspection of Figures 4.2 
and 4.3 imrrediately shows how phenylbutazone and sulphisoxazole compete 
strongly with warfarin for binding to albumin without reducing the number of 
potential sites per protein molecule. 
The procedures used in this chapter take the form of competitive 
binding assays. As such, they allow the binding properties of ligands to be 
examined in terms of their ability to compete with fluorescent probes for 
specific sites on albumin. Now ligands which are capable of displacing bound 
fluorescent probe may be difficult to measure themselves. For example, if 
the ligand is a non-fluorescent drug. a direct assessment of its binding to 
HSA may be impossible. Displacement studies like those described above offer 
a convenient way of demonstrating the affinity of any ligand for particular 
sites on HSA. 
Although results have been presented for only two fluorescent probes 
and a limited number of competitors. the methods could easily be used to 
study the binding and displacement of any number of fluorescent probes. The 
availability of several suitably designed fluorescent molecules could lead 
to a fuller characterization of drug binding sites on HSA. Eventually, it 
may even be possible to describe the structural features which are necessary 
for a ligand to bind to a particular region of the albumin molecule. 
The scope of the method used to examine the influence of competitor 
drugs on probe binding curves was limited by two factors. Firstly, it would 
rarely allow for an accurate determination of the association constant of the 
competi tor; very approximate values are the best that can be hoped for when 
more than one binding site is involved in the displacement interaction. This 
limitation is a general one and is not restricted to the present experimental 
approach. The second. perhaps less important limitation is the time required 
to produce full binding curves. 
The procedures outlined in Section 4.3. on the other hand, made for 
a very rapid assessment of ligand binding. Furthermore, while the experiments 
discussed in Section 4.2 were concerned with the influence of fixed quantities 
of potential competitors on the association constants and binding curves of 
fluorescent probes, the displacement studies of Section 4.3 were more suited 
to an examination of the effects of varying the competitor concentration. 
The complimentary nature of the two approaches proved very useful when 
seeking clarification of the behaviour of certain drugs in binding albumin. 
Before assessing the clinical significance of particular results. 
it is important to consider some problems associated with the extrapolation 
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of data from in vitro binding experiments. Most of the non-methodological 
problems are related to the albumin used in the experiments - its source 
and fatty acid content, and the concentration at which it is employed. 
Free, that is, unesterified fatty acid, the form in which fat is 
released from the adipose tissue storage deposits, is one of the most 
important metabo1ites transported by plasma albumin. Although the plasma 
free fatty acid concentration is quite variable, the molar ratio of free 
fatty acid to albumin is usually in the range 0.5 to 3.0 (see ftj-ller et 
a1,1982. Not surprisingly, it has been known for many years that serum 
albumin preparations also contain variable amounts of lipid impurity (Kenda1, 
1941) and the bulk of this impurity appears to consist of free fatty acids. 
Recently, Birkett et a1 (1978) have examined the fatty acid content of 13 
commercial HSA preparations. The figures varied from 0.03 to 9 moles of 
fatty acid per mole of albumin. According to the survey, the Hoechst 
preparations used in this work contains about 1.2 mole fatty acid/mole 
albumin. 
As discussed in Chapter 1, there is ample evidence to suggest that 
free fatty acids can alter t~e binding of drugs and endogenous 1igands to 
HSA. Indeed, there may even be a significant effect for changes in free 
fatty acid concentration within the physiological range (Spector et a1, 1973). 
Because of this, some workers employ a charcoal treatment based on that of 
Chen (1967) to strip free fatty acids from albumin before commencing binding 
studies. While, if the.procedure were widely adopted, it might be useful 
in allowing for a better cross-correlation of laboratory results, native 
HSA does contain bound fatty acids and it may be more appropriate to study 
ligand binding to the albumin molecule as found in vivo. With this pOint 
in mind, no attempt was made to produce defatted albumin. The strategy is 
probably further justified by the findings of Birkett, et al (1978) which 
suggests that the fatty acid content of the Hoechst material is within the 
limits normally found in plasma. 
Chen and Koester (1980) examined the fluorescence characteristics 
of several commercial samples of HSA before and after treatment to remove 
bound impurities. The emission spectra of the untreated samples varied in 
shape, and the relative quantum yields differed widely. Dialysis and 
charcoal treatment minimized the spectral differences, although the quantum 
yields still varied. It appears that fluorescent impurities were present in 
some sawples, while nonfluorescent quenching contaminants were present in 
others. The authors discuss various factors which may contribute to 
differences between commercial sources of HSA. 
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To make certain of obtaining consistent results, all experiments 
reported here were carried out using the same batch of albumin. 
There are a number of accounts in the literature concerning the 
effects of albumin concentration on the results of binding experiments 
(Bowmer and Lindup, 1978; Boobis and Chignell, 1979). Suggestions why the 
apparent association constants and the number of binding sites should be 
dependent upon the experimental protein concentration have been put forward 
by these authors. The maintenance of fixed quantities of albumin throughout 
each series of experiments should have avoided these complications. 
Furthermore, because the albumin concentration was kept low, dimer-formation 
would have been minimized. This concentration-dependent polymerization 
process, which can undoubtedly affect the binding of ligands to HSA, has 
been investigated by Zini et al (1981). 
Comparing the suitability of ANS and warfarin as fluorescent probes 
for albumin binding sites, it is clear that there are certain practical 
advantages to be gained by employing the former. Its fluorescence excitation 
and emission peaks are centred at longer wavelengths than those of warfarin 
and this renders it less $usceptible to inner-filter effects arising in the 
ultraviolet region of the spectrum when potential competitors are added. 
On binding to albumin, the fluorescence of ANS is much more intense than 
that of warfarin, while in free solution it has a much lower quantum yield; 
measurement of the bound fraction in the presence of the free is much easier 
with ANS. Furthermore, because the ANS fluorescence is at a longer wavelength 
than the warfarin fluorescence, interference from serum constitutes is much 
reduced. Nevertheless, as well as being a fluorescent molecule, warfarin 
does have the advantage of being a commonly adminstered drug: displacement 
of this fluorescent probe is certain to involve an important drug binding 
site on albumin. 
It is useful to consider the results obtained in this chapter in 
relation to what is already known about drug binding sites on albumin and 
to highlight those of possible clinical significance. 
While results showed unequivocally that warfarin, phenylbutazone 
and sulphisoxazole compete avidly for similar sites on HSA, none of these 
ligands exhibited a tendency to displace ANS from albumin binding sites. 
The conclusion that warfarin and ANS bind different sites on HSA is in 
accord with that of Sudlow et al (1975). 
Ranking drugs in order of their tendency to displace warfarin and 
ANS made it easier to appreciate the different affinities of these compounds 
for the two probe binding sites. Thus it became clear that the sulphonamide 
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drugs competed with warfarin for sites on albumin but had no effect on the 
bin:!;~; :f ,',~!~. Furthermore, the binding affinities of these antibacterial 
agents seemed to be highly dependent upon their side-chain substituents. 
Unfortunately, it is usually very difficult to relate binding affinities 
to specific structural features of the interacting molecules. Such 
rationalization normally requires information about the environment and 
geometry of the binding site on the macromolecule and needs to be supported 
by an extensive review of the binding of large numbers of ligands. 
Nevertheless there has been some speculation in the literature concerning 
the relationship between the structure of sulphonamide drugs and their 
binding to albumin. 
Hsu et al (1974) investigated the binding of 11 sulphonamide 
derivatives to bovine serum albumin and showed that binding affinities were 
enhonccd l;j' hydrophobic side-chain substitutions and decreased by hydrophilic 
side-chain substitutions in the parent molecule. The same authors claimed 
that methyl groups on pyrimidine ring of certain sulphonamide drugs increased 
the phenomenon of protein binding. This effect has also been reported for 
the binding of sulphonamides to HSA (Agren et a1, 1971). It is interesting 
to note that results in Figure 4.7 of this chapter suggest that sulphamerazine 
binds more strongly to HSA than does sulphadiazine; the only difference 
between the drugs is the methyl group on the pyrimidine ring of sulphamerazine. 
Hsu et a1 (1974) also found that the methoxazo1e ring in oxacillins 
seems to give these compounds greater binding affinities than the gro~p of 
penicil1ins at large. This substituent is also present in sulphisoxazole, 
and may account for its unusually high affinity for albumin binding sites 
(see Figure 4.3). 
Evidence for the relative importance of the binding forces involved 
in sulphonamide-albumin interactions is still rather contradictory. While 
the opinion of Scho1tan (1968) that most of the en~rgy of sulphonamide-
albumin binding is due to hydrophobic forces has received increasing support, 
other experimental evidence has suggested an important role for electrostatic 
interactions between the sulphonamide anion and positive charges on the 
protein surface. 
Moriguichi et al (1968) for example, evaluated the bidding of 19 
sulphonamides to bovine serum albumin and showed that the binding correlated 
with the pKa of the N' nitrogen of the sulphonamides. They proposed that 
their findings gave support to the view of Klotz (1953) that electrostatic 
forces are dominant in the binding of such anions to serum albumin. Agren 
et al (1971) investigated the binding of 13 sulphonamide drugs to HSA. For 
these drugs, a marked elevation in binding was observed on increasing the 
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pH from the acidic to the basic side of the pKa value. Thus the anionic form 
of Q ,"u-,t'ill,HlQllliue drug appears to be IOOre extensively bound than the 
uncharged species. The authors concluded that the major determinant in 
sulphonamide binding is electrostatic, and speculated on the involvement of 
an attraction between the sulphonamide anion and the positively charged amino 
acfds on either side of the single tryptophan residue in HSA. This region 
of the albumin 1OO1ecule has been proposed as a primary drug binding site by 
Swaney and Klotz (1970) and has been discussed in some detail in Chapter 1. 
Bearing in mind the competition between sulphonamide drugs and warfarin for 
binding albumin (see Figure 4.7), it is interesting to note that Fehske et 
al (1979) have identified the lone tryplophan residue as part of the warfarin 
binding site on HSA. 
As well as considering electrostatic forces, Agren et al (1971) also 
foulld cl dil~ct relationship between lipophilicity and binding of the 13 
sulphonami,des to HSA. However, a secondary role was attributed to hydrophobic 
binding. Nonetheless, Jardetzky and Wade-Jardetzky (1965) have used nuclear 
magnetic resonance to show that the hydrophobic part of the sulphonamide 
structure, probably the p-aminobenzene lOOiety, participates in binding. 
It seems clear then, that both electrostatic and hydrophobic forces 
are involved in the binding of sulphonamide drugs to HSA. The problem of 
data interpretation lies in the proper resolution of the various physiochemical 
effects involved in the interactions between these drugs and albumin. 
From results presented in this chapter it appears sulphisoxazole 
and warfarin bind strongly to the same class of sites on albumin. Now, 
displacement from HSA can be expected to have serious consequences for 
highly bound drugs that have a narrow therapeutic range and a low volume 
of distribution. The oral anticoagulants including warfarin fall into this 
categorY. However, desptte the theoretical possibilities of an interaction 
between the sulphonamides and the oral anticoagulants, there is no evidence 
as yet to suggest that such an interaction has any clinical significance 
whatever (Stockley, 1974). The importance of distinguishing between potential 
and actual drug interactions should not be overlooked. 
The observation that long-acting sulphonamide drugs are liable to 
displacement from albumin in vivo by more highly bound acidic agents such 
as phenylbutazone (Anton, 1960) is not surprising; it has been shOo-m in 
this chapter that sulphonan:ide drugs and phenylbutazone bind to the same 
class of sites on HSA. The clinical significance of this interaction has 
yet to be established. 
The ease with which phenylbutazone displaced warfarin from HSA and 
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from whole serum was consistent with t~e results of other studies (O'Reilly. 
1973; Solomon et al. 1968; McElnay and D'Arcy. 1980b). Indeed addition Qf 
phenylbutazone to the a~prol)date samples produced suclJ a large increB.se in 
the unbound fraction of th~ fluorescent pro~e that it is tempting to aS3ume 
that this displacem~nt mecharism is the mo~t important process contributing 
to the warfarin anti-inflammatory drug interactions observed in man. 
Ha.lever. as well as operating via the displacement of a drug from plasma 
protein binding sites. drug interactions may involve other processes suc; as 
modified absorption. metabolism. excretion and receptor-site response. and 
competition for tissue binding sites (see Section 1.2). Thus the tendency 
to attribute most drug interactions to only one of several tieoretically 
possible mechanisms is probably unrealistic. 
Alth~ugh considerable time and effort has been invested in studies 
of t~e binding of warfarin to HSA and its displacement by ph~ny1butazone a 
full understanding of the mechanism~ inv~lved in the interaction of these 
drugs has still to be achieved. Since these agents can produce potentially 
hazardous pharmacological effects when co-administered. compr'!hensive studies 
in human~ have not beer. attem~ted. Recently. however. a thorough 
i nvesti gati on of the effect, of phenyl butazone on \1arfarin pharmacoki neti cs 
and anticoagulant activity has been carried out in rats by Yacobi et al (1980). 
Thp interaction between these drugs wa~ found to involve at least tiree 
processes: an inhibition of warfarin biotransformation (deceased intrinsic 
clearCl.nce); displacement of warfarin from plasma protein binding sites; 
and an apparent ~otentiation of the anticoa9u1ant action produced by a given 
plasma warfarin concentration. The latter may have been caused. at least in 
part. by a direct anticoagulant effect of phenylbutazone. 
Results from the paper of Yacobi et a1 (1980) showed that 
phenylbutazone displaces more 11arfarin in vivo than it does in vitro. It 
appears 1 ikely t~at the displacement of warfarin in vivo is due not only to 
phenylbutazone but also to one or more of its metabolites. In fact. one of 
the major phenylbutazone metabolites - oxyphenylbutazone. is knol'm to bind 
strongly to albumin (Chignell. 1958) and probably competes with \~arfarin 
for albumin binding sites (Wosi1ait and Ryan. 1979). 
Theoretically. the more pronounced phenylbutazone displacing effect 
in vivo could be due to the accumulation of warfarin metabolites capable of 
competing with \~arfarin for albumin binding sites. Thus. inhibition of the 
metabolism and elimination of the S -isomer of warfarin by phenylbutazone has 
been suggested as an alternative mechanism for the increased anticoagu1aticn 
observed in humans (Lewis et al. 1974). The point that drugs which are 
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capable of comp2ting with each other for albumin binding sites might also 
compete for elimination and metabolic pathways was emphasized by Gillette 
(1973). 
In 1981 O'Reilly and Goulart attempted a study of certain aspects 
of the interaction between phenylbutazone and racenric warfarin in humans. 
In agreement with the work of Yacobi et al (1980) on rats, the interaction 
in humans appeared to be complex and multifactorial. 
It seems likely that other important drug interactions will be the 
result of several processes. So the effort required to elucidate fully the 
mechanism of a drug interaction can be enormous. On the other hand, because 
drugs that displace one another from albumin binding sites may also compete 
for elimination pathways, a study of competition for binding at the plasma 
protein level may have a role in the prediction of drug involvement in the 
unrelated elimination interaction mechanism. 
Results from this chapter also suggested that flufenamic acid could 
compete strongly for albumin binding sites with both warfarin and ANS. 
To a lesser degree, this behaviour was also exhibited by ethacrynic acid. 
A series of experiments involving the addition of two competitor drugs to a 
sample comprising fluorescent probe bound to albumin provided a neat 
confirmation of these findings. Further support for the results may be 
found in the microcalorimetric investigation by Otagiri et al (1978) which 
shows that more than one site contributes to the heat evolved when 
flufenamic acid binds to HSA. According to Chignell (1969~),flufenamic acid 
may bind to three very high affinity sites on HSA. 
The experiments used to confirm the existence of two separate 
binding sites on albumin for flufenamic acid and for ethacrynic acid 
involved a number of simultaneous binding equilibria. It is likely that 
further studies concerned with multiple binding equilibria will help in the 
interpretation of other, perhaps rather anomalous. experimental data. For 
instance, should a drug be bound to albumin at a certain class of binding 
sites and addition of a second drug, which is known to bind to a different 
class of·sites, cause displacement of the first, the presence of a third 
ligand bound reversibly to both sites may be implicated. Of course, if no 
such ligand can be identified, it may be necessary to check that the second 
drug does not bring about a displacement of the first simply by inducing a 
conformational change in the protein. 
There are also strong implications stemming from this part of the 
work for some in vivo studies. A drug may be shown by measurements in vitro 
to bind to a certain class of albumin binding sites. Circular dichroism 
- 240 -
experiments may subsequently reveal that on binding the small molecule, the 
protein suffers no marked changes in its three-dimensional conformation. 
Nevertheless, administration of this drug to a patient receiving multiple 
drug-therapy may well result in the displacement of drugs from chemically 
distinct and apparently unrelated classes of binding sites. Quite possibly, 
this would be due to the existence of other drugs or endogenous ligands 
which bind strongly at more than one class of binding site. Any shift in 
the equilibrium concentrations of these albumin-bound molecules could produce 
unexpected increases in the unbound fractions of certain drugs. Since 
these are the pharmacologically active fractions, a toxic response may ensue. 
To predi ct accurate ly such responses woul d requi re acomprehens ive knowledge 
of the concentrations and binding characteristics of all the drugs and 
ligands involved. Although there may never be sufficient information to 
allow a foolproof prognosis, a better understanding of these more complex 
interactions would surely result from a fuller characterization of both 
primary and secondary binding sites on HSA. 
The use of serum samples in the study of fluorescent probe and drug 
binding produced no problems over and above those encountered in the use of 
HSA solutions. With fresh serum samples the background fluorescence was 
quite acceptable. This rendered pretreatment of sera unnecessary. 
When a number of ligands were allowed to compete for binding sites 
with two fluorescent probes in whole serum and in suitably concentrated 
albumin solutions, the degree of displacement was found to be the same in 
both media.· This supports the idea that the binding sites for acidic drugs 
in human serum are mainly or exclusively those on albumin (Tillement et al, 
1981). While it is still conceivable that acidic drugs can bind to other 
plasma proteins, these sites will undoubtedly have relatively low binding 
affi ni ti es. 
In the case of sulphisomidine, considerably more fluorescent probe 
was displaced from serum than from albumin binding sites. Until further 
information is available, any explanation of the seeminglyhigheraffinity 
of sulphisomidine for whole serum must be rather speculative. 
Despite its usefulness, there is a major objection to the employment 
of fluorescence spectroscopy in a study of binding phenomena. Although this 
objection could apply equally well to other spectroscopic techniques, it is 
one which should not be overloOked. The possibility exists that a drug or 
other ligand may cause a change in the spectroscopic properties of a probe, 
in particular a change in the emission spectrum, by modifying the protein 
conformation and hence the environment of the fluorescent probe, rather than 
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by displacing the molecule from a specific class of binding sites. 
To verify ,some of the results obtained using fluorescence 
spectroscopy, the binding and displacement of fluorescent probes were 
examined by a separate technique, that is, equilibrium dialysis. Unlike 
the homogeneous fluorescence assay, the equilibrium dialysis procedure 
depended upon the physical separation of the bound and free fractions of 
the probe. More importantly, however, the analytical signal did not rely 
on any modifications in the spectroscopic properties of the fluorescent 
probe on binding to albumin. 
Some equilibrium dialysis experiments are discussed in the next 
chapter. 
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CHAPTER 5 
Equilibrium Dialysis A Classical Technique for Studying 
Drug-Protein Binding 
5.1 Principle of the Method 
Dialysis is a separation process that depends on the differential 
transport of solutes of dissimilar sizes across a porous barrier separating 
two liquids when the only driving force is a concentration gradient. The 
technique is normally used to separate solutes which are too large to cross 
the h~~~;p~ f~om those small enough to diffuse freely through it. 
Dialysis is very easily accomplished. The minimum requirements 
for simple dialysis are met when a semi-permeable membrane is used to 
stabilize a concentration gradient between a solution on one side and pure 
solvent on the other. The kinetic movement of the solute molecules will tend 
to drive them spontaneously through the membrane in ,the direction of lower 
concentration. At the same time'solvent molecules will move in the opposite 
direction in response to the osmotic pressure difference. The ability of the 
solute molecules to traverse the membrane depends on their size and shape. 
This concept of dialysis was first proposed by Graham in 1861 who 
used the process to separate solutes of widely differing sizes. Since then, 
the method has been refined to allow a higher degree of selectivity and adapted 
to give rise to a number of related techniques. The most important 
theoretical and practical aspects of dialysis,have been covered by Craig 
(1965 and 1968). 
Equilibrium dialysis - as its name implies - is based on the 
attainment of an equilibrium across the dialysis membrane. This equilibrium 
is achieved by the net transfer of dialysable molecules in response to an 
initial concentration gradient across the membrane. The more concentrated 
solution is called the retentate and the more dilute solution the diffusate. 
Equilbrium dialysis represents a very powerful experimental tool 
for studying the interactions between low molecular weight ligands and 
biological macromolecules. The method is founded on the reversibility of such 
interactions and permits the measurement of the distribution of the ligand 
between the bound and free forms. Its use in characterizing antibody-hapten 
binding has been reviewed by Karush and Karush (1971). 
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In practice, equilibrium dialysis is carried out in a unit comprising 
twu IIQi, ~eiis or chambers separated by a semi-permeable membrane. Initially, 
diluent buffer is placed in one half-cell and known quantities of ligand 
and macromolecule, say protein, are added to the other. Alternatively, the 
ligand and protein may be placed on opposite sides of the membrane. The 
solvent system, sample volume, pH and ionic strength should be identical in 
both half-cells. The two solutions are stirred continuously to allow them 
to stay in contact through the membrane until equilibrium is reached. The 
feasibility of the method arises because the dialysis membrane is impermeable 
for the macromolecule but allows the ready diffusion of all other solutes. 
While attainment of diffusion equilibrium across the membrane normally 
requires several hours, the chemical equilibrium for the binding reaction can 
be reached within a fraction of a second. 
After a pre-determined equilibrium period, the ligand concentration 
in the protein-free chamber is measured using an appropriate analytical 
method. If a true equilibrium has been achieved, this value must equal the 
concentration of unbound ligand in the chamber containing protein: the bound 
form is too large to cross the membrane. Knowing the total ligand 
concentration in the dialysis unit, the bound ligand concentration can be 
found by subtraction. It is sometimes possible to measure the equilibrium 
concentration of ligand in both half-cells. A knowledge of the total quantity 
of ligand added to the system is then unnecessary for a calculation of the 
bound fraction. 
The characteristics of the membrane are obviously very important in 
equilibrium dialysis work. It must have a well-defined pore diameter to 
prevent diffusion of the macromolecule. Adsorption of ligand and 
macromolecule on to the membrane should be as small as possible. The 
mechanical strength must be sufficient to avoid rupture but the membrane must 
not be too thick; the thinner the membrane the less the non~specific 
adsorption and the shorter the dialysis time. Fortunately, a very suitable, 
commercially available material exists in the form of extruded cellulose 
casing (Visking Tubing). This extremely reproducible casing has been used 
widely for preparative dialysis in biochemical work. 
A good preparation of the membrane will help to reduce blanks. 
Blanks may arise when membrane impurities perturb spectroscopic or other 
measurements of the free ligand. Thus, it is common practice to wash 
membranes several times before use. Once a membrane has been wetted, however, 
it should never be permitted to dry out again as this can alter its 
porosity. 
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Materials used to construct cells for equilibrium dialysis should 
have little or no tendency to adsorb any of the solutes under examination. 
Half-cells must fit tightly as any leakage of the dialysing solutions would 
lead to erroneous results. Some useful information on the design of 
equilibrium dialysing systems is presented in a paper by Weder et al, (1971). 
The diffusion of ligand across the membrane clearly represents 
the most important aspect of the equilibrium dialysis procedure. A good 
understanding of this process is essential if the method is to be fully 
exploited. 
The rate of diffusion of any single solute through a membrane 
depends on a number of factors, some of which are interdependent. They 
include the solute, the solvent and the temperature as well as the choice of 
membrane and the cell design. Nonetheless, under properly controlled 
conditions, and for an ideal, pure solute, the overall rate of diffusion 
across the membrane can be described by an equation which is analogous to 
Fick's Jaw for diffusion in free solution. This can be written as: 
Rate of diffusion : - DA ~ (5.1) 
where D is the diffusion constant, A is the area of the membrane, and ~ 
is the concentration gradient. 
If the rate of diffusion for a given solute and membrane is 
proportional only to the concentration gradient across the membrane, Fick's 
law is obeyed and the process is analogous to first order reaction kinetics. 
A plot of the logarithm of the concentration in the retentate against time 
should give a straight line. When a linear escape plot is produced 
experimentally, it suggests that the solute is behaving ideally over the 
range of concentration examined and is homogeneous with respect to size within 
the limits of discrimination of the membrane. 
Not all pure solutes give straight line escape plots. In these 
circumstances the results can be interpreted in terms of association, 
dissociafion, or slow conformational rearrangement of the dialysable molecule. 
More often than not, however, a deviation from linearity is an indication 
of an impurity in the preparation. Escape patterns and their interpretation 
are discussed more fully elsewhere (Craig, 1965). Escape plots are 
particularly valuable in the design of equilibrium dialysis experiments 
because they allow the approach to equilibrium to be fully characterized. 
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According to Fick's law, the rate of diffusion depends on the 
membrane surface area. The consequences of providing the maximum area for 
dialysis are at once obvious from equation 5.1. Thus in equilibrium dialysis, 
the dialysing volumes should be small enough so that they can form a thin 
film over the whole membrane surface. This is best achieved by continuously 
stirring the solutions on both sides of the membrane in a completely 
reproducible manner: the simplest procedure involves the slow rotation of 
the cells. 
It is important to control the temperature during dialysis runs 
because the rate of diffusion is directly proportional to the absolute 
temperature. This follows from the Stokes-Einstein equation: 
o = RT / 6R1; rN (5.2) 
where 0 is the diffusion coefficient, ~ is the viscosity, r is the 
radius of the molecule and N is Avogadro's constant. 
Equation 5.2 also shows how the rate of diffusion decreases with 
increasing solvent viscosity. The solvent can also influence the rate of 
dialysis by solvation, by conformational effects on the solute and by 
changing the state of association of certain dia1ysab1e molecules. As the 
role of the solvent in dialysis is quite complicated, equilibrium times 
should be re-examined whenever the solvent composition is changed. 
Since protein molecules constitute non-diffusab1e charged species, 
in many binding studies the distribution of diffusab1e ionic species between 
the half-cells is subject to the Gibbs-Donnan effect. If experiments 
involving albumin are performed at pH 7.4 Garn and Kimbe1 (1961) regard this 
to be acceptable although the isoe1ectric point is at a pH of about 4.9. 
In practice, moreover, the Gibbs-Donnan effect can be reduced to a negligible 
value for charged 1igands by including a sufficient concentration of inorganic 
ions in the solvent (Edsa11 and Wyman, 1958). An ionic strength of 0.1 is 
generally. adequate to render the effect insignificant. 
Although it is feasible to control most of the experimental and 
environmental variables associated with the diffusion of ligand across the 
membrane, the approach to equilibrium in dialysis studies can be influenced 
by the very parameter that is being measured; that is, the distribution of the 
ligand between the bound and free forms. 
It is common practice to establish the time to equilibrium in a 
buffer versus buffer system. A solution of the ligand is dialysed against 
the diluent buffer. The concentrations in the retentate and in the diffusate 
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are followed until there is a uniform distribution of the ligand across 
the dialysis membrane. The equilibrium period is then fixed and adhered to 
during subsequent binding studies. Unfortunately, as the extent of binding 
varies, so does the time to equilibrium. If the protein binds a substantial 
fraction of the total ligand, a longer equilibration period is required. 
To avoid potentially serious errors, it is important to establish that the 
reported values of free ligand concentration are the true equilibrium values 
for all bound fractions. 
5.2 Design of Dialysis Cells and Performance Tests 
Special dialysis cells were designed for use· in drug-protein binding 
studies. They were made from Tef10n (po1ymethacry1ate), a material which 
shows a low non-specific adsorption of proteins (Weder·et a1, 1971). A 
unit consisting of two half-cells is illustrated in Figure 5.1. 
The two halves of the cell were readily coupled by means of a 
single nickel screw which passed through a hollow, threaded column in the 
centre of each unit. When a dialysis membrane was trapped between the ha1f-
cells, two separate compartments were formed. Sample solutions were injected 
into these compartments via small entry ports in the walls of the cells. 
The ports were sealed with plastic screws. 
The total volume in each half-cell compartment was 2.8m1. This 
meant that with a sample of 2m1, a sufficiently large 'active' membrane area 
remained. 
Thorough mixing of samples and hence reasonable dialysing times 
were achieved by rotation of the complete cells. A device was produced 
which would accept and rotate a number of cells. The equipment consisted of 
two parallel rollers, one of which was driven by an electric motor. The 
other roller was free to rotate and positioned at a slightly higher level 
than the first. The roller bars were also displaced horizontally so as to 
take a hollow glass tube of specific internal diameter. Tests showed that 
the motion of the driven roller was faithfully transferred to the glass tube 
it supported; there was no tendency for the latter to slip. Moreover, 
because the dialysis cells fitted tightly into the hollow tube they could be 
guaranteed to rotate as one. 
When placed in the rotation assembly, the membranes in the dialysis 
cells were in the vertical position and at right-angles to the rotational 
axis. The motion of the cells meant that sample solutions came into contact 
with the whole area of the membrane. The rate of rotation could be adjusted 
at will by regulating the power supplied to the electric motor driving the 
assembly. 
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Visking tubing (Scientific Instrument Centre Ltd) was used as the 
dia1:,':~: ::::::±:--ane. Pieces of a convenient size were cut from the tubing and 
soaked in concentrated sodium carbonate solutions at lOOoC for about 16 hours. 
The membranes were then washed several times in boiling distilled water to 
remove any remaining soluble components. Treated membranes were stored at 
40C in distilled water. To avoid altering sample volumes, drops of water 
were removed from the membranes with adsorbent tissue prior to their insertion 
in the dialysis cells. However, membranes were never allowed to dry out. 
Before commencing on drug binding studies, the performance of the 
equilibrium dialysis equipment was examined thoroughly. Experiments were 
carried out to test for leakage of sample solutions and efforts were made to 
detect any spurious fluorescence signals arising from memb.rane contaminants 
or from molecule.s leaching out of the cell walls. The dialysing time for a 
low nivlccular weight ligand was also determined and the degree of solute 
adsorption on cell walls and membranes was investigated. Brief descriptions 
of the trials carried out with the new dialysing system are given below. 
The tightness of fit of the half-cells was tested using a coloured 
solution. A small quantity of potassium permanganate was dissolved in 
distilled water. Dialysis cells containing this solution were spun overnight 
at room temperature. Subsequent inspection of the membranes showed that the 
oxidized portions were stained brown and easily identifiable. The extremely 
sharp pattern of membrane oxidation illustrated in Figure 5.2 demonstrates 
quite clearly that there was no leakage of solution from the sample 
compartments. 
Several attempts were made to detect spurious signals caused by 
the removal of fluorescent substances from the dialysis membrane or the cell 
walls. Even after rotating a buffer solution in the sealed dialysis unit for 
up to 24 hours, there was no increase in the background fluorescence at any 
wavelength. 
The time required to reach equilibrium was found for a sample 
containing warfarin. 2ml aliquots of a solution of warfarin in O.lM Tris/HCl 
buffer, pH 7.4 were dispensed into several half-cells. An equal volume of 
unspiked buffer was then added to the other half of each of the dialysis 
cells. So, initially drug was only present on one side of the membranes. 
The loaded cells were placed on the rotation assembly and spun at a 
constant rate of 17 revolutions per minute. At specified times units were 
removed and the quantities of drug on either side of the membrane were assayed. 
To do this, measured volumes of solution were extracted from each of the half-
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cells and placed in the fluorimeter. Fluorescence intensities were recorded 
using tne wavelengths of maximum excitation and emission for warfarin in free 
solution. With the aid of the non-linear calibration curve shown in 
Figure 5.3, the data were analysed in terms of the concentrations of warfarin 
on either side of the membrane after the various dialysing times. The 
results are presented in Figure 5.4 and illustrate the approach to 
equilibrium across the cell. 
To check for the adsorption of ligand on to the Teflon walls of the 
dialysis cells or on to the membrane itself, the total concentration of 
warfarin recovered from each cell was plotted against time. As may be 
appreciated from the results shown in Figure 5.4, no significant decrease 
in the recovery of drug coul d be detected for peri ods of r.otati on up to 28 
hours. It may be concluded that there is no non-specific adsorption of 
warfarin within the dialysis cell. 
5.3 Application of Dialysing System to Drug-Protein Binding Studies 
5.3.1 Control of Fluid Shifts and Other Factors 
Preliminary performance tests in buffer versus buffer systems are 
essential if dialysis cells are to be applied properly to more complex 
systems. Nevertheless, careful thought is required when directing this 
information to the design of future experiments. Some simple theoretical 
arguments are useful in this context. Before introducing these ideas, 
however, it is worth examining the practical consequences of establishing an 
osmotic pressure gradient across the dialysis membrane. 
When equilibrium dialysis is used to determine the free ligand 
fraction in drug-protein binding studies, the results may be subject to large 
errors because of fluid shifts within the test system (Moll and Rosenfield, 
1978). These shifts can effect the volumes of solution on both sides of the 
membrane making interpretation of the data quite difficult. The phenomenon 
is obviously due to the osmotic activity of the protein molecules and so is 
more marked at high concentrations. Its effect may be lessened by increasing 
the rigidity of the dialysis membrane or by applying a compensating pressure 
within the protein-containing compartment (Kurz et al, 1977). 
Although the cells used in this study had been designed to resist 
changes in the volumes of the liquid samples initially added to either side 
of the membrane, it was important to test their effectiveness under the 
appropriate experimental conditions. 
Blue Dextran is a dye with a molecular weight of over two million. 
Molecules of this polymeric material are far too large to pass through the 
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pores of a dialysis membrane. The dye was employed as a marker to monitor 
volume changes in the cell compartments. Two solutions containing Blue 
Dextran were prepared; a third containing warfarin was also used: 
Solution A 
Solution B 
Solution C 
O.lM Tris/HCl pH 7.4/ 0.04% Blue Dextran 
" 11 / 5 x 10-6M HSA 
" / 2.5 x 10-3M Warfarin 
2ml of Solution A were added to both compartments of several dialysis cells. 
The loaded units were rotated at room temperature for 24 hours. After 
dialysing, the absorbances of the solutions in the half-cells were recorded 
at 630nm. The same procedure was followed Wor Solution B, although slightly 
higher readings were obtained because of a small contribution from the HSA. 
These control experiments were not subject to fluid shifts since the same 
solutions were present on both sides of the semi-permeable membranes; they 
simply provided a means of converting absorbance measurements obtained in 
spiked buffer and protein solutions directly into mg/ml of Blue Dextran. 
Consequently, when 2m1 of Solution A were dialysed against 2m1 of Solution B 
under the specified conditions, the final concentrations of Blue Dextran 
were readily available (see Table 5.1). 
Clearly, there had been no significant change in the concentrations 
of Blue Dextran originally present in the buffer- and protein-containing 
compartments even though a gradient of osmotic activity had existed across 
the membrane. In other words, no volume changes had been detected. 
Furthermore, when 200)J 1 of Solution C was added to 2m1 of Solution B before 
dialysing against 2ml of Solution A, the results showed that the initial 
discrepancy between the sample volumes on either side of the membrane had 
been maintained. 
Blue Dextran Concn. {mg/mll 
Dia lysing Buffer Compartment Protein Compartment 
System 
Before After Before After 
Dialysis Dialysis Dialysis Dialysis 
2m1 Solution A v 0.400 0.395 0.400 0.392 2ml Solution B 
2ml Solution A v 
2ml Solution B + 0.400 0.397 0.360 0.361 
0.2ml Solution C 
Table 5.1 
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The ability of the cells to halt the flow of water into the protein 
compartment depends on a fairly simple mechanism. This is the tendency of 
the air above the sample solutions on either side of the membrane to oppose 
any volume changes prevailed upon it. 
Immediately after a dialysis unit has been loaded and sealed, the 
air-pocket in each half-cell is at atmospheric pressure. If a protein 
solution is present in one half-cell and diluent buffer in the other, the 
osmotic flow of water across the membrane will increase the quantity of liquid 
in the protein compartment. Assuming the membrane is rigid, this flow will 
reduce the volume of the air above the protein solution while expanding the 
volume above the buffer solution. Thus as osmosis continues, an increasing 
back-pressure develops across the membrane opposing the movement of water 
into the protein compartment. 
When the flow of water across the membrane is counterbalanced by the 
back-pressure, then by definition the latter is the osmotic pressure of 
the solution. Now, osmotic pressure is a colligative property of solutions: 
it is a function of the number of solute molecules per unit volume. This is 
normally expressed as 1r = cIM RT, where M is the molecular weight, c is 
the concentration in g 1-1, R is the gas constant (0.0821 l-atm mo1-1 K-1), 
T is the absolute temperature and 1Yis the osmotic pressure in atmospheres. 
So, a 5 x 10-GM solution of HSA at 230C gives an osmotic pressure of 1.21 x 
10-4 atmospheres. In this instance the counterbalancing force required in 
the dialysis cell is extremely small compared to the atmospheric pressure 
already present above the sample solutions. In fact, assuming the usual 
0.8ml of air exists in both half-cells, and knowing that pressure is inversely 
proportional to volume, it is easy to show that a fluid shift of only a 
fraction of a micro1itre is needed to produce the required pressure 
differential. This change is much too small to detect. 
It is also easy to understand why the introduction of ligand molecules 
into the dialysis cells had no effect on the net osmotic flow. At 
equilibrium, the same quantities of unbound ligand will reside on either side 
of the membrane. Furthermore, the bound fraction will not change the number 
of non-diffusab1e solutes per unit volume in the protein compartment; so the 
osmotic pressure, being a colligative property, is also unchanged. Fluid 
shifts should not be a problem when these dialysis cells are used for drug-
protein binding studies. 
When warfarin was dialysed in a buffer versus buffer system, results 
showed that approximately 1G hours were required to establish equilibrium 
between the diffusate and the retentate (see Figure 5.4). All other 
diffusab1e 1igands under examination had molecular weights which were similar 
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or slightly lower than that of warfarin. Hence 16 hours probably 
represents the longest dialysing time likely to be encountered. 
In protein binding studies, however, the approach to equilibrium 
is affected not only by the rate at which the ligand crosses the membrane, 
but also depends on the concentration of the unbound fraction and the side 
of the membrane to which the ligand is first added. While it is easy to 
appreciate how these factors can influence the time needed to reach 
equilibrium, their potential to introduce serious errors into binding data 
has rarely been considered. Very recently, however, the approach to 
equilibrium in dialysis systems has been studied in detail by ~ie and 
Guentert (1982) and by McNamara and Bogardus (1982). Their methods of 
analysis are worthy of consideration because they make way for a critical 
examination of the design of the drug-protein binding experiments described 
in this section. 
According to 0ie and Guentert, when drug is initially added to the 
protein-containing compartment of the equilibrium dialysis cell, the 
concentration on the buffer side of the membrane at any time t is given by 
CB = COa (1 _ e-KT (l+a) t) (5.3) 
(1 + a) 
where Co is the initial drug concentration and KT is the rate constant 
governing the transfer of drug across the membrane. The term a is the 
unbound fraction in the protein compartment: a value of a = 0.01, for 
example, indicates that 1% of the drug is in the unbound form. 
When drug is initially added to the buffer side a similar equation 
is obtained: 
CB = Co (a + e-KT(l+a) t) (5.4 ) 
1 + a 
Although the actual concentration on the buffer side of the membrane 
is the variable of interest, in order to examine the influence of a on 
equilibration times it is better to express CB in relative terms. A 
fraction away from the true equilibrium concentration of drug in the buffer 
compartment is defined as 
co & = Absolute Value (CB - CB) 
cs'" 
(5.5) 
.. 
where CB is the value of CB as t tends to infinity. 
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Equations (5.3) and (5.4) show that CB = Co ex/(l+ ex) for both 
proteln ana buffer spiked samples. So in a form which is analogous to 
Equation (5.3), the time course of this fraction when drug is initially 
on the protein side is 
(5.6) 
When drug is initially placed on the buffer side of the membrane (see 
Equation 5.4), the time course of 0 is described by: 
e-KT (1+ ex) t 
oB = -=--...;..,...---
ex 
(5.7) 
The last two equations provide a ready means of finding KT from 
experimental data obtained in buffer versus buffer systems. Under these 
conditions, cx··= 1 and ln 0= -2KT t. Consequently, if the logarithm of 0 
is plotted against time for an ideal solute, a straight line of slope 
-2KT should result. The information contained in Figure 5.4 has been 
processed in this way and the escape plot is shown in Figure 5.5. 
The graph is clearly linear for dialysing times of 9 hours or less. 
(For longer dialysing times, the error in c becomes unacceptable as near-
equilibrium conditions prevail). As outlined in Section 5.1, the linear 
relationship indicates that the rate of dialysis depends simply on the 
concentration gradient across the membrane. It also shows that the solute 
has no tendency to associate or dissociate during the period of dialysis. 
The gradient of the straight line drawn in Figure 5.5 was found by 
regression analysis. It gives the value of KT as 0.147 hr-1. The importance 
of this term lies in its ability to test the approach to equilibrium under 
different experimental conditions. 
Consider first the buffer versus buffer system. The time to reach 
some fraction S from the true equilibrium concentration is given by 
t = -lnS/ 2KT • Using the value of KT determined by experiment, it is possible 
to find how close the system is to equilibrium at any stage. An idea of 
the approach to equilibrium is presented in Table 5.2. For this simple 
system it is not essential to calculate KT: the same information can be 
obtained by inspection of the raw experimental data (Figure 5.4). With more 
complicated systems, however, a knowledge of KT is invaluable for predicting 
suitable equilibration times. 
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Time of dialysis 
t (hr) 
2.36 
7.86 
10.19 
13.31 
15.66 
Table 5.2 
Approach to 
equilibrium in 
dialysis cell. 
Ligand is warfarin. 
When the different time courses exhibited by buffer and protein 
spiked samples are-examined, it soon becomes clear that the former requires 
more time to reach comparable cS values as a greater quantity of drug must 
be transported across the membrane. For example, if 1% of a drug is in the 
unbound fraction ( ~= 0.01), 99% of the initial mass present in a buffer 
spiked sample must cross the membrane to reach equilibrium. In a comparable 
protein spiked system, only 1% of the initial mass of drug must diffuse to 
the buffer side at equilibrium. 
A comparison of the two systems benefits from a consideration of the 
dialysis times required to reach a given value of cS. Rearrangement of 
Equation (5.6) for the protein spiked system produces 
tp = - 1 n cS p 
KT (1+~) 
(5.8) 
where tp is the time to reach some fraction cS p from the true equilibrium 
concentration when the drug is initially added to the protein side. So 
as the unbound fraction becomes smaller, tp reaches a limiting value 
- ~~cSp which is twice that of a buffer versus buffer system. 
On the other hand, when the buffer is spiked, the value of tB given 
by Equation (5.7) is 
tB = - (1n cS B + 1n ~) 
KT (1+~) 
(5.9) 
Instead of reaching a limiting value as ~decreases, tB continues to increase 
without bounds. 
Wherever possible then, drug should be added on the protein side 
of the membrane. This minimizes equilibration times and reduces potential 
problems such as drug degredation, microbial growth and protein 
denaturation. All drug-protein binding studies described in this chapter 
were performed using protein spiked samples. 
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Table 5.3 emphasizes the importance of the initial experimental 
conditions by comparing the time to reach concentrations 1% and 5% from 
the true equilibrium value for both buffer and protein spiked samples. 
Sine KT was taken to be 0.147 hr-1, the figures are applicable to warfarin 
binding studies. The practical advantage of initially placing the drug 
on the protein side of the membrane is obvious throughout the range of a, 
but becomes more obvious as a decreases. 
QC:' 
6= 0.05 1.0 
0.5 
0.1 
0.05 
0.01 
0.005 
0.001 
0= 0.01 1.0 
0.5 
0.1 
0.05 
0.01 
0.005 
0.001 
tB(hr) tp(hr) 
10.2 10.2 
16.7 13.6 
32.8 18.5 
38.8 19.4 J 
51.2 20.2 
56.2 20.3 
67.3 20.4 
15.7 15.7 
24.0 20.9 
42.7 28.5 
49.2 29.8 
62.0 31.0 
67.0 31.2 
78.2 31.3 
tB/tp 
1.00 
1.23 
1.77 
2.00 
2.54 
2.77 
3.31 
1.00 
1. 15 
1.50 
1.65 
2.00 
2.15 
2.50 
Table 5.3 
Influence of initial 
conditions and fraction 
unbound (a) on the time 
to reach a fracti on 0 
away from the equilibrium 
concentration. 
. KT = 0.147 hr-1 
Table 5.3 illustrates a second important point: the extent of 
ligand binding controls the approach to dialysis equilibrium in binding 
studies. Although the time to equilibrium is usually established in buffer 
versus buffer systems, it should really be found for the system with the 
smallest expected a value. All the results presented in Section 5.4 have 
been checked to ensure that acceptably low values of 0 hold whatever the 
unbound fraction. 
5.3.2 Experimental Procedures 
The binding of warfarin to HSA was studied using the apparatus 
described earlier in this chapter. A number of cells were fitted with 
dialysis membranes and sample solutions were introduced into the half-cells 
via the entry ports. 2m1 volumes of a 5 x 10-6M solution of HSA were 
dispensed in to one set of half-cells follo~ed by very small amounts of a 
concentrated v/arfarin solution. The diluent buffer used for both drug and 
protein was O.lM Tris/Hel pH 7.4. Across the membranes from the spiked 
protein samples, the matching half-cells contained 2ml of the diluent buffer. 
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Once loaded, the dialysis cells were placed on the rotation assembly 
and installed in a thermostated cage set at 230C. The samples were 
rotated for 18 hours at a constant rate of 17 revolutions per minute. During 
the dialysis runs, a maximum-minimum thermometer showed that the temperature 
variation about the mean was + O.20C. 
After dialysis, the concentration of free drug was determined from 
measurements of the warfarin fluorescence in the buffer compartment of each 
cell. As explained previously, this may be accomplished with the aid of a 
suitable calibration curve (see Figure 5.3). To perform the analysis 
automatically, a computer program called DIALB was devised. 
Simple experiments were carried out to test for possible background 
signals arising in the dialysis cells. It is conceivable that fluorescent 
species weakly bound to albumin can dissociate during dialysis and these could 
traverse the membrane to interfere with the assay of unbound ligand in the 
buffer compartment. However, no spurious signals could be detected in buffer 
samples dialysed against HSA for 18 hours. 
As fluid shifts had been shown to be negligible during the course of 
dialysis, the DIALB program assumed that initial discrepancies between the 
volumes of solution in each half-cell were maintained. This meant that any 
differences in the volumes of solution on either side of the membrane could be 
taken into account when the program went on to calculate the concentrations of 
total, free and bound ligand in the protein compartment. 
Now the bound ligand fraction being confined to the protein 
compartment was found by recalling the total quantity of ligand dispensed into 
the cell and subtracting the amounts of free ligand distributed between both 
the protein and the buffer compartments. At equilibrium, the concentrations 
of unbound ligand are the same on either side of the dialysis membrane and so 
the situation is described by 
CB Vp = TL - Cu VB - Cu Vp 
where CB and Cu are the equilibrium concentrations of bound and 
unbound ligand respectively, Vp and VB are the volumes of solution 
in the protein and buffer compartments rspectively, and TL is the total 
amount of ligand added to the system. Thus having determined CU, an 
equation of the form 
1 
CB = V; (TL - Cu (VB + Vp) 
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allowprl thp romputer program to establish the concentration of bound ligand 
in the protein compartment under the conditions specified by Vp, VB and 
TL' The routine finally presented the data in terms of the parameters 
of some commonly used binding Curves including the Scatchard representation 
(Scatchard, 1949). 
Equilibrium dialysis was used to study competition between ligands 
for specific binding sites on HSA. As usual warfarin and HSA were added to 
one compartment of the dialysis cell and diluent buffer to the other. After 
equilibrium had been reached across the membrane, the unbound fraction of the 
fluorescent probe was measured in the buffer compartment. DUring competitive 
binding studies, however, small quantities of other ligands were dispensed 
into the protein compartments of some of the dialysis cells already 
conta~n~ng warfarin and HSA. Following dialysis, increased levels of 
fluorescent probe in the buffer compartments were taken as evidence for 
competitive displacement from albumin binding sites. Because a fluorimetric 
assay was employed, it was sometimes necessary to take account of 
inner-filter effects arising from the presence of competitor in the buffer 
compartment. 
When equilibrium dialysis was used to examine the binding of 
sulphonamide drugs to HSA, the ligand concentrations on both sides of the 
membrane were determined spectrophotometrically. In these studies, drug and 
albumin were added to one half-cell and diluent buffer to the other. After 
equilibrium had been established acroSS the membrane, samples were extracted 
from each half-cell and the sulphonamide concentrations estimated by the 
method of Bratton and Marshall (1939). This procedure is based upon a 
coupling reaction which is carried out under acid conditions to produce a 
diazonium salt. The concentrations of the coloured product may be determined 
by measuring the sample absorbance at 545 nm. 
Experiments on spiked samples showed that the colourimetric assay 
was not restricted to buffer samples but could be used to determine the 
concentration of sulphonamide in a solution of HSA; the only complication was 
the subtraction of a small protein blank. It appeared that the acidic 
conditions used in the Bratton and Marshall coupling reaction were 
sufficiently extreme to denatUre the protein and to render any bound ligand 
available for diazotization. Thus two pieces of information were obtained 
from each dialysis cell; the concentration of unbound sulphonamide in the 
buffer compartment, and the total concentration of sulphonamide in the 
protein compartment. From the data it was a simple matter to calculate the 
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concentration of bound ligand in each cell and to analyse the results in 
terms of Scatchard plots. There was no need to recall the quantities of 
sulphonamide originally added to each cell - except. perhaps. to check the 
total amount of drug recovered after dialysis. 
5.4 Equilibrium Dialysis Results 
The smallest quantity of warfarin which could be measured in the 
buffer compartment was dependent upon the detection system and the 
experimental design. An approximate value for this quantity was found by 
inspection of the data used to construct the calibration plot shown in Figure 
5.3. Using standard methods of data processing. the limit.of detection 
turned out to be about 4 x 10-8 mol 1-1 warfarin. This figure was useful 
when checking the validity of points in the high-affinity region of the 
binding curve. For example. the lowest value of unbound warfarin in the 
curve of Figure 5.6 is S1 times that of the limit of detection and clearly 
falls well within the domain of the calibration curve. 
At the other end of the curve the bound ligand fraction should not 
be too low. This is so because the bound ligand is calculated as the 
difference between the total ligand and the free ligand. If this 
difference is small. the bound fraction can not be determined accurately. 
The smallest bound fraction included in the Scatchard plot was therefore 
restricted to about one quarter of the total ligand in the protein 
compartment. 
As explained in Section 5.3.1. it is desirable to estimate the time 
to equilibrium for the sample containing smallest unbound fraction a. This 
is the sample for which the approach to equilibrium is slowest. For the data 
presented in Figure 5.6. the lowest value of a is about 0.3. With the rate 
constant determined for warfarin. Equation (5.6) shows that in this case 97t 
of the free ligand has equilibrated after 18 hours. With the highest value 
of a included in Figure 5.6. it can be demonstrated that 99t of the unbound 
fraction will have reached equilibrium during the same period. Under the 
specified conditions. and over the range of values covered by the binding 
curve. the effect of a on the deviation from true equilibrium was therefore 
extremely small. No corrections were made to the binding curve. 
The Scatchard plots describing the binding of warfarin to HSA as 
measured by equilibrium and fluorescence enhancement are shown in Figure 5.6 
and appear to be in reasonable agreement. While the curves themselves are 
very similar. particularly at high values of r. discrepancies between the 
0.4 
0.2 
o 
FIGIJRE 5.6 
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• 
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1.0 
R 
Scatchard ~lots Describing the Binding of Warfarin to Human 
Serum Albumin • 
• Equilibrium Dialysis • 
• Fluorimetric Titration. 
2. 
Binding constants derived from data with the aid of the 
NKFIT program: 
Equilibrium gi!jysis n,= 0.61,'k,= 0.9lx106rf1, n,= 1.29, 
k.= 0.041x10 M • 
F1uorimetric6t!tration n,= 0.84, k,= 0.53x106rf1, n,= 1.05, 
k,= 0.026x10 M • 
The solid lines drawn in the figure were constructed using 
the above binding constants. 
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bin!l;;'0 .-;.;;;~.~;;ts are more apparent. It may be that too few data points were 
obtained in the equilibrium dialysis experiment to derive meaningful binding 
constants. 
Even over the proper working range of the assay, the results yielded 
by the equilibrium dialysis technique were of somewhat poorer precision than 
those obtained fn the corresponding fluorfmetric tftratfons. An attempt was 
made to fdentffy the major sources of fmprecfsfon fn the equflibrfum dialysis 
procedure. 
Whenever warfarfn was assayed in buffer versus buffer systems the 
results tended to exhibit very low coefffcients of variation. For example, 
when 2.5 x 10-8 moles of warfarfn were equilibrated across the dialysis 
membrane, the coefficient of variatfon was about 0.6%. Indeed, for a given 
conce~:t~::t:~n, the sample-to-sample variatfon was no greater than the 
variation between repeated measurements on fndivfdual samples. This 
suggested that the limitfng error in buffer versus buffer dialysis systems 
was associated with the recording of fluorescence intensities rather than 
with the loading and operatfon of the cells. 
As noted earlier, there was no adsorption of the drug to the 
dialysis membrane and cell surfaces. Simflarly, it has alreadY been 
demonstrated how the addition of protein to one half-cell resulted in a 
negligible fluid shift across the membrane. Only very rarely did membranes 
contain imperfections or split to give erroneous results. Furthermore, ff 
dfalysable compounds dissociated from albumin, they were non-fluorescent and 
did not fnterfere with the measurement of unbound ligand. The pH and buffer 
ionic strength should have been sufficient to elfminate the need for Donnan 
corrections (Garn and Kimbel, 1961; Edsall and Wyman, 1958). 
It fs possible that a partfal denaturation of the albumin occured 
durfng the perfod of dfalysis. Although not demonstrated experimentally, 
this would appear to be a potential source of error in the binding assay. 
Results obtained using the equflibrium dialysfs technique and 
demonstrating the displacement of warfarin from its albumfn binding sites are 
gfven fn Table 5.4. They show quite clearly that the ability to displace the 
fluorescent probe increases from sulphisomfdine to sulphfsoxazole to 
phenylbutazone. This observation agrees wfth the findings of the 
fluorescence enhancement work. 
When equilibruim dfalysis was used to study the displacement of ANS 
from HSA, no increase in the unbound fractfon was produced by addition of 
warfarin to the protein compartment. Again this result may have been 
predicted from previous fluorescence enhancement work. 
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Competitor Total Warfarin 
Competitor Concn (xl0·6 M) Concn. in Protein Compartment (xlO-'M) 2; Displacement 
Phenylbutazone 24.8 5.41 65.0 
Sulphisoxazole 25.0 6.26 13.7 
Sulphisomidine 24.8 6.54 2.5 
Sulphisoxazole 25.1 1.59 24.5 
Sulphisomidine 24.9 1.71 4.0 
Table 5.4 The displacement of warfarin from HSA as determined by 
equilibrium dialysis. 
However, while the fluorimetric procedure allowed the total 
protein, probe and competitor concentrations to be selected at will, the 
equilibrium dialysis studies of competitive binding were harder to control. 
Although any initial concentrations of albumin, probe and competitor could 
be placed in the protein compartment of the dialysis unit, the equilibrium 
concentration of both ligand were dependent upon their distribution across 
the membrane and hence on their protein-binding characteristics. This made 
it very difficult to achieve the same conditions in equilibrium dialysis and 
in fluorescence enhancement experiments. Results from the two techniques 
may be compared qualitatively but the figures relating to the percentage of 
probe displaced by a particular competitor are valid only under the 
specified conditions. 
A number of samples containing known quantities of sulphonamide 
drug were determined using the Bratton and Marshall procedure. A standard 
curve for sulphisomidine is plotted in Figure 5.7 and is linear over a wide 
concentration range. The log-log representation is simply for convenience. 
Although the extinction coefficient of the coloured product varies 
from drug to drug, linear standard curves were also obtained for 
sulphisoxazole and sulphadiazine. 
The standard curves were used to estimate sulphonamide 
concentrations in both buffer and protein compartments after dialysing 
spiked solutions of HSA against diluent buffer. To ensure that absorbance 
readings were high enough to fall within the working range of the standard 
curve yet still allow frea drug to be determined at low sulphonamide:albumin 
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ABSORBANCE (545nm) 
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CONCENTRATION (x10-5M) 
FIGURE 5.7 Calibration Plot for Su1phisomidine. 
Coefficient of linear regression for fitted line, r = 0.99995. 
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ratios, the concentration of HSA in the protein compartment was raised to 
10-4M. This concentration of albumin was still too low to produce a 
detectable fluid shift across the membrane. (Theoretical fluid shift~ 
0.02S). Furthermore, the absorbance of HSA at 545 nm remained far too small 
to interfere with measurements of the total sulphonamide in the protein 
compartment. 
As shown in Figure 5.8, linear Scatchard plots were obtained for 
sulphisoxazole and sulphisomidine. This suggests that these drugs bind to a 
single class of sites on albumin. The binding of sulphadiazine was so low 
that a categorical statement of curve shape is impossible. However, it seems 
most reasonable to assume that this Scatchard plot is also linear. 
Values for the binding constants were derived from the slopes and 
intercepts of the graphs in Figure 5.8. Sulphisoxazole clearly has the 
highest affinity for albumin binding sites. Thus a rank order correlation 
has been demonstrated between the binding affinities of the three 
sulphonamides and their capacities to displace warfarin from HSA (see 
Figures 4.5 and 4.7 and Table 5.4). 
It is worth recalling that an approximate value for the association 
constant of sulphisoxazole was obtained by measuring its ability to displace 
warfarin in a fluorimetric titration. The conclusion that k was roughly 
104 M-1 agrees with the findings of the corresponding equilibrium 
dialysis experiment. 
5.5 Co~arison of the Fluorimetric and Equilibrium Dialysis Methods for 
stu ying Drug-ProteIn BIndIng . 
Equilibrium dialysis provided a theoretically'sound and unambiguous 
experimental method for stu~ing the binding of drugs to HSA. However, the 
principle application of this conventional technique was to test the 
validity of results obtained using the homogeneous fluorimetric procedure. 
The significance of the apparent agreement between the two 
techniques is best appreciated by a comparative evaluation of the 
methodologies. The most important features are summarized in Table 5.5. 
In the context of this stu~, certain aspects of the procedures are 
worthy of elaboration. For instance, consider the uncertainties inherent in 
estimates of the unbound ligand. After equilibrium has been reached across 
the dialysis membrane the concentration of free ligand is measured directly 
in the buffer compartment. As long as an assay 'of sufficient sensitivity is 
available, small quantities of unbound ligand can be determined with 
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FIGURE 5.8 The Binding of Three Sulphonamide Drugs to HSA as 
Determined by Equilibrium Dialysis. 
• Sulphisoxazole; from Scatchard plot n=2.2, k=2.4xl04M- l • 
• Sulphisomidine ; from Scatchard plot n~2.l, k=1.3xl04M- l • 
.. 1 
• Sulphadiazine ; from Scatchard plot n=2.1, k=1.7xl03M- • 
Equilibrium dialysis 
Advantages: 
Disadvantages: 
Fluorescent probes 
Advantages: 
Disadvantages: 
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Table 5.5 
1. Direct measurement of unbound fraction. 
2. Easy interpretation of data. 
3. Flexible - there are a large number of 
techniques available for measuring unbound 
ligand. 
1. Tedious and time-consuming. 
2. May be complicated by fluid shifts. Donnan 
effects. instability of reagents. and by 
non-specific binding of solutes to membranes 
and cell surfaces. 
3. High consumption of reagents. 
4. Ligands must be small enough to diffuse 
readily through membrane. 
5. Time to equilibrium dependent on unbound 
fraction. 
6. Limited use in deriving structural information 
regarding nature of binding sites. 
1. Rapid titrations possible. 
2. Low consumption of reagents. 
3. Ligands need not be dialysable. 
4. May be used over wide concentration range. 
1. Indirect method for determing free fraction. 
2. Attenuation of signal by inner-filter 
effects. scattered light and background 
fluorescence. 
3. Interpretation of data is complicated. 
4. Limited number of suitable fluorescent probes. 
precision. The homogeneous fluorimetric procedure on the other hand relies 
on an indirect measurement of the free fluorescent probe: the bound probe is 
determined first and the free fraction calculated as the difference between 
this value and the total probe added. When most of the ligand is bound. the 
free fraction is perceived as a small difference between two relatively 
large numbers. Considerable uncertainties may therefore arise in the 
indirect estimation of small concentrations of free fluorescent probe. 
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Tf ~~llilibrium dialysis is more sufted to the measurement of small 
quantftfes of free ligand, the fluorfmetrfc procedure fs better adapted to 
an estimatfon of small quantftfes of bound lfgand. Wfth equilfbrfum 
dfalysfs the bound lfgand fs calculated as the difference between total and 
free lfgand. The fractional error in the measurement of these quantities 
wfll be amplified fn the bound lfgand ff the latter fs relatfvely small. So 
as the bound fractfon decreases, results obtafned with equflfbrfum dialysis 
will become progressively less relfable. Wfth the fluorfmetric procedure, 
the bound probe fs higly fluorescent and small quantitfes can normally be 
measured with precision. 
It fs fmperative that bfndfng curves obtafned using equflibrium 
dialysis and fluorfmetric methods are compared only over the appropriate 
ran~~= c~ ~ree and bound lfgand, and that the precisfon of the results fn 
different regfons of the curves fs properly apprecfated. Any signfficant 
disagreements between the two sets of data can then be properly assessed. 
The choice of a suitable technfque for measuring the unbound ligand 
in a dialysis cell clearly depends upon the system under studY and the 
quantities of reagents employed. 
Although the colourimetrfc assay of Bratton and Marshall (1939) is 
of limited sensitfvity, ft proved adequate for a studY of weakly bound and 
moderately bound sulphonamfde drugs. To examfne strongly bound 
sulphonamides, or to permit the use of lower albumin concentratfons, ft 
would probably be necessary to produce fluorescent rather than coloured 
sulphonamide derivatives (Sturgeon and Schulman, 1975). 
If equilfbrium dialysfs is used to studY systems fn which ligand is 
very extensively bound - for example, when hfgh affinfty antfbodfes are 
present - ft is necessary to use a very sensitfve assay, perhaps fnvolving 
radioactively labelled ligands of high specific actfvfty. Although this is 
undoubtedly a very powerful technfque and one that has been applfed to 
drug-protein binding studies, there are a number of problems associated with 
the use of radio-labelled lfgands (see Chapter 1). 
As far as equflfbrfum dfalysfs studfes are concerned, ft fs most 
convenfent ff the unbound lfgand has some intrfnsfc property whfch can be 
measured dfrectly. For fnstance, ff the free lfgand fs moderately 
fluorescent fn aqueous buffer ft can be determfned accurately and Simply. 
This is the case with warfarin. In comparison, ANS fs a more 'fdeal I 
fluorescent probe: ft is highly fluorescent when bound to proteins but only 
weakly fluorescent fn aqueous solution •. Consequently, a strafghtforward 
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f1un"<~"'-': determination of free ANS is not particularly sensitive. 
Nonetheless, if it is important to measure very small quantities of this 
ligand resort can be made to a more sensitive assay which involves 
extracting the ANS into a non-polar solvent and measuring the enhanced 
f1 uorescence. 
The equilibrium dialysis technique is obviously very flexible. As 
long as there is some way of measuring the free ligand, it can be applied to 
virtually any binding stu~. There are only comparatively few suitable 
fluorescent probes with which to characterize protein binding sites. 
Apart from its general applicability, the widespread use of 
equilibrium dialysis in drug-protein binding studies and in therapeutic drug 
monitoring owes much to the clinical significance of the linbound fraction. 
While other techniques can measure free drug levels, equilibrium dialysis 
provides the most reliable and often the most sensitive method for 
determining this important parameter. 
In general, the information supplied by equilibrium dialysis 
experiments is very simple to interpret. This means it is easy to apply the 
procedure to a quantitative stu~ of drug-protein binding. Nevertheless, 
its use in the derivation of structural information regarding the nature of 
the binding sites is very limited. The reverse is often true with 
fluorescent probes: data interpretation can be quite complicated but 
valuable information can be obtained about the binding sites themselves. 
For example, the polarity of the amino acids in the vicinity of the binding 
site, or the proximity of fluorescent residues such as tryptophan may be 
revealed. 
Equilibrium dialysis is a somewhat tedious and time-consuming 
technique. Unlike the method of fluorescence enhancement, equilibrium 
dialysis is unable to exploit the extreme rapidity with which drugs and 
proteins interact. Equilibrium times of the order of hours are required in 
spite of the fact that the binding interaction is practically instantaneous. 
Furthermore, because it is essentially a single-point method, equilibrium 
dialysis needs numerous separate experiments to complete a binding curve. 
In comparision, fluorimetric titrations are more rapid to execute and tend 
to demand less reagent. 
Micro-cells have been developed for equilibrium dialysis (Eisen, 
1971) and these allow small quantities of material to be tested. They also 
offer the advantage of shorter equilibration times than those encountered 
with standard equipment because of the thinner liquid layers. However, 
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extremely sensitive detection systems are necessary because of the small 
sample volumes. 
As well as being inconvenient, long time courses can pose severe 
practical difficulties in equilibrium dialysis work. Denaturation of the 
protein is often the most serious problem, but degredation of unstable 
ligands may also occur. Microbiological growth can interfere with the 
measurement of free ligand. Fortunately, the drugs and fluorescent probes 
used in this stuqy appeared to be reasonably stable over long periods. The 
linear escape curve for warfarin (Figure 5.5) confirmed there was no 
degredation during the course of dialysis. All the same, it is conceivable 
that HSA is not entirely stable when rotated for long periods in the 
dialysis cells. 
Other complicating factors associated with equilibrium dialysis are 
listed in Table 5.5. With the specially designed cells, fluid shifts were 
shown to be negligible over a wide range of protein concentrations. 
Non-specific binding of reactants to the dialysis membrane and the cell 
walls was not encountered, and precautions were taken to minimize Donnan 
effects. While much elementary considerations are frequently neglected in 
equilibrium dialysis work (Bridges and Wilson, 1976), the effect of a on the 
time to equilibrium is rarely mentioned at all in binding studies. If 
results are to be trusted, it is important to check that equilibrium 
conditions hold for all values of the unbound fraction. 
The dissociation of weakly 'bound species from albumin during 
dialysis may be a potential problem. If these are dialysable components 
they may influence the analytical data. Should fatty acids or other 
endogenous 1igands be removed, this could affect the availability of drug 
binding sites. Such phenomena may occasionally account for differences 
between the equilibrium dialysis and spectroscopic assessments of 
drug-protein binding. 
Practical difficulties associated with the fluorimetric titrations 
have bee!). discussed at length in previous chapters~ They include the 
sensitivity of the bound probe fluorescence to inner-filter effects, and the 
contributions of unbound probe and total protein to the recorded signal. 
The relative importance of the interfering factors depends on the choice of 
fluorescent probe. 
The major problem encountered with the f1uorimetric assay is in 
assessing the physical significance of the results. For instance, when a 
drug binds to albumin it may induce a conformational change in the protein. 
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Should this structural modification be sufficient to change the 
spectroscopic properties of a fluorescent probe alreaqy bound to albumin, it 
would be wrong to conclude that there had been a direct displacement 
interaction involving a specific binding site. However, the good agreement 
between the results of the equilibrium dialysis and the spectroscopic 
methods, suggests that the latter provides a valid technique for measuring 
drug-protein binding. 
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CHAPTER 6 
The Automation of Binding Studies Based on the Principle of Flow Injection 
Analysis 
6.1 Theoretical and Practical Aspects of Continuous Flow Analysis 
Over the last 20 years. there has been an increasing demand to use 
automated methods in chemical analysis.· In 1957 Skeggs introduced the idea 
of air-segmented continuous flow systems to medical laboratory analysis. and 
equipment based on this principle is now available in most clinical chemistry 
laboratories. A recent estimate suggests that more than 50.000 continuous 
flow units are currently in use (Holy. 1982). 
For many years following the work of Skeggs (1957). it was assumed 
that air segmentation of the flowing streams and attainment of a steady-
state signal were essential for continuous flow analysis. Lately much 
interest has focused on a more radical approach which dispenses with the 
need to mix the sample and reagent intimately and bases analysis on the 
dispersion patterns produced under laminar flow conditions. The feasibility 
of this technique was demonstrated independently by RUZiC'ka and Hansen (1975). 
and Stewart et al (1974). They performed similar experiments by injecting 
samples directly into the carrier stream and have proved that analysiS 
without air segmentation is not only possible but also advantageous. R3zicka 
and Hansen have called the technique flow injection analysis (FIA). 
The renewed interest in flow-stream systems using non-segmented 
analysis is reflected in the expanding literature on FIA. There are a 
DV v 
number of excellent reviews of the technique by Ruzicka and Hansen (1978). 
Betteridge (1978). R~~icka and Hansen (1979b). R~zicka and Hansen (1980). 
Ranger (1981) and Rocks and Riley (1982). A textbook on the subject has 
also been published (RU~itka and Hansen. 1981). Only the essential features 
of FIA will be covered in this section; more comprehensive treatise are 
available in the literature. 
In FIA a small precise volume of sample is injected into a non-
segmented carrier stream of a reagent which moves in a laminar flow towards 
and through a suitable detector. The simplest flow injection system 
(Figure 6.1(a)) consists of a pump P which is used to propel a carrier 
stream of reagent R through a thin tube; an injection port. by means of 
which a well-defined volume of a sample solution S is injected into the 
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(a) Simple FIA System. 
S 
C [d {)>--,V'v-----iDI--------.· W 
RC D 
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(b) Synchronous Merging Zone FIA System. 
Air I R "\. W 
S / 
W RC D 
P 
(c) Simple Gas Segmented System 
FIGURE 6.1 Configurations of Different Continuous Flow Systems 
S - sample, R ~ reagent, P - pump, RC - reaction coil, 
D - detector, W - waste, C - inert carrier. 
- 275 -
carrier; a reaction coil RC in which the sample zone disperses and reacts 
wi .. ,' "'"' I.UlIll"UIICIILs of the carrier stream; and a flow-through detector from 
which the measured stream passes to waste W. 
In practice the technique is founded on a combination of three 
principles: precise sample injection. controllable sample dispersion and 
reproducible timing. However. the most important feature of FIA, and the 
one which distinguishes it from other forms of continuous flow analysis, is 
the presence of a sample-carrier interface over which concentration gradients 
develop during the course of analysis. The conditions governing the 
dispersion of the sample zone in the flowing carrier stream are considered 
below: manipulation of the dispersion allows particular analytical 
reqUirements to be satisfied. 
When water flows slowly and steadily through a pipe the frictional 
forces oetween the layers of moving liquid establish a longitudinal velocity 
profile. Under such conditions of 1aminar flow the velocity at the walls 
is zero. and that at the centre is twice the mean (Taylor, 1953). This 
gives rise to a parabolic velocity profile (Figure 6.2(a». In the absence 
of molecular diffusion. a sample placed into a moving stream would take up 
the shape shown in Figure 6.2(b). Under these theoretical conditions, the 
sample would have an inf'inite1y long tail by the time it reached the detector 
and there would be an unacceptable carry over between samples. Fortunately. 
because of molecular diffusion, this case does not arise. Diffusion of 
molecules between the carrier and sample plug serves to limit the convective 
dispersion and effectively mixes sample and reagent. This process is 
illustrated in Figure 6.2(b). A molecule (A) placed centrally in the plug 
will tend to diffuse into a region of lower concentration; by so doing 
there is a high probability that it will move into a layer of liquid moving 
at a slower longitudinal velocity. Thus radial diffusion (diffusion 
perpendicular to the direction of flow) modifies the shape of the leading 
edge of the sample plug. A molecule originally in position B likewise 
diffuses into the carrier solution; in this case it encounters a layer of 
faster moving liquid which carries it towards the centre of the sample zone. 
So sample and carrier molecules. the latter including reagent. are mixed. 
Of course longitudinal diffusion of the sample molecules also occurs. 
However. Tay10r (1953) showed that dispersion by longitudinal diffusion can 
be ignored relative to that caused by the main flow pattern. whereas radial 
diffusion is always important in narrow tubes and at low flow rates it may 
even be the major mechanism for sample dispersion. The moderating effect 
of diffusion-induced dispersion on the longitudinal dispersion caused by 
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FIGURE 6.2 Velocity Profiles and Shapes of Injected Sample Zones. 
(ab) Laminar flow, parabolic velocity profile. ( ) Sample dispersion caused by laminar flow without diffusion, 
(c) Sample shape resulting from laminar flow with molecular 
1\ 
(a) 
diffusion. 
(d) Secondary flo~1 pattern in cross-section of tightly 
coiled tube at high velocity. 
(e) Velocity profile in coiled tubes at high flow velocity. 
A 
(b) (c) (d) 
FIGURE 6.3 Diagrammatic Representation of Effects of Convection and 
Radial Diffusion on Concentration Profiles of Samples 
Honi tored at a Suitable Di stance Downstream from Injection. 
(a) No dispersion. 
(b) Dispersion predominantly by convection. 
(c) Dispersion by convection and diffusion. (d) Dispersion predominantly by diffusion. 
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the carrier flow is shown in Figure 6.2(c) and explains the low carryover 
and high sample throughput possible with FIA. 
Originally the low carryover of FIA was attributed to turbulent 
0" " flow (Ruzicka and Hansen, 1975). A set of key experiments by Betteridge 
and Rozicka (1976) suggested that the mixing process was diffusion 
controlled and this was strengthened by the discovery of Taylor's paper. 
It is now recognized that FIA operates effectively only under conditions of 
laminar flow (Betteridge, 1978) and the misconception that turbulent flow 
is essential has been dispelled. 
While Taylor (1953) derived a mathematical descriotion of dispersion 
related to convective flow and molecular diffusion, R~~i~ka and Hansen (1978) 
borrowed the chemical engineering model of 'tanks-in-seri.es' to explain 
dispersion and concentration profiles in FIA systems and to identify the 
main variables that can be manipulated to achieve the desired degree of 
mixing. Reijn et al (1980) have also presented some theoretical aspects of 
FIA. Only the practical implications of these studies will be considered 
here. 
The physical dispersion of the sample cone between the points of 
injection and detection is reflected in the peaks recorded by the flow-
through detector (Figure 6.3). The relative importance of the dispersive 
processes depends upon the choice of experimental parameters. Changes in 
the flow rate, tube diameter, injected volume, line length, diffusion 
coefficient of the analyte, or any combination of these factors can alter 
the dispersion of the sample in the carrier stream as seen by the detector. 
Sample size is a very important analytical parameter and has a 
av v . 
marked effect on peak shape. RuzicKa and Hansen (1981) have consldered 
the effect of sample size on dispersion separately from that due to the 
flow. They showed that if increasing volumes of dyed solution are injected 
into a flow stream, the height of individual peaks will increase until an 
upper limit or steady state has been reached. At this stage the recorded 
signal will correspond very closely to the concentration of undiluted qye 
~ 
and the dispersion 0 will be virtually unity. If Si is the volume of 
sample required to reach 50% of the steady state signal, injecting two Si 
volumes gives 75% of the maximum signal corresponding to 0=1.33, and so on. 
So 0=1 can never truly be reached in FIA. For a limited dispersion of the 
sample zone, approximately two Si volumes are required; in other applications 
less than one Si will suffice. The effects of sample size are considered in 
Section 6.2. 
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It is clear that the peak shape will also be influenced by the 
sample and carrier matrices because the whole of the plug, matrix and sample 
is diffusing into the carrier. The higher the viscosity of a particular 
sample, the lower its dispersion (Betteridge and R~zicka, 1976); therefore 
a more viscous sample zone will be less effectively mixed with the carrier 
stream. This may be an important consideration when dealing with serum samples. 
To give large signals and a high throughput with minimum carryover, 
longitudinal dispersion of the sample zone should be kept as small as 
possible. Coiled tubes are useful in this context because they are better 
than straight tubes at limiting this type of dispersion. At high flow 
velocities in tightly coiled narrow-bore tubes, centrifugal forces generate 
a secondary flow perpendicular to the main axial flow (Figure 6.2(d)). 
Axial flow velocity being greatest near the centre of the tube, centrifugal 
forces will cause fluid near the centre to be forced towards the outer wall. 
This modifies the parabolic velocity profile and produces an approximately 
linear profile (Figure 6.2(e}) which limits sample dispersion and permits a 
very high sample throughput. 
There are other factors to control when maximizing throughput. The 
smallest sample size consistent with adequate sensitivity should be selected, 
and both the line length (distance between the points of sample injection 
and detection) and the tube diameter should be small. The line length is 
an important variable in controlling throughput because the sample dispersion 
increases as the square root of the distance travelled. In theory, it is 
even more appropriate to limit dispersion by reducing the bore of the tubing. 
Tubes with internal diameters of more than about 1.Omm are unsuitable 
because of excessive carryover. On the other hand, practical considerations 
exclude the use of very narrow tubes. For instance, reaction tubes of less 
than 0.3mm internal diameter are easily blocked and at lengths greater than 
1 or 2m they may cause sufficient back pressure to prevent the maintenance 
of a reasonable flow rate. Furthermore, as the most commonly used detector -
the spectrophotometer - requires an optical path length of at least O.Smm, 
narrower manifold tubing can cause non-uniformity of flow just in the region 
where the sample is measured. The choice of tube diameters is therefore 
rather restricted in FlA; 0.3mm to O.Bmm covers the range of acceptable 
internal diameters. 
Between the points of injection and detection the sample plug will 
have been physically dispersed to a degree which is governed by the flow 
conditions. In addition, some chemical reactions may have taken place at 
the sample-carrier interface. The recorded signal will reflect both processes. 
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The analytical readout in FIA is usually obtained from the peak 
height, which in turn is related to sample concentration. RBzicka and 
Hansen (1978) define dispersion 0 as the ratio of the concentration of the 
sample solution before and after the dispersive process has taken place. This 
provides a simple practical method of measuring dispersion and allows one 
set of flow conditions to be compared with another. Dispersion can be 
classified as limited (0=1-3), medium (0=3-15) and large (0)15). The 
different degrees of dispersion can be employed in the following ways. 
If the original composition of the sample solution is to be measured, 
dispersion in the flow stream should be limited so that the.readout obtained 
at the centre of the sample zone is not affected by any mixing with the 
carrier molecules. Hence, with limited dispersion the sample integrity is 
maintained to a high degree. This is ideal when little or no dilution of 
the sample is required and the flow injection system is simply serving as a 
delivery system for the introduction of samples into measuring devices. 
As the samples undergo little dispersion, very high throughputs are possible. 
Medium dispersion is of prime importance in this study. It 
encompasses numerous analytical applications in which the sample zone is 
mixed with the carrier stream, or perhaps with several reagents in sequence. 
to produce a reaction product that can be measured by a flow-through detector. 
Th.e centre of the sample zone must be mixed effectively with the reagent 
molecules and so for many systems· the extent and rate of chemical interactions 
have to be taken into account when designing suitable flow conditions. Not 
only must sufficient mixing take place between the sample zone and reagent. 
but the residence time must be long enough to allow adequate formation of the 
products before the detector is reached. In this work a suitable compromise 
is sought between the requirements of mixing and reaction time on the one 
hand and maximum acceptable broadening of the sample zone on the other 
because an increase in zone width lowers the sampling frequency. For slow 
reactions, then, the residence time should be extended by decreasing the 
velocity of the carrier stream, not by increasing the line length. The 
latter would tend to increase dispersion and produce band broadening. To 
cater for slow chemical reactions it is often best to select flow conditions 
where the reaction is incomplete but reproducible. This is possible with 
FIA since the high reproducibility of mixing and timing in the non-segmented 
stream produces a valid analytical result without the need to reach 
equi 1i bri urn. 
Large dispersion may be exploited to obtain a suitable sample 
dilution or to produce a concentration gradient which is stretched over a 
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longer period of time. A sample which is too concentrated for assay can be 
injected into a manifold designed to give a high dispersion and so be 
effectively diluted. Ver,y highly dispersed patterns, best produced by 
including a mixing chamber between the injection port and the detector, have 
been used to perform flow injection titrations. 
As mentioned previously, reproducible timing is an important feature 
of FIA. Clearly, the time which elapses between the introduction of the 
sample into the carrier stream and its arrival at the detector depends upon 
the flow rate. Since there are no compressible gas bubbles in flow-injection 
manifolds, even extremely short residence times can be maintained 
reproducibily. Nonetheless, if the signal is to be read on the rapidly 
ascending part of the response curve. it is essential to .check that the 
timing is well-controlled; any fluctuations in flow rate that affect the 
residence time of the sample in the system will result in imprecise peak 
heights. There are several ways of achieving the constant steady flow of 
fluids necessary for quantitative FIA. 
Peristaltic pumps are commonly used to propel the carrier stream 
in flow injection systems. The main drawback of the peristaltic pump is 
that the stream is never completely pulse-free. Well-designed pumps with 
many closely spaced rollers are often acceptable because they tend to 
generate a pulsation of high frequency but low amplitude. Sometimes. 
however. damping devices are required with peristatic pumps in order to 
reduce pulsation of the carrier stream. Constant pressure-head devices, on 
the other hand, provide pulse-free flow patterns but they are not as 
versatile as peristaltic pumps. For simple flow-injection experiments. a 
pressurized gas will give a uniform flow. 
Once a steady flow has been established by the pumping system. it 
should not be disrupted by other units connected to the manifold. Avoiding 
perturbation of the carrier stream is of prime concern when designing the 
sample injection valve. Ideally the injection process should place a well-
defined sample zone of precise volume and short duration into the 
continuously moving carrier stream without disturbing the latter at all. 
The first of the inlet systems to gain widespread acceptance was 
the simple flap valve shown in Figure 6.4(a) and devised by R~zicka and 
Hansen (1975). Its main shortcoming is its reliance on the skill of the 
operator; the volume of the sample is controlled by the position of the 
plunger and the form of the injected plug depends on the speed with which 
the plunger is depressed. When disposable plastic syringes are used. the 
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minimum reproducible sample volume may be rather large for routine work. 
in comparison to flap valves, rotary injection valves offer a more 
practical way of introducing precise sample volumes into the carrier stream. 
With this system two independent flow systems are used. The rotary valve 
shown in Figure 6.4(bj consists of a moveable core furnished with a 
volumetric cavity for containing the sample, and a bypass which allows the 
carrier stream to flow uninterupted while the volumetric cavity is in the 
"fill" position. The filling may be done with a syringe or by aspiration 
with a pump. When the valve is turned into the inject position, the sample 
plug is swept directly into the carrier stream because the bypass is adjusted 
to have a higher hydrodynamic resistance than the volumetric cavity. After 
a specified time, the valve is returned to its initial position where it is 
washed and filled with another sample while the analysis proceeds. This 
injection system produces minimal disruption of the carrier stream and 
allows small volumes to be dispensed very preCisely. 
Turbulence in the flow stream can also be minimized by ensuring 
that connections between the various components of the manifi1d have a low 
dead volume. It;s particularly important to avoid turbulent flow in the 
detector. Coils and connecting lengths of tubing should be well attached on 
a s.olid support so that the flow path remains unchanged during each set of 
experiments. If loose pieces of tubing are moved and the radius of bent 
sections altered inadvertant1y, flow patterns. and .hence peak shapes may be 
affected. 
The technique described so far consists of a single flowing reagent 
carrier stream into which is injected a sample of precise volume. The 
resulting product is measured downstream (see Figure 6.1(a)). A number of 
refinements to this basic technique have extended the scope of the method. 
Since they proved useful in the present study, two important developments 
are discussed below. 
The stopped-flow technique allows reaction kinetics to be examined. 
By a carefully controlled intermittant pumping, the sample zone can be moved 
through the flow line until the reagent and sample have mixed to the 
required degree. Stopping the carrier stream so that the reaction proceeds 
in the flow cell permits rate measurements to be made. Of course, such a 
reaction rate measurement will only be successful if the movement of the 
carrier stream is brought to a complete standstill so that the same section 
of the sample zone is held within the flow cell during the course of the 
reaction. Indeed FIA theory shows that when the carrier stream is held 
stationary, dispersion of the sample zone will cease - except for a 
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negligible contribution from molecular diffusion - and remain constant 
irresp~Ctlve of the period of residence in the flow cell (R3zicka and 
Hansen, 1979a). 
Another reason for operating a flow-injection system in the stopped-
flow mode is to increase the sensitivity· of measurement. This is applicable 
if an extension of the residence time improves the yield of detectable 
product. Thus Lim et al (1980) increased the sensitivity of an automated 
immunoassay procedure by stopping the flow in a heated reaction coil and 
allowing sufficient reaction products to develop before pumping the sample 
zone through the detector. 
The second refinement to the conventional flow injection technique 
avoids the relatively high reagent consumption which is the main disadvantage 
of all continuous flow systems. This is the method of merging zones first 
described by Bergamin et a1 (1978) and illustrated diagramatically in 
Figure 6.1(b). Unlike the basic technique which consumes reagent continuously 
even when no sample is present in the apparatus, the principle of merging 
zones is based on the injection of sample and reagent plugs into separate 
inert carrier streams which are synchronized so that the sample and reagent 
met and mix in a reproducible manner. Distilled water or dilute buffer may 
be used as a carrier in both streams. Thus only very small quantities of 
reagent are required per test and no reagent is used during start-up or 
shut-down. 
A novel method of dealing with concentrated samples based on the 
merging zone principle was developed by Mindegaard (1979). Sample and 
reagent were injected slightly out of synchrony so that the reagent just 
overlapped the dilute tail of the sample zone. By this method, serum albumin 
was measured in undiluted samples. Braithwaite and Miller (1979) have also 
applied flow injection analysis to the determination of albumin in whole 
serum. 
Rather surprisingly, while FIA has proved useful in fields as diverse 
as water and environmental control, and agricultural and pharmaceutical 
analysis, relatively few clinical chemists have so far exploited this new 
concept (Rocks and Ri1ey, 1982). Nonetheless, FIA appeared to offer the 
best means for automation of the drug-protein binding studies described in 
earlier chapters and, as outlined below, the technique had a number of 
important advantages over gas-segmented flow analysis. 
Conventional continuous flow analysers are based on the use of 
air-segmented streams. The purpose of segmentation is to prevent sample 
carryover and to assist in mixing. In such analysers the samples are 
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successively aspirated from individual wells into a tube and forwarded through 
a pump where the flowing stream is regularly segmented by air bubbles 
delivered by another pump. Further downstream a reagent is added to all 
individual segments which then pass through a reaction coil. Before signals 
are recorded the air segmentation has to be removed in a debubbler. To allow 
for the introduction and removal of air from the liquid stream, gas-segmented 
flow analysers tend to be relatively complicated. As shown in Figure 6.l(c), 
even the simplest chemistry requires a four-channel pump; the corresponding 
flow injection system needs only one channel (Figure 6.l(a)). 
The compressibility of the bubbles in air segmented streams leads 
to a pulsating flow. The uneven flow, coupled with the fact that the sample 
has to travel through the pump, means that exact timing is not possible in 
segmented continuous flow analysers. To minimize the effects of irregularities 
in the sampling time, bubble-segmented systems are designed to attain at 
least 95% of the steady state Signal. Besides reducing the throughput, 
this requires larger sample volumes than are used in FIA. Since the 
movement of a segmented carrier stream can not be stopped and restarted 
nearly as exactly as a nonsegmented stream, continuous kinetic analysis is 
not possible in gas segmented flow systems. 
Both types of continuous flow analyser are known to give a similar 
reproducibility of measurement. However, while wash cycles are necessary 
in gas-segmented analysis to prevent sample carryover, they are not required 
in FIA. 
So there were clearly a number of technical reasons for favouring 
FlA over conventional continuous flow analysis: these included a higher 
sampling rate, a more rapid readout and a smaller sample volume. The flow 
injection system was also much cheaper and simpler to construct in the 
laboratory. Most importantly, though, dispersion of the sample zone could 
be controlled in FIA and this offered a more flexible approach to the 
automation of the drug-protein binding studies. 
Although there is an obvious need for automation in analytical and 
-clinical chemistry, there are no other reports in the literature concerning 
the application of FIA to the study of drug-protein interactions. 
6.2 The Application of· FIA to a Study of Drug-Protein Binding using 
Fluorimetric Detection 
The feasibility of applying single channel conventional FIA to a 
study of the binding of ligands to HSA was assessed in a series of 
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preliminary experiments. The marked increase in fluorescence exhibited by 
ANS on binding to albumin offered a simple means of monitoring the course 
of the interaction in the flow stream. The effects of line length, flow 
rate, sample volume and residence time were examined in an attempt to produce 
acceptable peak heights and sampling frequencies. 
A simple septum or flap injection valve, similar to the one depicted 
in Figure 6.4(a), was used in the initial studies. Tubing having an internal 
diameter of 0.76mm ran between the injection valve and a silica flow-cell 
positioned centrally in the sample compartment of the fluorimeter (Baird 
Atomic F1uoripoint Spectrof1uorimeter). The carrier stream was propelled 
by a peristaltic pump (Mini-S type, Ismatec, Zurichlor by a constant head 
device. The fewest possible connections were employed between the flow line 
and the other components of the manifold. In a further effort to preserve 
the 1aminar flow of the carrier, care was taken to avoid dead volumes at 
junction points. ANS was used as the carrier reagent and small volumes of 
a solution of HSA were injected manually through the flap valve. Peak 
profiles were recorded by measuring the fluorescence in the flow cell using 
wavelengths corresponding to the excitation and emission maxima of a1bumin-
bound ANS. 
Suitable flow rates were readily established with the peristaltic 
pump. Unfortunately, the peaks suffered considerable distortion due to 
pulsation of the carrier stream. Pulsing was reduced by including a coiled 
tube between the pump and the sample injection port. Nonetheless, even very 
long lengths of" tubing were incapable of totally suppressing pulsation of 
the carrier stream. A constant pressure head in the form of a Mariotte flask 
(Pharmacia Uppsa1a, Sweden) was used to propel the carrier stream. This 
simple method produced completely pulse-free flow patterns and was used 
routinely in the flow injection studies. 
The effect of various parameters on peak shape and height were 
investigated using a flow rate of 1.1 m1 min-1 and a line length of 60cm. 
The concentration of ANS in the carrier stream was 5 x 10-6M, and the 
injected sample comprised a 5 x 10-6M solution of HSA. The diluent for 
both carrier and reagent was O.lM Tris/HC1 pH 7.4. 
When 50111 sample volumes were used reproducible signals were obtained 
but these tended to be in the form of double peaks. Clearly, en route to 
the detector there had been insufficient dispersion to allow effective mixing 
and subsequent interaction between the centre of the sample zone and the 
carrier stream. While albumin at the leading and tailing edges of the sample 
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(a) Sample Flap Injection Valve 
(b) Rotary injection valve. 
FIGURE 6.4 Injection Valves. 
Cross-section of flap valve. Carrier 
flows through A. On depressicn of 
syringe. septum is forced down and 
sample occupies resulting depression. 
Septum regains original position and 
forces sample into carrier stream. 
Multi-injection valve consisting of 
a rotor(2) sandwiched between two 
stators (1 and 3). the whole being 
clamped together by a bolt. The 
rotor has three volumetric bores.of 
which one is sh(1.~n filled by sarr.p1e 
solution S. the excess of which is 
drained through the bottom stator 
at (a). In the rotor position 
shown. the carrier stream C bypasses 
the rotor via a shunt. entering the 
valve through the bottom stator 
at (b). After turning the rotor in 
the direction indicated tile sample 
zone is swept by the carrier stream 
into the system because the bypass 
conduit has a higher hydrodynamic 
f1o\~ resistance. 
- 286 -
plug had reacted with ANS to give measureable quantities of the highly 
fluorescent product, the central segment was largely devoid of the bound 
species and produced a trough in the output signal. 
Experiments using the stopped-flow technique showed that these 
double peaks could be transformed into single peaks of higher intensity. A 
delay of one minute was found to be sufficient to allow almost complete 
binding of sample and reagent under the specified conditions. 
As expected, an increased dispersion of the sample zone in the 
flowing reagent stream also resulted in single peaks. This was achieved by 
inserting a coil between the injection port and the detector. The increased 
dispersion produced broadening of the samples peaks and so reduced the 
maximum sampling rate. 
Without stopping the carrier stream or inserting a coiled tube in 
the flow line, the consequences of lowering the sample size were noted. 
Under these conditions of low total dispersion, decreasing the volume of 
HSA injected from 50 to 20~1 had no effect on peak height. For premixed 
samples this would correspond to a steady-state signal. However, with a 20~1 
sample volume, thorough mixing was achieved in the flow stream; single 
peaks were observed and the height of the response curves could not be 
increased by stopping the flow. Below 20~l, the peak heights decreased with 
sample volume and below about 10~1 the signal was proportional to the injected 
volume. So, in order to exhibit the necessary degree of dispersion, the flow 
system demanded a sample volume of 20~1 or less. 
Employing the simple single-channel arrangement, using a flow rate 
of l.lml min-l , a line length of 60cm and injecting 20\.11 sample volumes, 
preliminary observations were made on the displacement of ANS from HSA by 
flufenamic acid. While the displacement interaction was clearly demonstrated 
(see Figure 6.5), the equipment fell short of the requirements necessary for 
a routine quantitative study of drug-protein binding. The shortcomings of 
the flap injection valve were severe, particularly when such small sample 
volumes were required; peak heights were of poor reproducibility and depended 
to a large degree on the technique of the operator. A more sophisticated 
system was required to exploit the potential of the flow injection technique. 
A commercially available double-injection valve and modular FIA 
system (Bifok, Sollentuna, Sweden) offered a number of advantages over the 
conventional single channel arrangement. The Bifok rotary injection valve 
a 11 owed the sampling procedure to be partially automated. Thi s meant that 
small samples could be injected precisely without disrupting the carrier 
FL 1.ll'lpe<:;feNfr 
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FIGURE 6.5 The Displacement of AtlS from Human Serum Albumin by F1ufenamic 
Acid; Conventional FIA Technique. 
20~1 sample volumes were injected via the flap valve into a 
carrier stream containing 5 x 10-611 MS. In the first series 
of peaks the samples were a1iquots of a 5 x 10-GM HSA sglution 
in the second series, albumin samples contained 2 x 10- M 
f1ufenamic acid. 
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stream. The manifold components in the system could be arranged in any 
des~~:: ::~~:nce and were designed to fit together with the minimum dead 
volume. Standard HPLC connections between the manifold tubes also helped 
to suppress the creation of turbulent flow. The modular design of this 
system and the double-injection facility gave a far greater flexibility of 
operation than had been possible with the simple equipment. 
The double-injection valve was particularly suited to the technique 
of merging zones. This refinement allowed binding studies to be performed 
with even greater economy of reagents. Drug and protein solutions were made 
up in O.lM Tris/HCl pH 7.4 and the same buffer was used as the carrier stream. 
The sample (HSA) and reagent (ANS) solutions were injected into separate 
carrier streams (see Figure 6.1(b)). The inert buffer carrier streams were 
synchronized so that the reagent and sample zones merged and partially mixed. 
For further mixing the reagent/sample zone was passed through a short length 
of coiled tubing before it entered the flow cell in the fluorimeter. 
To check that the two zones arrived simultaneously at the confluence 
of the separate buffer streams, air bubbles were injected into both lines. 
Since the peristallic pump again produced unacceptable pulsing, Mariotte 
flasks were set up on both carrier streams in symmetrical fashion. For fine 
adjustments to the merging of the bubbles, the vertical heights of the flasks 
could be altered slightly. As a further test of the accuracy of merging, and 
to ensure that viscosity differences between the sample and the reagent did 
not significantly change their flow rate, solutions were visualized with 
bromophenol blue. The dye was not present during the binding studies. 
An electronic timing device was used routinely with the rotary 
injection valve. This device controls the length of the injection period 
when sample is being swept from the volumetric cavity into the carrier stream. 
It is possible to inject all the sample contained in the cavity by allowing 
a long clearance time. If prefered, however, the tail of the sample zone may 
be restricted by letting the motor return the rotor to the load position before 
all the sample has been cleared. In practice, there was no need to reduce 
tailing and a convenient sample volume could be obtained by injecting all of 
the material contained in the volumetric cavity. Furthermore, a lower 
reproducibility of injection is probably obtained when only partial sample 
0" " clearance is allowed (Ruiicka and Hansen, 1981). 
To monitor the clearance of material from the volumetric cavities of 
the double-injection valve, albumin and ANS were injected simultaneously into 
the two carrier streams and the fluorescent product was measured downstream. 
For a given flow rate, the peak heights showed an initial increase with the 
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clearance time. However, when sufficient time had been allocated to allow 
removal of all the sample and reagent from the injection manifold, the peak 
heights reached a limiting maximum which was independent of further increases 
in the clearance time. Thus the correct setting for the electronic timer 
was established for the appropriate flow rate. 
Merging zone FIA was employed successfully in two separate studies. 
The first involved an assessment of the capacity of a number of drugs to 
displace warfarin and ANS from both albumin and serum binding sites. The 
second application demonstrated the feasibility of producing complete binding 
curves using flow injection analysis. 
The displacement of ANS from HSA was performed under controlled 
conditions. The flow rate in these experiments was 1.4m1 min-1 and the timer 
on the injection valve was set at 3.0s. This meant that 35~1 of sample (HSA) 
and reagent (ANS) were consumed for each operation of the valve. The 
internal diameter of the tubing was 0.76mm. The volume of the silica flow 
cell was 45~1. The time lapse between the merging of the sample and reagent 
zones, and the arrival of material in the fluorimeter flow-cell was 15s, 
corresponding to a line length of 45cm. Peak heights were measured with the 
excitation and emission monochromators set at 375mm and 470mm, respectively. 
Under the given flow conditions, and with the specified amounts of material, 
the reaction between HSA and ANS appeared to have reached completion before 
passing through the fluorimeter; stopping the carrier flow and hence 
increasing the incubation period had no effect on peak heights. Sampling 
rates of 60 samples hr-1 were possible without incurring carryover. 
The sample and reagent concentrations were selected so that the bound 
probe fraction was large. This ensured that subsequent displacement 
interactions were concerned mainly with primary binding sites. Hence solutions 
of 10-5M HSA and 10-5M ANS were injected into the separate carrier streams. 
At least five peaks were recorded. Immediately afterwards, the same 
concentrations of albumin and fluorescent probe were injected, but the latter 
contained either 10-4 or 10-5M quantities of a competitor drug. Again 
several consecutive signals were recorded. 
When solutions containing albumin and ANS were injected separately 
into the carrier stream, no fluorescence could be detected at the analytical 
wavelength. The inner-filter effects were also shown to be negligible. 
Consequently, the signals recorded after merging of the sample and reagent 
zones were dependent only upon the concentration of bound fluorescent probe. 
None of the competitor drugs had measurable inner-filter effects •. Any 
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decrease in the recorded signal was therefore interpreted as a displacement 
of the bound fluorescent probe from HSA. 
The displacement of ANS from serum binding sites was studied using 
the same merging zone FIA system. Serum samples were diluted 50-fold in 
Tris/HC1 buffer prior to assay. A very small background signal was detected 
from the serum itself but this did not complicate interpretation of the 
results. 
A similar flow injection procedure was followed when studying the 
effect of a number of drugs on the binding of warfarin to HSA. Here, 
6 x 10-5M HSA and 1 x 10-5M warfarin solutions were injected simultaneously 
into the separate carrier streams. The effects of incorporating different 
drugs into the warfarin solution were recorded as changes in the peak 
heights. The ratio of albumin to warfarin was chosen so that the high 
affinity sites on the protein molecule were unsaturated. The absolute 
quantities of the reactants provided sufficient sensitivity for the accurate 
measurement of peak signals, but the albumin concentration was kept low 
enough to avoid the problems encountered with viscous samples. 
While warfarin itself had a negligible inner-filter effect, the 
blanks in the assay were not zero. A small signal was detected from both 
the albumin and the free fraction of the fluorescent probe. Consequently 
there was not a truly linear relationship between the peak height recorded 
by the fluorimeter and the concentration of bound fluorescent probe. 
Nevertheless, because the bound probe contributed by far the greater part 
of the signal, the error in calculating the fraction displaced directly 
from the peak height was small. Furthermore, this discrepancy could be 
completely rectified by recalling the degree to which the fluorescence of 
warfarin was enhanced on binding to albumin. 
Of the potential competitor drugs investigated, only f1ufenamic acid 
had a significant inner-filter effect. At the higher concentration tested, 
it reduced the measured signal by 1.5%. This small attenuation of the 
fluorescence was taken into consideration when calculating the quantity of 
warfarin displaced by f1ufenamic acid. 
The second major application of the merging zone technique concerned 
the production of a complete Scatchard plot. The aim was to describe the 
binding of ANS to HSA over a wide concentration range. To give adequate 
sensitivity, the Perkin-E1mer model MPF 448 fluorescence spectrometer was 
used as the detector. Preliminary work confirmed that this instrument was 
powerful enough to record signals from the most dilute samples. No other 
changes were made to the merging zone flow injection system already described. 
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As usual, solutions were made up in O.lM Tris/He1 pH 7.4 and the 
so";- :"'~;-, ... ~, employed as the carrier. A flow rate of 3.0m1 min-1 was 
employed. Using a clearance time of Ss, 35~1 volumes of ANS and HSA 
solutions were released simultaneously into the separate carrier streams 
from the double injection valve. Injections were performed at one minute 
intervals. Fluorescence intensities were measured at 460nm using an 
excitation wavelength of 375nm and a spectral bandwidth of 20nm. HSA and 
ANS solutions were maintained at 230C ~ 0.50C immediately prior to injection. 
The fluorescence intensity of unit concentration of bound probe 
was determined by measuring peak heights obtained with HSA:ANS ratios of 
greater than 10:1. Under these conditions, the albumin was able to 
accommodate essentially all of the injected fluorescent probe. However the 
stopped-flow technique was used to check that the binding interaction had 
reached c:J!!!pletion before the sample zone passed through the detector. 
Variations in detector response or carrier flow patterns were 
monitored by measuring the fluorescence emitted by quinine sulphate solutions 
injected into the buffer stream. This was done· before each sample measurement 
and formed a series of useful reference peaks. 
Over an appropriate range of concentrations, no signals could be 
detected when HSA or ANS alone were released into the carrier stream. The 
linearity of the response of the detector to bound fluorescent probe was 
established by plotting peak heights against concentration of bound probe. 
In addition. inner-filter effects were shown to be negligible. Hence when 
a 5 x 10-5M solution of HSA was injected into one carrier stream and 
increasing quantities of ANS into the other, it was a simple matter to 
convert intensity measurements into concentrations of bound fluorescent probe. 
A knowledge of the total concentration of ANS in each injected plug allowed 
the unbound concentrations to be found by difference. 
To determine the absolute concentration of HSA at the point of 
detection, it was necessary to measure the extent to which the sample had been 
dispersed during its passage along the flow line. A solution containing 
known concentrations of albumin and ANS was placed in the flow cell and the 
steady-state signal recorded. The same concentrations of protein and 
fluorescent probe were injected into the synchronized carrier streams and 
following the standard procedure, the product was measured in the flow cell. 
The ratio of the steady-state signal to the FIA peak heights gave an 
accurate estimation of the dispersion within the flow system. Sufficient 
information had then been accumulated to allow for the construction of a 
complete Scatchard plot. 
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6.3 Results Obtained using the Flow System 
The peaks presented in Figure 6.5 show how a conventional flow 
injection system can be used to demonstrate competitive binding phenomena. 
The ability of flufenamic acid to displace ANS from human serum albumin is 
registered as a decrease in the output signal. The ratio of the recorded 
peak heights suggests that the specified concentration of flufenamic acid 
displaces approximately 44% of the bound fluorescent probe. This result 
corresponds closely to the value obtained using the static method (see 
Table 4.11). From the width of the flow injection peaks it is clear that 
a maximum throughput of about 240 samples hr-l is possible with this 
arrangement. However because a single channel system was employed, the 
flow rate of l.lml min- l meant that a minimum of 275~1 of· reagent was 
consumed for each measurement. 
Amongst other things, the method of merging zones offered a more 
efficient use of reagent than had been possible with the conventional 
technique. Results obtained with this method and depicting the competition 
for albumin binding sites between ANS and a number of acidic drugs are 
shown in Figure 6.6. Only 35~1 volumes of sample and reagent were required 
for each measurement. The maximum sampling rate of 60 samples hr-l may 
be deduced from the peak profiles. 
Table 6.1 is a summary of the results of several merging zone 
experiments in which ANS and acid drugs were competing for binding sites on 
albumin. An attempt has been made to compare these results with others 
obtained under the equivalent static conditions. It is worth considering 
the basis of this comparison. 
When sample and reagent met and mix in the merging zone technique, 
there is a dilution of the reactants. If equal volumes are injected on 
both lines and if mixing of the zones is instantaneous and complete, there 
will be an immediate halving of the concentrations of the various components 
in the merging streams. In reality there is always a short delay before 
merging of the zones is complete. However, as long as the mixing process 
is reproducible, this delay is of no practical significance. Furthermore, 
diffusion-induced dispersion of sample, reagent and product becomes the 
dominant mixing process as material is carried towards the detector. Despite 
the complexity of the dispersion pattern involved, flow injection theory 
(R~~i~ka and Hansen, 1978) shows that the concentration ratio of reagent: 
sample will always remain constant in the case of merging zones - except, 
of course, for the consumption in the required chemical reaction - regardless 
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FIGURE 6.6 The Displacement of ANS from Human Serum Albumin by a Number of 
Acidic Drugs: Merging Zone FIA Technique. 
35~1 volumes of 10-5M HSA and 10-5M ANS solutions were injected 
into synchronized buffer carrier streams flowing at 1.4ml min- l • 
Potential competitor drugs were then included in the solutions 
of fluorescent probe. 
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Drug ~oncentration % Displacement of bound ANS 
FIA Static 
F1ufenamic acid 10-4M 44.6 + 2.8 
10-4M 48.1 + 2.1 53.82 + 0.16 
1O-4M 47.5 + 2.2 
5x10-5M 40.7* 40.9* 
10-Srl 19.8 + 2.8 
10-SM 21.6 + 1.6 16.13 + 0.20 
10-SM 17.8 + 2.4 
Ethacryni c aci d 1O-4M 30.3 + 0.6 
10-4M 30.S + 0.7 37.62 + 0.80 
10-4M 31.1 + 1. 0 
5x10-5M 28.9* 27.8* 
1O-5M 16.6 + 0.8 13.74+0.14 10-SM 16.3 + 0.3 
2-p-(chlorophenoxy) 10-4M 14.7 + 0.5 17.92 + 0.45 
-2-methyl proprionic 1O-4M 15.9 + 0.7 
acid 
10-SM 4.5 + 0.8 5.38 + 0.14 lO-SM 4.6 + 0.6 
Phenyl butazone 10-~ 18.2 + 1.4 19.06 + 0.26 10-4f,1 20.2 + 0.7 
10-5M 4.0 + 0.3 4.19 + 0.18 10-SM 3.S + 0.7 
Warfari n 10-4M 8.3 + 0.7 
10-4M 7.4 + 0.8 9.46 + 0.14 
1O-4M 3.3 + 0.9 
10-SM 0.7+1.7 3.15 + 0.12 10-5M 1.2 + 0.5 
Sul;Jhisoxazole 1O-~ 4.5 + 0.8 
10-4M 5.0 + 0.5 3.57 + 0.14 
10-4M 4.7 + 0.6 
5xlO-SH 1. 7* 2.8* 
1O-5M 1.8 + 0.5 0.99+0.17 
Sulphisomidine 1O-4M 1.1+1.2 1.84 + 0.10 lO-SM 0.5 + 1.2 0.26 + 0.12 
TABLE 6.1 The Displacement of ANS from its albumin binding sites by 
acidic drugs. FIA and static results. 
* Results of experiments using 50-fold diluted normal human serum; in 
other cases the sample was 1O-5t~ human serum albumin. 
ANS concentration 5 x 10-6M - 10-SM. 
Results ± standard deviation; typically 10 readings. 
I 
, 
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of how far the zones have travelled. Consequently a direct comparison with 
static methods is usually possible. To achieve this in practice. the same 
concentration ratios of HSA. fluorescent probe and competitor were added to 
a 1cm fluorimeter cell as had been injected into the merging carrier streams. 
The normal static procedure was employed and the results were analysed using 
the FLUORB program. 
As shown in Table 6.1. agreement between the two methods was 
generally good. Nonetheless. there were some initial differences. 
particularly with f1ufenamic and ethacrynic acids. Both drugs appeared to 
displace ANS more readily in the flow injection experiments. Evidence was 
produced to show that such discrepancies were due to kinetic aspects of the 
binding interaction. The merging zone experiments were repeated but delays 
of one minute or more were introduced by stopping the flow. In the absence 
of a competitor. this process had no effect on peak heights. When f1ufenamic 
acid was present. intensity changes of about 30% were observed after 
stopping the flow. An allowance for kinetic effects produced a better 
agreement between the results of the flow injection and static techniques. 
Table 6.1 also shows that the method of merging zones can be used 
to study whole serum samples. Again. the results suggest an excellent 
agreement between the flow injection and the static procedures. 
A summary of the results of the flow injection work on warfarin 
displacement is given in Table 6.2. A small part of the original data used 
to compile this table is shown in Figure 6.7. The relative capacity of a 
number of drugs to displace the fluorescent probe from binding sites on HSA 
confirms the findings of earlier. static work. 
A Scatchard plot representing the binding of ANS to HSA and 
constructed with data from one of the titrations described in Chapter 3 is 
shown in Figure 6.8. For comparison. the results obtained using the merging 
zone flow injection technique are included in the same graph. There is an 
excellent agreement between the two sets of data. As indicated. the degree 
of dispersion in the flow line ensured that the albumin concentration at 
the point of detection was quite similar to that used in the static procedure. 
Typical flow injection peaks. made up of replicate measurements on 
a single sample. are included alongside the Scatchard plots. The peaks are 
quite sharp and the separation of their maxima reflects the sampling rate 
of 60 samples hr-1• The mean of these peak heights was calculated and used 
to specify one of the points in the binding curve. The coefficient of 
variation of the replicate measurements was 1.85% and gives some idea of the 
precision obtainable with the flow injection method. 
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Drug Concentration S Displacement of bound warfarin 
Phenyl butazone 1O-5M 15.9 + 1.3 
w§.i 18.0 + 0.5 1O-5M 15.1 + 1.1 w~ 39.4 + 2.5 1O-~1 35.1 + 1.6 2X10-~M 61.7 + 1. 2 
2x10- M 60.9 + 1.2 
2x10-4M 61.2 + 1.2 
F1ufenamic acid 10-4M 42.1 + 1.5 
10-'\1 41.6 + 1.5 1O-~ 39.2 + 1.4 2x10-~M 59.8 + 1.8 
2x10- M 61.2 + 1.7 
Ethacryni c aci d W~ 24.2 +0.9 
1O-4M 25.7 + 1.2 
10-4M 25.7 + 0.6 
10-'\j 24.6 + 1.3 
2x10-4M 35.6 + 1. 7 
2x10- 4M 35.9 + 1.2 
2x1 0-4~1 35.7 + 0.2 
Sulphisoxazole w5f.1 1.3 + 2.2 
10-4M 9.1 + 0.5 
1O-4M 11.6 + 0.4 
2x10-:M 20.8 + 1.7 
2x10- M 21.3 + 1.4 
2-p-(ch1orophenoxy)- 10-4M 5.7 + 1.7 
2-methy1 propionic 10-4M 2.9 + 1.3 
acid W~ 4.3 + 0.7 2X10-~ 10.2 + 1.4 
2x10- 11.9 + 1.0 
Su1phisomidine 1O-4M 0.8 + 1.7 
w1M 1.8 + 0.9 
2x10-Si 5.4 + 1.4 
2x10- 4M 3.7 + 0.8 
TABLE 6.2 The displacement of \~arfarin from its albumin binding sites 
bY,acidic drugs as measured by FIA. 
Concentration of human serum albumin samples 6 x 10-5~t. 
Concentration of warfarin 10-5M. 
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97.097.1 98.296.9 
Fluorescence ~. ~ 
Intensity 1\ 11 
36.7 38.0 36.3 38.2 
-60s No Competi tor 2x10-4M Phenylbutazone 
61.7% 
76.6 76.1 76.0 76.0 75.9 75.9 74.0 75.0 77.2 
\::;;;i~'" \ \ 
Fluorescence 
Intensi ty 
No Competitor 10-4M Su1phisomidine 
85.4 84.9 85.0 
75.0 75.3 75.3 
No Competi tor 10-4M Sulphisoxazole 
1 11 •6% 
FIGURE 6.7 The Displacement of Warfarin from Human Serum Albumin by a 
Number of Acidic Drugs: Merging Zone FIA Technique. 
35~1 volumes of 6x10-5M HSA and 1x10-5M warfarin solutions were 
injected ioto synchronized buffer carrier streams flowing at 
1.4m1 min-1• Potential competitor drugs were then included in 
the sol uti ons of f1 uorescent probe. 
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1.0 
50.5 50.7 51.0 49.448.7 50.9 
-60s 
2.0 
• 
3.0 R 
FIGURE 6.B The Binding of ANS to HSA as Measured by Fluorescence 
Titration (0) and Merging Zone FIA (.). 
Typical flovl-injection peaks are illustrated. 
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6.4 Discussion of Methods and Findings 
Flow injection analysis has been applied successfully to a study 
of drug-protein binding. The method has a number of advantages over the more 
conventional procedures described in previous chapters. The flow-injection 
system was readily automated, results could be generated quickly and only 
very small sample volumes were required. A further economy was made by 
using the merging zone technique to minimize reagent consumption. 
The short path length across the flow cell meant that inner-filter 
effects were reduced ten-fold compared to those encountered ~/ith the standard 
lcm fluorimeter cell. Consequently, calibration plots of fluorescence 
intensity versus concentration were linear over much wider ranges in the flow 
injection experiments. This resulted in a considerable simplification in 
the analysis of results. 
The avoidance of troublesome inner-filter effects was particularly 
valuable when assessing the ability of several drugs to displace fluorescent 
probes from albumin and serum binding sites. If, as then, a number of 
absorbing species are present in solution, allowing for their combined 
inner-filter effects can be quite difficult. Hence in this application the 
flow injection system was able to exploit the benefits of fluorimetric 
detection while avoiding some of the problems associated with inner-filter 
phenomena. 
Unlike many other methods of studying drug-protein binding, FIA can 
be used to examine reaction kinetics. For instance, measuring signals under 
non-equilibrium conditions can increase the displacement effect that is 
observed in competitive binding studies: a 30% increase was encountered with 
flufenamic acid in serum. This amplification could provide additional 
analytical information with which to characterize drug-protein interactions. 
While a greater flexibility of operation can be achieved with the 
flow injection system, the method was less sensitive than the equivalent 
static procedure. Although dispersion of the sample zone could be controlled 
to give an acceptable Signal, another variable which influences peak heights -
the flow cell diameter - was severely restricted because turbulence had to 
be avoided. The necessarily short path length of the flow through detector 
generally means that fluorescence measurements in FIA are of limited 
intensity: if samples of similar composition are included in a lcm cuvette 
and in a flow cell of path length 1.2mm, the former emits a correspondingly 
stronger signal. 
To compensate for this fact, a higher gain is normally required 
when the fluorimeter is used' as a flow-through detector. This invariably 
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reduces the signal:noise ratio and can adversely affect the reproducibility 
of the assay. It is clear from the results in Table 6.1 that some loss of 
precision was encountered on going from a static to a flow injection 
procedure. 
Interpretation of the results of the flow injection experiments 
required an understanding of the effects of reaction kinetics and sample 
dispersion. Armed with this information, a surprisingly good agreement has 
been demonstrated between the flow injection and static methods of assessing 
displacement phenomena. The flow injection system was used satisfactorily 
with diluted serum as well as with pure albumin solutions. The relatively 
high degree of dispersion within the manifold ensured that differences in 
viscosity between serum and albumin samples were negligible. If undiluted 
sera are used in low dispersion manifolds, viscosity differences may 
influence the results. 
The data shown in Figure 6.8 represent the first attempt to construct 
a complete drug-protein binding curve using FIA. The agreement with the 
static method is excellent. Although there were no reports of such work in 
the literature, these results suggested that merging zone flow injection 
analysis could be used successfully in quantitative binding stUdies. 
Recently, Abdu11ahi et a1 (1983) have extended the FIA work to investigate 
the binding of basic drugs to a - acid glycoprotein. 
As an aid to future drug-protein binding studies, it might be useful 
to convey data directly from the fluorimeter to a microcomputer. The routines 
used to analyse the binding data and perform curve-fitting routines could be 
programmed into the microcomputer. In this way, binding constants would be 
generated rapidly and conveniently· from the flow injection results. The 
introduction of microprocessors to control the injection procedure and the 
carrier flow velocity would make for a more precise and robust assay. 
Optimization of the experimental variables would also be easier. 
Given the significant advantages of·FIA over conventional continuous 
flow systems, it is rather surprising how little use has been made of the 
technique in the field of clinical chemistry. Rocks and Riley (1982) have 
summarized the clinically relevant species so far determined by FIA. 
However, many of the assays developed to measure these substances must be 
regarded as feasibility studies only. The work of Lim et al (1980) in which 
the combined techniques of merging zones and stopped-flow were used in a 
homogeneous energy-transfer fluoroimmunoassay of albumin clearly shows the 
potential of the flow injection approach. It appears that the major obstacle 
to the adoption of FIA into routine clinical chemistry laboratories is the 
absence of a suitable, commercially available, fully automated flow injection 
ana lyser. 
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CHAPTER 7 
Discussion 
An accurate procedure for the assessment of the degree of binding 
of fluorescent probes to proteins has been developed. Unlike earlier 
methods, the procedure takes account of the contribution of the free 
fluorescent probe to the total signal. This refinement leads to a more 
reliable determination of association constants, particularly for 
fluorescent molecules which exhibit only a moderate change in thei r 
spectroscopic properties on binding to proteins. The procedure was used to 
examine the binding of two fluorescent probes to human serum albumin. 
There appears to be only one other case in which an attempt has been made 
to account for the fluorescence of the un bound ligand when analysing binding 
data (Maes et a1, 1982). 
Once the intensity of the signals emitted by the protein-bound and 
unbound forms of a fluorescent probe had been established, no physical 
separation of the bound and free fractions in unknown samples was required. 
Inner-filter effects and background signals were fully accounted for during 
the resolution of the analytical signal into contributions from free and 
bound fluorescent probe. Computer programs were written to carry out the 
necessary data processing and to generate binding curves and constants. 
In the absence of these programs, i t ~Iould have been extremely tedi ous to 
consider the separate factors comprising the total signal; moreover, the 
introduction of simplifying assumptions would have led to conclusions of 
questionable validity. 
The methods of correcting fluorescence intensity measurements for 
inner-filter effects were discussed in some detail. The abilit~' of the 
recommended correction procedure to account for the distortion of the 
calibration curves was examined in theoretical as well as in practical 
terms. Inner-filter effects are a common problem in analytical fluorimetry 
and may be worthy of further attention. 
Binding constants for the interactions between warfarin and HSA, 
and between ANS and HSA were determined by fitting data to the two-site 
Scatchard model. An objective measure of the goodness of fit was used. 
This is clearly a more satisfactory approach than the simple visual means 
of curve-fitting which are sometimes employed; subjective influences on the 
visual decomposition of binding curves are notorious. 
Whenever additional parameters are introduced into a binding 
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equation, the goodness of fit to a given set of results will increase. 
This is simply a consequence of the additional flexibility of the model. 
Ultimately, if as many parameters are present as data points, the curve may 
pass through every point. A compromise must be sought between adding new 
parameters and improving the goodness of fit. Within the limits of 
experimental error, the binding of warfarin and ANS to HSA was adequately 
described by a two-site Scatchard model. While it would have been a simple 
task to extend the analysis to a three-site binding equation, interpreting 
the meaning of a very small change in the goodness of fit would have been 
more difficult. It would have involved the construction of several binding 
curves, each containing a large number of data points, and the application 
of a statistical test to discern whether the increase of the goodness of 
fit on including additional parameters in the model was significantly more 
than could be expected on the basis of chance alone (Munson and Robard, 1980). 
This process would have had to be repeated for each binding curve, 
including those obtained in the presence of competitor drugs. 
The limitations of the different mathematical models of ligand-
protein binding were discussed in Section 1.7. The binding constants 
derived for the interaction between the two fluorescent probes and HSA 
must therefore be understood in the context of the two-site Scatchard model. 
The fact that the Scatchard plots have negative slopes over their entire 
ranges means that the results can be fitted to the Scatchard model. Although 
the absence of positive slopes in these curves indicates that positive 
cooperativity is not apparent in the binding processes under examination, 
it is not possible to deduce from this that all the assumptions inherent 
in the generalised Scatchard model are satisfied. In other words, the 
existence of other allosteric phenomena in the binding of warfarin and ANS 
to HSA cannot be ruled out. 
The procedures for measuring free and bound levels ef fluorescent 
probes ~Iere used to assess the affinities of various drugs for specific 
sites on HSA. By examining the effect of drugs on the binding curves of 
a fluorescent probe it was possible to identify those ligands which 
competed for common sites on albumin. Drugs which produced a large reduction 
in the bound fraction of a fluorescent probe were taken as having a high 
affinity for that particular binding site. 
It appears from the results of Chapter 4 that warfarin and ANS 
bind to separate regions of the albumin molecule. Thus while warfarin, 
phenylbutazone and some sulphonamide drugs were shown to compete for the 
same class of sites on HSA, these compounds did not affect the binding of ANS. 
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Certain other drugs were shown to bind avidly to b_oth the warfarin and ANS 
b~;-,';;,,~ ~;t~. of albumin, that is, to sites I and II respectively. The 
distribution of these drugs between two high-affinity sites ef HSA was 
confirmed by studies of the binding equi1ibria between three 1igands and 
albumin. The possible clinical consequences of the administration of drugs 
which can bind avidly to more than one class of binding sites on HSA were 
discussed. 
The crystal structure and molecular conformation of the fluorescent 
probes warfarin and ANS have been determined using X-ray crysta110graphic 
techniques (Va1ente et a1, 1975; Cody and Hazel, 1976). Unfortunately, a 
full understanding of the ability of these molecules to bind to different 
sites on the albumin molecule may only be available when the complete 
three-dimensional structure of the protein is revealed. 
,h", competi tion between fluorescent probes and drugs for protein 
binding was examined using whole sera as well as purified albumin solutions. 
No pretreatment of serum samples was required. Almost all of the drugs 
under examination displaced the same quantities of fluorescent probe 
irrespective of whether binding was to total serum proteins or to albumin 
alone. The results were consistent with the view that albumin is the major 
binding protein for acidic drugs in human serum. 
The observed displacement interactions involving fluorescent probes 
and drugs supported the common-site model. This proposes that only a 
finite number of ligand binding sites exist on albumin and drug displacement 
interactions are a result of direct competition for common binding sites. 
However, the vie~1 that non-competitive mechanisms may have had a role in 
at least some of the observed displacement interactions cannot be dismissed 
out of hand. Certainly the cooperative viewpoint of displacement phenomena 
has a number of advocates, for example Madsen and E11is (1981), and Weber 
(1975). Moreover, the ability of many 1igands to induce conformational 
changes in the albumin molecule is well-known, although in some cases the 
changes may be small and restricted to the immediate environment of the 
binding site. On the other hand, recent progress has been made in the 
identification of specific regions of the albumin molecule which are involved 
in the binding of drugs. Current evidence concerning the location of the 
major drug binding sites of HSA has been examined in Section 1.4.2; so far 
only three important drug binding sites have been identified. It \~ou1d 
seem reasonable to suppose, therefore, that direct competition for 
individual binding sites is a real effect, but its importance relative to 
non-competitive mechanisms in displacement interactions has yet to be 
resolved and will surely be dependent upon the drugs involved. 
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Recognising the fact that changes in the spectroscopic properties 
of ,,~ nlhumin-bound fluorescent probe may not be the result of a displacement 
interaction at all. but could be due simply to a slight rearrangement of 
the immediate environment when a second ligand binds to the same protein 
molecule. equilibrium dialysis was used to check the findings of the 
fluorescence titrations. As demonstrated in Chapter 5. there was a good 
agreement between the results of the spectroscopic and equilibrium dialysis 
techniques. This would appear to validate the use of the homogeneous 
fluorescence assay in the assessment of drug-protein binding. The 
importance of considering the effect of the unbound fraction on the time to 
dialysis equilibrium was stressed. Thus. as well as. examining the results 
of the two techniques. the comparative evaluation included an assessment of 
practical aspects of the fluorimetric and equilibrium dialysis procedures. 
Flow injection analysis (FIA) was identified as the most promising 
means of automating the ligand-binding assays. A high sample throughput 
and a low consumption of reagents were achieved using the merging zone flow 
injection technique. The semi-automated system could handle diluted whole 
serum as well as pure albumin solutions. A complete binding curve was 
constructed using the results of flow-injection experiments. The procedure 
also illustrated some kinetic aspects of the displacement of fluorescent 
probes from albumin. 
The agreement between the results of the flow injection and 'static' 
methods was very good. Hence. flow injection analysis should provide the 
opportunity to examine the binding properties of large numbers of drugs 
and fluorescent probes. and would allow numerous serum samples to be 
handled routinely and effeciently. 
The advantages of FIA in automated analysis have been questioned 
even recently (Holy. 1982). However. these criticisms may be coloured by 
a commercial interest in the promotion of segmented continuous flow 
analysers. Moreover, the arguments in favour of flow injection analysis 
are compelling (Hansen and Ruzicka. 1982; Stewart. 1982) and should help 
to dispel any remaining doubts as to the potential of this technique in 
clinical chemistry and other fields of analysis. 
The procedures outlined in Chapter 3 were concerned with measuring 
levels of free and bound fluorescent probe in a mixture. The principle 
technique required that the fluorescence intensities of the free and 
protein-bound forms of the probe were first determined and then used to 
interpret the signal emitted by a sample containing both species into 
components from the bound and free fluorescent probe. In its simplest 
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representation, this involved the solution of two simultaneous equations. 
In the context of thi s work, efforts were a1 so made to achieve the spectral 
resolution of the emission bands of the free and protein-bound f1uoresccent 
probes. The technique of derivative and synchronous fluorescence 
spectroscopy were of some use in improving the discrimination between the 
peaks of interest. However, the resolution was insufficient to permit 
direct quantitative measurements of bound and free levels of warfarin and 
ANS. Nonetheless, it was possible to identify the class of fluorescent 
probes which could benefit most from the application of the derivative and 
synchronous techniques to the resolution of the overlapping peaks of bound 
and free ligand. 
Recently, differences in fluorescence polarization have been used 
to resolve the overlapping spectra of free and bound f1uophors (Roeme1t 
et a1, 1980). This is an interesting technique but it is of fairly limited 
sensitivity. In spite of this, a procedure for measuring total drug levels 
in serum has been developed (TDx System, Abbot Laboratories Ltd) which is 
based upon a competitive binding immunoassay and uses the principle of 
fluorescence polarization t~ measure tracer-antibody binding directly. The 
need for the physical separation of free and antibody-bound tracer is 
eliminated. 
The clinical implications of some of the drug displacement 
interactions encountered in this study were discussed in Section 4.4. 
Caution ~as stressed in attributing too much emphasis to the role of plasma 
protein binding displacement in drug interactions. Drugs which are likely 
to be involved in clinically important displacement interactions will be 
highly bound to plasma proteins at normal dosing levels, have a small 
apparent volume of distribution and display a relatively narrow range of 
therapeutic concentration at their sites of action. This should be borne 
in mind when attempting to predict the clinical significance of the 
competition between drugs for albumin binding sites. 
The coumarin anticoagulants, in particular, are knovm to be 
involved in hazardous drug interactions. Hence the choice of warfarin as 
a fluorescent probe for monitoring drug displacement interactions is 
especially relevant. Of course, it should be appreciated that drug 
interactions involving warfarin are likely to be dependent upon several 
factors, only one of which is displacement from plasma protein binding sites. 
While plasma protein binding displacement is only very occasionally 
a major underlying mechanism of drug interactions, the study of protein 
.bfnding and displacement may still assist in the identification of 
potentially dangerous combinations of drugs. Drugs which compete for 
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plasma protein binding sites may also compete for eliw.ination and metabolic 
pathways and for tissue binding sites. Further studies of drug-albumin 
binding may also provide a better understanding of the molecular aspects of 
drug-protein and drug-receptor interactions. 
The importance of plasma protein binding on the distribution, 
metabolism, elimination and pharmacological activity of drugs has been 
discussed in Section 1.1. As the free drug concentration in plasma reflects 
the expected pharmacological effect, it is certainly prudent to consid.er 
this fraction for drug plasma level monitoring rather than the total 
concentration, particularly when a drug is highly bound at therapeutic 
levels. 
Under most physiological conditions there is relatively little 
interindividual difference in protein binding of drugs and so the free drug 
concentration is a fairly constant percentage of the total. However, in 
patients with renal and hepatic diseases, or when hypoalbuminemia is 
present, the free drug concentration may be substantially increased so that 
toxic effects can occur when the total drug concentration is within the 
usual therapeutic range. In such circumstances the free drug should be 
measured. Similarly, if drug displacement is likely to accompany the 
co-administration of highly protein-bound drugs, the monitoring of free 
drug levels is clearly indicated. 
Unfortunately, it is normal practice to determine total drug 
levels in the blood rather than free drug levels, even for highly bound 
drugs. It is hardly surprising th~t the measurement of total blood levels 
frequently gives poor correlations with therapeutic or toxicological effects. 
In clinical situations that are known or assumed to be associated with 
significant changes in plasma protein binding, the use of total drug 
measurements may lead to serious errors in estimating dosage requirements. 
In the past drug monitoring has usually been concerned with the 
total drug in plasma and not just the free fraction. This has been due to 
difficulties in separating the bound and free fractions and in determining 
the frequently very l(M levels of unbound drug. The recent introduction of 
disposable ultrafilters may have only partially alleviated the problem 
(Ruprah et al, 1981). 
The development of new methods for resolving bound and free drug 
should lead to a better assessment of the relationship between drug levels 
and therapeutic activity. Moreover, compared to total drug neasurements, 
this approach will provide a more satisfactory foundation on which to base 
any adjustments of drug administration. The new methods ~ay depend upon 
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the concept of free ligand assays introduced by Midgley and Wilkins (1982). 
Free drug levels could be monitored by measuring the competition between 
fluorescent probes and drugs for binding to specific antibodies or other 
proteins mixed with patient serum samples. The fluorescent probe would be 
chosen to bind strongly to the added specific binder (which also binds the 
drug), but to have little or no affinity for binding to native drug binders 
such as albumin in the biological fluid. Only a small quantity of the 
fluorescent molecule would be added so as not to disturb the bindiny 
equilibrium of the drug. The major obstacle to the development of such 
drugs is likely to be the synthesis of suitable fluorescent compounds. 
An obvious extension to the work of this study is an investigation 
of the binding of acidic drugs to blood proteins other than albumin -
possibly a,-acid glycoprotein and a -fetoprotein (AFP).It would be 
particularly interesting to compare the drug binding properties of human 
serum albumin and AFP in the light of the probable homology of their amino 
sequences and primary structures. In addition an examination of the binding 
of drugs to AFP may give a better understanding of the relationship between 
the binding capacities of maternal and fetal plasma. 
Fl uorescent probes are a 1 re ady provi ng useful in the characteri zati on 
of the plasma protein binding of basic drugs. The synthesis of new site-
specific fluorescent probes should give a further impetus to this work. 
Advances in tissue techniques may make it easier to obtain samples 
for drug binding studies. The displacement of drugs from tissue binding 
sites has a high potential for adverse effects, and fluorescent probes may 
be increasingly important in investigations of drug interactions at tissue 
binding sites. 
The continued use of fluorescent probes in drug-protein binding 
studies is assured. It is to be hoped, however, that many of the 
contradictions and discrepancies which have appeared in the literature on 
the binding of drugs to human serum albumin will be avoided in the future. 
This will only occur if there is a better understanding of the analytical 
methods employed and a fuller appreciation of the limitations of the 
available binding models. 
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